



ASRM 2024

Equity, Access, and Innovation
Denver, Colorado
October 19-23, 2024

FINAL PROGRAM



ASRM Scientific Congress Policies and Disclaimers

ABSTRACT EMBARGO POLICY

ASRM asks that authors maintain an embargo on information in the abstracts, along with any additional information that will be presented at the Congress, until the day and time scheduled for presentation at the Congress, with the exception of certain abstracts that are included in ASRM’s press releases for the Scientific Congress – these will usually have an embargo set a few hours earlier than the scheduled presentation time. For more information regarding what may be released publicly before the Congress, or how to comply with the embargo, please contact publicaffairs@asrm.org.

ADA STATEMENT

The American Society for Reproductive Medicine fully complies with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Accommodations for Disabilities: Please notify Lee Pearce at lpearce@asrm.org a minimum of 10 working days in advance of the event if a reasonable accommodation for a disability is needed.

ANTI-HARASSMENT AND NONDISCRIMINATION POLICY FOR MEETINGS

It is the policy of the American Society for Reproductive Medicine that all participants in Society activities will enjoy an environment free from all forms of discrimination, harassment, and retaliation. ASRM is committed to the philosophy of equal opportunity and treatment for all members regardless of race, color, religion, age, gender, sexual orientation, gender identity, national origin, citizenship, disability, military status, or any other reason not related to scientific merit. [Click here to read the full policy.](#)

[CLICK HERE TO VIEW A FULL LIST OF ASRM MEETING POLICIES ON THE ASRM CONGRESS WEBSITE.](#)

AUTHORSHIP INTEGRITY POLICY

ASRM holds scholarly veracity and responsible conduct and research reporting as essential for maintaining the integrity of research enterprise and discovery. This policy provides a clear understanding of the expectations of authorship. [Click here to read the full policy.](#)

CANCELLATION POLICY

The American Society for Reproductive Medicine reserves the right to cancel this activity due to unforeseen circumstances. In the event of such cancellation, the full registration fee will be returned to the registrant.

CODE OF CONDUCT

ASRM is committed to providing a professional, collegial, safe, supportive, and respectful in-person and on-demand meeting environment. We expect individuals to uphold the professional and educational purposes of ASRM. Anyone who feels unsafe or experiences unwelcome conduct, who observes or experiences unacceptable behavior, or who believes there has been a violation of this Code of Conduct, is encouraged to immediately notify one of the ASRM employees and/or send an e-mail to asrm@asrm.org. ASRM reserves the right to take actions most likely to ensure the safety and security of participants, including the termination of a participant’s account for the remainder of the event. ASRM also reserves the right to communicate with employers, participant sponsors, vendors, local law

enforcement, media, and the public as ASRM deems appropriate related to its response under this Code of Conduct.

CONTINUING MEDICAL EDUCATION POLICY

The American Society for Reproductive Medicine (ASRM) is a multidisciplinary organization dedicated to the advancement of the science and practice of reproductive medicine. It is of the best interest of ASRM to implement internal firewalls to prevent the sharing of information acquired from promotional activities, ensure content validity, and determine any potential conflicts of interest. [Click here to read the full policy.](#)

DISCLAIMER STATEMENT

The content and views presented in this educational activity are those of the faculty/ authors and do not necessarily reflect those of the American Society for Reproductive Medicine. This material is prepared based on a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity to make clinical decisions about individual patients.

EQUAL OPPORTUNITY STATEMENT

The American Society for Reproductive Medicine values and promotes diversity among its members, officers, and staff. The Society prohibits discrimination toward any member or employee due to race, color, religion, age, gender, sexual orientation, national origin, citizenship, disability, military status, or other basis prohibited



ASRM Scientific Congress Policies and Disclaimers

by law. ASRM strives to achieve gender, racial, and ethnic balance in hiring and governance. ASRM maintains policies, procedures, and personnel actions that conform to the letter and spirit of all laws and regulations pertaining to equal opportunity and nondiscrimination in employment, appointments, and elections to office.

MEDIA REGISTRATION POLICY

The American Society for Reproductive Medicine welcomes members of the press, publishing in all forms of print, electronic, audio, and visual media, to cover our Scientific Congress & Expo. [Click here to read the full policy.](#)

RELEVANT FINANCIAL RELATIONSHIP POLICY

ASRM's policy is that all financial relationships and roles with ineligible companies be subject to review. All voluntary non-employee persons involved in accredited activities must report all financial relationships, regardless of the monetary amount received, annually and whenever a change occurs. Financial relationships will be mitigated by the procedures outlined below. This policy is intended to supplement, but not replace, any applicable state and federal laws governing financial relationships applicable to nonprofit and charitable organizations. [Click here to read the full policy.](#)

REFUND/NON-ATTENDANCE POLICY

Cancellations received on or before September 11th, will receive a full refund minus a \$150 processing fee. Cancellation requests must be submitted in writing. Cancellations received after September 11th will not be eligible for a refund. Recorded Content Bundle Fees are non-refundable.

HOW TO REGISTER



Register online at www.asrmcongress.org and receive immediate confirmation!



On-site in Denver, Colorado

Registration and Information

Choices may be limited on-site. Pre-registration is recommended.

[Click here for registration rates.](#)

ON-SITE REGISTRATION DESK: COLORADO CONVENTION CENTER	Saturday, October 19	9:00 AM – 6:00 PM
	Sunday, October 20	7:00 AM – 6:00 PM
	Monday, October 21	7:00 AM – 6:00 PM
	Tuesday, October 22	7:00 AM – 5:00 PM
	Wednesday, October 23	7:00 AM – 12:00 PM

BE SURE TO VISIT THE EXPO HALL	Monday, October 21	9:00 AM – 4:30 PM
	Tuesday, October 22	9:00 AM – 4:30 PM
	Wednesday, October 23	9:00 AM – 2:00 PM

Children under 16 are allowed on the Expo Floor only when accompanied/supervised by an adult. No strollers allowed.



Welcome Message from ASRM President Dr. Paula Amato

This year's ASRM Scientific Congress & Expo theme is EQUITY, ACCESS, AND INNOVATION. Dr. Genevieve Neal-Perry, Scientific Congress Program Chair, and Dr. Erica Marsh, Postgraduate Program Chair, and their teams have designed a comprehensive and exciting program for Congress attendees. The richness of the program is designed to address the educational and practice needs of physicians, advanced practice providers, nurses, andrology and embryology laboratory personnel, genetic counselors, mental health practitioners, and practice managers, as well as practitioners in public health, allied health, law, and ethics.

Our weekend begins with an exciting lineup of on-site Postgraduate Courses. The Postgraduate Program Committee has collaborated with our affiliated societies, professional and special interest groups, as well as domestic and international Society Partners, to present a wide range of multi-disciplinary Postgraduate Courses designed to meet the needs of all our members.

In keeping with our ASRM 2024 Scientific Congress theme of "Equity Access, and Innovation," we have invited a diverse group of dynamic plenary speakers this year who will engage us in a variety of topics.

We welcome our members, trainees, and colleagues from around the world to the ASRM 2024 Scientific Congress & Expo! We look forward to seeing you in person and value your participation and engagement in all the educational and networking opportunities provided.



ASRM 2024 Ticketed Events

Ticketed events listed in the daily schedule are marked with a  icon.


SATURDAY, OCTOBER 19, 2024

Postgraduate Courses 


SUNDAY, OCTOBER 20, 2024

Postgraduate Courses 

Hands-On Courses
(Limited In-person access only) 


Society for Reproductive Endocrinology
and Infertility (SREI) Members' Retreat: 
8:00 PM – 12:00 PM
\$250 for SREI Members /
\$300 for Non-SREI Members

ASRM & CADE Foundation Social Media Summit 
8:00 AM – 11:00 AM | \$25 registration required


ASRM 2024 President's Gala 
6:00 PM - 11:00 PM
Tickets are \$500 per person
with all proceeds benefiting the ASRM Research Institute.
Purchase your ticket at www.asrmcongress.org when you
register for the Congress.

DAILY

Resident Learning Sessions (KEEP Program) 
Monday, Tuesday, and Wednesday
(Lunch provided. Registration required.)

Roundtable Luncheons 
Monday, Tuesday, and Wednesday
12:20 PM - 1:20 PM | \$75/day

TUESDAY, OCTOBER 22, 2024

Women's Council Breakfast 
6:45 AM - 7:45 AM | \$70 Fee





Daily Schedule Key to Abbreviations

AFFILIATED SOCIETIES	SART	Society for Assisted Reproductive Technology
	SMRU	Society for Male Reproduction and Urology
	SRBT	Society of Reproductive Biologists and Technologists
	SREI	Society for Reproductive Endocrinology and Infertility
	SRS	Society of Reproductive Surgeons
PROFESSIONAL GROUPS	APPPG	Advanced Practice Provider Professional Group
	ARM	Association of Reproductive Managers
	GCPG	Genetic Counseling Professional Group
	LPG	Legal Professional Group
	MHPG	Mental Health Professional Group
NPG	Nurses' Professional Group	
SPECIAL INTEREST GROUPS	AESIG	Androgen Excess Special Interest Group
	AISIG	Artificial Intelligence Special Interest Group
	ATCSIG	Access to Care Special Interest Group
	CIMSIG	Complementary and Integrative Medicine Special Interest Group
	ChSIG	Chinese Special Interest Group
	CFPSIG	Complex Family Planning Special Interest Group
	EndoSIG	Endometriosis Special Interest Group
	EPSIG	Early Pregnancy Special Interest Group
	ERSIG	Environment and Reproduction Special Interest Group
	FPSIG	Fertility Preservation Special Interest Group
	FSIG	Fibroids Special Interest Group
	HDSIG	Health Disparities Special Interest Group
	IRMSIG	Imaging in Reproductive Medicine Special Interest Group
	ISIG	Indian Special Interest Group
	IVMSIG	In Vitro Maturation Special Interest Group
	LGBTQSIG	LGBTQ Special Interest Group
	MOISIG	Menopause and Ovarian Insufficiency Special Interest Group
	NutriSIG	Nutrition Special Interest Group
	PAGSIG	Pediatric and Adolescent Gynecology Special Interest Group
	PGTSIG	Preimplantation Genetic Testing Special Interest Group
	PSSIG	Physician-Scientists' Special Interest Group
	RISIG	Reproductive Immunology Special Interest Group
	RMSCBSIG	Regenerative Medicine and Stem Cell Biology Special Interest Group
	SocMeSIG	Social Media Special Interest Group
	TSIG	Turkish Special Interest Group
WC	Women's Council	
PARTNER GROUPS	AE-PCOS Society	Androgen Excess and Polycystic Ovary Syndrome Society
	ALMER	Latin American Association for Reproductive Medicine
	AMMR	Mexican Association of Reproductive Medicine
	ASPIRE	Asia Pacific Initiative in Reproduction
	CFAS	Canadian Fertility and Andrology Society
	CSRM	Chinese Society of Reproductive Medicine
	ESHRE	European Society of Human Reproduction and Embryology
	ISAR	Indian Society for Assisted Reproduction
	JSAR	Japan Society of Assisted Reproduction
	MEFS	Middle East Fertility Society
	SSR	Society for the Study of Reproduction



Indicates a ticketed event



These icons are used on the schedule to indicate which types of credits are offered. See page x for a detailed listing of available credits.





Program Planning Committee and ASRM Board of Directors

ASRM 2024 SCIENTIFIC CONGRESS PROGRAM PLANNING COMMITTEE

- Paula Amato, MD, ASRM 2024 President
- Genevieve Neal-Perry, MD, PhD, 2024 Scientific Congress Program Chair
- Danny Schust, MD, 2024 Interactive Sessions Chair
- Kathleen Hwang, MD, 2024 Roundtables Chair
- Erica Marsh, MD, MSCI, FACOG, Postgraduate Program Chair
- Divya Shah, MD, Med, Postgraduate Co-Chair
- Joshua Halpern, MD, MS, Postgraduate Coordinating Chair
- Laurie J. McKenzie, MD, SART Representative
- Jim Dupree, MD, SMRU Representative
- Dara Berger, PhD, SRBT Representative
- Mary Ellen Pavone, MD, MSC, SREI Representative
- Bala Bhagavath, MD, SRS Representative
- Mahshid Albrecht, ARM Representative
- Ellen Johnson, MGCS, LCGC, GCPCG Representative
- Shoshana Kunin-Leavitt, Esq., LPG Representative
- Julie Bindeman, PsyD, MHPG Representative
- Jared C. Robins, MD, MBA, Chief Executive Officer (Ex Officio)
- Chevis N. Shannon, DrPH, MBA, MPH, MERC, Chief Education and Science Officer (Ex Officio)
- Callie Armstead, MA, Educational Meetings Manager

ASRM OFFICERS AND BOARD OF DIRECTORS 2023 – 2024

ASRM OFFICERS

- Paula Amato, MD, President
- Elizabeth Ginsburg, MD, President-Elect
- Robert E. Brannigan, MD, Vice President
- Michael A. Thomas, MD, Immediate Past President
- Marcelle I. Cedars, MD, Past President
- Jessica B. Spencer, MD, Secretary-Treasurer

ASRM BOARD OF DIRECTORS AT-LARGE MEMBERS

- Ruben Alvero, MD
- Eve Feinberg, MD
- Sangita Jindal, PhD
- Paul Lin, MD
- Akanksha Mehta, MD
- Kim L. Thornton, MD

ASRM BOARD OF DIRECTORS AFFILIATED SOCIETY MEMBERS

- Steven Spandorfer, MD (SART)
- Kathleen Hwang, MD (SMRU)
- Marina Gvakharia, MD, PhD (SRBT)
- Erica Marsh, MD (SREI)
- Mindy Christianson, MD (SRS)

ASRM CHIEF EXECUTIVE OFFICER

- Jared C. Robins, MD, MBA

ASRM CHIEF EDUCATION AND SCIENCE OFFICER

- Chevis Shannon, DrPH, MBA, MPH, MERC





ASRM 2024

TABLE OF CONTENTS

Schedule-At-A-Glance	9-18
Continuing Education Credits	19
Continuing Professional Development	20
Postgraduate Program	21-37
Hands-on Courses	38-40
Needs Assessment & Learning Objectives	41
Daily Schedule	42-50
Speaker Index	51-54
Disclosures	55-71
Roundtables	73-77
Video Abstracts	78-80
Oral Abstracts	81-102
Poster Abstracts	103-146
Abstract Disclosures	147-156
Non-CME: Exhibitors	157-159
Non-CME: Spotlight & Engagement Pavilion	160-163



SCHEDULE-AT-A-GLANCE POSTGRADUATE

SATURDAY, OCTOBER 19, 2024

1:00 PM - 5:00 PM

PG01	Think B.I.G.: Breaking Boundaries, Increasing Access, Generating Innovation	
PG02	Inequity in Management of Uterine Fibroids Can be Addressed by Innovations in Non-Surgical and Surgical Management	
PG03	The Future of Reproduction: From Stem Cells to Gametes	
PG04	Enhancing Fertility Care: Integrative Approaches for Patient Satisfaction through their Journey Across the Practice	
HOC-01	Automating Success: Revolutionizing IVF Lab Practices with AI and Automation	

Saturday Afternoon Break: 3:00 PM - 3:30 PM





SCHEDULE-AT-A-GLANCE POSTGRADUATE

SUNDAY, OCTOBER 20, 2024

8:00 AM - 5:00 PM

PG05	Building Families Via Donor Conception: Understanding the Donor Recipient Consultation	
PG06	Show Me the Data! Evidence-Based Evaluation and Management of Recurrent Pregnancy Loss	
PG07	Is PGT Changing Again-Are You Prepared for What is Coming and How Can You Get Involved?	
PG08	Highlights for the New or Novice REI Nurse	
PG09	A Comprehensive Approach to Male Fertility Optimization: Initial Evaluation to Medical & Surgical Interventions	
PG10	MEFS: Recurrent Implantation Failure: Is it Time for ConsenNHP on 'ConsenNHP Statements'?	
PG11	AMMR and ALMER- Integration of Precision Medicine in Reproduction: From Gametes to the Endometrium (Spanish)	
PG12	TSRM: Fine Tuning Frozen Embryo Transfers	
PG13	IFS and ISAR: "Fertile Horizons- Mastering Ovulation Induction for ART Success"	
HOC-02	Hands-On Surgical Techniques in Male Infertility Microsurgery	
HOC-03	Cryopreservation in Practice: Hands-on Training in Vitrification and Slow Freezing of Reproductive Tissues	

1:00 PM - 5:00 PM

PG14	ESHRE: Genetic Testing in Assisted Reproduction	
PG15	Integrating Open Donor Options Into Your Practice	

Sunday Morning Break: 10:00 AM - 10:30 AM
 Sunday Lunch Break: 12:00 PM - 1:00 PM (only for PG and HOC participants in full-day sessions)
 Sunday Afternoon Break: 3:00 PM - 3:30 PM



8:00 AM - 12:00 PM	SREI Practice Retreat- Elevating Excellence: Updating Current Practice for Better Outcomes
8:00 AM - 12:00 PM	ASRM X CADE Social Media Summit
6:00 PM - 11:00 PM	ASRM 2024 President's Gala





SCHEDULE-AT-A-GLANCE

MONDAY, OCTOBER 21, 2024

6:45 AM - 7:45 AM		ASRM 2024 Opening Ceremony Continental Breakfast
7:45 AM - 8:30 AM		ASRM 2024 Opening Ceremony
8:30 AM - 9:15 AM	Plenary	President's Guest Plenary Lecture: Embryo Models from Stem Cells- The Principles of Self-Organization NSCG NPWH ACOG CME NON-PHYS CME
9:15 AM - 10:00 AM	Plenary	Herbert H. Thomas Plenary Lecture: Shaping the Future of Gender-Diverse and Women's Health: A Roadmap for Equity and Innovation NSCG ACOG CME NON-PHYS CME
10:00 AM - 10:45 AM	MONDAY MORNING BREAK	
10:45 AM - 11:45 AM	Clinical	<p>APPPG: Professional Development of an REI Advanced Practice Provider – How to be Involved within the Clinic and Outside of the Office CME NON-PHYS CME</p> <p>GCPG: Clinical and Legal Aspects of PGT-M Testing in the IVF Clinic NSCG NPWH LPG</p> <p>LPG: Navigating Post Dobbs: What Should Clinics Do in the Changing Landscape NASW NSCG LPG PSY</p> <p>MHPG: Ethical and Cultural Considerations in Reproductive Care NASW NSCG NPWH PSY</p> <p>NPG: Make Every Minute Count! NSCG NPWH</p>
	Interactive	<p>Diversity and Inclusion: What Can We Do Better? - A Discussion Utilizing the SART Registry Research NSCG NPWH PSY ACOG CME NON-PHYS CME</p> <p>It's New, but Is It True? Assessing the Value of Newly Marketed Technologies in Fertility Care NSCG NPWH ACOG CME NON-PHYS CME</p>
10:45 AM - 12:00 PM	Symposia	<p>Optimizing Sperm Selection: Integrating Established and Emerging Techniques NSCG ACOG CME NON-PHYS CME</p> <p>Mullerian Anomalies: Review of the New Classification System, Optimal Imaging Techniques and Surgical Pearls NSCG NPWH ACOG CME NON-PHYS CME</p> <p>ESHRE: Polygenic Embryo Scores (PES) NSCG NPWH ACOG CME NON-PHYS CME</p>
10:45 AM - 12:15 PM	Abstract	<p>2024 Scientific Congress Prize Paper (1 of 2)</p> <p>Oral Abstract Session: Business of Medicine & Professional Development</p> <p>Oral Abstract Session: Genetics- PGT (1 of 2)</p> <p>Oral Abstract Session: Fertility Preservation- General (1 of 2)</p> <p>Oral Abstract Session: ART- Lab</p> <p>Oral Abstract Session: Pre-Clinical and Basic Research- Animal Models</p>



SCHEDULE-AT-A-GLANCE

MONDAY, OCTOBER 21, 2024

10:45 AM – 12:15 PM	Abstract	Video Abstract Session: Surgery
11:45 AM - 12:15 PM	Abstract	Oral Abstract Session: Advance Practice Providers (1 of 2)
		Oral Abstract Session: Genetic Counseling (1 of 3)
		Oral Abstract Session: Law, Policy, and Advocacy (1 of 3)
		Oral Abstract Session: Mental Health (1 of 3)
		Oral Abstract Session: Nursing (1 of 3)
12:20 PM – 1:20 PM	MONDAY LUNCH BREAK	
	Live Events	Journal Club Global
		Access to Care Seminar Series: Gender Affirming Care
		ASRM Corporate Member Council Industry Session: Partnering with Industry to Advance Patient Care
	Roundtable	RTM-01 – RTM-27
1:30 PM – 2:15 PM	Plenary	David and Rosemary Adamson Excellence in Reproductive Medicine Lecture: Weathering Inequities and their impact on Maternal and Infant Health Outcomes among Black and other Marginalized Birthing People in the United States NPWH ACOG CME NON-PHYS CME
		Menopause Keynote Lecture: “Everyone is Different”: Addressing Menopause Disparities and Inequities Across Race and Ethnicity NPWH ACOG CME NON-PHYS CME
1:30 PM – 2:30 PM	Interactive	Rebiopsy: When is it Beneficial? NSCG ACOG CME NON-PHYS CME Balancing the Scale: A Weight-Inclusive Approach to Address Obesity in Male and Female Infertility NPWH PSY ACOG CME NON-PHYS CME
1:30 PM – 2:45 PM	Live Events	The Best of <i>Fertility and Sterility</i> 2024
	Abstract	2024 Scientific Congress Prize Paper (2 of 2) Oral Abstract Session: SMRU Traveling Scholars Reproductive Medicine (Non Infertility)- PCOS and Menopause Oral Abstract Session: Health Disparities & Health Equity- General (1 of 2) Oral Abstract Session: ART-Outcomes Oral Abstract Session: Pre-Clinical and Basic Research- Stem Cells and Regenerative Medicine
	Symposia	MEFS: Artificial Intelligence in ART: Concepts, Applications and Regulations NSCG NPWH ACOG CME NON-PHYS CME Uterus Transplantation: Preparing for the Next 100 Procedures NSCG NPWH ACOG CME NON-PHYS CME Integrated Behavioral Health Care in Reproductive Medicine: How and Why to Include Mental Health Professionals in Infertility Care Teams NASW NSCG NPWH LPG PSY ACOG CME NON-PHYS CME



SCHEDULE-AT-A-GLANCE

MONDAY, OCTOBER 21, 2024

2:45 PM – 3:30 PM		MONDAY AFTERNOON BREAK
3:00 PM – 5:00 PM	Live Events	SMRU Early Career & Fellows Symposium
3:30 PM – 4:30 PM	Interactive	Opening our Doors: A Collaboration on Expanding Access NSCG NPWH PSY ACOG CME NON-PHYS CME
3:30 PM – 4:45 PM	Abstract	Oral Abstract Session: Surgery
		Oral Abstract Session: Technology & Innovation
		Oral Abstract Session: Genetics- PGT (2 of 2)
		Oral Abstract Session: Health Disparities & Health Equity- General (2 of 2)
		Oral Abstract Session: Infertility- General
		Oral Abstract Session: Pre-Clinical and Basic Research- General (1 of 2)
4:45 PM – 6:15 PM	Symposia	Protecting the Rights of Vulnerable Families in the Current Legal Climate: Legal Ethical and Medical Considerations NASW NSCG NPWH PSY ACOG CME NON-PHYS CME
		Understanding the Science and Genetic Counseling Approach for Mosaic Embryos to Better Support Our Patients' Decision-Making NSCG NPWH PSY ACOG CME NON-PHYS CME
		CFAS: Microbiotas, Biomarkers, and Endometriosis NSCG NPWH ACOG CME NON-PHYS CME
		Ovarian Tissue Cryopreservation and Auto-transplantation: From Retrieval to Restoration NSCG NPWH ACOG CME NON-PHYS CME
4:45 PM – 6:15 PM	Live Events	ASRM Society Social Hour

TUESDAY, OCTOBER 22, 2024

6:30 AM – 7:30 AM	Live Events	Women's Council Breakfast
8:30 AM – 9:15 AM	Plenary	Camran Nezhat, M.D., Lectureship in Innovations in Medicine: Are Robots Coming for Our Jobs? How AI is Revolutionizing Obstetric Ultrasound NSCG NPWH ACOG CME NON-PHYS CME
9:15 AM – 10:00 AM	Plenary	SSR Keynote Lecture: Environmental Endocrine Disruptors and Female Reproductive Aging
10:00 AM – 10:45 AM		TUESDAY MORNING BREAK



SCHEDULE-AT-A-GLANCE

TUESDAY, OCTOBER 22, 2024

10:45 AM – 11:45 AM	Clinical	<p>APPPG: Perfecting an APP’s Craft: Tips and Tools for HSG, Office Hysteroscopy, SIS, and 3D Ultrasound NPWH</p> <p>GCPG: Demystifying the Significance of Segmental Aneuploidy: How Close Are We? NSCG NPWH</p> <p>LPG: Equity in 3rd Party Reproduction: Understanding Barriers and Identifying Strategies in Maximizing Coverage and Care for Underserved Communities NSCG NPWH</p> <p>MHPG: Weathering as Potential Stressor in Reproductive Medicine- Should We Be Talking about Stress Differently? Implications for Medical Treatment and Mental Health NASW NSCG NPWH PSY</p> <p>NPG: Managing Patient Expectations NSCG</p>
	Interactive	<p>Vantage Points: A Human Resources Discussion from Every Angle ACOG CME NON-PHYS CME</p> <p>AI, Digital Transformation and Robotics: Current Status and Future Trends in Reproductive Care NSCG ACOG CME NON-PHYS CME</p>
10:45 AM – 12:00 PM	Symposia	<p>KSRM: Innovative Treatment Approaches for Ovarian Dysfunction NSCG NPWH ACOG CME NON-PHYS CME</p> <p>Reproductive Considerations for Men and Women with Chronic Disease, from Getting Pregnant to Giving Birth and Beyond NSCG NPWH PSY ACOG CME NON-PHYS CME</p>
10:45 AM – 12:15 PM	Abstract	<p>Oral Abstract Session: SART CORS</p> <p>Oral Abstract Session: Fertility Preservation- General (2 of 2)</p> <p>Oral Abstract Session: Health Disparities & Health Equity- Underrepresented and Underserved Populations</p> <p>Oral Abstract Session: ART- General</p> <p>Oral Abstract Session: Infertility- Diagnosis & Treatment</p> <p>Oral Abstract Session: Pre-Clinical and Basic Research (2 of 2)</p> <p>ASRM Research Institute: Researcher Spotlight</p>
11:45 AM - 12:15 PM	Abstract	<p>Video Abstract Session: ART and Surgery</p> <p>Oral Abstract Session: Advance Practice Providers (2 of 2)</p> <p>Oral Abstract Session: Genetic Counseling (2 of 3)</p> <p>Oral Abstract Session: Law, Policy, and Advocacy (2 of 3)</p> <p>Oral Abstract Session: Mental Health (2 of 3)</p> <p>Oral Abstract Session: Nursing (2 of 3)</p>



SCHEDULE-AT-A-GLANCE

TUESDAY, OCTOBER 22, 2024

12:20 PM – 1:20 PM		TUESDAY LUNCH BREAK
	Live Events	<p>Carlos Simón Translational Research Symposium</p> <hr/> <p>Access to Care Seminar Series: Invisible Disparities: Seizing the Opportunity to Drive Change Sponsored by Ferring Pharmaceuticals, Inc</p>
	Roundtable	RTT-01 – RTT-27
1:30 PM – 2:15 PM	Plenary	<p>SRS Keynote Lecture: MAC 2021 and Management of Mullerian Anomalies ACOG CME NON-PHYS CME</p> <hr/> <p>Contraception Keynote Lecture: Policy Solutions to Promote Equitable Contraceptive Access</p>
1:30 PM – 2:30 PM	Interactive	<p>Keeping Your Cool When Things Get Hot: Supporting Patient in Perimenopause NASW NSCG NPWH PSY ACOG CME NON-PHYS CME</p> <hr/> <p>When is a Good Time to Discuss Family Planning Goals for LGBTQ+ Individuals? NASW NSCG NPWH PSY ACOG CME NON-PHYS CME</p>
	Live Events	ESHRE/ASRM 2024 Premature Ovarian Insufficiency (POI) Guidelines- New Data and Updated Recommendations
1:30 PM – 2:45 PM	Abstract	<p>Oral Abstract Session: Benign Gynecological Disease- Endometriosis and Adenomyosis</p> <hr/> <p>Oral Abstract Session: Reproductive Urology (1 of 2)</p> <hr/> <p>Reproductive Medicine (Non Infertility)- General</p> <hr/> <p>Oral Abstract Session: Infertility- Outcomes</p> <hr/> <p>Oral Abstract Session: ART- Artificial Intelligence</p>
	Symposia	<p>SART a Retrospective NSCG ACOG CME NON-PHYS CME</p> <hr/> <p>KY Cha Symposium: Rescue and Regenerate Embryo Implantation and Uterine Interaction NSCG NPWH ACOG CME NON-PHYS CME</p> <hr/> <p>The ABOG Foundation - Kenneth J. Ryan Ethics Symposium: Polygenic Risk Scoring of Embryos (PGT-P)- Medical Benefit or Ethical Risk? NSCG NPWH ACOG CME NON-PHYS CME</p> <hr/> <p>Strengthening Infertility on the Global Health Agenda: A Joint WHO/ASRM Symposium CME NON-PHYS CME</p>
2:45 PM – 3:30 PM		TUESDAY AFTERNOON BREAK
3:30 PM – 4:30 PM	Interactive	<p>Transcending Challenges in Third Party Reproduction for Minority Couples NSCG NPWH PSY ACOG CME NON-PHYS CME</p> <hr/> <p>Future of Reproductive Urology: Direct to Consumer Shift-Increased Access or Undermining Foundations? NSCG NPWH CME NON-PHYS CME</p>



SCHEDULE-AT-A-GLANCE

TUESDAY, OCTOBER 22, 2024

3:30 PM – 4:45 PM	Abstract	<p>Oral Abstract Session: ART- Clinical (1 of 2)</p> <p>Oral Abstract Session: Fertility Preservation- Infertility and Cancer</p> <p>Oral Abstract Session: Genetics- Mosaicism</p> <p>Oral Abstract Session: Recurrent Pregnancy Loss</p> <p>Oral Abstract Session: Patient Centered Care</p>
3:30 PM – 4:45 PM	Symposia	<p>AMMR: The Future of Reproductive Medicine; New Technologies (Spanish) NSCG NPWH ACOG CME NON-PHYS CME</p> <p>New Frontiers in Male Reproduction: Translating from Bench to Bedside NSCG NPWH ACOG CME NON-PHYS CME</p>

WEDNESDAY, OCTOBER 23, 2024

8:00 AM – 8:45 AM	Plenary	<p>Samuel C. Pang LGBTQ+ Leadership in Education and Research Keynote: Standing up for LGBTQ+ Health- My Journey to the Presidency of the American Medical Association</p> <p>NPWH ACOG CME NON-PHYS CME</p>
8:45 AM – 9:15 AM	Live Events	ASRM 2024 Member’s Business Meeting
9:15 AM – 10:00 AM	Plenary	<p>Reproductive Urology Keynote: From Double Helix to Double Trouble: Sperm DNA Fragmentation Unveiled</p> <p>NPWH ACOG CME NON-PHYS CME</p>
10:00 AM – 10:45 AM	WEDNESDAY MORNING BREAK	
10:45 AM – 11:45 AM	Clinical	<p>APPPG: Where Needs Exist, We Can Do Better: Advanced Practice Practitioners in Independent, Low-tech Practices Fill the Accessibility Gap for Marginalized Populations NPWH</p> <p>GCPG: Mosaic Transfer- The Good and the Bad NSCG NPWH</p> <p>LPG: Who’s Driving the Bus? Challenges in Navigating Independent Gestational Surrogacy Arrangements</p> <p>NASW NSCG NPWH LPG PSY</p> <p>MHPG: When the Field is Divided- Should We Test Partners of Gestational Carriers? NASW NSCG NPWH PSY</p> <p>NPG: REI Nursing Competencies- National and International Perspectives NPWH</p>
	Interactive	<p>Quality Management for ART Labs: Unlocking Potential with Process Improvement Utilizing SART CORS NSCG ACOG CME NON-PHYS CME</p> <p>“Fresh Squeeze” or “Flash Freeze”? An Interactive Debate of Two Sperm Procurement Strategies for ART NSCG ACOG CME NON-PHYS CME</p>



SCHEDULE-AT-A-GLANCE

WEDNESDAY, OCTOBER 23, 2024

10:45 AM – 12:00 PM	Live Events	FDA: Reproductive HCT/P Donor Eligibility and Compliance Update
10:45 AM – 12:00 PM	Symposia	Pre/Post Cancer Reproductive Care and Counseling in Pediatric and Young Adult Age Groups NSCG NPWH ACOG CME NON-PHYS CME
		Endometrial Immunopathology in Reproductive Failure CME NON-PHYS CME
10:45 AM – 12:15 PM	Abstract	Oral Abstract Session: Benign Gynecological Disease- PCOS and Fibroids
		Oral Abstract Session: Complex Family Planning
		Oral Abstract Session: Genetics- General
		Oral Abstract Session: ART- Clinical (2 of 2)
		Oral Abstract Session: Infertility- Environmental Factors and Nutrition
		Oral Abstract Session: Reproductive Urology (2 of 2)
11:45 AM – 12:15 PM	Abstract	Oral Abstract Session: Law, Policy, and Advocacy (3 of 3)
		Oral Abstract Session: Mental Health (3 of 3)
		Oral Abstract Session: Nursing (3 of 3)
12:20 PM – 1:20 PM	WEDNESDAY LUNCH BREAK	
	Live Events	Access to Care Seminar Series: Reproductive Considerations in People with Sickle Cell Disease Sponsored by Ferring Pharmaceuticals, Inc
	Roundtable	RTW-01 – RTW-27
1:30 PM – 2:30 PM	Interactive	Sticky Situations: Surgical Management Techniques for Retained Products of Conception NSCG NPWH CME NON-PHYS CME
		Mosaic Embryo Transfer Following PGT-A What Does the Data Say / How Do We Communicate with Patients NSCG NPWH CME NON-PHYS CME
		Navigating the Complexities of Early Pregnancy: Insights from the Post-Dobbs Era NSCG NPWH LPG PSY ACOG CME NON-PHYS CME
1:30 PM – 2:45 PM	Symposia	The Need for Trauma-Informed Care in the REI Patient Population NASW NSCG NPWH PSY ACOG CME NON-PHYS CME
		Biotech Partnerships That Drive Reproductive Health Innovation: How Sperm and Oocyte Biotech Collaboration Can Lead to Innovations that Benefit Patients and Science NSCG ACOG CME NON-PHYS CME
		Emerging Climate-Change Related Threats to Human Reproduction NSCG NPWH ACOG CME NON-PHYS CME
		Minimally Invasive Approaches to Management of Uterine Fibroids: Advantages and Limitations NSCG NPWH ACOG CME NON-PHYS CME



SCHEDULE-AT-A-GLANCE

WEDNESDAY, OCTOBER 23, 2024

2:45 PM – 3:30 PM	WEDNESDAY AFTERNOON BREAK	
3:30 PM – 4:30 PM	Interactive	<p>The Burden of Bias: Considerations in the Diagnosis/Management of Endometriosis in Black, Indigenous, and People of Color</p> <p>NSCG NPWH ACOG CME NON-PHYS CME</p> <hr/> <p>Understanding the Impact of Abortion Restrictions on IVF</p> <p>NSCG NPWH LPG ACOG CME NON-PHYS CME</p> <hr/> <p>Parent & Donor Disclosure Pathways: Cases, Challenges, and Solutions Across the Lifespan</p> <p>NSCG NASW NPWH PSY ACOG CME NON-PHYS CME</p>
3:30 PM – 4:45 PM	Symposia	<p>Cutting-Edge and Innovative Multidisciplinary Approaches to Male Reproductive Surgery</p> <p>NSCG NPWH ACOG CME NON-PHYS CME</p> <hr/> <p>The Howard and Georgeanna Jones Symposium on ART: The AI Revolution in ART- Separating Reality from Hype</p> <p>NSCG NPWH ACOG CME NON-PHYS CME</p>

From Denver to Your Desk:

Rewatch or catch up on what you missed with the ASRM 2024 Recorded Content Bundle!

Purchase the ASRM 2024 Recorded Content Bundle and get access to recordings from:

- Plenaries
- Clinical Sessions
- Symposia
- Interactive Sessions

Add the Recorded Content Bundle at the Registration desk, or purchase after the Congress in the ASRM Academy Online Catalog at www.asrm.org.

Recorded content, which includes video recordings of speakers and slides, will be available in ASRM Academy between November 20, 2024 and October 1, 2025.



Course does not provide a certificate of completion or credits.



View Pricing





Continuing Medical Education | Continuing Education Credits

ASRM 2024 SCIENTIFIC CONGRESS DESIGNATION STATEMENT

The American Society for Reproductive Medicine designates this activity for a maximum of 15.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ASRM 2024 POSTGRADUATE PROGRAM DESIGNATION STATEMENT

The American Society for Reproductive Medicine designates Post Graduate Courses 01-04 and 15 are approved for a maximum range of 3.25 to 4.5 AMA PRA Category 1 Credits™ per course. Post Graduate Courses 05-14 for a maximum range of 3.25 to 6.75 AMA PRA Category 1 Credits™. Hands-on courses HOC02 and HOC03 are approved for 6.50 per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

THE AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS (ACOG)

The American College of Obstetricians and Gynecologists has approved the application, awarding 15.75 Cognates for the Scientific Congress, 3.25 Cognates for Postgraduate Course 2, 6.50 Cognates for Postgraduate Course 10, and 6.75 Cognates each for Postgraduate Courses 6 and 11.

AMERICAN BOARD OF BIOANALYSIS (ABB)

The American Society for Reproductive Medicine has been approved to provide Professional Enrichment Education Renewal (PEER) credit through the American Board of Bioanalysis for this event. Up to 1.1 CEUs (11 hours) will be recognized for Post-Graduate Courses 3, 4, 7, 9, 11, 12, 13, 14 and Hands-on courses 1, 2, and 3. Scientific Congress has been approved for up to 11.5 hours or .11 CEUs.

The American Board of Bioanalysis (ABB)

The CME icon designates that continuing education credits are available, check the online schedule or app to see which types are available for that session.

certification examination will be held at the Hyatt Regency Denver at the Colorado Convention Center on Saturday, October 19, 2024, from 7 AM to 5 PM. To sit for the ABB examination, applicants must apply online at : www.abb.org, submit all required documentation, and be approved by the ABB Board. The application and required documentation must be received by ABB no later than August 9, 2024, to be considered for the October 19 exam. For more information, contact ABB by telephone: 314-241-1445, email: abb@abbcert.org, or visit www.abbcert.org.

NATIONAL ASSOCIATION OF NURSE PRACTITIONERS IN WOMEN'S HEALTH (NPWH)

The National Association of Nurse Practitioners in Women's Health Continuing Education Approval Program has reviewed and approved the following continuing education credits: Postgraduate courses 1-4 for up to 3.50 contact hours; Postgraduate courses 5-15 for up to 6.75 contact hours; and ASRM 2024 Scientific Congress and clinical sessions for up to 15 contact hours. NPWH Activity No. 23-12. CA CEP Number 13411.

AMERICAN PSYCHOLOGICAL ASSOCIATION (PSY)

The Mental Health Professional Group (MHPG) of the American Society for Reproductive Medicine is accredited by the American Psychological Association to sponsor continuing education for psychologists. MHPG is responsible for the program and its content. Continuing education credits will be available for select sessions at the Scientific Congress, including Postgraduate Courses 01—Think B.I.G.: Breaking Boundaries, Increasing Access, Generating Innovation; 04—Enhancing Fertility Care: Integrative Approaches for Patient Satisfaction Across the Practice Journey; 05—Building Families Via

Donor Conception: Understanding the Donor Recipient Consultation; 08—Highlights for the New or Novice REI Nurse; and 15—Integrating Open Donor Options Into Your Practice, as well as MHPG Clinical Sessions CSM03, CSM04, CST04, CSW03, and CSW04

NATIONAL ASSOCIATION OF SOCIAL WORKERS (NASW)

The National Association of Social Workers has approved up to 14 contact hours of continuing education credits, with Approval #886496548-9545. This includes Postgraduate Courses PG05—Building Families Via Donor Conception: Understanding the Donor Recipient Consultation—and PG15—Integrating Open Donor Options Into Your Practice. Additionally, selected ASRM Congress sessions and clinicals have also been approved.

NATIONAL SOCIETY OF GENETIC COUNSELORS (NSGC)

The National Society of Genetic Counselors (NSGC) has approved up to 2.6 CEUs (26.00 Category 1 contact hours) for ASRM 2024 Scientific Congress & Expo, including Postgraduate Courses 01, 03, 05, 06, 07, 09, 10, 11, 12, 14, and 15. The American Board of Genetic Counseling (ABGC) will accept these CEUs for genetic counselor certification and recertification. Participants requesting NSGC CEUs will incur a \$40 service fee added to their meeting registration, which covers the processing and issuance of CEU certificates by the NSGC.

LEGAL CREDITS

ASRM Legal Professional Group has approved specific sessions at the Scientific Congress for continuing legal education credits, amounting to a total of 7.50 contact hours. Additionally, Postgraduate Course 04—Enhancing Fertility Care: Integrative Approaches for Patient Satisfaction Across the Practice Journey—provides 3.50 credit hours. For detailed information on CLE sessions and courses, please refer to the meeting schedule. Attendees should verify with their respective regulatory boards the acceptance of these continuing education credits.





How to Claim Continuing Medical Education/ Continuing Education Credits

ASRM CONTINUING EDUCATION PROGRAMS

The goal of ASRM is to sponsor educational activities that provide learners with the tools needed to conduct research, practice the best medicine, and provide the best, most current care to patients. ASRM follows the policies of the Accreditation Council for Continuing Medical Education (ACCME). CME must adhere to the ACCME Standards of Integrity in Continuing Medical Education, address specific, documented, clinically significant gaps in physician knowledge, competence, or performance, and be proven to be effective in improving physician knowledge, competence, performance, or outcomes. All planners and presenters must disclose all financial relationships that have been active within the past 24 months. The CME Subcommittee and the Executive Program Committee reviewed these disclosures, resolving perceived potential relevant financial relationships.

THE ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION (ACCME)

The American Society for Reproductive Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

How to Claim

Continuing Medical Education/Continuing Education Credits or Print a Certificate of Attendance

For Postgraduate (PG) Courses:

1. **Access the evaluation site** using the link received from registration or ASRM meeting app. Log in with Registration ID, name, or email address. (used to register)
2. Select credit type you are claiming.
3. Postgraduate courses purchased will be listed on account.
4. Complete evaluation for **all** Postgraduate courses listed to claim credits.
5. Please verify the total number of credits claimed.
6. **Download, print or email** your credit certificate(s) or certificate of attendance.

For the Scientific Congress (SC):

1. **Access the evaluation site** using the link received from registration or ASRM meeting app. Log in with Registration ID, name, or email address. (used to register)
2. Select credit type you are claiming.
3. Select all session(s) for which you wish to claim credits.
4. Please remember you must complete an assessment for **each** session, for which you are claiming credits.
5. Please verify the total number of credits claimed.
6. **Download, print or email** your credit certificate(s) or certificate of attendance.

The following may receive honoraria and/or discounted or free registration: Plenary, Symposia, and Interactive Session speakers, and Pre-Congress faculty. Honoraria are not provided for Roundtable presenters, Oral and Poster Abstract presenters, and Video presenters.

Disclosures of faculty and presenters for the Postgraduate and Scientific Congress may be in a presentation slide, printed material, or oral statement, and will be listed in the ASRM Final Program. Abstract authors' disclosures will be listed in the 2024 Program. Roundtable presenters should provide a copy of their disclosure to participants at their table.

THE FINAL DATE TO CLAIM CREDIT FOR ASRM 2024 IS NOVEMBER 8, 2024 AT 11:59 PM CST.

Email questions to education@asrm.org.





ASRM 2024 Postgraduate Program

POSTGRADUATE PROGRAM COMMITTEE

ERICA MARSH, MD, MSCI, FACOG
Postgraduate Program Chair

DIVYA SHAH, MD, MEd
Postgraduate Co-Chair

JOSHUA HALPERN, MD
Postgraduate Coordinating Chair

SATURDAY, OCTOBER 19, HALF DAY COURSE 1:00 PM - 5:00 PM (NO LUNCH)

PG01

Think B.I.G.: Breaking Boundaries, Increasing Access, Generating Innovation
Association of Reproductive Managers (ARM)

CME NON-PHYS CME NPWH NSCG PSY

FACULTY

Jessica Medvedich, MBA, BSN, RN, NE-BC (Chair)
IVI RMA
David B. Sable, MD
Columbia University
Daniel J. Kaser, MD
Reproductive Medicine Associates of Northern California

TARGET AUDIENCE

Practice Managers, Owners, Supervisors, Clinicians

CREDIT TYPE

CME, Non-PhysCME, NPWH, NSGC, PSY

NEEDS ASSESSMENT

The infertility crisis affects 1 in 6 couples according to the World Health Organization. The number of fertility treatment cycles each year provides proof we are only servicing a small portion of those who need advanced reproductive technologies. The problem of access to care and health equity in the fertility market must be evaluated from the past to the current state, as well as, from a variety of perspectives (clinical, business, scientific, legal). It is important to continuously evaluate the issue and the solutions to the problem if we are going to reach those who are being left behind without hope.

DESCRIPTION

This course evaluates the current state of access and health equity of infertility treatment and the innovative solutions that will shape the future. The investment into the fertility field has brought several start-up ventures, research, and innovation in fertility treatments clinics can utilize to increase access, improve patient experience, solve staffing shortages, increase cycle success and allow for growth. Business administrators, physicians, and managers have to sift through these resources to

determine how and when to incorporate them into their practices responsibly.

ACGME COMPETENCIES

Communication, Roles/Responsibilities, Values/Ethics, Interpersonal and Communication Skills, Practice-based Learning and Improvement, Professionalism, Systems-based Practice

LEARNING OBJECTIVES

1. Identify disparities and causes of inequity in fertility care.
2. Apply solutions that will promote increased access within your practice.
3. Assess types of digital solutions and identify associated benefits and challenges.
4. Define the latest innovations, trends, and technologies shaping the future of ART.
5. Distinguish unique challenges related to care access in third party reproduction.
6. Cite collaborations and partnerships clinics can establish to increase access to care.
7. Evaluate how to build and foster networks focused on promoting care equity.
8. Discover innovative approaches to financing fertility treatment and how to integrate them into your clinic.
9. Predict how innovations in fertility care will impact the clinical setting and the patient journey.





SATURDAY, OCTOBER 19, HALF DAY COURSE 1:00 PM - 5:00 PM (NO LUNCH)

PG02

Inequity in Management of Uterine Fibroids Can be Addressed by Innovations in Non-Surgical and Surgical Management

ACOG CME NON-PHYS CME NPWH

FACULTY

Bala Bhagavath, MBBS (Chair)
University of Wisconsin, Madison
Wael Saad Elbanna, MSc, EBCOG-EFOG
Teaching hospitals
Maria Victoria Bariani, PhD

TARGET AUDIENCE

Physicians, APPs, Nurses, Basic Science Researchers

CREDIT TYPE

ACOG, CME, Non-PhysCME, NPWH

NEEDS ASSESSMENT

Many providers are unaware of the huge disparity in the provision of care for uterine fibroids. We have also been unable to find ways to prevent development of uterine fibroids. The latest 'gap analysis and educational needs assessment' identified education regarding basic science of fibroids and addressing the role of vitamin D in uterine fibroids will address that gap in knowledge in addition to being clinically relevant. Non-surgical and minimally invasive options as alternatives to abdominal myomectomy was also identified as an educational need. Quite specifically, tips/tricks to move from abdominal myomectomy to minimally invasive myomectomy was highlighted in the needs.

DESCRIPTION

The course will educate the participants on the serious disparity in provision of care to women of color suffering from uterine fibroids. This will not only highlight the disparity in USA but around the world especially in the African continent. Prevention will be predominantly basic science focused but with clinical relevance. Non-surgical and

minimally invasive surgical alternatives to abdominal myomectomy aimed at improving options provided to women and hopefully decrease inequity in care.

ACGME COMPETENCIES

Medical Knowledge, Patient Care and Procedural Skills

LEARNING OBJECTIVES

1. Identify vulnerable population of women who do not get optimal care for uterine fibroids.
2. Discuss ways to address the disparity in provision of care.
3. Examine their own biases in the provision of optimal care including gaps in their knowledge and skillset.
4. Describe basic science research-based evidence for role of vitamin D in causation of uterine fibroids.
5. Explain Clinical evidence for role of vitamin D in formation of uterine fibroids.
6. Summarize evidence in favor of vitamin D supplementation for prevention of fibroid growth.
7. Discuss the non-surgical alternatives for uterine fibroid management.
8. Explain the pros and cons of each of the non-surgical alternatives.
9. Choose the appropriate non-surgical option for a given clinical scenario.
10. Tabulate the minimally invasive alternative for abdominal myomectomy.
11. State the pros and cons of each of these minimally invasive alternatives.
12. Choose the appropriate minimally invasive option for a given clinical scenario.





SATURDAY, OCTOBER 19, HALF DAY COURSE 1:00 PM - 5:00 PM (NO LUNCH)

PG03

The Future of Reproduction: From Stem Cells to Gametes Regenerative Medicine and Stem Cell Biology SIG



FACULTY

- Sue Hammoud, PhD (Chair)
University of Michigan
- Kyle E. Orwig, PhD
University of Pittsburgh School of Medicine
- Edward J. Grow, PhD
University of Texas Southwestern Medical Center

TARGET AUDIENCE

This interprofessional course is designed for translational researchers, physicians, advanced practice providers, nurses, practice managers, patients, and families as well as attorneys.

CREDIT TYPE

ACOG, ABB/PEER, CME, Non-PhysCME, NPWH, NSGC

NEEDS ASSESSMENT

Infertility is a prevalent issue, estimated to affect 8%-12% of couples in their reproductive age, with approximately 50% of cases being labeled as idiopathic infertility, where the cause remains unknown. Among infertile males, around 15-20% exhibit either azoospermia or oligospermia, while a subset of females experiences premature ovarian insufficiency (POI). Unfortunately, in both cases, the lack of gametes poses significant challenges to achieving successful reproduction. Restoring fertility in individuals with oogenic and spermatogenic failures has become a pivotal focus in the field of reproductive medicine, representing the next frontier. In response to this pressing need, numerous research groups worldwide are diligently working towards developing innovative technologies. The success of this endeavor will heavily rely on effective communication and collaboration between clinicians and scientists. By joining forces, these experts can pool their knowledge, expertise, and resources to create groundbreaking solutions in the domain of reproductive medicine. Through such collaborative efforts, advancements can be made to offer renewed hope to individuals and couples facing infertility issues.

DESCRIPTION

This course will delve into recent advancements in the use of stem cells for generating male and female gametes, along with testicular and ovarian support cells. These cutting-edge technologies hold tremendous promise for addressing infertility issues and enhancing reproductive

health for many patients worldwide. In vitro gametogenesis represents the future of reproductive medicine, and it is crucial to raise awareness among clinicians about these groundbreaking developments. By staying informed about these advancements, we can better shape the future of reproductive healthcare and open new avenues for improving the lives of many individuals

ACGME COMPETENCIES

Medical Knowledge

LEARNING OBJECTIVES

1. Gain a better understanding of what goes into training and retaining REI while gaining additional knowledge about advancement in REI.
2. Explain the therapeutic potential of stem cells for restoring male and female fertility.
3. Discuss the molecular and genetic pathways involved in gonad and germ cell development.
4. Describe the developmental processes of oocyte and sperm maturation both in vivo and in vitro.
5. Analyze the development and application of gonadal organoid technology.
6. Evaluate the safety and efficacy considerations of in vitro gametogenesis (IVG).
7. Examine regulatory pathways relevant to IVG technologies.
8. Debate strategies for fertility preservation post-chemotherapy and radiotherapy in both males and females.
9. Foster collaborations between clinicians and basic scientists to identify clinical needs and gaps in fertility research.





SATURDAY, OCTOBER 19, HALF DAY COURSE 1:00 PM - 5:00 PM (NO LUNCH)

PG04

Enhancing Fertility Care: Integrative Approaches for Patient Satisfaction through their Journey Across the Practice Society for Reproductive Endocrinology & Infertility (SREI), Society of Reproductive Biologists and Technologists (SRBT), Legal Professional Group (LPG)



FACULTY

Joe Conaghan, BSc, PhD, HCLD-CCRM (Chair)

Lisa A. Rinehart, JD, RN

US Fertility

Eduardo Hariton, MBA, MD

Reproductive Science Center of the SF Bay Area

TARGET AUDIENCE

The target audience for this course is fertility clinic directors, practice managers, clinic staff in patient-facing roles, reproductive medicine trainees, and other key stakeholders seeking strategies to optimize clinic operations, the patient experience, and financial performance.

CREDIT TYPE

ABB/PEER, CME, LPG, Non-PhysCME, NPWH ,PSY

NEEDS ASSESSMENT

Facing challenges in enhancing the patient’s experience, fertility clinics often struggle with staff skill gaps in business operations, marketing, and patient engagement. This course aims to shift focus on improving the patient journey and satisfaction. Leveraging insights from consumer marketing and service industries, it will offer practical strategies to elevate the patient’s experience significantly. Participants will learn to optimize scheduling, enhance patient retention, utilize AI for insightful feedback, and develop tailored package options. Interactive workshops and case studies will provide hands-on learning, enabling clinics to implement patient-centered care practices that exceed expectations. The ultimate goal is to equip fertility clinics with the capabilities to increase patient loyalty, satisfaction, and strengthen fiscal health amidst industry challenges, ensuring a thriving practice focused on delivering exceptional patient care.

DESCRIPTION

This course offers fertility clinic staff innovative strategies to elevate the patient journey and satisfaction, centering on patient-focused care. It emphasizes optimizing scheduling to minimize wait times and enhance patient engagement. Through interactive sessions and practical exercises, participants will learn to foster patient loyalty, improve clinic efficiency, and navigate the complexities of the fertility care industry. The curriculum is designed to empower clinics with the tools needed

for a thriving practice, focusing on increasing patient satisfaction and contributing to the financial health of the clinic amidst industry challenges.

ACGME COMPETENCIES

Communication, Roles/Responsibilities, Teams and Teamwork, Values/Ethics, Practice-based Learning and Improvement, Professionalism, Systems-based Practice

LEARNING OBJECTIVES

1. Identify common reasons for patient dropout and revenue declines facing fertility clinics using data and metrics.
2. Apply updated marketing and engagement strategies to enhance patient experience and optimize conversion funnel.
3. Utilize CRM platforms and AI analytics to gather insights and understand patient priorities.
4. Develop competitive pricing models and package options to drive utilization and clinic revenue.
5. Implement techniques to improve patient scheduling, retention, and loyalty long-term.
6. Establish workflows to coordinate clinic, nursing, lab, and business operations for fiscal fitness and growth.





SUNDAY, OCTOBER 20, HALF DAY COURSE 8:00 AM - 12:00 PM (NO LUNCH)

PG05

Building Families Via Donor Conception: Understanding the Donor Recipient Consultation

Mental Health Professional Group (MHPG)

CME NASW NON-PHYS CME NPWH NSGC PSY

FACULTY

Vickie Schafer, PhD PLLC (Chair)
Joelle Ehre, MA, LMFT
Private Practice
Tonya Wood, PhD
Pepperdine University

TARGET AUDIENCE

The target audience for this course includes mental health professionals (licensed marriage and family therapists, social workers, psychologists, counselors, psychiatrists), nurses, and attorneys.

CREDIT TYPE

CME, NASW, Non-PhysCME, NPWH, NSGC, PSY

NEEDS ASSESSMENT

Reproductive mental health professionals routinely receive calls from anxious fertility patients saying, "I'm about to undergo Donor IVF, and I need a Psych Eval—do you have time this week?" This scenario represents a gap in understanding of an important step in ethical third party reproduction: the donor recipient consultation. When conducted thoroughly and early in the treatment process, these consultations support patients and their future offspring by providing crucial information about donor selection, disclosure, and identity development necessary to successful family building in the post-anonymous gamete donation era. This course will fill ASRM-identified gaps including access to counseling and mental health support; provider struggles with communication to meet patients where they are; and reproductive psychology to address the emotional impact on males who need to use donor sperm. The course will also strive to fill DEI gaps by addressing the needs of a diverse range of fertility patients, including addressing the challenges of donor recipients of color and LGBTQ intended parents.

DESCRIPTION

This course will cover key topics to be included in a donor recipient consultation and present a family-building model that MHPs, attorneys, nurses, and REIs can draw upon to better support patients and to improve the lives of future donor-conceived people. Participants will learn about the psychological, social, and relational aspects of family building through donor conception including coping with the loss of

genetic connection, choosing a genetic contributor, and responding to the unique challenges that come with parenting a donor-conceived child. Key legal topics for mental health professionals and others will be covered.

ACGME COMPETENCIES

Communication, Roles/Responsibilities, Teams and Teamwork, Values/Ethics, Interpersonal and Communication Skills, Practice-based Learning and Improvement

LEARNING OBJECTIVES

1. Explain why the donor recipient meeting is a consultation, not an evaluation.
2. List the main components of a donor recipient consultation and how they should be documented.
3. Describe major differences between donor recipient consults for infertility, single parents by choice, and same-sex parents and the role of culture in meeting patients where they are.
4. Explain the differences between non-identified, open-identity, and directed donors and how the end of donor anonymity is impacting donor decision-making.
5. Discuss key considerations for a successful directed donor arrangement.
6. Provide examples of how you would support intended parents in taking the perspective of their future child when considering donor selection.
7. Summarize the reasons it is important to talk about race, ethnicity, and religion in regards to choosing sperm, egg, and embryo donors.
8. Illustrate how a child's identity can be impacted when a donor's race differs from that of the recipient parents.
9. Discuss how support can be provided to recipients who are struggling to find donors with similar characteristics in race or ethnicity.
10. Describe when is the best time to share with a child their donor conception from an identity development perspective.
11. Provide examples of how a donor recipient parent can talk to their child about their donor conception.
12. Explain why disclosure of donor conception is an active process throughout development in all family types.



SUNDAY, OCTOBER 20, FULL DAY COURSE 8:00 AM - 5:00 PM

PG06

Show Me the Data! Evidence-Based Evaluation and Management of Recurrent Pregnancy Loss Early Pregnancy SIG



FACULTY

Dana B. McQueen, MD (Chair)
IVI RMA
Lia A. Bernardi, MD
Reproductive Endocrinology and Infertility, Northwestern University
Erin Masaba, MD
University of Rochester
Aleksandar Stanic-Kostic, MD, PhD
University of Wisconsin-Madison

TARGET AUDIENCE

Course for REI physicians, advanced practice nurses, physician assistants, and nurses

CREDIT TYPE

ACOG, CME, Non-PhysCME, NPWH, NSGC

NEEDS ASSESSMENT

Recurrent Pregnancy Loss (RPL) is a devastating condition affecting 5% of couples and only 50% of couples find a cause. Patients with recurrent pregnancy loss are often highly motivated to find physician partners who are knowledgeable in the evidence-based evaluation and management of this condition. As fellowship training focuses more heavily on assisted reproductive technology, there is a knowledge gap among reproductive endocrinology, infertility physicians, and nurses regarding recurrent pregnancy loss. In addition, given the time that has passed since the last ASRM update to the RPL practice bulletin, there is a need to review data and consolidate recommendations for the standard of care.

DESCRIPTION

This course will review the evaluation and management of recurrent pregnancy loss. The topics will include the anatomic, genetic, endocrine, autoimmune, and male evaluation. The genetic evaluation will discuss karyotype, POC testing, and latest data on genetic markers (as highlighted in ASRM GAP ANALYSIS). The anatomic evaluation will include data from the TRUST trial. The role of chronic endometritis and the microbiome in RPL will also be reviewed. Treatments for unexplained RPL will be discussed, including luteal progesterone and IVF with PGT-A. Participants should leave this course with an improved understanding of the latest in data-driven recurrent pregnancy loss management.

ACGME COMPETENCIES

Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement

LEARNING OBJECTIVES

1. Define recurrent pregnancy loss.
2. Describe when an evaluation of recurrent pregnancy loss is indicated.
3. Describe the anatomic evaluation of recurrent pregnancy loss.
4. Understand the evidence surrounding uterine septum surgery in the treatment of recurrent pregnancy loss.
5. Understand the evidence surrounding uterine fibroids and pregnancy loss.
6. Describe the genetic evaluation of recurrent pregnancy loss.
7. Understand the methods available for testing products of conception and the pros and cons of each.
8. Understand the impact of an unbalanced translocation on the risk of pregnancy loss.
9. Understand the role of chronic endometritis and the microbiome in recurrent pregnancy loss.
10. Describe treatment regimens for chronic endometritis.
11. Describe the autoimmune evaluation of recurrent pregnancy loss.
12. Understand the management of anti-phospholipid antibody syndrome.
13. Understand the association between male factors and recurrent pregnancy loss.
14. Describe empiric treatment options for recurrent pregnancy loss, including luteal progesterone and IVF with PGT-A.





SUNDAY, OCTOBER 20, FULL DAY COURSE 8:00 AM - 5:00 PM

PG07

Is PGT Changing Again-Are You Prepared for What is Coming and How Can You Get Involved? Preimplantation Genetic Testing SIG



FACULTY

Dagan Wells, BSc, PhD (Chair)
Juno Genetics / University of Oxford
Carmen Rubio Lluesa, PhD
Igenomix
Nathan R Treff, PhD, HCLD
Genomic Prediction, Inc.
Daniella Gilboa, MSc
AIVF

TARGET AUDIENCE

This course is aimed at anyone across the IVF ecosystem that would like to hear from experts in the field the latest information on genetic and non-genetic assessment of embryos, including physicians, nurses, and embryologists.

CREDIT TYPE

ABB/PEER, CME, Non-PhysCME, NPWH, NSGC

NEEDS ASSESSMENT

PGT, as a field, has been in existence for over 30 years now and has seen a series of technologic and clinical advancements over this span of time. With more new testing methods for embryos available every year (time lapse imaging, analysis of spent culture medium, and polygenic risk scoring, to name a few), it is becoming increasingly difficult for the clinical team at the IVF center to keep up with this dizzying array of new information. In this day-long course, we aim to bring up a number of topics/technologies and review a few of the latest technological advancements in PGT in the context of reviewing and presenting the latest data and technology from the labs/centers developing them.

DESCRIPTION

This course will cover a series of newly developing topics in preimplantation genetic assessment of embryo health and well-being. The speakers come from a cross-section of experts in the PGT and Genetics fields and will cover topics including cell free DNA assessment of embryos from spent culture medium, time lapse imaging/artificial intelligence, and polygenic risk scoring. Beyond these topics that are front and center today clinically, we will delve further into the future to discuss topics like whole embryo sequencing, whole exome/specific panel testing during routine IVF, alternative analyte testing, as

well as genome editing of gametes.

ACGME COMPETENCIES

Communication, Medical Knowledge

LEARNING OBJECTIVES

1. Discuss how much cell free DNA is contained in spent culture medium and what are the 'rules' around optimal capture of the DNA.
2. Describe the biological difference between nuclear and cell free DNA and the technical impact on the ability for NGS to screen for aneuploid in the embryo.
3. Discuss the current state of clinical non-invasive PGT-A.
4. Outline the clinical utility and limitations of non-invasive PGT-A
5. Compare and contrast the clinical application of non-invasive PGT-A compared to standard biopsy PGT-A.
6. Explain the possibility of offering PGT-M and/or -SR non-invasively.
7. Summarize the current state of TLI across the globe.
8. Describe the current state of utilizing AI, Machine Learning, etc., across embryology.
9. Show how AI/Machine Learning plays a part in improving IVF care.
10. Compare and contrast the different approaches and limitations in determining the ploidy status of an embryo with TLI vs PGT-A
11. Discuss the current state of PGT-P across the globe
12. Interpret the current state of PGT-P and the future outlook as more general genomic data becomes available.
13. List some future perspectives on genomics and IVF, including whole embryo sequencing/whole exome sequencing, alternative testing analytes, and genome editing in gametes.





SUNDAY, OCTOBER 20, FULL DAY COURSE 8:00 AM - 5:00 PM

PG08

Highlights for the New or Novice REI Nurse Nurses' Professional Group (NPG)

CME NON-PHYS CME NPWH PSY

FACULTY

Jamie Feingold, MSN, NP-C, WHNP-BC (Chair)
University of Rochester
Jennifer M. Wood, BSN, AAS
Shady Grove Fertility
Caitlin Hebert, RN, BSN
Angela K. Lawson, PHD
Northwestern University

TARGET AUDIENCE

This course is intended to educate Nurses as well new APP's in the REI field.

CREDIT TYPE

CME, Non-PhysCME, NPWH, PSY

NEEDS ASSESSMENT

Recruiting, training, and retaining skilled nurses in REI can be challenging. We need to invest in training our new nurses and immerse them in an environment where they feel like they can collaborate with other nurses in the field as well as interact with different disciplines from diverse practices. This course for the new or novice nurse provides a review of some of the basic information that an REI nurse needs to be competent in their role, gives the new REI nurse exposure to different practice styles, and offers networking with other nurses and practices.

DESCRIPTION

As part of training and investing in our REI nurses, this course reviews the basics of REI nursing, REI biology, the infertility work up, and stimulation protocols; highlights special patient populations in REI; and provides discussion about how the REI nurse needs to take care of not only their patients but also themselves.

ACGME COMPETENCIES

Communication, Teams and Teamwork, Medical Knowledge

LEARNING OBJECTIVES

1. Gain a better understanding of what goes into training and retaining REI while gaining additional knowledge about advancement in REI.
2. Understand the different phases of the menstrual cycle in relation to prepping a patient for their treatment cycle.
3. Explain what is entailed in a comprehensive infertility evaluation.
4. Explain what common test results mean.
5. Gain additional knowledge regarding different types of stimulation protocols.
6. Apply principles of nutrition and lifestyle while caring for the infertility patient.
7. Obtain a deeper understanding of different patient populations such as same sex couples, single women, transgender patients, and patients undergoing fertility preservation.
8. Give consideration to appropriate mental health resources when taking care of the infertility patient.
9. Gain an awareness of how we ensure that, as a health care provider, we are taking care of not only our patients, but also ourselves.





SUNDAY, OCTOBER 20, FULL DAY COURSE 8:00 AM - 5:00 PM

PG09

A Comprehensive Approach to Male Fertility Optimization: Initial Evaluation to Medical & Surgical Interventions Society for Male Reproduction and Urology (SMRU), Society of Reproductive Surgeons (SRS), Access to Care SIG, Fertility Preservation SIG



FACULTY

Akanksha Mehta, MD (Chair)
Emory University School of Medicine
Matt Coward, MD, FACS
Atlantic Reproductive Medicine
Sevann Helo, MD
Mayo Clinic
James F. Smith, MD
UCSF

TARGET AUDIENCE

This course targets clinicians and fertility health care providers (Advanced Practice Nurses, General OB/Gyn) who have interest in male fertility with a beginning or intermediate level of male reproductive health knowledge and provides the latest clinical developments in male fertility for experts in male fertility (Reproductive Urologists, REI).

CREDIT TYPE

ABB/PEER, CME, Non-PhysCME, NPWH, NSGC

NEEDS ASSESSMENT

Of the 15% of couples who struggle to conceive each year, approximately 50% are partially or entirely due to male reproductive problems. Male subfertility is often multifactorial and can include contributions from medical and surgical factors as well as lifestyle and occupational exposures. Early evaluation of these factors is key to helping couples on their fertility journey. Many clinicians lack the knowledge and skills to consistently provide high quality information to patients and appropriately refer to male fertility experts. Current ASRM guidelines recommend a complete male factor evaluation for couples with an abnormal semen analysis. While utilization of ART has steadily increased in recent years, only 20% of male partners receive an evaluation. The role of the reproductive urologist in the modern ART practice is to diagnose serious or life-threatening conditions, identify and treat reversible causes of infertility, define untreatable causes of testis failure and to perform procedures to enable IVF/ICSI. The careful evaluation and successful treatment of male factor infertility leads to optimization of ART outcomes such as improved IUI and IVF success rates through multiple mechanisms including improved semen quality and lower sperm DNA

fragmentation rates.

DESCRIPTION

This course will enable non-fertility specialist clinicians (eg. APP, OB/Gyn, general urologist, trainees) who see patients at the beginning of their fertility journey to be well-informed about male reproductive and sexual health, gain semen analysis interpretation skills, understand barriers (and their mitigation) in access to male reproductive care, and learn when to refer to male reproductive specialists. This course will also present the latest clinical developments in male infertility including advancements in the medical and surgical management of the infertile male. This will highlight the role of the reproductive urologist in optimizing outcomes with the modern ART practice.

ACGME COMPETENCIES

Communication, Roles/Responsibilities, Teams and Teamwork, Interpersonal and Communication Skills, Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement, Systems-based Practice

LEARNING OBJECTIVES

1. Understand the medical and surgical factors associated with male reproductive and sexual health including the basic evaluation.
2. Recognize the general health conditions associated with male reproductive and sexual health and describe when to refer to male reproductive health experts.
3. Develop the expertise to interpret the semen analysis and understand when to refer a patient for further evaluation after obtaining the semen analysis.
4. Understand barriers that exist in the treatment of male reproductive health and help non-fertility and fertility specialists develop the tools they need to break down barriers in access to male reproductive health care.
5. Describe the different types of environmental gonadotoxins that impact male fertility, describe the mechanisms and degree of severity by which gonado toxins affect spermatogenesis, and review the evidence and/or lack of evidence on the cumulative effect of these exposures.
6. Describe the effect of psychological stress on male partner quality of life and gonadal function and review the main clinical studies evaluating stress and male fertility.



SUNDAY, OCTOBER 20, FULL DAY COURSE 8:00 AM - 5:00 PM

PG09
cont.

A Comprehensive Approach to Male Fertility Optimization: Initial Evaluation to Medical & Surgical Interventions

Society for Male Reproduction and Urology (SMRU), Society of Reproductive Surgeons (SRS), Access to Care SIG, Fertility Preservation SIG



LEARNING OBJECTIVES, CONT.

- Outline the potential role of antioxidants in reducing oxidative stress and describe the main clinical trials in antioxidant use for male infertility.
- Understand the impact of male age on reproductive outcomes, learn optimal times to cryopreserve samples for men across the age spectrum, and gain understanding of ways to break down barriers to cryopreservation.
- Summarize the standard of care and cutting-edge techniques for isolating sperm in NOA and OA patients in the andrology lab.
- Review how optimization of male infertility improves sperm retrieval outcomes and determine how to select the optimal sperm retrieval approach for your patient.
- Understand what sperm DNA fragmentation means, learn how to review how abnormal sperm DNA fragmentation impacts natural and assisted reproductive outcomes, and discuss how to lower sperm DNA fragmentation rates.
- Counsel patients about different microfluidic sperm sorting and sperm epigenetic testing options and describe the outcomes which result from these technologies.
- Determine the optimal patient who may benefit from microfluidic sperm sorting and epigenetic testing and review limitations to current sperm sorting and epigenetic testing options.





SUNDAY, OCTOBER 20, FULL DAY COURSE 8:00 AM - 5:00 PM

PG10

MEFS: Recurrent Implantation Failure: Is it Time for Consensus on ‘Consensus Statements’? Middle East Fertility Society



FACULTY

Johnny T. Awwad, MD, HCLD (Chair)
Sidra Medical & Research Center
Mohamed A. Aboulghar, MD
Cairo University, Egyptian IVF Center
Paul Pirtea, MD
Hospital FOCH
Catherine Racowsky, PhD, HCLD
Hospital FOCH

TARGET AUDIENCE

REI and OB/GYN physicians, urologists and other specialty physicians, laboratory scientists and technologists, reproductive biology researchers, geneticists, nurses, business partners, and legal professionals.

CREDIT TYPE

ACOG, CME, Non-PhysCME, NPWH, NSGC

NEEDS ASSESSMENT

Despite significant advances in Reproductive Medicine, endometrial implantation remains the rate-limiting step for a desired reproductive success, and numerous couples still suffer failures despite the repeated replacement of good-quality embryos. The experience of recurrent implantation failure (RIF) represents a heavy burden for couples seeking IVF success. Much is still unknown regarding the causes of implantation failure, and studies on the etiology, evaluation, and management for RIF are often flawed due to the lack of standard criteria and absence of stratification for potential contributing factors. Considering the predominantly idiopathic nature of the condition, the most challenging question is about the value, nature, and timing of any investigation, which in many instances remain very costly and often non-yielding resulting in overdiagnosis and overtreatment. For these reasons, there is an urgent need to look with a fresh new eye at how RIF ought to be defined, identified, investigated, and managed. Unfortunately, the available literature has not produced clinical data of sufficient quality to support a universally agreed definition of RIF and to permit the development of evidence-based clinical guidelines. A ‘Good Practice’ document, based on published research and available expertise, is, nonetheless, required to meet growing challenges at the daily clinical practice level.

DESCRIPTION

This course discusses the physiology of embryo implantation, delves into the potential causes of implantation failure, debates what constitutes a reasonable definition for recurrent implantation failure, and appraises the relevance of immunologic, genetic, anatomical, hematological, microbiological, and endocrinological factors which influence the crosstalk between the embryonic and endometrial interfaces. Many plausible causes are at various stages of research, and very few have clear implications in the treatment of RIF. This course is also intended to highlight the investigations and interventions that require further research to achieve progress for the successful management of RIF.

ACGME COMPETENCIES

Communication, Teams and Teamwork, Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement, Professionalism, Systems-based Practice

LEARNING OBJECTIVES

1. Describe the normal immuno-physiology of Implantation and recognize the physiological pathways responsible for endometrial receptivity.
2. Comprehend pathophysiological mechanisms implicated in failed embryo implantation.
3. List conventional definitions of Recurrent Implantation Failure and appraise them based on insights derived from recent research.
4. Recognize the effects of immunologic, genetic, anatomical, hematological, microbiological, and endocrinological defects on implantation.
5. Analyze the cost benefit of common diagnostic tests and work-up strategies in the management of recurrent implantation failure.
6. Define the embryonal, endometrial, and idiosyncratic factors that contribute to the implantation failure of a euploid embryo.
7. Create consenNHP about what constitutes an acceptable workup for patients with recurrent IVF failures.
8. Debate the strengths and weaknesses of current definitions of recurrent implantation failure.
9. Assess the cost-effectiveness of common therapies for the management of recurrent implantation failure.
10. Discuss the impact of male factor infertility on implantation and the potential contribution to recurrent implantation failure.
11. Discuss the implications of preimplantation genetic testing in couples experiencing recurrent implantation failure.
12. Evaluate the role of advanced diagnostic techniques such as genetic screening, immunological testing, and imaging modalities in recurrent implantation failure.
13. Critically evaluate recent research findings and their potential implications for clinical practice.





SUNDAY, OCTOBER 20, FULL DAY COURSE 8:00 AM - 5:00 PM

PG11

AMMR and ALMER- Integration of Precision Medicine in Reproduction: From Gametes to the Endometrium (Spanish) AMMR and ALMER



FACULTY

Martha Luna Rojas, MD (Chair)
RMA International Mexico, SC

Eduardo Castro Valderrama, MD (Chair)
Medical Director

Alejandro Chavez-Badiola, MD, PhD
Conceivable Life Sciences, IVF 2.0 LTD, NHFC Mexico

Cristian R. Alvarez Sedo, BSc, MSc, PhD
FERTILIA

Nabil Arrach, PhD
Fertility & Genetics

Antonio Vidal Pascual Rodriguez, BSC
Instituto de Ciencias en Reproducción Humana "Vida" - Guadalajara

Gaston J. Rey-Valzacchi, MD
Procreate

Carlos Simon, MD; PhD
Professor Obstetrics and Gynecology, University of Valencia; Senior Lecturer PT, BIDMC Harvard University; President Carlos Simon Foundation

TARGET AUDIENCE

Physicians, Reproductive Specialists, Embryologists, and Nurses

CREDIT TYPE

ABB/PEER, ACOG, CME, Non-PhysCME, NPWH, NSGC

NEEDS ASSESSMENT

The ambition of precision medicine is to design and optimize the pathway for diagnosis, therapeutic intervention, and prognosis by using large multidimensional biological datasets that capture individual variability in genes, function, and environment. This offers clinicians the opportunity to more carefully tailor early interventions—whether treatment or preventative in nature—to each individual patient. Precision medicine increasingly incorporates and integrates data beyond genomics, such as epigenomics, metabolomics, and imaging. Increasingly, the robust use and integration of these modalities in precision medicine require the use of artificial intelligence and machine learning. The increasing knowledge and interpretation of data from biological and genetic analyses will enhance our understanding of physiological or pathological events during oogenesis, spermatogenesis and embryo development and thus promote personalized diagnosis and treatment. This PG course

is designed to offer health professionals in the reproductive field, comprehension and competence on the application of precision medicine for the assessment of oocytes, sperm, embryos, and the endometrium.

DESCRIPTION

Our objective is to introduce concepts related to precision medicine in the reproductive field. To explain how precision medicine can be applied in assessing oocytes, sperm, embryos, and endometrial development. We will review the advantages and limitations when evaluating the phenotypes and genotypes of the gametes, embryos, and endometrium, as well as the benefits/limitations associated to artificial intelligence. We envision that both precision medicine and AI will play a key role in the IVF clinic of the future, improving outcomes but also reducing pregnancy complications and allowing couples to be in better control of their reproductive process.

ACGME COMPETENCIES

Teams and Teamwork, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

LEARNING OBJECTIVES

1. Define the term "Precision Reproductive Medicine" (PRM) and how to implement tools that allow the integration of clinical and genomic data into our daily practice.
2. Identify current challenges to implement PRM in LATAM, such as the training and adaptation to change by physicians and embryologist, the cost of technology, and social, ethical, and regulatory aspects within each country.
3. Correlate morphological features, as well as the genotype of an oocyte, to the reproductive potential it will exhibit during its embryological development.
4. Explain how, through artificial intelligence, we can predict the outcome of an oocyte upon fertilization, which may allow to better counsel patients who are undergoing oocyte cryopreservation or other assisted reproductive techniques.
5. Integrate morphological, genetic, and artificial intelligence features upon evaluating and selecting sperm for ART.
6. Compare different sperm selection techniques and understand advantages and limitations of each
7. Explain early embryo developmental morphology through artificial intelligence with blastocyst development potential and blastocyst ploidy status.



SUNDAY, OCTOBER 20, FULL DAY COURSE 8:00 AM - 5:00 PM

PG11
cont.

AMMR and ALMER- Integration of Precision Medicine in Reproduction: From Gametes to the Endometrium (Spanish) AMMR and ALMER

ABB-PEER ACOG CME NON-PHYS CME NPWH NSCG

LEARNING OBJECTIVES, CONT.

8. Define recurrent implantation failure and understand the current work-up and strategies used in LATAM countries to enhance reproductive outcome in patients with recurrent implantation failure.
9. Recognize endometrial morphological features through ultrasound using artificial intelligence and describe its genetic profile to allow the confirmation of endometrial receptivity and enhance the prediction of achieving implantation.
10. Outline how the implementation of these selection techniques within the gametes, embryos, and endometrium can augment our patients' reproductive outcome, while assuring patients' safety by promoting single embryo transfer.
11. Promote the participation of IVF clinics in LATAM to engage in clinical research within this field.
12. Explain the growth potential of PRM in the near future.





SUNDAY, OCTOBER 20, FULL DAY COURSE 8:00 AM - 5:00 PM

PG12

TSRM: Fine Tuning Frozen Embryo Transfers Turkish Society of Reproductive Medicine



FACULTY

Baris Ata, MD, MSc (Chair)
ART Fertility Clinics
Juan A. Garcia-Velasco, MD, PhD
IVI RMA Madrid
Sezcan Mumusoglu, MD
Hacettepe University
Hakan Yarali, MD
Anatolia IVF and Women's Health Center

TARGET AUDIENCE

Clinicians attending frozen embryo transfer cycles.

CREDIT TYPE

ABB/PEER, CME, Non-PhysCME, NPWH, NSGC

NEEDS ASSESSMENT

The majority of embryo transfer cycles are with vitrified warmed embryos. Yet, optimal frozen embryo transfer protocols individualized to patients' needs remain undefined. While recent studies suggest ovulatory cycles can be more effective and safer, the need for close monitoring and limited flexibility remain problems. Inappropriate protocol choice or inadequate monitoring limits live birth rates as well as increasing the risks for obstetric complications. Having more insight about comparative advantages of ovulatory vs programmed cycles, monitoring methods for natural cycles, scheduling and flexibility of natural cycles, and effectiveness of luteal support will enable patient and purpose tailored protocols that optimize effectiveness, safety, and scheduling needs.

DESCRIPTION

The course will cover all aspects of frozen embryo transfer cycles, including the design of the stimulation protocol for a freeze all cycle, comparisons of ovulatory vs programmed cycles in different patient characteristics, monitoring of natural cycles, scheduling options for programmed and ovulatory cycles, and luteal support. The course is designed as a team based learning activity. The participants will be divided to round tables to discuss course topics with moderation by faculty. At the end of each session, teams will present their conclusions on the subject for larger group discussion. The course will conclude with real-life case discussions.

ACGME COMPETENCIES

Medical Knowledge, Patient Care and Procedural Skills

LEARNING OBJECTIVES

1. List indications of a freeze-all cycle.
2. Distinguish between elective and non-elective freeze-all.
3. Compare the advantages and disadvantages of different ovarian stimulation protocols for planned (non-elective) freeze-all cycles.
4. Describe the advantages and disadvantages of ovulatory endometrial preparation protocols (i.e., natural or stimulated cycles) for frozen-thawed embryo transfer compared to programmed (a.k.a., hormonal or artificial) cycles.
5. Illustrate a programmed cycle for frozen thawed embryo transfer.
6. Demonstrate a flexible schedule and a programmed cycle while maintaining its efficacy.
7. Assess the need for individualized luteal phase support in programmed cycle
8. Compare the advantages and disadvantages of modified natural and true natural cycle endometrium preparation protocols.
9. Plan and monitor the modified natural cycle for a frozen thawed embryo transfer.
10. Explain the advantages and disadvantages of alternative methods (such as LH, progesterone, ultrasonography) for monitoring the true natural cycle for frozen thawed embryo transfer.
11. Evaluate the need for luteal support in natural cycles (i.e., true natural and modified natural cycles).
12. Design an ovarian stimulation protocol for frozen-thawed embryo transfer.
13. Select the appropriate protocol according to the patient's characteristics and needs.





SUNDAY, OCTOBER 20, FULL DAY COURSE 8:00 AM - 5:00 PM

PG13

IFS and ISAR: “Fertile Horizons- Mastering Ovulation Induction for ART Success”

Indian SIG, IFFS, and ISAR



FACULTY

Nandita Palshetkar, MD (Chair)
Bloom IVF
Ameet Shashikant Patki, MD, DNB, FRCOG
Medical Director
Kanad Dev Nayar, MD, DGO, Dip.Obst.(Ire), FICOG
Akanksha IVF Centre
Kuldeep Jain, MD
Fellowship, ART - KJIVF and Laparoscopy Center

TARGET AUDIENCE

Post Graduates, Clinicians, Fellows, Embryologists

CREDIT TYPE

ABB/PEER, CME, Non-PhysCME, NPWH

NEEDS ASSESSMENT

The practice gap addressed by this course lies in the variable knowledge and skill competency among healthcare professionals involved in assisted reproductive technologies (ART), particularly in the realm of ovulation induction. Clinical significance arises from the pivotal role of controlled ovarian hyperstimulation in ART success, as inadequate knowledge and skills may result in suboptimal patient outcomes. This gap is prevalent, impacting reproductive specialists, gynecologists, and embryologists globally. The course aligns with ASRM’s “Gap Analysis and Educational Needs for Planning” by focusing on the identified need for enhanced education in ovarian stimulation protocols and monitoring techniques. With evolving evidence and updated guidelines in the field, the course provides a platform for practitioners to integrate the latest knowledge into their practices, fostering improved patient care and outcomes in the dynamic landscape of assisted reproduction.

DESCRIPTION

This comprehensive 8-hour course on ovulation induction in ART delves into menstrual cycle physiology, various stimulation protocols, and monitoring techniques. Participants will explore the nuances of ovarian function, learn to tailor stimulation protocols, and understand the complications and alternative approaches. Activities include case studies and interactive discussions. By bridging the practice gap identified in ART education, participants will gain enhanced knowledge and competency in ovarian stimulation, empowering them to optimize patient outcomes. Ultimately, this course aims to elevate participants’ skills, ensuring a more proficient and confident approach to ovulation induction in assisted reproductive technologies.

ACGME COMPETENCIES

Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement, Systems-based Practice

LEARNING OBJECTIVES

1. Understand ovarian physiology.
2. Master stimulation protocols.
3. Refine monitoring techniques.
4. Mitigate risks and complications.
5. Explore alternative approaches.
6. Optimize ovulation triggering.
7. Enhance OPU procedures.
8. Apply evidence-based practices.





SUNDAY, OCTOBER 20, HALF DAY COURSE 1:00 PM - 5:00 PM (NO LUNCH)

PG14

ESHRE: Genetic Testing in Assisted Reproduction ESHRE



FACULTY

Antonio Capalbo, PhD (Chair)
Juno Genetics
Nicolas Garrido Puchalt, MSc, PhD
IVI Foundation - Instituto de Investigación Sanitaria La Fe (IIS La Fe)
Efthymia Constantinou, MSc, MBA
The Cyprus Institute of Neurology and Genetics

TARGET AUDIENCE

This course is designed for reproductive medicine specialists: gynaecologists, andrologists, genetic counsellors, embryologists, medical and laboratory geneticists, nurses, and researchers who want to broaden their knowledge on the latest findings about the genetic causes of male and female infertility in human, identifying carriers of genetic disorders and preimplantation genetic testing for monogenic defects and chromosomal abnormalities.

CREDIT TYPE

ABB/PEER, CME, Non-PhysCME, NPWH, NSGC

NEEDS ASSESSMENT

The use of genetic testing in reproductive medicine has been expanding with the aim of improving the understanding, detection, and prevention of infertility and genetic disease. The field of reproductive health has extremely benefited by the application of genomic approaches for a precise genetic diagnosis. Nowadays, 10% of infertility cases are still classified as idiopathic infertility. As an increasing number of couples go through medical assisted reproduction, new pathological endophenotypes have been uncovered that may disrupt the development of gametes and embryos, and their investigation encourages a better understanding of the role of genetics in infertility. Other genetic testing applications have also significantly evolved through the years. This course addresses the need to understand key genetic testing approaches in reproductive medicine and discuss issues associated with their implementation. In particular, the course will aim to demonstrate how the diagnosis of male and female infertility can be improved by current genetic testing approaches and to discuss what technologies and approaches may be available for detecting genetic disease through ECS and PGT, their advantages, and limitations.

DESCRIPTION

This course will present the latest developments in the application of genomics in reproductive medicine. Attendees will learn about the genetics of male and female infertility, the expanding role of sequencing techniques and their application in reproductive medicine from preconception to embryo implantation, and prenatal diagnosis, by using ECS and PGT as main approaches for detecting and dealing with genetic conditions. The course will highlight how genomic medicine can optimize diagnosis and treatment of infertility and improve reproductive decision making.

ACGME COMPETENCIES

Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement

LEARNING OBJECTIVES

1. Describe reproductive genomics approaches in a clinical setting.
2. Explain the use of genomics in preconception by using ECS and PGT.
3. Discuss the use of genomics in preimplantation and prenatal prevention of diseases by using ECS and PGT.
4. Utilize the updated knowledge in genetic counselling of infertile couples.
5. Apply evidence presented to provide the best possible care to the patient.
6. Summarize the role of the latest genetic discoveries in the investigation/assessment of infertility.
7. Describe how to critically analyze papers assessing clinical utility of pre-conception and pre-implantation genomic tests.
8. Name the available guidelines for the design of a gene panel for carrier screening purposes.



SUNDAY, OCTOBER 20, HALF DAY COURSE 1:00 PM - 5:00 PM (NO LUNCH)

PG15

Integrating Open Donor Options Into Your Practice Mental Health Professional Group (MHPG),
Legal Professional Group (LPG)



FACULTY

Lisa S. Schuman, LCSW (Chair)
The Center for Family Building
Mark P. Leondires, MD
Illume Fertility
Daragh Castaneda, BA
Inception Fertility - Pacific Fertility Center

TARGET AUDIENCE

Mental Health Professionals, Reproductive Endocrinologists,
Nurses, Practice Managers, and Patient Navigators

CREDIT TYPE

ABB/PEER, ACOG, CME, Non-PhysCME, NPWH, NSGC

NEEDS ASSESSMENT

Historically, the main objective for most fertility specialists has been to attain a healthy pregnancy. However, openness and connection between donors, recipients, offspring, and donor related siblings is increasing rapidly and will soon be commonplace. Direct to consumer genetic testing made the promise of anonymity impossible, and all parties affected have voiced the many ways "anonymous programs" have caused difficulties for all involved who are searching for connection and information. LGBTQIA+ and single individuals pursuing parenthood have increased in recent years, and those patients typically support open options from the start. Last, research has demonstrated that children fare best when they understand their origins from a young age; therefore, the number of those desiring connection is likely to continue to increase. Donors have also been affected as they are often not prepared for the lifetime implications of donating their gametes. For programs to help these future families, open donor options and donor education should be offered more widely. This presentation will also ensure that the challenges related to providing more opportunities for identity release in egg donation programs are addressed for donors and recipients of color.

DESCRIPTION

This course will educate the audience about changes in the donor conception landscape and why changing their perspective to include a new paradigm is important. They will learn options for helping the families they create have healthy connections and consider an improved consent process for donors to help them make clearer decisions about the families they help bring into being. Open donor models and informed consent examples will be offered. The audience will be given the opportunity to use the information they learn to create new options for their programs in a small group format.

ACGME COMPETENCIES

Communication, Roles/Responsibilities, Teams and Teamwork,
Interpersonal and Communication Skills, Systems-based Practice

LEARNING OBJECTIVES

1. Identify the ways in which the world of donor conception has changed and why anonymity can no longer be guaranteed.
2. Explain the future implications of these changes for the donors, recipients, offspring, and genetic relatives.
3. Describe new information to include in recipient counseling and donor screening.
4. Describe the benefits and challenges of maintaining an anonymous donor program.
5. Summarize the process of creating an open donor program and the benefits of a collaborative team approach.
6. Recommend options for an open donor program in a clinic setting.
7. Differentiate donor and recipient options within a clinic donor program.
8. Assess donor and recipient options and challenges in an egg bank.
9. Name three ways openness can work in a clinic.





SATURDAY, OCTOBER 19, HALF DAY COURSES 1:00 PM - 5:00 PM (NO LUNCH)

HOC-01

Automating Success: Revolutionizing IVF Lab Practices with AI and Automation- A Hands On Workshop

ABB-PEER

FACULTY

Hadi Shafree, PhD (Chair)
Division of Engineering in Medicine, Harvard Medical School
Daniella Gilboa, MSc
AIVF
Gerard Letterie, MD
Seattle Reproductive Medicine

TARGET AUDIENCE

This course is designed to educate reproductive endocrinologists, embryologists, IVF lab directors, and other ART professionals on AI applications in assisted reproductive technologies.

CREDIT TYPE

ABB-PEER

NEEDS ASSESSMENT

This hands on course will address the ASRM-identified gap in unbiased education on Artificial Intelligence (AI) integration in IVF labs and will address the common deficiency among embryologists in effectively utilizing AI and automation. Additionally, this course offers an objective evaluation of current AI technologies for embryo selection and for workflow automation. By providing insights from experts in the fields of AI and ART along with real-world perspectives, participants will gain the knowledge needed to strategically adopt validated AI applications, thus bridging the gap between hype and utility, ultimately improving patient care and advancing reproductive medicine in alignment with ASRM's objectives.

DESCRIPTION

In the rapidly advancing field of embryology, the integration of Artificial Intelligence (AI) and automation, such as timelapse microscopy or cryostorage has become increasingly significant. This proposal aims to combine two crucial aspects: the introduction of AI in embryology for embryo evaluation and the provision of necessary resources for hands-on learning. By leveraging AI tools alongside innovative technology and training resources, we can enhance the accuracy, efficiency, and decision-making processes within embryology practices.



SUNDAY, OCTOBER 20, FULL DAY COURSES 8:00 AM - 5:00 PM

HOC-02

Hands-On Surgical Techniques in Male Infertility Microsurgery Society for Male Reproduction and Urology (SMRU) with in-kind support from Nikon, Ethicon, Olympus, and ASSI.



FACULTY

Richard Schoor, MD (Chair)
NYU Langone Hospital- Long Island
David Shin, MD
Hackensack University Medical Center
Sheldon Marks, MD
International Center for Vasectomy Reversal

TARGET AUDIENCE

This course is designed for urologists with some experience in microsurgery who are motivated to improve their skills.

CREDIT TYPE

Non-Physician CME
CME

NEEDS ASSESSMENT

While microsurgery cannot be mastered in a day, microsurgery skills can be improved upon readily. Many urologists get little to no microsurgery training throughout their residency programs, for a number of reasons. Aside from a handful of varicocelectomy surgeries, most graduates of urology residencies will see very few vasovasostomy or epididymovasostomy surgeries, let alone perform even one. Even at the fellowship level, the number of vasectomy reversal surgeries done per year per fellow has been in decline and, with only a few exceptions, many fellows complete their fellowships with less than 10 vasectomy reversal surgeries under their belts. When they get into practice, it can take a decade or longer to build up a sufficient volume of vasectomy reversals to remain confident and proficient in one's skills. During that interval, skills can decline, and important techniques can be forgotten; techniques that can make the difference between success and failure.

DESCRIPTION

With our "boot camp" intense immersion course, attendees of any skill level will attain proven valuable tips, tricks, and tools from experienced microsurgeons that they can take back to their own practices and patients. Over an 8 hour period, our course exposes trainees and urologists at any skill lever to microsurgical techniques, instrumentation selection, and simulated surgery in a hand's on manner. Attendees will leave this course as better microsurgeons. In addition, attendees will receive valuable training in the business skills needed to develop, maintain, and grow a world class vasectomy reversal and andrology practice.





SUNDAY, OCTOBER 20, FULL DAY COURSES 8:00 AM - 5:00 PM

HOC-03

Cryopreservation in Practice: Hands-on Training in Vitrification and Slow Freezing of Reproductive Tissues ARTLAB IVF Training Center, World Embryology Training & Skills & Embryology and Andrology Training - IVF Academy. In-kind support from Hamilton Thorne, IVF Store and ART/LAB.



FACULTY

Eva Schenkman, PhD (Chair)
ARTLAB Consulting
Laura Detti, MD
Baylor College of Medicine
Liesl Nel-Themaat, PhD, MBA, HCLD
Stanford University
Helen Picton, BSc, PhD
University of Leeds

TARGET AUDIENCE

This course is designed to educate reproductive medicine specialists, embryologists, cryobiologists, and clinical lab technicians on practical techniques for cryopreserving ovarian and testicular tissues.

CREDIT TYPE

Non-Physician CME
CME
ABB-PEER

NEEDS ASSESSMENT

Hands-on training in cryopreservation protocols is lacking in many IVF labs, despite growing demand for fertility preservation services. Practical skills development is needed to translate theoretical knowledge into proficient technique. This course addresses the need for standardized training to improve staff competency in ovarian and testicular tissue cryopreservation. Participants will master best practice techniques through an intensive curriculum focused on optimizing every step of the protocol. Hands-on sessions will reinforce lectures on current evidence for vitrification, slow freezing, cryoprotectant perfusion, cooling/warming rates, storage, and thawing. By bridging gaps between theory and practice, this course strengthens participant proficiency in reproductive tissue cryopreservation. The ultimate goal is to equip lab staff with the specialized skills necessary to achieve excellent outcomes for patients seeking fertility preservation. Participants will be prepared to implement standardized techniques that align with current evidence upon returning to their labs.

DESCRIPTION

This intensive hands-on course will build competency in cryopreserving reproductive tissues. Through lectures and lab sessions, participants will learn protocols and techniques for optimized vitrification and slow freezing of ovarian and testicular tissues. Topics span harvesting, cryoprotectant perfusion, cooling/warming rates, storage, and thawing. Participants will gain increased knowledge of cryopreservation principles and hands-on skills. By bridging theory and practice, this course improves cryopreservation performance and addresses gaps in practical lab training for preserving reproductive tissues.





Needs Assessment and Description

ASRM 2024 Scientific Congress & Expo is focused on “Equity, Access, and Innovation.” This comprehensive program caters to the educational and career development needs of professionals across the field of reproductive medicine. This inclusive program offers skill-building through advanced hands-on courses, profession-specific breakout sessions, interactive symposia, dynamic sessions led by experts in our field, and hot-topic special sessions.

The meeting advances knowledge related to all areas of reproductive medicine, from female and male fertility and infertility to menopause, cryopreservation, and innovative research moving the field forward. Attendees will identify and gain strategies to improve access to reproductive health services while exploring the unique needs of diverse populations and marginalized communities. Experts will share experiences through case-based learning and lead discussions around the ethical and legal issues impacting clinical care. The ASRM 2024 Scientific Congress & Expo will arm attendees with cutting-edge approaches to advance their practice, increase awareness of artificial intelligence (AI) to better serve patients, and share knowledge about advancements in reproductive medicine.

We look forward to a dynamic and impactful Congress that stimulates skill-building, knowledge-sharing, and collaboration that will move the field of reproductive medicine forward.

LEARNING OBJECTIVES

At the conclusion of the Scientific Congress, participants should be able to:

1. Explain how REI practices can promote equitable access to reproductive health services through innovative approaches.
2. Apply strategies to improve access to reproductive health services, considering diverse patient populations and geographical contexts.
3. Investigate innovative approaches, technologies, and advancements in reproductive medicine, fostering creativity and progress in the field.
4. Review the latest scientific advances in embryo biology and assessment of the optimization of embryo transfer.
5. Describe the ethical, legal, and psychosocial ramifications of third-party reproduction.
6. Discuss current knowledge of endometriosis, fibroids, recurrent pregnancy loss, contraception, and polycystic ovary syndrome.
7. Explain the relevance of genetics and genomics to reproductive care.
8. Propose appropriate treatments for reproductive dysfunctions in females and males at different ages throughout life-childhood, adolescence, adulthood, and reproductive senescence.

ACGME COMPETENCIES

Practice-based learning and improvement
Interpersonal and communication skills
Patient care
Medical knowledge
Professionalism
Systems-based practice

INTERPROFESSIONAL COMPETENCIES

Values/ethics for interprofessional practice
Roles/responsibilities
Interprofessional communication
Teams and teamwork





Scientific Congress
DAILY SCHEDULE

Monday, October 21, 2024

6:45 AM - 7:45 AM

ASRM 2024 Opening Ceremony
Continental Breakfast

7:45 AM - 8:30 AM

ASRM 2024 Opening Ceremony

8:30 AM - 9:15 AM

Plenary President's Guest Plenary Lecture:
Embryo Models from Stem Cells- The
Principles of Self-Organization
Endowed by Ortho Women's Health



Magdalena Zernicka-Goetz, PhD
California Institute of Technology

9:15 AM - 10:00 AM

Plenary Herbert H. Thomas Plenary Lecture:
Shaping the Future of Gender-Diverse and
Women's Health : A Roadmap for Equity
and Innovation

Endowed by Ortho Pharmaceutical Corporation



Laurie Zephyrin, MBA, MD, MPH
Commonwealth Fund

10:00 AM - 10:45 AM

Monday Morning Break

10:45 AM - 11:45 AM

Interactive Sessions

It's New, but Is It True? Assessing the
Value of Newly Marketed Technologies
in Fertility Care



Eve C. Feinberg, MD (Chair)
Northwestern University Feinberg School of Medicine
Jessica R. Walter, MD, MSCE
Northwestern University Feinberg School of Medicine
Jessica B. Spencer, MD, MSc
Emory Reproductive Center

Diversity and Inclusion: What Can
We Do Better? - A Discussion
Utilizing the SART Registry Research



Jennifer F. Kawwass, MD (Chair)
Emory University (Emory GYN / OB, Emory
Reproductive Center)
Phillip A. Romanski, MD
RMA of New York
Steven D. Spandorfer, MD
NewYork-Presbyterian Hospital/Weill Cornell Medical
Center; Daniela Diego, MD, Emory University

Clinical Sessions

LPG: Navigating Post Dobbs: What Should
Clinics Do in the Changing Landscape



Nidhi Desai, JD (Chair)
Desai & Miller
Angela K. Lawson, PhD
Northwestern University
Sangita K. Jindal, PhD
Montefiore Institute for Reproductive Medicine and
Health and University of Washington

NPG: Make Every Minute Count!



Rebekah J. Huff, MS, RNC (Chair)
Nurse Manager
Sara Mooney, BA
Practice Administrator
Jennifer M. Wood, BSN, AAS
Shady Grove Fertility

GCPG: Clinical and Legal Aspects of PGT-M
Testing in the IVF Clinic



Amy C. Vance, MS, CGC (Chair)
Bay Area Genetic Counseling
NH Pan L. Crockin, JD
Georgetown Law Center
Crockin Law & Policy Group
Jeanne E. O'Brien, MD
Shady Grove Fertility
Amy Jordan, MS, LCGC
Luminary Genetics

APPPG: Professional Development of
an REI Advanced Practice Provider -
How to be Involved within the Clinic and
Outside of the Office



Shana Perman, PA-C (Chair)
Shady Grove Fertility
Nicole K. Callahan, MS, NP
Mayo Clinic

MHPG: Ethical and Cultural Considerations
in Reproductive Care



Angela R. Bethea-Walsh, PhD (Chair)
Bethea Consulting and Psychological Services, P.C.

10:45 AM - 12:00 PM

Symposia

ESHRE: Polygenic Embryo Scores (PES)



Antonio Capalbo, PhD (Chair)
Juno Genetics
Antonio Capalbo, PhD
Juno Genetics
Anja Bisgaard Pinborg, MD, PhD
Fertility Clinic

Optimizing Sperm Selection: Integrating
Established and Emerging Techniques



Denny Sakkas, PhD (Chair)
Boston IVF
James M. Hotaling, MD
University of Utah
Alejandro Chavez-Badiola, MD, PhD
New Hope Fertility Center Mexico

Mullerian Anomalies: Review of the
New Classification System, Optimal
Imaging Techniques and Surgical Pearls



Samantha M. Pfeifer, MD (Chair)
Weill Medical College of Cornell University
Maribel Acien, Prof.
San Juan University Hospital
Miguel Hernandez, University
Jacqueline Carla Yano, MD
National Institute of Child Health and Human
Development



Scientific Congress
DAILY SCHEDULE

Monday, October 21, 2024

10:45 AM - 12:15 PM

Abstracts

2024 Scientific Congress Prize Paper (1 of 2)

Oral Abstract Session: Business of Medicine & Professional Development

Oral Abstract Session: Genetics- PGT (1 of 2)
Oral Abstract Session: Fertility Preservation-General (1 of 2)

Oral Abstract Session: ART- Lab

Oral Abstract Session: Pre-Clinical and Basic Research- Animal Models

Video Abstract Session: Surgery

Oral Abstract Session: Advance Practice Providers (1 of 2)

Oral Abstract Session: Genetic Counseling (1 of 3)

Oral Abstract Session: Law, Policy, and Advocacy (1 of 3)

Oral Abstract Session: Mental Health (1 of 3)

Oral Abstract Session: Nursing (1 of 3)

12:20 PM - 1:20 PM

Monday Lunch Break

Live Events

Roundtables TICKETED EVENT
RTT-01 - RTT-27

Journal Club Global

1:30 PM - 2:15 PM

Plenary

Menopause Keynote Lecture: "Everyone is Different": Addressing Menopause Disparities and Inequities Across Race and Ethnicity

Endowed by AstraZeneca



Yamnia Cortes, PhD, MPH, FNP-BC, FAHA
University of Iowa

David and Rosemary Adamson Excellence in Reproductive Medicine Lecture: Weathering Inequities and Their Impact on Maternal and Infant Health Outcomes Among Black and other Marginalized Birthing People in the United States



Arline T. Geronimus, ScD
University of Michigan

1:30 PM - 2:30 PM

Interactive Sessions

Balancing the Scale: A Weight-Inclusive Approach to Address Obesity in Male and Female Infertility



Bobby Najari, MD (Chair)
New York University Grossman School of Medicine
Richard S. Legro, MD
Penn State College of Medicine
Emily S. Jungheim, MD
Feinberg School of Medicine

Rebiopsy: When is it Beneficial?



Paulina Nassab, MS, CGC (Chair)
Igenomix
Colleen A. Lynch, PhD
CooperSurgical Fertility Solutions
Kim Skellington, MS
Modern Reproduction

1:30 PM - 2:45 PM

Symposia

Integrated Behavioral Health Care in Reproductive Medicine: How and Why to Include Mental Health Professionals in Infertility Care Teams



Julia T. Woodward, PhD (Chair)
Duke University Fertility Center
Lisa A. Rinehart, JD, RN
US Fertility
Paul C. Lin, MD
Seattle Reproductive Medicine

Uterus Transplantation: Preparing for the Next 100 Procedures



Elliott G. Richards, MD, PhD (Chair)
Cleveland Clinic
Liza Johannesson, MD, PhD
Baylor University Medical Center
Kathleen O'Neill, MD
University of Pennsylvania

MEFS: Artificial Intelligence in ART: Concepts, Applications and Regulations



Johnny T. Awwad, MD, HCLD (Chair)
Sidra Medical & Research Center
Botros Rizk, MD, HCLD (Chair)
Elite IVF Center
Piotr Sankowski, PhD
Professor
Nikica Zaninovic, PhD
Weill Medical College of Cornell University
Charles L. Bormann, PhD
Massachusetts General Hospital Fertility Center,
Massachusetts General Hospital and
Harvard Medical School

Live Event

The Best of Fertility and Sterility 2024

Juan C Farfan, MD, PhD
Instituto Bernabeu
Charles A. Easley IV, PhD
University of Georgia
Florence Belva, MD, PhD
Manuel Viotti, PhD
Kindlabs (Kindbody)/Zouves Foundation
Sarah D Cascante, MD
NYU School of Medicine



Scientific Congress
DAILY SCHEDULE

Monday, October 21, 2024

Abstracts

2024 Scientific Congress Prize Paper
(2 of 2)

Oral Abstract Session: SMRU Traveling
Scholars

Reproductive Medicine (Non Infertility)-
PCOS and Menopause

Oral Abstract Session: Health Disparities &

Health Equity- General (1 of 2)

Oral Abstract Session: ART-Outcomes

Oral Abstract Session: Pre-Clinical
and Basic Research- Stem Cells and
Regenerative Medicine

2:45 PM – 3:30 PM
Monday Afternoon Break

3:00 PM – 5:00 PM

Live Event

SMRU Early Career & Fellows Symposium

Ryan P. Smith, MD (Chair)
University of Virginia

Joshua A. Halpern, MD
Posterity Health

James F. Smith, MD
UCSF

Linnea R. Goodman, MD
RMANJ

Matt Coward, MD, FACS
Atlantic Reproductive Medicine

Aaron Spitz, MD
Private Practice

Kathleen Hwang, MD
University of Pittsburgh Medical Center

James M. Dupree, MD, MPH
University of Michigan

James M. Hotaling, MD
University Of Utah

Akanksha Mehta, MD
Emory University School of Medicine

Cigdem Tanrikut, MD
Shady Grove Fertility

3:30 PM – 4:30 PM

Interactive Sessions

Opening our Doors: A
Collaboration on Expanding Access

NSCG NPWH PSY ACOG CME NON-PHYS CME

Amanda Adeleye, MD (Chair)
The University of Chicago

Serena H. Chen, MD
Division Director Reproductive Medicine

April M. Rutter
Hera Fertility

3:30 PM – 4:45 PM

Symposia

Ovarian Tissue Cryopreservation and
Auto-transplantation: From Retrieval to
Restoration

NSCG NPWH ACOG CME NON-PHYS CME

Joseph M. Letourneau, MD (Chair)
University of Utah

Helen M. Picton, PhD
University of Leeds

Kutluk H. Oktay, MD, PhD
Yale University School of Medicine

Understanding the Science and Genetic
Counseling Approach for Mosaic Embryos
to Better Support Our Patients' Decision-
Making

NSCG NPWH PSY ACOG CME NON-PHYS CME

Amy C. Vance, MS, CGC (Chair)
Bay Area Genetic Counseling

Manuel Viotti, PhD
Kindlabs (Kindbody)/Zouves Foundation

Claudia Pascale, PhD
Reproductive Mental Health Associates

Protecting the Rights of Vulnerable
Families in the Current Legal Climate:
Legal Ethical and Medical Considerations

NASW NSCG PSY ACOG CME NON-PHYS CME

Heather E. Ross, JD (Chair)
Ross & Zuckerman, LLP

Lauri Pasch, PhD
University of California, San Francisco

Jennifer Hirshfeld-Cytron, MD, MSCI
Northwestern University Feinberg School of Medicine,
Department of Obstetrics and Gynecology, Division of
Reproductive Endocrinology and Infertility

CFAS: Microbiotas, Biomarkers, and
Endometriosis

NSCG NPWH ACOG CME NON-PHYS CME

Alex Lagunov, MSc (Chair)
CCRM IVF

Jocelyn Marika Wessels, PhD
McMaster University

Sony Sierra, MD
University of Toronto

Abstracts

Oral Abstract Session: Surgery

Oral Abstract Session: Technology &
Innovation

Oral Abstract Session: Genetics- PGT
(2 of 2)

Oral Abstract Session: Health Disparities &
Health Equity- General (2 of 2)

Oral Abstract Session: Infertility- General

4:45 PM – 6:15 PM

Live Event

ASRM Society Social Hour



Scientific Congress
DAILY SCHEDULE

Tuesday, October 22, 2024

6:30 AM – 7:30 AM

Live Event

Women’s Council Breakfast

8:30 AM – 9:15 AM

Plenary

Camran Nezhat, MD, Lectureship in Innovations in Medicine: Are Robots Coming for Our Jobs? How AI is Revolutionizing Obstetric Ultrasound

Dr. Camran Nezhat pioneered the technique of video-assisted endoscopy, which revolutionized modern-day surgery. He performed some of the most advanced procedures with this technique for the first time, and by doing so, he opened up vistas for endoscopic surgeons all over the world.

NSCG NPWH ACOG CME NON-PHYS CME

Jeffrey S. A. Stringer, MD
UNC School of Medicine

9:15 AM – 10:00 AM

Plenary

SSR Keynote Lecture: Environmental Endocrine Disruptors and Female Reproductive Aging

NSCG NPWH ACOG CME NON-PHYS CME

Jodi A. Flaws, PhD
Department of Comparative Biosciences,
University of Illinois

10:00 AM – 10:45 AM

Tuesday Morning Break

10:45 AM – 11:45 AM

Clinical Sessions

APPPG: Perfecting an APP’s Craft: Tips and Tools for HSG, Office Hysteroscopy, SIS, and 3D Ultrasound

NPWH

Tamara Tobias, NP (Chair)
Seattle Reproductive Medicine
Anne R. Judge, NP
Seattle Reproductive Medicine – Kirkland
Hayley Rapp, DNP
Reproductive Medicine Associates of New Jersey

GCPG: Demystifying the Significance of Segmental Aneuploidy: How Close Are We?

NSCG NPWH

Rawan I. Awwad, MS, CGC (Chair)
Fairfax EggBank
Amber Gamma, MS
IVI RMA America
Tony Gordon, PhD

LPG: Equity in 3rd Party Reproduction: Understanding Barriers and Identifying Strategies in Maximizing Coverage and Care for Underserved Communities

NSCG NPWH

Amani Hanson, JD, MBA (Chair)
Hanson Reproductive Law
Tarun Jain, MD
Northwestern University
Barbara Lynn Collura, MA
RESOLVE: The National Infertility Association

MHPG: Weathering as Potential Stressor in Reproductive Medicine- Should We Be Talking about Stress Differently? Implications for Medical Treatment and Mental Health

NASW NSCG NPWH PSY

Dr. Loree Johnson, PhD, LMFT (Chair)
Independent Practice
Karenne Fru, MD, PhD
Oma Fertility

NPG: Managing Patient Expectations

NSCG

Caitlin Hebert, RN, BSN (Chair)
Shady Grove Fertility
Lindsey N. McBain, BA
IVI, RMA

Interactive Sessions

AI, Digital Transformation and Robotics: Current Status and Future Trends in Reproductive Care

NSCG ACOG CME NON-PHYS CME

Carol Lynn Curchoe, PhD, HCLD (Chair)
ART Compass
Cristina Hickman, PhD
Fairtility

Vantage Points: A Human Resources Discussion from Every Angle

ACOG CME NON-PHYS CME

Hary Hokianto, MBA (Chair)
Boston IVF
Mahshid Albrecht, MBA
UC San Diego Health
Annemarie Paradise, MSHRM
IVIRMA

10:45 AM – 12:00 PM

Symposia

KSRM: Innovative Treatment Approaches for Ovarian Dysfunction

NSCG NPWH ACOG CME NON-PHYS CME

Jung Ryeol Lee, MD, PhD (Chair)
Department of Obstetrics and Gynecology, Seoul National University College of Medicine
Young Sik Choi, MD, PhD
Severance Hospital, Yonsei University College of Medicine
Ji Hyang Kim, MD, PhD
Fertility Center, CHA Bundang Medical Center, CHA University

Reproductive Considerations for Men and Women with Chronic Disease, from Getting Pregnant to Giving Birth and Beyond

NSCG NPWH PSY ACOG CME NON-PHYS CME

Nannan Thirumavalavan, MD (Chair)
University Hospitals Cleveland Medical Center/Case Western Reserve University
Manesha Putra, MD
University of Colorado Anschutz Medical Campus
Rachel NHPan Weinerman, MD
University Hospitals Fertility Center/Case Western Reserve University

10:45 AM – 12:15 PM

Abstracts

Oral Abstract Session: SART CORS

Oral Abstract Session: Fertility Preservation-General (2 of 2)

Oral Abstract Session: Health Disparities & Health Equity- Underrepresented and Underserved Populations



Scientific Congress
DAILY SCHEDULE

Tuesday, October 22, 2024

Abstracts, cont.

Oral Abstract Session: ART- General

Oral Abstract Session: Infertility- Diagnosis & Treatment

Oral Abstract Session: Pre-Clinical and Basic Research (2 of 2)

ASRM Research Institute: Researcher Spotlight

Video Abstract Session: ART and Surgery

Oral Abstract Session: Advance Practice Providers (2 of 2)

Oral Abstract Session: Genetic Counseling (2 of 3)

Oral Abstract Session: Law, Policy, and Advocacy (2 of 3)

Oral Abstract Session: Mental Health (2 of 3)

Oral Abstract Session: Nursing (2 of 3)

12:20 PM - 1:20 PM
Tuesday Lunch Break

Live Event

Roundtables TICKETED EVENT RTT-01 - RTT-27

1:30 PM - 2:15 PM

Plenary

Contraception Keynote Lecture: Policy Solutions to Promote Equitable Contraceptive Access

Endowed by Tap Pharmaceutical



Maria Isabel Rodriguez, MD, MPH
Oregon Health & Science University

SRS Keynote Lecture: MAC 2021 and Management of Mullerian Anomalies
Endowed by Ethicon Endo-Surgery



Samantha M. Pfeifer, MD
Weill Medical College of Cornell University

1:30 PM - 2:30 PM

Interactive Sessions

Keeping Your Cool When Things Get Hot: Supporting Patient in Perimenopause



Danielle A. Kaplan, PhD (Chair)
NYU Langone School of Medicine
Piave Pitisci Pitisci Lake, MD
Piave Pitisci Lake, MD, LLC

When is a Good Time to Discuss Family Planning Goals for LGBTQ+ Individuals?



Bhuchitra Singh, MD, MPH, MBA (Chair)
Johns Hopkins University School of Medicine
Brent Monseur, MD, ScM
Stanford University School of Medicine
Amelia Swanson, PhD
Health Psychology Associates of Illinois PLLC

Interactive Sessions

ESHRE/ASRM 2024 Premature Ovarian Insufficiency (POI) Guidelines- New Data and Updated Recommendations

Amanda Nicole Kallen (Chair)
University of Vermont Larner College of Medicine
Marcelle I. Cedars
University of California San Francisco

1:30 PM - 2:45 PM

Abstracts

Oral Abstract Session: Benign Gynecological Disease- Endometriosis and Adenomyosis

Oral Abstract Session: Reproductive Urology (1 of 2)

Reproductive Medicine (Non Infertility)-

General

Oral Abstract Session: Infertility- Outcomes

Oral Abstract Session: ART- Artificial Intelligence

Symposia

Strengthening Infertility on the Global Health Agenda: A Joint WHO/ASRM Symposium



Paula Amato, MD (Chair)
Jared Robins, MD, MBA (Chair)
Oregon Health & Science University
American Society For Reproductive Medicine
ARC Fertility

Gitau Mburu, MD, DTM&H, MPH, PhD
WHO

Madeleine Short Fabic, MHS
USAID

Amal Benbella, MD
Rabat Medical School

Laura Nene, MD
University of Pretoria

The ABOG Foundation - Kenneth J. Ryan Ethics Symposium: Polygenic Risk Scoring of Embryos (PGT-P)- Medical Benefit or Ethical Risk?



Dorit Barlevy, PhD (Chair)
Baylor College of Medicine

Leila Jamal, PhD
Johns Hopkins/NIH Genetic Counseling Training Program

Todd Lencz, PhD
Zucker School of Medicine at Hofstra/Northwell

SART a Retrospective



Lindsey N. McBain, BA (Chair)
IVI RMA

Amy E. Sparks, PhD
University of Iowa Center for Advanced Reproductive Care



Scientific Congress DAILY SCHEDULE

Tuesday, October 22, 2024

KY Cha Symposium: Rescue and Regenerate Embryo Implantation and Uterine Interaction

Endowed by Ethicon Endo-Surgery



Tiencheng Arthur Chang, PhD, HCLD, ELD (Chair)
University of Texas Health Science Center

Ayman Al-Hendy, MD, PhD
University of Chicago

Sue Hammoud, PhD
University of Michigan

2:45 PM – 3:30 PM

Tuesday Afternoon Break

3:30 PM – 4:30 PM

Interactive Sessions

Future of Reproductive Urology:
Direct to Consumer Shift-Increased
Access or Undermining Foundations?



Kevin Chu, MD (Chair)
University of Miami Miller School of Medicine

Kevin J. Campbell, MD
University of Florida College of Medicine

Joshua A. Halpern, MD
Northwestern University Feinberg School of Medicine

Transcending Challenges in Third Party Reproduction for Minority Couples



Michael K. Simoni, MD (Chair)

RMA of NJ

Tolulope Bakare, MD
Posterity Health

Stacey Lynn Edwards-Dunn, DMin, MPH
Fertility for Colored Girls

3:30 PM – 4:45 PM

Abstracts

Oral Abstract Session: ART- Clinical (1 of 2)

Oral Abstract Session: Fertility Preservation-
Infertility and Cancer

Oral Abstract Session: Genetics- Mosaicism

Oral Abstract Session: Recurrent Pregnancy
Loss

Oral Abstract Session: Patient Centered
Care

Symposia

New Frontiers in Male Reproduction: Translating from Bench to Bedside



Ryan Flannigan, MD, FRCSC (Chair)
University of British Columbia

Timothy Jenkins, PhD
Brigham Young University

Sriram Venkata Eleswarapu, MD, PhD
University of California, Los Angeles

AMMR: The Future of Reproductive Medicine; New Technologies (Spanish)



Martha Luna Rojas, MD (Chair)
RMA International Mexico, SC

Ruben Tlapanco, MD (Chair)
Cesar Millan, MSc

Conceivable Life Sciences
Gerardo Mendizabal, PhD

Conceivable Life Sciences
Alejandro Chavez-Badiola, MD, PhD
New Hope Fertility Center Mexico



Scientific Congress
DAILY SCHEDULE

Wednesday, October 23, 2024

8:00 AM – 8:45 AM

Plenary

Samuel Pang LGBTQ+ Leadership in Education and Research Keynote: Standing up for LGBTQ+ Health- My Journey to the Presidency of the American Medical Association

NPWH ACOG CME NON-PHYS CME

Jesse M. Ehrenfeld, MD, MPH, FAMIA, FASA
Medical College of Wisconsin

8:45 AM – 9:15 AM

Live Event

ASRM 2024 Member’s Business Meeting

9:15 AM – 10:00 AM

Reproductive Urology Keynote: From Double Helix to Double Trouble: Sperm DNA Fragmentation Unveiled

NPWH ACOG CME NON-PHYS CME

Sandro C. Esteves, MD, PhD
ANDROFERT - Center for Male Reproduction

10:00 AM – 10:45 AM

Wednesday Morning Break

10:45 AM – 11:45 AM

Clinical Sessions

APPPG: Where Needs Exist, We Can Do Better: Advanced Practice Practitioners in Independent, Low-tech Practices Fill the Accessibility Gap for Marginalized Populations

NPWH

Liam Kali, BA (Chair)
Maia Midwifery and Fertility Services, PLLC
Disha Mistri, MSN, NP, RN
OM Fertility

GCPG: Mosaic Transfer- The Good and the Bad

NSCG NPWH

Meaghan Doyle, MS, CGC (Chair)
DNAide Genetic Counselling
Mary Carney, MS
Spring Fertility
Caroline McCrae, MS
Spring Fertility

LPG: Who’s Driving the Bus? Challenges in Navigating Independent Gestational Surrogacy Arrangements

NSCG NPWH

Lila Seif, JD (Chair)
New Family Fertility Law, APC
Ariadna Cymet Lanski, PsyD
Solo Private Practice
Judith Hoechst, JD, RN, RNC
Private Practice

MHPG: When the Field is Divided- Should We Test Partners of Gestational Carriers?

NASW NSCG NPWH PSY

Tonya Wood, PhD (Chair)
Pepperdine University
Julie Bindeman, PsyD
Integrative Therapy of Greater Washington

NPG: REI Nursing Competencies- National and International Perspectives

NPWH

Robin S. Scott, MSN, NP (Chair)
SOUTIEN Fertility
Francesca Steyn, BSc (Hons)
Nursing Royal College of Nursing

Interactive Sessions

Quality Management for ART Labs: Unlocking Potential with Process Improvement Utilizing SART CORS

NSCG ACOG CME NON-PHYS CME

Alison Bartolucci, PhD (Chair)
University of Connecticut Health Center, Center for Advanced Reproductive Services
Kevin J. Doody, MD
CARE Fertility
G. David Ball, PhD

Reprod Med & Infertil Assoc, UPMC, HFCRM
“Fresh Squeeze” or “Flash Freeze”? An Interactive Debate of Two Sperm Procurement Strategies for ART

NSCG ACOG CME NON-PHYS CME

Peter Chan, MD (Chair)
McGill University
Peter N. Schlegel, MD
Weill Cornell Medicine
Ajay Nangia, MBBS
University of Kansas Medical Center
Mitchel C. Schiewe, PhD
California Fertility Partners
Scott H. Purcell, PhD
Virginia Fertility and IVF

10:45 AM – 12:00 PM

Live Event

FDA: Reproductive HCT/P Donor Eligibility and Compliance Update

Simone P. Porter, MD, MPH
Food and Drug Administration
Center for Biologic Evaluation and Research

Symposia

Pre/Post Cancer Reproductive Care and Counseling in Pediatric and Young Adult Age Groups

NSCG NPWH ACOG CME NON-PHYS CME

Kutluk H. Oktay, MD, PhD (Chair)
Yale University School of Medicine
Leslie Coker Appiah, MD
The University of Colorado School of Medicine and Children’s Hospital Colorado
Gwendolyn P. Quinn, PhD
New York University School of Medicine

Endometrial Immunopathology in Reproductive Failure

CME NON-PHYS CME

Youssef Derbala, MD (Chair)
Derbala Reproductive Immunology
Svetlana Dambaeva, PhD
Rosalind Franklin University of Medicine and Science
Nathalie Ledee, MD, PhD
Matricelab Innove



Scientific Congress DAILY SCHEDULE

Wednesday, October 23, 2024

10:45 AM - 12:15 PM

Abstracts

Oral Abstract Session: Benign

Gynecological Disease- PCOS and Fibroids

Oral Abstract Session: Complex Family Planning

Oral Abstract Session: Genetics- General

Oral Abstract Session: ART- Clinical (2 of 2)

Oral Abstract Session: Infertility- Environmental Factors and Nutrition

Oral Abstract Session: Reproductive Urology (2 of 2)

11:45 AM - 12:15 PM

Abstracts

Oral Abstract Session: Law, Policy, and Advocacy (3 of 3)

Oral Abstract Session: Mental Health (3 of 3)

Oral Abstract Session: Nursing (3 of 3)

12:20 PM - 1:20 PM

Wednesday Lunch Break

Live Event

Roundtables RTW-01 – RTW-27

1:30 PM – 2:30 PM

Interactive Sessions

Mosaic Embryo Transfer Following PGT-A What Does the Data Say/How Do We Communicate With Patients

Gary L. Harton, PhD (Chair)

Grow Consulting

Emily Mounts, MS

Juno Genetics

Chelsey Audra Leisinger, PhD, HCLD

CCRM Fertility

Sticky Situations: Surgical Management Techniques for Retained Products of Conception

Jennifer Chin, MD (Chair)

University Hospital of Washington Medical Center

Stacy Young, MD

UCSF

Abigail Liberty, MD, MPH

Oregon Health & Science University

Navigating the Complexities of Early Pregnancy: Insights from the Post-Dobbs Era

Erin Masaba, MD (Chair)

University of Rochester

Nidhi Desai, JD

Desai & Miller

1:30 PM – 2:45 PM

Symposia

Minimally Invasive Approaches to Management of Uterine Fibroids: Advantages and Limitations

Bala Bhagavath, MBBS (Chair)

University of Wisconsin, Madison

Mindy S. Christianson, MBA, MD

Cleveland Clinic Foundation

Zaraq Khan, MD

Mayo Clinic

Emerging Climate-Change Related Threats to Human Reproduction

Audrey Jane Gaskins, ScD (Chair)

Emory University Rollins School of Public Health

Shuo Xiao, MBBS, PhD

Rutgers University School of Pharmacy

Bryn E. Willson, MD

Cedars-Sinai Medical Center

Biotech Partnerships That Drive Reproductive Health Innovation: How Sperm and Oocyte Biotech Collaboration Can Lead to Innovations that Benefit Patients and Science

Stanton C. Honig, MD (Chair)

Yale University

James F. Smith, MD

UCSF

Brian Miller, PhD

Center for Advanced Reproductive Services

The Need for Trauma-Informed Care in the REI Patient Population

Emily Ehlers, RN, BSN (Chair)

The Fertility Partners

Kristen Chambliss, PhD

Independent Practice

Jeanine Price, DNP, MSN

Shady Grove Fertility - Houston

2:45 PM – 3:30 PM

Wednesday Afternoon Break

3:30 PM – 4:30 PM

Interactive Sessions

Parent & Donor Disclosure Pathways: Cases, Challenges, and Solutions Across the Lifespan

Michele Martens, DNP, RN (Chair)

Vanderbilt University School of Nursing

Melanie Mikkelsen, MSW, LICSW

Hold Hope, LLC; Melissa Lindsey, Donor Conceived Community

The Burden of Bias: Considerations in the Diagnosis/ Management of Endometriosis in Black, Indigenous, and People of Color

Lisa Jeannette Green, MD, MPH (Chair)

Prisma Health

Rebecca Flyckt, MD

University Hospitals Fertility Center/Case Western



Scientific Congress
DAILY SCHEDULE

Wednesday, October 23, 2024

University

Gabrielle Whitmore, MD, MBS
University of Colorado School of Medicine

**Understanding the Impact of
Abortion Restrictions on IVF**

NSCG NPWH LPG ACOG CME NON-PRIVS CME

Shaalini Ramanadhan, MD (Chair)
Oregon Health & Science University
Shaalini Ramanadhan, MD
Oregon Health & Science University
Sigal Klipstein, MD
InVia Fertility
NHPan L. Crockin, JD
Georgetown Law Center, Crockin Law & Policy Group

3:30 PM – 4:45 PM

Symposia

**The Howard and Georgeanna Jones
Symposium on ART: The AI Revolution in
ART- Separating Reality from Hype**

Endowed by EMD Serono

NSCG NPWH ACOG CME NON-PRIVS CME

Michael Fanton, PhD (Chair)
Alife Health, Inc
Nikica Zaninovic, PhD
Weill Medical College of Cornell University
Eduardo Hariton, MBA, MD
Brigham and Women's Hospital, Harvard Medical
School

**Cutting-Edge and Innovative
Multidisciplinary Approaches
to Male Reproductive Surgery**

NSCG NPWH ACOG CME NON-PRIVS CME

Pietro Bortoletto, MD (Chair)
Boston IVF-The Eugin Group
Rebecca Holmes, DPhil, HCLD
CCRM
Nahid Punjani, MD, MPH
Mayo Clinic





ASRM 2024
SPEAKER INDEX

Aboulgar, Mohamed	PG-10
Acién, Maribel	SYM-02
Adamson, Geoffrey	SYT-06
Adeleye, Amanda	INM-05
Aghajanova, Lusine	LIVS-01
Ahmed, Hina	RTT-16
Al-Hendy, Ayman	SYT-04
Albrecht, Mahshid	INT-01
Ali, Mohamed	RTM-23
Allen, Christine	RTM-25
Alvarez Sedo, Cristian	PG-11
Amato, Paula	SYT-06, LIVT-07
Amberger, Joy	PG-07, HOC-01
Appiah, Leslie	RTT-21, SYW-01
Arian, Sara	PG-02
Arrach, Nabil	PG-11
Ata, Baris	PG-12
Awwad, Johnny	PG-10, SYM-04
Awwad, Rawan	CST-02
Bakare, Tolulope	INT-05
Baken, Robyn	PG-04
Baker, Morgan	LIVT-08
Baker, Valerie	RTM-16, LIVT-08
Ball, G. David	INW-01
Bariani, Maria Victoria	PG-02
Barlevy, Dorit	SYT-05
Bartolucci, Alison	INW-01
Bastuba, Martin	PG-09
Bate, Ojong	LIVW-03
Bauer, Jessica	PG-06
Baxi, Asha	RTW-19
Belva, Florence	LIVM-07
Benbella, Amal	SYT-06
Bernardi, Lia	PG-06
Bethea-Walsh, Angela	CSM-04
Bhagavath, Bala	PG-02, SYW-05

Bindeman, Julie	LIVT-08, CSW-04, RTW-20
Boots, Christina	RTT-05, LIVM-03
Bormann, Charles	SYM-04
Bortoletto, Pietro	SYW-06, LIVM-03
Brabner, Vonda	PG-03
Brandão, Pedro	RTW-16
Brannigan, Robert	LIVS-01
Broadwell, Christina	PG-06
Broussard, Alicia	PG-03
Brown, Jennifer	PG-15
Cakmak, Hakan	LIVS-01
Caldwell, Ann	LIVM-03
Callahan, Nicole	CSM-01
Callum, Pamela	RTM-07
Campbell, Kevin	INT-06
Capalbo, Antonio	PG-14, SYM-03
Carlsson, Inger Britt	LIVT-08
Carney, Mary	CSW-02
Cascante, Sarah	LIVM-07
Castaneda, Daragh	PG-15
Castro Valderrama, Eduardo	PG-11, RTW-23
Catherino, William	RTT-25
Cebert, Morine	RTW-12
Cedars, Marcelle	LIVT-06
Chambliss, Kristen	SYW-02
Chan, Peter	INW-02
Chang, Tiencheng Arthur	SYT-04
Chantilis, Samuel	PG-14
Chavarro, Jorge	RTM-22
Chavez-Badiola, Alejandro	PG-11, SYM-01, SYT-07
Chen, Serena	INM-05
Chin, Jennifer	INW-03
Choi, Young Sik	SYT-01
Christianson, Mindy	SYW-05, LIVW-03
Chu, Kevin	INT-06

Cil, Aylin	RTW-02
Collura, Barbara	CST-03
Conaghan, Joe	PG-04
Constantinou, Efthymia	PG-14
Corbett, Kaitlin	PG-02, PG-06
Cortes, Yamnia	PLM-04
Coward, Matt	PG-09, LIVM-08
Cozzubbo, Tyler	LIVT-08
Craig, LaTasha	RTM-14
Crockin, Susan	CSM-02, INW-07
Curchoe, Carol	INT-02, RTW-14
Cymet Lanski, Ariadna	CSW-03
Dambaeva, Svetlana	SYW-08
Dayo, Olumayowa	LIVT-08
De Vos, Michel	RTW-03
Derbala, Youssef	SYW-08
Desai, Nidhi	CSM-03, INW-05
Desai, Vrunda	LIVM-05
Deti, Laura	HOC-03, RTT-24
Devine, Kathleen	LIVS-01
Diederich, Leann	PG-05
Diego, Daniela	INM-01
Dinsmore, Britta	PG-15
Dong, Allan	PG-06
Doody, Kevin	INW-01
Doyle, Meaghan	CSW-02
Dupree, James	LIVM-08
Easley, Charles	LIVM-07
Eaton, Jennifer	LIVS-01
Edwards-Dunn, Stacey	INT-05
Ehlers, Emily	SYW-02
Ehre, Joelle	PG-05
Ehrenfeld, Jesse	PLW-01
Ekk, Susan	HOC-03
Elbanna, Wael	PG-02
Eleswarapu, Sriram	SYT-08
Esteves, Sandro	PLW-02, RTM-13



ASRM 2024
SPEAKER INDEX

Evans, Blake	RTT-20
Fanton, Michael	SYW-07
Farfan, Juan C	LIVM-07
Feinberg, Eve	INM-02
Feingold, Jamie	PG-08, RTM-04
Flannigan, Ryan	SYT-08
Flaws, Jodi	PLT-02
Flyckt, Rebecca	INW-06, RTT-03
Fru, Karenne	CST-04
Fuzesi, Peter	RTT-08
Gamper Meenan, Jennifer	RTM-19
Garcia-Velasco, Juan	PG-12
Gardella, Jennifer	PG-15
Garrido Puchalt, Nicolas	PG-14
Garrison, Pauline	PG-07, HOC-01
Gaskins, Audrey	SYW-04
Geronimus, Arline	PLM-03
Gilboa, Daniella	PG-07, HOC-01, RTM-11
Gingold, Julian	RTT-09
Goldstein, Jerald	PG-04
Golovinov, Vladyslav	PG-12
Goodman, Linnea	LIVM-08
Gordon, Keith	LIVM-05
Gordon, Tony	CST-02
Goudas, Vasilios	RTT-01
Green, Hannah	RTW-11
Green, Lisa	INW-06, LIVW-03
Grobel, Maya	PG-15
Grow, Edward	PG-03
Grynberg, Michael	RTM-02
Habash Robinson, Rana	PG-04
Hall, Karen	RTT-18
Halpern, Joshua	INT-06, LIVM-08
Hammer, Karissa	PG-02
Hammoud, Sue	PG-03, SYT-04
Hansen, Karl	LIVM-03

Hanson, Amani	CST-03
Hariton, Eduardo	PG-04, RTW-15, SYW-07
Harton, Gary	INW-04, RTT-17
Hebert, Caitlin	PG-08, CST-05, RTT-04
Helo, Sevann	PG-09
Herati, Amin	HOC-03
Hickman, Cristina	INT-02
Hill, Micah	LIVM-03
Hirshfeld-Cytron, Jennifer	SYM-07
Hobbs, Cassie	RTM-09
Hoechst, Judith	CSW-03, RTM-21
Hogerty, Jaime	PG-03
Hokianto, Hary	INT-01
Holmes, Rebecca	SYW-06
Honig, Stanton	SYW-03
Hotaling, James	SYM-01, LIVM-08
Huff, Rebekah	CSM-05
Hwang, Kathleen	LIVM-08
Imudia, Anthony	RES-03
Ivani, Kristen	RTM-24
Jain, Kuldeep	PG-13
Jain, Tarun	CST-03
Jamal, Leila	SYT-05
Jenkins, Timothy	SYT-08
Jessup, Molly	RTT-06
Jha, Priyanka	RTW-22
Jindal, Sangita	CSM-03
Johannesson, Liza	SYM-05
Johnson, Dr. Loree	CST-04
Johnson, NESTA	RTT-22
Jordan, Amy	CSM-02
Judge, Anne	CST-01
Jungheim, Emily	INM-04
Jurgenson, Heather	PG-08
Kali, Liam	CSW-01
Kallen, Amanda	LIVT-06

Kaplan, Danielle	INT-03, RTW-10
Kaplun, Amber	CST-02
Kaser, Daniel	PG-01
Katz, Maria	RTM-18
Kawwass, Jennifer	INM-01, LIVS-01
Khan, Zaraq	SYW-05
Kim, Ji Hyang	RTW-27, SYT-01
Kirkpatrick, Shannon	RTT-15
Klipstein, Sigal	INW-07, RES-01, LIVT-07
Kotlyar, Alexander	RTT-19
Lagunov, Alex	SYM-09
Lake, Prave Pitisci	INT-03
Lawson, Angela	PG-08, CSM-03, LIVS-01
Ledee, Nathalie	SYW-08
Lee, Elizabeth	LIVT-08
Lee, Jung Ryeol	RTM-26, SYT-01
Legro, Richard	INM-04, LIVM-03
Leisinger, Chelsey	INW-04
Lencz, Todd	SYT-05
Leondires, Mark	PG-15
Letourneau, Joseph	SYM-10
Letterie, Gerard	HOC-01
Liberty, Abigail	INW-03
Likes, Creighton	RTM-10, RTW-13
Lin, Paul	SYM-06, LIVS-01
Lindsey, Melissa	INW-08
Loret de Mola, J. Ricardo	RTT-11
Luft, Ann	LIVT-08
Luna Rojas, Martha	PG-11, SYT-07
Lynch, Colleen	INM-03
Maloney, Trevor	PG-09
Marks, Sheldon	HOC-02
Marsh, Courtney	RTT-14



ASRM 2024
SPEAKER INDEX

Martens, Michele	INW-08	Palermo, Gianpiero	HOC-01	Robins, Jared	SYT-06
Masaba, Erin	PG-06, INW-05, RTW-21	Palshtekar, Nandita	PG-13	Rodriguez, Maria	PLT-04
Mburu, Gitau	SYT-06	Paradise, Annemarie	INT-01	Romanski, Phillip	INM-01
McBain, Lindsey	CST-05, RTM-12, SYT-03	Parry, John Preston	RTW-04	Ross, Heather	SYM-07
McCrae, Caroline	CSW-02	Pascale, Claudia	SYM-08	Rubin, Elizabeth	LIVM-04
McMurray, Megan	HOC-02	Pasch, Lauri	SYM-07, LIVT-07	Rubio Lluesa, Carmen	PG-07
McQueen, Dana	PG-06	Pascual Rodriguez, Antonio	PG-11	Rutter, April	INM-05
Medvedich, Jessica	PG-01	PATIL, MILIND	PG-10	Sable, David	PG-01, RTT-26
Mehta, Akanksha	PG-09, LIVM-08	Patki, Ameet	PG-13	Sakkas, Denny	SYM-01, LIVM-05
Mendizabal, Gerardo	SYT-07	Pecker, Lydia	LIVW-03	Sankowski, Piotr	SYM-04
Meseguer, Marcos	RTT-23	Peralta, Stacey	PG-11	Sauerbrun-Cutler, May-Tal	RTW-05
Mikkelsen, Melanie	INW-08	Perman, Shana	CSM-01	Schafer, Vickie	PG-05
Millan, Cesar	SYT-07	Pfeifer, Samantha	PLT-03, SYM-02	Schenkman, Eva	HOC-03
Miller, Brian	SYW-03	Picton, Helen	HOC-03, SYM-10	Schiewe, Mitchel	INW-02
Minhas, Brijinder	PG-01	Pinborg, Anja	SYM-03	Schlegel, Peter	INW-02
Missmer, Stacey	LIVT-04	Pirtea, Paul	PG-10	Schon, Samantha	LIVM-03, LIVT-04
Mistri, Disha	CSW-01	Porter, Simone	LIVW-02	Schoor, Richard	HOC-02
Monseur, Brent	INT-04	Portugal, Aileen	LIVT-08	Schoyer, Kate	RTT-12
Mooney, Sara	CSM-05, RTW-09	Price, Jeanine	RTT-27, SYW-02	Schuman, Lisa	PG-15
Mounts, Emily	INW-04	Punjani, Nahid	SYW-06	Scott, Robin	CSW-05
Moussa, Raff	PG-13	Purcell, Scott	PG-07, INW-02	Seale, Amelia	PG-10
Mumusoglu, Sezcan	PG-12	Putra, Manesha	SYT-02	Segal, Thalia	RTM-01
Munch, Erika	LIVS-01	Quinn, Gwendolyn	SYW-01	Segarra, Jamie	PG-06
Najari, Bobby	INM-04	Racowsky, Catherine	PG-10	Seif, Lila	CSW-03
Nangia, Ajay	INW-02	Ramanadhan, Shaalini	INW-07	Senapati, Suneeta	RTM-08
Nassab, Paulina	INM-03, RTW-17	Rapp, Hayley	CST-01	Shafiee, Hadi	HOC-01
Nayar, Kanad Dev	PG-13	Rarig, Niki	PG-02, PG-09, RTT-10	Shannon, Chevis	LIVM-05
Nel-Themaat, Liesl	HOC-03	Reid, Jessica	RTW-25	Shikanov, Ariella	LIVM-04
Nene, Zozo	SYT-06	Rembisz, Katie	RTW-06	Shin, David	HOC-02
O'Brien, Jeanne	CSM-02	Rey-Valzacchi, Gaston	PG-11	Shively, Lydia	PG-06
O'Neill, Kathleen	SYM-05	Richard-Davis, Gloria	LIVT-04	Short Fabic, Madeleine	SYT-06
Ogle, Alicia	PG-06	Richards, Elliott	SYM-05	Sierra, Sony	SYM-09
Oktay, Kutluk	RTT-02, SYM-10, SYW-01	Rinehart, Lisa	PG-04, SYM-06	Simon, Carlos	PG-11
Orwig, Kyle	PG-03	Rios, Julie	RTM-06	Simon, Judy	RTM-05
		Rizk, Botros	SYM-04	Simoni, Michael	INT-05
				Singh, Bhuchitra	INT-04
				Siques Barnett, Jeannette	PG-03
				Skellington, Kim	INM-03



ASRM 2024
SPEAKER INDEX

Smith, James	PG-09, RTT-07, SYW-03, LIVM-08	Terry-Leonard, Gretchen	LIVM-05	Widra, Eric	LIVM-03
Smith, Ryan	RTM-03, LIVM-08	Thirumavalavan, Nannan	SYT-02	Willson, Bryn	SYW-04
Snider, Alyssa	RTW-18	Thompson, Kimberly	PG-06	Winters Miller, Ellen	PG-05
Spandorfer, Steven	INM-01	Tlapanco, Ruben	RTM-15, SYT-07	Wiweko, Budi	RTW-26
Sparks, Amy	SYT-03	Tobias, Tamara	CST-01	Wood, Jennifer	PG-08, CSM-05
Spencer, Jessica	INM-02	Treff, Nathan	PG-07, RTW-24	Wood, Tonya	PG-05, CSW-04
Spitz, Aaron	LIVM-08	Ulrich, Nicole	LIVT-08	Woodward, Julia	SYM-06
Stanic-Kostic, Aleksandar	PG-06	Vance, Amy	CSM-02, SYM-08	Xiao, Shuo	RTW-01, SYW-04
Steyn, Francesca	CSW-05	Vij, Sarah	RTW-08	Xu, Min	HOC-01
Stringer, Jeffrey	PLT-01	Viotti, Manuel	SYM-08, LIVM-07	Yano, Jacqueline	SYM-02
Stroumsa, Daphna	LIVM-04	Walter, Jessica	INM-02	Yarali, Hakan	PG-12
Strug, Michael	RTM-20	Weinerman, Rachel	SYT-02	Yi, Kyong Wook	RTM-27
Sung, Linda	PG-01, PG-07	Wells, Dagan	PG-07, RTM-17	Young, Stacy	INW-03
Swanson, Amelia	INT-04	Wessels, Jocelyn	SYM-09	Zaninovic, Nikica	SYM-04, SYW-07
Tandulwadkar, Sunita	RTT-13	Whitmore, Gabrielle	INW-06	Zephyrin, Laurie	PLM-02
Tanrikut, Cigdem	LIVM-08	Whynott, Rachel	LIVT-08	Zernicka-Goetz, Magdalena	PLM-01



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Abbara, A.	Myovant Sciences ^{6a}
Abel, A.	Gameto, Inc. ^{6a}
Acosta Gomez, F.	Conceivable Life Sciences ^{23a}
Adamson, G. D.	Advanced Reproductive Care, Inc. ^{13a} ; Labcorp ^{6a} ; Organon ^{8a} (Panelist at ESHRE)
Adeleye, A.	Carrot ^{2a} ; CCRM ^{3a} ; Frame ^{2a} ; Kompass Diagnostics ^{2a}
Ahmed, H.	Kindbody ^{23a}
Akinwale, A.	Igenomix ^{3a}
Al-Hendy, A.	Pfizer ^{6a} ; Sumitomo ^{6a}
Alikani, M.	Conceivable Life Sciences ^{1b} ; Conceivable Life Sciences ^{6a} ; Kindbody ^{8b} (SAB); TMRW ^{8b} (SAB); TMRW ^{8a} (Scientific Advisory Board); TMRW ^{8b} (SAB)
Allaire, C.	Abbvie ^{5a} ; Ferring ^{5a}
Álvarez López, Á. E.	Conceivable Life Science ^{23a}
Alvero, R. J.	Hannah Life Technologies ^{28a} (Scientific Advisor with stock options); Orchid Bioscience ^{8a} (Scientific Advisor with stock options); Parity Health Inc ^{8a} (Scientific Advisor with stock options)
Armer-Cabral, M.	Natera ^{3a}
Arrach, N.	Progenesis ^{1a}
Averbuch, D.	Embie Clinic ^{123a}
Awwad, R. I.	Fairfax EggBank ^{3a} ; Maven Clinic ^{8a}
Baker, M.	CooperSurgical ^{6a}
Baker, V. L.	Ferring ^{6a} ; IBSA ^{6a}
Bakir, V.	Istanbul Memorial Hospital ^{6a}
Baldwin, K.	California Cryobank by CooperSurgical Inc ^{3a}
Barbosa Duarte Filho, O.	Ferring Pharmaceuticals ^{47c} ; Merck ^{8c} ; Organon ^{8c}
Bar-Chama, N.	Genentech/ Roche Pharmaceuticals ^{45a} ; WINFertily ^{6a}
Barnes, C.	Intelon Optics ^{3a}
Barrachina, F.	Gameto Inc. ^{3a}
Barragan, C. P.	Conceivable Life Sciences ^{23a}
Bartolucci, A.	Cooper Surgical ^{6a}
Baum, M.	FertilAI ^{2a}
Bedaiwy, M. A.	Abbvie ^{5a} ; Pfizer ^{5a}
Belarmino, A.	Fellow Health ^{6a}
Beltsos, A.	Ferring ^{7a} ; Future Fertility ^{2a} ; Kindbody ^{123a} ; TMRW ^{2a}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Benaglia, L.	Organon ^{6a}
Benbella, A.	MERCK ^{8a}
Berga, S. L.	Biogen ^{6a} ; ClearBlue ^{6a} ; Emblem ^{6a} ; Medscape ^{5a} ; Myovant ^{6a} ; Omnicuris ^{58a}
Berger, D. S.	Eastern Virginia Medical School ^{5a} ; Fertility Tomorrow ^{6a} ; Illume Fertility ^{6a} ; Triangle Genomics ^{2a}
Bernie, H. L.	BK Ultrasound ^{6a} ; Boston Scientific ^{6a} ; Coloplast ^{6a} ; SMSNA ^{8a} (I am on the Board of Directors for the SMSNA)
Bethea-Walsh, A. R.	Bethea Consulting and Psychological Services, P.C. ^{8a}
Bhagavath, B.	Portal Instruments ^{6a}
Boskey, E. R.	SAGE Publications ^{8a}
Bowden, A.	Walnot, Inc ^{12a}
Brannigan, R. E.	American Board of Urology ^{8a} (Examination Committee Senior Consultant); American Urological Association ^{8a} (AUA Update Series Editorial Committee Member)
Brass, N.	CooperSurgical ^{3a}
Brinson, A.	Maven Clinic ^{6a}
Brogaard, K.	Inherent Biosciences ^{12a}
Brzozowski, M.	MIM Solutions ^{3a}
Butts, S. F.	American Gynecologic and Obstetrical Society ^{8a} (Council, Member at Large); Doximity ^{5a} ; Endocrine Society ^{58a} (Board of Directors); Ferring Pharmaceuticals ^{6a}
Callum, P.	Amulet Capital ^{6a} ; Calitar Consulting, LLC ^{1a} ; Cooper Surgical, Inc ^{6a} ; Everie ^{6a} ; Ivy Fertility ^{6a} ; Juniper Genomics ^{6a} ; SCRC Medical Group ^{6a} ; Tandem Genetics ^{8b} (Part Time Employee); Tandem Genetics ^{1a}
Cameron, K. E.	Becton Dickinson ^{3b} ; Siemens Healthineers ^{3b}
Capalbo, A.	Juno Genetics ^{1a}
Cardona, C.	Androvia ^{3a}
Casanova, C.	Igenomix ^{3a}
Castellón García, J.	Igenomix S.L ^{3a}
Catherino, W. H.	American Board of Obstetrics and Gynecology ^{8a} (Division Member, REI); American Society for Reproductive Medicine ^{8a} (Editor-in-Chief, F&S-Sciences); Bayer ^{6a} ; EMD-Serono ^{3b} ; Pfizer ^{6a} ; Sumitomo Pharma ^{6a}
Caviglia, E.	Novagen ^{3a}
Cedars, M. I.	AGOS ^{8a} (Executive Board member)
Chae, H. Kai	Health ^{1a} ; ROKIT Healthcare ^{1a}
Chan, A.	AbbVie ^{23a}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Chan, J. L.	Binto ^{8a}
Chandramohan, D.	Orchid Health ^{3a}
Chang, Z.	Alife Health ^{3a}
Chaudhari, A.	Johnson and Johnson ^{6a} ; Richard Wolf Medical ^{6a}
Chen, S. H.	Cooper Genomics ^{57a} ; EMD Serono ^{5a} ; EngagedMD ^{6a} ; Ferring ^{7a} ; FertilityAnswers ^{2a} ; Levy Health ^{8a} (Medical Advisory Board); Theralogix ^{8a} (Medical Advisory Board)
Chen, X.	Univfy Inc. ^{38a}
Choi, J.	Ferring ^{6a} ; Progyny ^{8a} (Medical Advisory Board member); Progyny ^{13a}
Chung, E. H.	Turtle Health ^{6a}
Cinnioglu, C.	NextGen Genetics MSO, LLC ^{123a}
Civello, D.	Fellow Health, Inc. ^{6a} ; GRAIL, Inc. ^{3a}
Clemente, M.	Igenomix S.L ^{3a}
Cohen, J.	Althea Science ^{12a} ; Conceivable Life Sciences ^{123a} ; IVF 2.0 ^{2a} ; KindBody ^{28a} ; TMRW ^{28a}
Conaghan, J.	American Board of Bioanalysis ^{1a} ; Irvine Scientific ^{7a}
Copeland, M.	Sumitomo Pharma America, Inc. ^{6a}
Copperman, A. B.	Progyny ^{12a}
Cordts, E. B.	Ferring Pharmaceuticals ^{7a} ; Merck Group ^{7a} ; Organon ^{7a}
Costa Borges, N.	Conceivable Life Sciences ^{6c} ; Embryotools SL ^{2a}
Cowan, P.	Vitrolife ^{3a}
Cozzolino, M.	Theramex, Organon, IBSA ^{57a}
Craig, L. B.	American Board of Obstetrics & Gynecology, division of REI ^{5a} ; Ferring Pharmaceutical ^{8a} (site investigator for a study); Ferring Pharmaceuticals ^{6a} ; MayHealth ^{8a} (site investigator)
Crockin, S. L.	Howard and Georgeanna Jones Foundation ^{8a} (board member)
Cuevas, I.	Cercle ^{2a}
Czyrznica, A.	Juno Genetics US Inc ^{3a}
Dahan, M. H.	Elsevier ^{8a} (Editor of a Text Book on Infertility); EMD Serono ^{467a} ; Ferring ^{67a} ; Journal of Clinical and Experimental Obstetrics and Gynecology ^{38a} (Editor and Chief of the Journal); Organon (As Merck) ^{6a} ; OriginElle Fertility Center ^{1a} ; OvaSciences ^{6a} ; Web of Science Inc ^{8a} (Editor of a text book on IVM)
Dai, Y.	Lady Technologies ^{6a}
Dalton, V.	Medical Letter ^{8a} (Contributing Editor); Merck ^{8a} (Expert witness); Society of Family Planning ^{8a} (Course Instructor); Up to Date ^{8a} (Author)



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Davis, L. B.	Ito Pharmacy ^{2a}
De Vos, M.	Gameto ^{5a}
Deering, K. L.	EMD Serono ^{6c}
Desai, V.	Amgen ^{45b} ; AstraZenica ^{46b} ; Bayer ^{6b} ; Boreinger-Ingelheim ^{46b} ; BristolMeyer ^{6b} ; CooperSurgical ^{3a} ; Cytokinetics ^{46b} ; Novartis ^{45b}
Dhillon, W. S.	Imperial Health Charity ^{4a} ; MRC ^{4a} ; Myovant Sciences Ltd ^{6a} ; NIHR ^{4a}
Di Berardino, T.	CooperSurgical ^{3a}
Diamond, M. P.	Advanced Reproductive Care ^{28a} (Board of Directors); Augusta University ^{8a} (Patent Pending)
Diaz Gimeno, P.	IVI RMA Global ^{468a}
Díaz, Y.	Novagen ^{3a}
Di-Castro Shashua, S.	Embie Clinic Ltd. ^{3a}
Divaraniya, A. A.	Oova, Inc. ^{1a}
Diwekar, U.	Opt-IVF LLC ^{12a}
Dokras, A.	Ablacare/Mayhealth ^{6a} ; AEPCOS Society ^{8a} (Executive Director); Ferring ^{6a} ; Organon ^{6a} ; Veera Health ^{6a}
Domar, A. D.	Curio ^{6a} ; EMD Serono ^{4a} ; Ferring ^{7a} ; Inception Fertility ^{3a} ; Oto ^{4a} ; UptoDate ^{6a}
Dong, A.	3M ^{2a} ; Abbvie ^{2a} ; Johnson and Johnson ^{2a} ; Medtronic ^{2a} ; Pfizer ^{2a} ; Solventum ^{2a} ; Viking Therapeutics ^{2a}
Doody, K. J.	Ferring Pharmaceutical ^{6a}
Doyle, M.	Alberta Reproductive Centre ^{6a} ; DNAide Genetic Counselling ^{1a} ; Pollin Fertility Inc. ^{6a}
Duncan, F. E.	Merck KGaA ^{6a}
Dupree, J. M.	ASRM ^{8a} (Program Committee Member); Blue Cross Blue Shield of Michigan ^{4a} ; Ferring; Lipocine ^{2a} ; NIH ^{4a} ; Posterity Health ^{28a} (Scientific Advisory Board); SSMR ^{1a}
Ehlers, E.	Kindbody ^{3a}
Ehrenfeld, J. M.	Augmedix ^{5a} ; Extrico Health ^{8a} (Advisor); Masimo ^{6a}
Elemento, O.	Acuamark DX ^{8a} ; AstraZeneca ^{8a} ; Champions Oncology ^{8a} ; Eli Lilly ^{8a} ; Freenome ^{8a} ; Genetic Intelligence ^{8a} ; Harmonic Discovery ^{8a} ; J&J/Janssen ^{8a} ; OneThree Biotech ^{8a} ; Owkin ^{8a} ; Sanofi ^{8a} ; Volastra ^{8a} ; Volastra Therapeutics ^{8a}
Emery, B. R.	Inherent BioScience ^{2a} ; Wasatch Biolabs ^{12a}
Espinoza Figueroa, J.	Conceivable Life Sciences ^{2a}
Esteves, S. C.	Med.E.A. ^a
Fabbro, M.	NOVAGEN ^{3a}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Fanton, M.	Alife Health ^{3a}
Feinberg, E. C.	Ferring ^{6a}
Fernandez, C.	Novagen, Cegyr ^{3a}
Fisch, M. J.	Carelon Medical Benefits Management ^{3a} ; Elevance Health ^{2a}
Fjeldstad, J.	Future Fertility ^{3a}
Flannigan, R.	Boston Scientific ^{4a} ; Teumo Health Technologies Inc ^{2a}
Flaws, J. A.	Society for the Study of Reproduction ^{8a} (Secretary)
Flores Saiffe Farías, A.	Conceivable Life Sciences ^{23a}
Frattarelli, J. L.	Pacific Coast Reproductive Society ^{8a} (Board of Directors, Past-President)
Fuzesi, P.	Asian Egg Bank ^{123a}
Gada, R.	ReUnite Rx ^{1a}
Galain, M.	Novagen ^{3a}
Gardella, J. R.	Biogen ^{23a}
Garnsey, H.	Genomic Prediction ^{3a}
Garro, D.	Genomic Prediction ^{8a}
Gaskins, A. J.	Doveras Fertility, Inc. ^{8a} (I am an advisor to and hold stock options in this company)
Genest, G.	Ferring ^{5a} ; Organon ^{58a}
Ghamande, S.	GSK ^{57a}
Gilboa, D.	AIVF ^{1a}
Gilchrist, R. B.	City Fertility ^{6a}
Girod, R.	Orchid Health ^{3a}
Glucksman, H. P.	Intelon Optics ^{3a}
Goldman, K. N.	WnDrHLTH ^{6a}
Goldman, R. H.	UpToDate ^{8a} (Peer-Reviewer)
Gomez, C.	Igenomix R&D SL ^{3a}
Gómez, M.	Igenomix SL ^{3a}
Gonzalez, S.	Cooper Surgical ^{3a}
Goodman, L. R.	LiNA Medical ^{6a}
Gordon, T.	CooperSurgical ^{23a}
Gottesman, J.	Embie ^{13a}
Gray Valbrun, T.	The White Dress Project ^{1a}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Grobel, M. O.	Empower with Moxi ^{1a}
Grow, D. R.	Ferring ^{6a}
Guo, V.	Juno Genetics US Inc ^{3a}
Guzman, L.	Cooper Surgical ^{6a} ; Gameto Inc ^{4c}
Haddad, G.	Aspire Houston Fertility Institute ^{12a}
Hajirasouliha, I.	Fairtility ^{7a} ; Noor Sciences Inc. ^{6a}
Halicigil, C.	Progenesis ^{6a}
Halpern, J. A.	Posterity Health ^{3a}
Hansen Lindner, L.	Channel Medical Systems ^{6a} ; Gynesonics ^{67a}
Hansen, K. R.	May Health ^{4a} ; May Health ^{6a}
Hariton, E.	Alife Health ^{6a} ; Best Shot Inc ^a ; Cercle AI ^{6a} ; Evernow ^{6a} ; Fertilidad Integral ^{6a} ; Granata Blo ^{1a} ; Oya Care ^{6a} ; Rescripted ^{6a} ; Ro/Modern Fertility ^{23b} ; Ro/Modern Fertility ^{6a} ; US Fertility ^{3a}
Harton, G. L.	A IVF ^{6a} ; BioSkrbyb Genomics ^{3a} ; Cryos International ^{5a} ; Grow Consulting F&G ^{13a}
Hebert, C.	Holland & Knight LLP ^{3b} ; US Fertility ^{3a}
Hehemann, M. C.	Boston Scientific Corp ^{6a} ; Coloplast Corp ^{6a} ; Endo International PLC ^{7a}
Hennebold, J. D.	iGenomix ^{8a} (Sponsored Research Agreement); Notify Therapeutics ^a (Sponsored Research Agreement); Regeneron ^{8a} (Sponsored Research Agreement)
Henrich, N.	Maven Clinic ^{3a}
Herati, A. S.	lina medical ^a ; olympus ^{7a} ; Roman Health Ventures ^{2a} ; Teleflex ^{67a}
Hernandez, E. G.	Conceivable Life Sciences ^{23a}
Hickman, C.	Apricity ^{123a} ; Aria Fertility ^{123a} ; Avenues ^{123a} ; Fairtility ^{12356a} ; IVF Professionals ^{123a} ; Ovom ^{123a}
Hickman, C.	Apricity ^{123a} ; Aria Fertility ^{123a} ; Avenues ^{123a} ; Fairtility ^{12356a} ; IVF Professionals ^{123a} ; Ovom ^{123a}
Higgins, E.	Merck ^{6a} ; Organon ^{6a}
Hogerty, J. M.	Center For Reproductive Biology of Indiana (CRBI) ^{6a} ; Missouri Fertility ^{6a}
Homer, M. V.	Alife ^a ; U. S. Fertility ^{2a} ; USF Pharmaceutical Contracting Alliance ^{2a}
Honig, S. C.	Clarus ^{67a} ; coloplast ^{6a} ; endo ^{7a} ; Fellow ^{2a} ; genentech ^{6a} ; Haleon ^{6a} ; HIMS ^{6a} ; Posterity Health ^{2a} ; Winfertility ^{6a}
Hornberger, K. L.	Igenomix ^{6a} ; Seattle Sperm Bank ^{8a} (Part Time Company Employee)
Hotaling, J. M.	Abbvie, Pfizer, Novartis, Elli Lilly (wife as rheumatologist) ^{6b} ; Advanced Conceptions ^{2a} ; Andro360 ^{2a} ; Carrot Fertility ^{6a} ; FirmTech ^{12a} ; Inherent Bio ^{2a} ; Maximus ^{2a} ; Paterna bio ^{12a} ; Repronova; StreamDx ^{2a} ; Turtle Health ^{26a}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Hourvitz, A.	Fertilai ^{26a}
Hourvitz, R.	FertilAI ^{123a}
Huddleston, H. G.	Allara ^{6a} ; Amazon ^{6a} ; May Health ^{6a}
Hudson, C.	DxNow, Inc ^{6a} ; Hamilton Thorne LTD ^{6a} ; Levy Health ^{8a} ; Sama Fertility ^{6a} ; TMRW Life Sciences ^{3a}
Hund, M. F.	Hoffmann-La Roche Ltd ^{2a} ; Roche Diagnostics International Ltd ^{3a}
Hwang, K.	Reprotech ^{6a} ; SSMR ^{8a} (Officer)
Isley, L.	CooperSurgical ^{123a}
Isreal, R.	Embie Clinic, Ltd ^{123a}
Iturriaga, A.	Juno Genetics ^{3a}
Itzhak, N.	FertilAI ^{3a}
Jahnke, H. R.	Maven Clinic ^{3a}
Jalas, C.	Juno Genetics ^{3a}
Jaswa, E.	Oura ^{8a}
Jellerette-Nolan, T. J.	Ferring Pharmaceuticals ^{3a}
Jeon, Y.	Life Science, LG Chem, Ltd. ^{3a}
Jindal, S. K.	Ferring ^{8a}
Joag, S.	Opt-IVF LLC ^{12b} ; Opt-IVF LLC ^{1a} ; Stochastic Research Technologies LLC ^{12b} ; Stochastic Research Technologies LLC ^{1a} ; Stochastic Research Technologies LLC ^{12b}
Johnson, L.	Dr. L. Johnson, Marriage Therapist, Inc ^{1a}
Johnson, M.	Gameto ^{23a}
Jones, C. A.	CooperSurgical ^{3a}
Kadoch, I.	Ferring ^{456a}
Kali, L. Maia	Midwifery & Fertility Services PLLC ^{13a}
Kallen, A. N.	ACOG ^{8a} (Past Connecticut Section Chair); Flo ^{8a} (Medical Reviewer); Healthline ^{8a} (Medical Reviewer)
Kanakasabapathy, M.	Fujifilm Irvine Scientific ^{8a} (Licensed an IP)
Kantor, B.	Fairtality Ltd. ^{3a}
Katz, M. H.	Orchid Health ^{3a}
Kayali, R.	IGENOMIX ^{3a}
Kelly, L.	Ferring Pharmaceuticals ^{3a}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Kenfield, S. A.	Fellow Health, Inc. ^{6a}
Khoroshevskaya, A.	Roche Diagnostics GmbH ^{6a}
Kim, H.	Bayer ^{6a} ; LG Chemical ^{6a} ; Merck ^{6a} ; Organon ^{5a}
Kim, H.	Kai Health ^{3a}
Kirkpatrick,	S. Vitrolife Group ^{3a}
Klatsky, P.	Gameto ^{123a}
Kohler, T.	Coloplast ^{6a}
Kort, J. D.	Progyny ^{6a}
Korzeniewski, S.	J. Comanche Biopharma ^{6a}
Kotlyar, A.	Pfizer ^{6a}
Kramme, C. C.	Gameto ^{123a}
Krieg, A. J.	Notify Therapeutics ^{8a}
Krier, E.	Vitrolife, Inc ^{3a}
Krivoi, A.	Future Fertility ^{12a}
Lanes, A.	BORN Ontario ^{6a}
Larman, M.	Vitrolife ^{12a}
Laufer, M. R.	NextGen Jane ^{26a}
Laven, J. S.	AnshLabs ^{45a} ; ART Pred ^{4a} ; Ferring ^{456a} ; Gedeon Richter ^{6a} ; Merck ^{4a} ; Roche Diagnostics ^{4a}
Leahy, D.	Genomic Prediction ^{3a}
Ledee, N.	Innovation Lab MatriceLab Innove ^{128a} (related patent PCT/EP2013/065355)
Lee, C.	Pfizer ^{5a}
Lee, H.	Kai Health ^{12a}
Lee, H.	Life Science, LG Chem, Ltd. ^{3a}
Lee, H.	Vitrolife, Inc ^{3a}
Lee, J.	Life Sciences, LG Chem, Ltd. ^{6a}
Lee, S.	CHA Biotech ^{3a}
Legro, R. S.	Celmatix ^{6a} ; Covis ^{6a} ; Exeltisa; Guerbet ^{4a} ; Insudd ^{6a} ; Monsanto ^{6a} ; Novo Nordisk ^{6a} ; Organon ^{6a}
Leonard, C.	CooperSurgical ^{3a}
Leondires, M. P.	EMD Serono ^{7a} ; Granata Bio ^{6a} ; IBSA Pharmaceuticals ^{6a}
Letourneau, J. M.	EMD Serono ^{6a}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Li, S.	Orchid Health ^{3a}
Lin, P. C.	PCRS ^{8a} (At large board member)
Lipshultz, L. I.	Lipocine ^a
Lockwood, K.	CooperSurgical, Inc. ^{3a} ; UnitedHealthcare ^{2a}
Lu, S.	Yikon Medical ^{1a}
Luz, A.	FertilAI ^{12a}
Lynch, C. A.	CooperSurgical ^{3a}
Madden, T.	Bayer Healthcare Pharmaceuticals ^{58a} (serve on data safety monitoring committee for Phase 4 studied); CooperSurgical ^{5a} (serve on data safety monitoring committee for Phase 4 studied)
Madrigal, T.	Igenomix SL ^{3a}
Magwood, A.	Igenomix ^{3a}
Maman, E.	Fertilai ^{2a}
Mancera Zapata, D. L.	Conceivable Life Sciences ^{23a}
Marchante, M.	Gameto ^{3a}
Marin, D.	Genomic Prediction Inc. ^{3a}
Marks, S. F.	Springer ^{8a}
Marsh, E. E.	ACOG ^{8a} (Board Member); Alnylam ^{6a} ; Myovant Sciences ^{6a} ; SREI ^{8a} (President)
Martinez Carreon, D. S.	Conceivable Life Sciences ^{3a} ; Conceivable Life Sciences ^{2a}
Martins da Silva, S.	ESHRE ^{8a} (Associate Editor); Ferring pharmaceuticals ^{457a} (Associate Editor); IBSA ^{7a} (Associate Editor); Merck SeronoX ^{7a} (Associate Editor)
Maseelall, P. B.	Pinnacle Fertility ^{28a} (Medical board member)
Masterson, T. A.	Zuir Fertility ^{26a}
Matia-Algué, Q.	Embryotools ^{3a}
McBain, L. N.	IVI RMA ^{3a}
McCulloh, D. H.	Biogenetics Corporation ^{3a} ; Biogenetics Laboratory ^{3a} ; Buffalo IVF ^{6a} ; Gameto, Inc ^{136a} ; New York University Langone Fertility Center ^{36a} ; ReproART:Georgian American Center for Reproductive Medicine ^{1a} ; Sanford Reproductive Endocrinology ^{6a} ; Sperm and Embryo Bank of New York ^{3a}
McKenzie, L.	Springworks Pharmaceuticals ^{6a}
McLaughlin, J. E.	Merck ^{8a} (Co-author Merck manual)
Mecklai, K.	Modern Fertility (A Ro Company) ^{6a}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Medvedich, J.	IVI RMA ^{3a}
Mehta, A.	Posterity Health ^{8a} (Medical Advisory Board Member)
Mendizabal, G.	Conceivable Life Sciences ^a ; IVF2.0 ^a
Mercuri, N.	Future Fertility ^{3a}
Merz, C. B.	Abbott Diagnostics ^{6a} ; Board of Director for iRhythm ^{5a} ; SHL Telemedicine ^{5a}
Meseguer, M.	AIVF ^{8a} (Speaker Fee); Angelini ^{8a} (Speaker Fee); Cooper Surgical ^{8a} (Speaker); Fertility ^{8a} (Speaker fee); Ferring ^{8a} (Speaker Fee); Fujifilm ^a (Speaker Fee); Genea Biomedx ^{8a} (speaker fee); Gideon Richter ^{8a} (speaker fee); Merck ^{8a} (Speaker Fee); Theramex ^{8a} (Speaker fee); Vitrolife ^{8a} (speaker fee)
Mestres, E.	Embryotools ^{3a}
Mex Puc, A.	Vitrolife ^{3a}
Mikhail, E.	Abbvie ^{4a} ; DotLab ^{4a} ; Myovant ^{4a} ; Organon ^{4a}
Mikkelsen, M.	Hold Hope ^{8a} (owner)
Millan, C.	Conceivable Life Sciences ^{23a}
Miller, B.	CooperCompanies ^{2a} ; First Fertility ^{3a} ; TMRW Life Sciences ^{2a}
Miller, C. E.	Blue Seas Med Spa ^{8a} (Investor); Gynesonics ^{26a} ; Hologic ^{8a} ; LiNA Medical ^{6a} ; Medtronic ^{6a} ; Olympus ^{6a} ; RF Medical, Co. Ltd. ^a ; Seikagaku Corporation ^a ; Storz ^{6a}
Miller, J.	CooperSurgical ^{3a}
Miller, K. A.	aLIFE Health, Inc ^{8a} (Scientific Advisory Board); Fairfertility ^{8a} (Scientific Advisory Board); Future Fertility ^{8a} (Scientific Advisory Board); Genomic Prediction Inc. ^{78a} (Scientific Advisory Board); Igenomix ^{68a} (Scientific Advisory Board)
Miller, R.	Inherent Biosciences ^{3a}
Min, H.	tomocube ^{3a}
Missmer, S. A.	Abbot ^a ; AbbVie ^a ; AbbVie ^{4a} ; Frontiers in Reproductive Health ^{5a} ; ZEG Berlin ^a
Miyasaka, M.	Regeneron ^{8a}
Miyazaki, K.	Ferring Pharmaceuticals Co., Ltd. ^{5c}
Mol, B. W.	Ferringa; Merck ^{6a} ; Norgine ^{6a} ; ObsEva ^{26a} ; Organon ^{4a}
Moran, E.	FertilAI ^{3a}
Morris, M. E.	Neumora ^{2a} ; Oviva ^{6a}
Moss, C.	Maven ^{3a}
Mounts, E.	Juno Genetics ^{3a}
Munne, S.	GenEmbryomics ^{12a} ; Genembryomics ^{1a} ; Homu Health Ventures ^{1a} ; Overture Life ^{1a} ; Progenesis ^{3a}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Nagy, Z. P.	Inception ^{2a}
Nangia, A.	Ferring ^{4a} ; NICHD ^{4a} ; South Central section of the American Urological Association ^{8a} (Treasurer)
Nassab, P.	Igenomix ^{3a}
Nayot, D.	Bird&Be Company ^{28a} ; Future Fertility ^{26a} ; MonCap ^{2a} ; The Fertility Partners ^{26a}
Nel-Themaat, L.	Noor Sciences ^{6a}
Nene, L.	Ferring ^{8a} ; Organon ^{4a}
Nezhat, C.	Baxter ^{6a} ; Levalap CAST Surgical ^{6a} ; Pfizer ^{7a}
Nguyen, E. T.	Univy Inc. ^{38a} (Stock Optionee)
Nicholson, T. M.	Tasso, Inc ^{12b}
Nodar, F.	Cegyr ^{2a}
Nolte, D.	Exact Sciences ^{8a} (Summer Intern); Fellow Health, Inc. ^{3a}
Noriega Hoces, L.	Gameto Inc ^{4c}
Obedin-Maliver, J.	Folx Inc ^{6a} ; Hims Inc ^{6a} ; Ibis Reproductive Health ^{6a} ; Upstream, Inc ^{6a}
Ocegueda-Hernández, V.	Conceivable Life Sciences Mexico ^{23a}
Oktay, K. H.	Innovation Fertility ^{1a}
Ostermeier, G. C.	Androvia LifeSciences ^{3a}
Pal, L. Flo	health ^{6a} ; WinFertility ^{68a} (Consulting medical director)
Palshekar, N.	Bloom IVF Group ^{1a}
Papaleo, E.	Ferring ^{456c} ; Gedeon Richter ^{4c} ; IBSA ^{4c} ; Merck ^{5a} ; Organon ^{4c} ; Theramex ^{4c}
Papier, S. D.	ALMER ^{5a}
Paradise, A.	IVI America, LLC ^{3a}
Parmar, S.	Natera, Inc ^{3a}
Parry, J.	ACOG ^{8a} ; Parryscope ^{128a}
Partridge, A. H.	Novartis ^{8a} ; Wolters Kluwer ^{8a}
Pascale, C.	Brownstone Surrogacy ^{3a} ; Zuri Fertility ^{8a}
Pascual Rodriguez, A. V.	MIM Fertility ^{6a}
Patel, A.	Organon ^{7a} ; Viiv ^{6a}
Paulsen, B.	Gameto, Inc. ^{3a}
Pavone, V.	Theramex ^{8c}
Pecker, L. H.	Novo Nordisk ^{6a}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Penzias, A. S.	AutoIVF ^{8a} ; Fairtility ^{8a}
Peppercorn, M. M.	GSK ^{3b}
Perman, S.	Ferring - Advanced Practice Provider Speaker Bureau ^{7a}
Petrozza, J. C.	IMMA ^{8a} (Unpaid consultant); NESA ^{6a}
Pfeifer, S. M.	ASPIRA ^a ; ASPIRA ^a ; Granata Bio ^b
Picton, H. M.	IVF Bioscience ^{6a} ; CytoSwim Ltd ^{6a} ; IVFmicro Ltd ^{2a} ; Medical Research Council, UK, ^{8a} ; Medical Research Council, UK ^{4a} ; Medical Research Council, UK, Populations Systems Medicine Board ^{8a} (Member of Grant Review Board); Notify Therapeutics ^{6a} ; Research Council of Norway ^{8a} (Chair of a Centre of Excellence, Grant Review Panel); Shenzhen Peking University Medical Centre, China ^{8a} (International board member for proposed Female Fertility Preservation Center affiliated to Shenzhen Peking University Medical Centre (non stipendary)); The Research Foundation Flanders (FWO) ^{8a} (Expert grant review panel member for the TBM programme); U-Ploid Technologies ^{8a} (Expert grant review panel member for the TBM programme); University of Leeds/UKRI Impact accelerator award ^{4a} ; Nuffield Council on Bioethics ^{8a}
Piechota, S.	GAMETO INC ^{3a}
Pier, B.	American College of Obstetrics and Gynecology ^{8a} (Member of Clinical Practice Bulletin Committee, Gynecology)
Pinborg, A. B.	Ferring ^{45a} ; Gedeon Richter ^{45a} ; Merck A/S ^{45a}
Pini, P.	Fairtility ^{6a}
Pisarska, M. D.	ABOG ^{8a} (Board of Director); Ferring ^{5a}
Podgursky, B.	Orchid Health ^{3a}
Pollack, S. E.	Ferring Pharmaceuticals ^{8a}
Polyzos, N. P.	Alife ^{2a} ; Besins Healthcare ^{456a} ; Ferring ^{45a} ; Fertilla ^{2a} ; IBSA ^{546a} ; Merck Serono ^{456a} ; Organon ^{456a} ; Roche Diagnostics ^{45a} ; Theramex ^{45a}
Purcell, S. H.	PS Fertility ^{6a}
Puscheck, E. E.	AbbVie ^{4c} ; Allergan ^{4c} ; American Institute of Ultrasound in Medicine ^{8a} (Gynecologic ultrasound Community Co-chair); Bayer Pharmaceutical ^{4c} ; GSK ^{4a} ; Moderna ^{4a} ; Myovant ^{4a} ; ObsEva ^{4c} ; Pfizer ^{4c}
Putra, M.	Myriad, Inc ^{8a} (Research funding)
Qi, W.	Future Fertility ^{3a}
Rabkina, L.	Igenomix ^{3a}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Ratts, V.	Aesculap Implant Systems ^{6b} ; Bill and Melinda Gates Foundation ^{4a} ; Kaliber ^{2b} ; Medtronic ^{48b} (Royalties); Midwest Imaging ^{2b} ; MRI Partners of Chesterfield ^{2b} ; Nocimed ^{2b} ; Optum Fertility Solutions Expert Panel ^{8a} (Expert panel member); OuroBoros ^{2b} ; Pain and Rehabilitation Specialists, LLC ^{2b} ; Paradigm Spine ^{2b} ; St. Louis Spine and Orthopedic Surgery Center ^{2b}
Rembisz, K.	Igenomix ^{3a}
Retzloff, M.	Medtronic ^{6a} ; Organon ^{7a}
Reuveny, S.	FertilAI ^{3a}
Reyes Llamas, M.	Conceivable Life Sciences ^{23a}
Richard-Davis, G.	Astell ^{7a} ; Ferring ^{8a} ; Millicent ^{9a} ; Serono ^{8a}
Richter, K. S.	San Diego Fertility Center ^a
Rico, V.	Conceivable Life Sciences ^{23a}
Rienzi, L.	FINOX AG ^{5a} ; IBSA nature ^{5a} ; Merck AB ^{5a} ; Merck Healthcare KGaA ^{5a} ; MERCK SERONO Co.,Ltd ^{5a} ; MERCK SERONO MIDDLE EAST FZ LTD. ^{5a} ; ORGANON ITALIA S.R.L ^{5a}
Rizk, B. M.	Elite IVF ^{8a}
Rodrigo, L.	Igenomix ^{3a}
Roeca, C.	Ferring Pharmaceuticals ^{6a}
Rosenberg, S. M.	Pfizer ^{4a}
Rowe, M.	Takara Bio USA, Inc. ^{3a}
Rubio Lluesa, C.	Igenomix (Vitrolife Group) ^{3a}
Ruiz, M.	Igenomix SL ^{3a}
Russack, J. S.	LifeAire Systems, LLC ^{3a}
Rutter, A. M.	Hera Fertility 12a; Missouri Fertility Foundation ^{3a}
Ryan, R.	Eisai Inc ^{3b}
Saben, J.	Natera ^{23a}
Sable, D. B.	Hamilton Thorne LTD ^{1a} ; Serono ^{6a}
Sadrudin Ali, S.	ASRM QA Committee ^{8a} (Committee member); SRBT ^{8a} (Committee Member)
Sakkas, D.	ALIFE ^{8a} (Options); AUTOIVF ^{8a} (Options); EMD Serono ^{7a} ; Intelon ^{8a} ; Legacy ^{8a} (Options); TMRW ^{8a} (Options)
Santoro, N.	Amazon (Project Ember/Emblem) ^{6a} ; Ansh Labs ^{6a} ; Astellas Pharma ^{6a} ; FertilityIQ ^{6a} ; Menogenix Inc. ^{8a} (Advisory Committee)
Sasamoto, N.	Aspira Women's Health ^{4c}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Schaa, K. L.	Allay Life ^{3a}
Schafer, V.	Pregnancy and Postpartum Health Alliance of Texas ^{8a} (Volunteer Board Member-Treasurer); Vickie Schafer, Ph.D. PLLC ^{18a} (This is my private practice where I provide psychological services- some are patients receiving fertility treatments or using third party reproduction)
Scheib, J. E.	The Sperm Bank of CA ^{8a} (employee parttime)
Schenkman, E.	Adonis IVFa; ARTLAB ^{168a} (Owner); Gattaca Genomics ^a (Owner); Mellowood Medica ^{16a}
Schlegel, P. N.	Igyxos ^{6a} ; NY Mens Health Medical ^{18a} ; Posterity Health ^{8a} (Equity ownership); ReproNovo ^{6a} ; Roman Health ^{8a} (Equity ownership); Theralogix ^{6a} ; Xenetic BioScience ^{6a}
Schnorr, J. A.	Cycle Clarity ^{2a}
Schone, E.	Cassava Sciences Inc ^{2b} ; ELEVANCE HEALTH INC ^{2a} ; JOHNSON & JOHNSON ^{2a} ; Johnson & Johnson ^{2b}
Schuch, N.	Orchid Health ^{3a}
Schuman, L. S.	Serono ^{58a} (Talk at conference)
Schust, D. J.	UnIVfy ^{8a} (stock options)
Scott, R. S.	Soutien: Fertility ^{8a}
Sefogah, P. E.	Fogarty Northern Pacific Global Health Fellowship grant ^{4c} ; University of Michigan Clinical Simulation Center ^{4c}
Segars, J. H.	Aspira ^{8a} ; Myovant ^{8a} ; Organon LLC ^{8a}
Seidman, D. S.	AIVF Ltd., Tel-Aviv ^{12a}
Seitz, S.	Fairfax Cryobank ^{3a}
Sella, T.	Astrazeneca ^{8a} ; Eli Lilly ^{5a} ; Gilead ^{8a} ; Menarini ^{5a} ; Novartis ^{5a} ; Roche ^{5a}
Seriola, A.	SCRANTON BV ^{4a}
Shafiee, H.	Firtility Inc ^{28a} (Co-founder); Verlity LLC ^{28a} (Co-founder); XX ^{8a} (IP licensing)
Sharara, F. I.	Ferring Pharmaceuticals ^{57a}
Sharma, P. A.	Bird and Be ^{8a} ; Carrot Fertility ^{8a} ; Future Fertility ^{8a}
Shen, V.	Juno Genetics US Inc ^{8a}
Shim, J. Y.	UpToDate ^{6a}
Shin, A.	Intelon Optics Inc ^{3a}
Shin, D.	Fellow Health ^{2a}
Shin, Y.	Life Science, LG Chem, Ltd ^{3a}
Siddiqui, N.	Orchid ^{123a}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Sigman, M.	American Society of Andrology ^{8a} (on executive committee); Bay Area Medical ^{2a}
Sillman, J.	Roche Diagnostics International ^{3a}
Simon, J. A.	AbbVie, Inc., Bayer Healthcare LLC., Dare ´ Bioscience; Ipsen, Mylan/Viatis Inc., Myovant Sciences, Sebela Pharmaceuticals Inc. ^{4a} ; Astellas Pharma, Inc., Mayne Pharma, Inc., Myovant Sciences, Inc., Pfizer Inc., Pharmavite LLC., Scynexis Inc. ^{7a} ; ayer HealthCare Pharmaceuticals Inc., Besins Healthcare, Biote Medical, LLC, California Institute of Integral Studies (CIIS), DareÂ ´ Bioscience, Femasys Inc., Khyria, Madorra Pty Ltd., Mayne Pharma, Inc., Pfizer Inc., Vella Bioscience Inc. ^{6a} ; Sermonix Pharmaceuticals ^{2a}
Skellington, K.	Cooper Genomics ^{36a}
Smith, J. F.	Fellow Health ^{1a} ; Inherent Biosciences ^{28a} (Scientific advisor); Posterity Health ^{28a} (Scientific Advisor)
Smith, K. N.	EMD Serono ^{5a} ; Ferring ^{7a}
Smith, R. P.	PS-Fertility ^{12a}
Snabes, M. C.	AbbVie ^{23a}
Snider, A.	Igenomix ^{3a}
Soltész, D.	RMA of New York ^{1a}
Sondekoppam, R.	CIVCO Ltd ^{6a}
Souter, V.	Natera ^{23a}
Spiro, S.	Maven Clinic ^{3a}
Spitz, A.	2ndMD ^{6a} ; contraline ^{6a} ; fellow ²³⁶ ; Mosie baby ^{6a}
Srouji, S. S.	Ferring ^{8a} (Served on Ferring advisory board once)
Stachecki, J.	Innovative Cryo Enterprises II LLC ^{1a}
Stankewicz, T.	Igenomix ^{3a}
Stewart, E. A.	AbbVie ^{6a} ; Alnylam ^{6a} ; Aska ^{6a} ; UpToDate ^{5a} ; WEB MD ^a
Strait, E.	Vitrolife, Inc. ^{3a}
Strug, M.	Elsa Fertility ^{2a}
Suraj, V.	Alife Health ^{3a}
Swanson, A.	Fertilitywise ^{6a}
Swanson, T. J.	Univfy Inc. ^{38a}
Tabbaa, S.	lady Technologies ^{1a}
Taft, R.	Intelon Optics ^{4c}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Talati, A. N.	Billion to One ^{4a}
Tamimi, R. M.	Sterigenics ^{6a}
Tanaka, B.	Ferring Pharmaceuticals, Inc. ^{3a}
Tanrikut, C.	New England Cryogenic Center ^a ; Society for the Study of Male Reproduction ^a ; Swimmers ^a
Tao, X.	Juno Genetics US Inc ^{3a}
Tauber, Y.	AIVF ^{3a}
Taylor, H. S.	Abbvie ^{4c} ; Dot Lab ^{2a} ; Organon ^{4c}
Tek, V.	Takara Bio USA, Inc ^{3a}
Thirumalaraju, P.	XX ^{8a} (IP licensee)
Thomas, J. W.	Abbvie ^{23a}
Thomas, M. A.	Levocept ^{48a} (Monies to University. Clinical trial); Organon ^{48a} (Monies to University. Clinical Trial)
Thornton, K. L.	Alife ^{8a} (clinical advisor); Boston Museum of Science ^{8a} (museum advisory board); Ferring Pharmaceuticals ^{8a} (Consultant to review e-learning modules to educate and better understand the impact of our educational efforts and treatment efforts on minorities in the community); Labcorp ^{8a} (Clinical Advisory Board); Pharmaceutical Contracting Alliance ^{2a}
Throckmorton, A. D.	Exactech, Inc ^{28b} ; gilead ^{2a} ; gilead ^{2b} ; osteocentrics ^{6b} ; pacira ^{6b} ; responsive arthroscopy ^{28b} ; Saunders/Mosby-Elsevier ^{8b} ; Shoulder JAM ^{2b} ; Zimmer ^{68b}
Tobias, T.	Ferring Pharmaceuticals ^{67a}
Travis, A. J.	Androvia LifeSciences ^{12a}
Treff, N. R.	EMD Serono ^{7a} ; Genomic Prediction Inc ^{12a}
Tsai, S.	Intuitive ^{6a} ; Pfizer ^{6a}
Tsai, S.	ME ^{2a}
Tubman, V. N.	Novartis Pharmaceuticals ^{6a}
Turek, P. J.	AlphaSperm, Inc ^{12a} ; Arex Bioscience ^{6a} ; Arex Bioscience, Inc ^a ; BioQ, Inc ^{2a} ; CellArts, Inc ^{12a} ; Contraline, Inc ^{6a} ; Doximity, Inc ^{2a} ; Future Family ^{2a} ; Give Legacy Inc ^{2a} ; Inherent Biosciences ^{6a} ; Inherent Biosciences, Inc ^a ; MandalMed, Inc ^{12a}
Tur-Kaspa, I.	Embryonics ^{8a} (Medical Advisory Board); Ferring ^{8a} (Advisory Boards)
Ubaldi, F. M.	MedEA ^{7a} ; IVI-RMA Global ^{23a} ; IVIRMA ITALIA SRL ^{1a} ; Merck, Organon, Ferring, Gedeon Richter, Ibs ^a , Cooper Surgical, Cook ^{6a}
Ulfig, M.	MIM Solutions ^{3a}
Updike, A. J.	Vitrolife, Inc ^{3a}



ASRM 2024
INVITED SPEAKER DISCLOSURES INDEX

All speakers at the ASRM 2024 Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Valbuena Perilla, D.	Igenomix R&D ^{3a}
Valencia, R.	Conceivable Life Sciences ^a ; IVF 2.0 LTD ^{8a} (Advisor)
Vance, A. C.	Bay Area Genetic Counseling ^{6a}
Vaughan, D. A.	Ferring ^{6a} ; Testasy ^{2a}
Venetis, C.	Ferring ^{45a} ; IBSA ^{5a} ; Merck ^{45a} ; Merck, Sharpe & Dohme ^{5a} ; Organon ^{5a} ; Virtus Health ^{2b}
Vij, S. C.	SPD Diagnostics ^{6a}
Villanueva, P.	Gameto Inc ^{4c}
Vitek, W. S.	Turtle Health ^{6a}
Wagner, L.	Celgene/Bristol Myers Squibb ^{6a}
Walimbe, P.	CooperSurgical ^{3a}
Wells, D.	Juno Genetics ^{23a}
Wessels, J. M.	Afynia Laboratories ^{123a}
Wise, L. A.	AbbVie, Inc. ^{6a}
WorriLOW, K. C.	LifeAire Systems ^{123a}
Wozniak, K.	Southern California Assisted Reproductive Biologists ^{8a} (Board Member)
Wrochna, M.	MIM Solutions ^{3a}
Wygocki, P.	MIM Solutions ^{12a}
Xanthopoulou, L.	Cooper Companies ^{23a}
Xia, Y.	Orchid Health ^{3a}
Xu, H.	Takara Bio ^{3a}
Xu, J.	Genomic Prediction, Inc. ^{1a}
Yao, M. W.	Univfy Inc. ^{1238a} (Director and Inventor); Univfy Inc. ^{8a} (ASRM Corp Council)
Yong, P.	Ohnut ^a
Young, S.	Medtronic ^{5a}
Zaninovic, N.	AIVF ^{6a} ; Apricity ^{6a} ; Fairtility ^{6a}
Zapala, A.	MIM Solutions! ^a
Zelinski, M. B.	Expanse Bio/Gaia Life ^a ; Oviva Therapeutics ^a
Zepeda, A.	Fairtility ^{23a}
Zhan, Y.	Juno Genetics ^{3a}
Zielen, M.	MIM Solutions ^a

DON'T MISS THE 2024

**ASRM
x
CADE**

SOCIAL MEDIA SUMMIT

**DENVER, CO
10.20.24**

Join us for the ASRM x CADE Social Media Summit, hosted by the ASRM Social Media Special Interest Group and moderated by Dr. Camille Hammond of the Cade Foundation. This event will equip you with the tools and knowledge to excel in social media within reproductive medicine!

Gain expert insights, network with influencers and peers, and participate in hands-on activities, including creating and receiving feedback on your own social media post. Don't miss this chance to elevate your digital presence and make a lasting impact in the field!

Sign up during the ASRM Scientific Congress & Expo registration or register separately at www.asrmcongress.org.



Sponsored by Gattaca Genomics



MONDAY, OCTOBER 21, 2024

**Environment and Reproduction
Special Interest Group**

RTM-01

**Wildfire Smoke and Human
Reproduction**

Thalia Segal, MD
Collab Fertility

**In Vitro Maturation Special
Interest Group**

RTM-02

Meet IVM Experts

Michael Grynberg, MD, PhD
Hôpital Antoine Béchère

**Society of Reproductive
Surgeons**

RTM-03

**Vasectomy Reversal vs ART After
Vasectomy - Indications**

Ryan Smith, MD
University of Virginia

Nurses' Professional Group

RTM-04

**Food for Fertility: Nutrition and Trying to
Conceive**

Jamie Feingold, MSN, NP-C, WHNP-BC
University of Rochester

Nutrition Special Interest Group

RTM-05

**Food First: Role of Whole Foods in
Promoting IVF Success**

Judy Simon, MS, RDN
Mind Body Nutrition, PLLC

**Fertility Preservation Special
Interest Group**

RTM-06

**Fertility Preservation in Non-oncologic
Patients and Emerging Therapies**

Julie Rios, MD
University of Pittsburgh Medical Center

**Genetic Counseling Professional
Group**

RTM-07

**Considerations for PGT-M Positive
Embryo Transfers**

Pamela Callum, MS
Tandem Genetics

**Society for Assisted
Reproductive Technology**

RTM-08

**Conducting Research with SART: The Ins
and Outs of Navigating the SARTCORs
Database**

Suneeta Senapati, MD, MSCE
University of Pennsylvania

**Health Disparities Special
Interest Group**

RTM-09

**Navigating Fertility Awareness: Bridging
Gaps in Health Literacy**

Cassie Hobbs, MD
Warren Alpert Medical School of Brown
University; Women & Infants Hospital of
Rhode Island

**Social Media Special Interest
Group**

RTM-10

**Social Media Use for the REI: Grow
Your Practice While Also Educating and
Dispelling Myths**

Creighton Likes, MD, MS
CCRM-Greenville

**Artificial intelligence Special
Interest Group**

RTM-11

**Tech Trailblazers: Entrepreneurs
Innovating the Path to Parenthood with
Artificial Intelligence**

Daniella Gilboa, MSc

**Association of Reproductive
Managers**

RTM-12

**Growing Pains - Expanding Office and
Laboratory Space**

Lindsey McBain, BA
IVI RMA

**Society for Male Reproduction
and Urology**

RTM-13

**The Use of Testicular Sperm in Non-
azoospermic Males**

Sandro Esteves, MD, PhD
ANDROFERT - Center for Male
Reproduction

**Society for Reproductive
Endocrinology & Infertility**

RTM-14

Starting a New REI Fellowship

LaTasha Craig, MD
The University of Oklahoma Health
Sciences Center

AMMR

RTM-15

**AMMR: Panorama Actual de la
Medicina Reproductiva en México
(Pública vs Privada). Current Perspectives
of Reproductive Medicine in Mexico
(Public vs Private) (SPANISH)**

Ruben Tlapanco, MD

**Society for Assisted
Reproductive Technology**

RTM-16

**Optimizing FET Protocols: How Best to
Get that Little Embryo to Take!**

Valerie Baker, MD



**Preimplantation Genetic Testing
Special Interest Group**

RTM-17

Can New DNA Amplification Strategies Overcome Technical and Biological Challenges Facing PGT-M, Improving the Accuracy of Diagnosis and Increasing Patient Access?

Dagan Wells, BSc, PhD
Juno Genetics / University of Oxford

RTM-18

Whole Genome Sequencing of Embryos – Is it Possible, Reliable, Desirable....?

Maria Katz, MSc, LCGC
Orchid Health

**Mental Health Professional
Group**

RTM-19

Gestational Carriers: History of Depression and Anxiety

Jennifer Gamper Meenan, BSN, RN, LCSW
IVIRMA

**Early Pregnancy Special Interest
Group**

RTM-20

Prevention and Treatment of Asherman's Syndrome.

Michael Strug, DO, PhD

Legal Professional Group

RTM-21

When an Informed Consent Just Won't Do: Understanding the Importance of Contracts in Embryo Donation Arrangements

Judith Hoechst, BA, JD, RN, RNC
Private Practice

**Androgen Excess Special
Interest Group/AE-PCOS Society**

RTM-22

Use of Antimullerian Hormone (AMH) to as a Diagnostic Criterion for PCOS Diagnosis

Jorge Chavarro, DSc, MD
Harvard T.H. Chan School of Public Health

Fibroids Special Interest Group

RTM-23

Nip it in the Bud: Early Identification and Prevention of Uterine Fibroids

Mohamed Ali, PhD
University of Chicago

**Society of Reproductive
Biologists and Technologists**

RTM-24

Leading with Purpose: Aligning Mission, Vision, and Values for Effective Leadership

Kristen Ivani, PhD
Reproductive Science Center of the San Francisco Bay Area

ASRM Technology Committee

RTM-25

One- Solution Automation of IVF Laboratories: Increasing Safety and Decreasing Costs

Christine Allen, MS, PhD
EliteIVF

ASFP

RTM-26

ASFP: Initiating Fertility Preservation: From Clinical Practice to Countrywide Implementation

Jung Ryeol Lee, MD, PhD
Seoul National University Bundang Hospital

KSRM

RTM-27

KSRM: Cell Therapy for Endometrial Regeneration

Kyong Wook Yi, MD, PhD
Professor

TUESDAY, OCTOBER 22, 2024

**Menopause and Ovarian
Insufficiency Special Interest
Group**

RTT-01

Endocrine Disruptors and Ovarian Reserve

Vasilios Goudas, MD

Turkish Special Interest Group

RTT-02

Present and Future of Fertility Preservation

Kutluk Oktay, MD, PhD
Yale University School of Medicine

**Society of Reproductive
Surgeons**

RTT-03

Fertility Preservation Surgery: Ovarian Transposition, Ovarian Tissue Transplantation and Uterine Transposition

Rebecca Flyckt, MD
University Hospitals Fertility Center/Case Western University

Nurses' Professional Group

RTT-04

From Potential to Performance: A Round Table Discussion on Developing Leadership Programs

Caitlin Hebert, RN, BSN

Nutrition Special Interest Group

RTT-05

Healthy Weight Loss: Nutritional Support with GLP1 α

Christina Boots, MD, MSCI
Northwestern University

**Advanced Practice Providers
Professional Group**

RTT-06

Advanced Practice Providers in Male Reproductive Health - How the Role is Evolving

Molly Jessup, NPc
The Turek Clinic



Society for Male Reproduction and Urology; Society of Reproductive Surgeons

RTT-07

Guiding Growth: Mentoring for Professional Development

Ranjith Ramasamy, MD
University of Miami

Association of Reproductive Managers; Society of Reproductive Biologists and Technologists

RTT-08

Compliance - Lab, Procedure Room Accreditation, Annual Cycles, and Best Practices

Peter Fuzesi, MS

Society for Assisted Reproductive Technology

RTT-09

PGTA Transfer- One at a Time is the ONLY Way to GO!

Julian Gingold, MD, PhD
Montefiore Institute for Reproductive Medicine

Complementary and Integrative Medicine Special Interest Group

RTT-10

Pain Management and Beyond: Supporting Patients with Endometriosis Using Integrative Medicine

Niki Rarig, ND, LAc
East West Natural Medical Center

AMMR

RTT-11

AMMR: El Manejo del Endometrioma en Medicina Reproductiva- AMMR. The Management of Endometrioma in Reproductive Medicine- AMMR (SPANISH)

J. Ricardo Loret de Mola, MD
Southern Illinois University School of Medicine

Society for Reproductive Endocrinology & Infertility

RTT-12

Strategies for Natural Cycle Frozen Embryo Transfer

Kate Schoyer, MD
Medical College of Wisconsin

Indian Special Interest Group

RTT-13

Unchain The Melody of Myomectomy

Sunita Tandulwadkar, MD
Solo Clinic

LGBTQ Special Interest Group

RTT-14

Delivering High Quality, Inclusive and Accessible Infertility Healthcare to LGBTQ+ Individuals

Courtney Marsh, MD, MPH
University of Kansas Medical Center

Preimplantation Genetic Testing Special Interest Group

RTT-15

Are PGT Results Impacted by Differences in Embryological Technique?

Shannon Kirkpatrick, MS, TS, ELD

Society for Assisted Reproductive Technology

RTT-16

SART 101 for APPs

Hina Ahmed, MS
Kindbody

Preimplantation Genetic Testing Special Interest Group

RTT-17

Can Morphokinetics or Other Non-Invasive Methods Substitute for PGT-A?

Gary Harton, PhD

Mental Health Professional Group

RTT-18

Beyond the Biological Clock: The Dynamics of Advanced Age Parenthood

Karen Hall, PhD
Center For Infertility Counseling

Endometriosis Special Interest Group

RTT-19

The Role of the Immune System in Endometriosis

Alexander Kotlyar, MD
Genesis Fertility and Reproductive Medicine

Social Media Special Interest Group

RTT-20

Using Social Media To Benefit Health Care Providers/Clinics

Blake Evans, DO
University of Oklahoma Health Sciences Center

Fertility Preservation Special Interest Group

RTT-21

Female Contraception During Active Cancer Treatment

Leslie Appiah, MD

Access to Care

RTT-22

How the Current U.S. Legal Landscape is Affecting Access to Fertility Services

Nesta Johnson, JD
National Center for Lesbian Rights



Society of Reproductive Biologists and Technologists

RTT-23

Boosting AI Predictions: Novel Techniques to Optimize Implantation Forecasts.

Marcos Meseguer, PhD
IVIRMA Global Research Alliance, IVIRMA Valencia, IVI Foundation, La Fe Health Research Institute

Imaging in Reproductive Medicine Special Interest Group

RTT-24

Ultrasound Diagnosis of Endometrial Pathology Relevant to Fertility

Laura Detti, MD
Baylor College of Medicine

Physician-Scientists' Special Interest Group

RTT-25

Flourishing in an Academic Career

William Catherino, MD, PhD
Uniformed Services University of the Health Sciences

RTT-26

New Technologies and Innovation: The Investors Vantage Point

David Sable, MD
Columbia University

Advanced Practice Providers Professional Group

RTT-27

Preview Into an Upcoming ASRM White Paper - Integrating and Defining Collaborations Between REIs and APPs

Jeanine Price, DNP, MSN
Shady Grove Fertility - Houston

WEDNESDAY, OCTOBER 23, 2024

Environment and Reproduction Special Interest Group

RTW-01

Organoid and Organ-on-Chip Technologies to Study Environmental Exposures on Female Reproduction

Shuo Xiao, MBBS, PhD

Turkish Special Interest Group

RTW-02

Global Experience with Oocyte Cryopreservation

Aylin Cil, MD
American Hospital

In Vitro Maturation Special Interest Group

RTW-03

Meet Experts in In Vitro Maturation of Oocytes

Michel De Vos, MD, PhD
UZ Brussel

Society of Reproductive Surgeons

RTW-04

Office Hysteroscopy

John Preston Parry, MD, MPH
Positive Steps Fertility

Fertility Preservation Special Interest Group

RTW-05

Psychosocial Aspects and Decision Making for Pregnancy or Surrogates for ER+ Breast Cancer

May-Tal Sauerbrun-Cutler, MD
Brown University Medical School

Genetic Counseling Professional Group

RTW-06

PGT-A Surprises: What Should We Do with Incidental Findings?

Katie Rembisz, MS
Igenomix

Society for Male Reproduction and Urology and the Society of Reproductive Surgeons

RTW-08

Reproductive Management for the Couple After Vasectomy: Making the Case for Vasectomy Reversal vs. In Vitro Fertilization

Sarah Vij, MD
Cleveland Clinic Foundation

Association of Reproductive Managers

RTW-09

HR - Employee Development, Catering to the Newer Generation, and Motivating the Team

Sara Mooney, BA
Practice Administrator

Society for Assisted Reproductive Technology

RTW-10

Maximizing Patient Well-Being During ART: Lessons Learned from Mental Health Professionals

Danielle Kaplan, PhD
NYU Langone School of Medicine

RTW-11

PGT-A Consent: The Minimum of What We Should Discuss with Patients

Hannah Green, MS, CGC

Health Disparities Special Interest Group

RTW-12

Why the Distrust? A Deep Dive into the Origins and Topics that Spur Distrust in Healthcare Among the Minority Community.

Morine Cebert, PhD, FNP-C
Duke University School of Nursing



Social Media Special Interest Group

RTW-13

Social Media Use for the REI: How it can be Used to Grow Your Practice

Creighton Likes, MD
CCRM-Greenville

Artificial intelligence Special Interest Group

RTW-14

Embracing the AI Evolution: Navigating the Impacts of Artificial Intelligence on Embryology Careers

Carol Curchoe, PhD, HCLD

Society for Reproductive Endocrinology and Infertility

RTW-15

Addressing the Provider Gap in Reproductive Endocrinology and Infertility

Eduardo Hariton, MBA, MD
Reproductive Science Center of the SF Bay Area

LGBTQ Special Interest Group

RTW-16

Reciprocal IVF/ ROPA (Reception of Oocytes from PArtners) Method

Pedro Brandão, MD, PhD, EFOG, EFRM
IVIRMA Global Research Alliance

Preimplantation Genetic Testing Special Interest Group

RTW-17

The Intersection of Carrier Screening and PGT-M

Paulina Nassab, MS, CGC
Igenomix

Preimplantation Genetic Testing Special Interest Group

RTW-18

Segmental Aneuploidies: Detection and Clinical Considerations

Alyssa Snider, PhD
Igenomix

Indian Special Interest Group

RTW-19

Adjuvants in Poor Ovarian Responders

Asha Baxi, MBBS, MS, FRCOG, FICOG
Motherhood Hospital, Indore, M.P.(India)

LGBTQ Special Interest Group and the Mental Health Professional Group

RTW-20

Three's Company: Considerations in Working with Polyamorous Families

Julie Bindeman, PsyD
Integrative Therapy of Greater Washington

Early Pregnancy Special Interest Group

RTW-21

The Impact of Lifestyle and Environment on Pregnancy Loss

Erin Masaba, MD
University of Rochester

ALMER

RTW-23

ALMER: PGT-A ¿Qué tan útil es para NHP pacientes? PGT-A. How Useful is it For Your Patients?(SPANISH)

Eduardo Castro Valderrama, MD
Medical Director

Society of Reproductive Biologists and Technologists

RTW-24

PGT for Polygenic Disease

Nathan Treff, PhD, HCLD
Genomic Prediction, Inc.

ASFP

RTW-26

ASFP: Fertility Preservation in Endometriosis

Budi Wiweko, MD, MPH, PhD

KSRM

RTW-27

KSRM: Platelet-Rich Plasma Therapy for Endometrial and Ovarian Dysfunction to Enhance IVF Success

Ji Hyang Kim, MD, PhD
Fertility Center, CHA Bundang Medical Center, CHA University



Video Abstract Session: Surgery

Moderator: John C Petrozza, MD and Michael Eisenberg, MD

10:45 AM		Welcoming Remarks	11:28 AM	V-4	LAPAROSCOPIC APPROACH TO INTERSTITIAL ECTOPIC PREGNANCY: USING A TOURNIQUET SUTURE AND DILUTED VASOPRESSIN. Luis Oswaldo De La O Perez, PhD ¹ and Carlos Armando Bravo Dr, MD ² , ¹ GESTAR, Monterrey, NL, Mexico, ² Hermosillo, Son, Mexico
10:50 AM	V-1	ISTHMOCELE: ONE PROBLEM, MANY FACES. Danielle A Aase, MD and Zaraq Khan, MD, Mayo Clinic, Rochester, MN			
10:58 AM		Discussion	11:35 AM		Discussion
11:03 AM	V-2	OVARIAN TISSUE ALLOTTRANSPLANTATION BETWEEN GENETICALLY NON-IDENTICAL SIBLINGS WITH HLA INCOMPATIBILITY AND IMMUNOSUPPRESSION. Kathryn D Coyne, MD ¹ , Rebecca Flyckt, MD ² , Daniel C Brennan, MD ³ , Anibal G Melo, MD ⁴ , Rowena Delos Santos, MD ⁵ and Sherman Silber, MD ⁶ , ¹ University Hospitals Cleveland Medical Center, OH, ² University Hospitals Fertility Center/Case Western Reserve University, Beachwood, OH, ³ The Johns Hopkins Hospital, Baltimore, MD, ⁴ St. Luke's Hospital, ⁵ Washington University School of Medicine, ⁶ Infertility Center of St. Louis, Chesterfield, MO	11:40 AM	V-5	HYSTEROSCOPY TO ASSIST IN DIAGNOSIS AND TREATMENT OF PREGNANCY OF UNKNOWN LOCATION. Sara C Pierpoint, MD ¹ and Linnea R Goodman, MD ² , ¹ Charlottesville, VA, ² VA Fertility and IVF, Charlottesville, VA
11:11 AM		Discussion	11:48 AM		Discussion
11:16 AM	V-3	LAPAROSCOPIC ULTRASOUND DURING MINIMALLY INVASIVE MYOMECTOMY. Evelyn Minis, MD ¹ , Christopher Ke Arkfeld, MD ² , Victoria W Fitz, MD, MS ³ and John C Petrozza, MD ⁴ , ¹ Massachusetts General Hospital Fertility Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, ² Cambridge, MA, ³ Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴ Massachusetts General Hospital, Boston, MA	11:53 AM	V-6	HYSTEROSCOPY FOR EARLY PREGNANCY LOSS: MANAGING EPL WITH A REPRODUCTIVE SURGERY MINDSET. Kelly Ryan, MD ¹ , Mary McKenna, MD ² , Kirsten Sasaki, MD ³ and Charles E. Miller, MD ⁴ , ¹ Western Springs, IL, ² Chicago, IL, ³ Advocate Lutheran General Hospital, Naperville, IL, ⁴ Rosalind Franklin University of Medicine and Science (Professor), North Chicago, IL
11:23 AM		Discussion	12:01 PM		Discussion
			12:06 PM	V-7	FACING UNEXPECTED; OVARIAN CYST TURNS OUT TO BE FIMBRIAE HERNIATED THROUGH THE OVARY. Golnaz Namazi, MD, University of California, Riverside, School of Medicine, Riverside, CA
			12:11 PM		Discussion



Video Abstract Session: Surgery

Moderator: John C Petrozza, MD and Michael Eisenberg, MD

- 10:45 AM **Welcoming Remarks**
- 10:50 AM **V-8 SEEING THE INVISIBLE: SUBCELLULAR MORPHOLOGY MEASUREMENT OF LIVE SPERM THROUGH AI-BASED VIRTUAL STAINING.** Wenyuan Chen, MS¹, Haocong Song, BE¹, Zhuoran Zhang, PhD², Changsheng Dai, PhD³, Guanqiao Shan, PhD¹, Hang Liu, PhD¹, Aojun Jiang, MS¹, Shivani Nirmalbhair Dhanani, BSc⁴, Shruti Bhaskar Pathak, BSc⁴, Clifford Librach, MD⁴ and Yu Sun, PhD¹, ¹University of Toronto, Toronto, ON, Canada, ²The Chinese University of Hong Kong, Shenzhen, Shenzhen City, Guangdong Province, China, ³Dalian University of Technology, Dalian, China, ⁴CReATe Fertility Centre, Toronto, ON, Canada
- 10:58 AM **Discussion**
- 11:03 AM **V-9 PLOIDY ANOMALIES REVEALED BY ANALYSIS OF CHROMOSOME DYNAMICS FROM 3PN EMBRYOS CONTAINING SMALL PRONUCLEI.** Saki Hashimoto, BS¹, Yuta Kida, MS², Mikiko Tokoro, PhD¹, Noritaka Fukunaga, PhD² and Yoshimasa Asada, MD, PhD², ¹Asada Ladies Clinic, Nagoya-Shi, Japan, ²Asada Ladies Clinic, Nagoya, Japan
- 11:11 AM **Discussion**
- 11:16 AM **V-10 CLINICAL PROCEDURES FOR IN VITRO MATURATION (IVM) TREATMENT.** Michel De Vos, MD, PhD¹, Ingrid Segers, PhD², Ye Yuan, PhD³, Christian Clark Kramme, PhD⁴ and Robert B Gilchrist, PhD, Prof.⁵, ¹UZ Brussel, Brussels, Belgium, ²Universitair Ziekenhuis Brussel, Brussel, Belgium, ³Colorado Center for Reproductive Medicine, Lone Tree, CO, ⁴Gameto Inc., New York, NY, ⁵University of New South Wales, Millers Point, NSW, Australia
- 11:24 AM **Discussion**
- 11:29 AM **V-11 AUTOMATED SPERM EVALUATION IN TESTICULAR TISSUE FOR AZOOSPERMIA.** Haocong Song, BE¹, Wenyuan Chen, MS¹, Shanshan Wang, MS², Miao Hao, MS³, Guanqiao Shan, PhD¹, Changsheng Dai, PhD⁴, Hang Liu, PhD¹, Aojun Jiang, MS¹, Haixiang Sun, MD PhD² and Yu Sun, PhD¹, ¹University of Toronto, Toronto, ON, Canada, ²Nanjing Drum Tower Hospital, Nanjing, China, ³Soochow University, Suzhou, China, ⁴Dalian University of Technology, Dalian, China
- 11:37 AM **Discussion**
- 11:42 AM **V-12 VARIATIONS IN HYSTEROSCOPIC APPEARANCE OF PARTIAL SEPTATE UTERI AND ARCUATE UTERI.** Sydney Daviskiba, MD¹ and Mostafa I Abuzeid, MD², ¹Henry Ford Hospital, Detroit, MI, ²Henry Ford Health, Center for Reproductive Medicine – Department of Women’s Health Services, Rochester Hills, MI
- 11:50 AM **Discussion**
- 11:55 AM **V-13 MANAGEMENT OF AN ATYPICAL ROBERT’S UTERUS VIA SYNCHRONIZED HYSTEROSCOPY AND LAPAROSCOPY.** Jasmine Eliwa, MD¹, Evelina Manvelyan, MD², Emily Marra, MD³, Kathryn D Coyne, MD⁴, Joseph Findley, MD⁵, Steven R. Lindheim, MD⁶ and Rebecca Flyckt, MD³, ¹University of Tennessee Health Sciences Center, Memphis, TN, ²University Hospitals Fertility Center Case Western Reserve University, Beachwood, OH, ³University Hospitals Fertility Center/ Case Western Reserve University, Beachwood, OH, ⁴University Hospitals Cleveland Medical Center, OH, ⁵University Hospitals Cleveland Medical Center, Beachwood, OH, ⁶Baylor Scott and White Health, Temple, TX
- 12:03 PM **Discussion**



MONDAY, OCTOBER 21, 2024

10:45 AM - 12:15 PM

OSM-01 2024 Scientific Congress Prize Paper Session (1 of 2)

The first six papers are candidates for the ASRM Scientific Congress Prize Paper Awards. Six additional candidates will be presented during the 2024 Scientific Congress Prize Paper (2 of 2) session Monday from 1:30-2:45 PM.

Table with 4 columns: Time, ID, Title, Author. Rows include: 10:45 AM O-1 OVARIFY: UTILIZING A MACHINE LEARNING MODEL AND CLINICAL FEATURES TO PREDICT POLYCYSTIC OVARY SYNDROME. A. T. Evans; 10:56 AM O-2 LONG-TERM FOLLOW-UP OF OOCYTE DONORS: THOUGHTS AND FEELINGS ABOUT DONATION AND FUTURE CONTACT WITH CHILDREN FROM THE DONATION. S. R. Holley; 11:07 AM O-3 ROLE OF TENASCIN C IN LESION FORMATION IN EARLY PERITONEAL ENDOMETRIOSIS. M. Moriyama; 11:18 AM O-4 ESTABLISHMENT OF IN VITRO IMPLANTATION MODEL USING NEWLY DEVELOPED ENDOMETRIAL ORGANOID. I. Tamura; 11:29 AM O-5 AN INTEGRATED PREIMPLANTATION GENETIC TEST COMBINING PRIMARY TEMPLATE DIRECTED AMPLIFICATION, COPY NUMBER VARIATION AND ALLELE FREQUENCY DATA TO GENERATE THE MOST COMPLETE VIEW OF MOSAIC EMBRYOS. C. Weier; 11:40 AM O-6 A NOVEL TIME-LAPSE 3D IN VITRO CO-CULTURE SYSTEM TO CHARACTERIZE EXTRACELLULAR COMMUNICATION ASSOCIATED WITH IMPLANTATION SUCCESS. K. J. McCarty

MONDAY, OCTOBER 21, 2024

10:45 AM - 12:15 PM

OSM-02 ORAL ABSTRACT SESSION: BUSINESS OF MEDICINE & PROFESSIONAL DEVELOPMENT

Table with 4 columns: Time, ID, Title, Author. Rows include: 10:45 AM O-13 COST-EFFECTIVENESS ANALYSIS OF PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) IN GOOD PROGNOSIS PATIENTS. A. J. Dunn; 10:56 AM O-14 COST EFFECTIVE ANALYSIS OF PGT-A IN IVF CYCLES AMONG PATIENTS AGE 38-40 YEARS OLD. C. Diribe; 11:07 AM O-15 ECONOMIC BENEFIT OF AN EPIGENETIC MALE INFERTILITY ASSESSMENT. K. Brogaard; 11:18 AM O-16 FERTILITY PRESERVATION AND INFERTILITY TREATMENT IN FEMALE SURGICAL TRAINEES IN ALBERTA: A SURVEY OF TRAINEE KNOWLEDGE, ATTITUDES, AND NEEDS. S. Bowden; 11:29 AM O-17 REPRODUCTIVE ENDOCRINOLOGIST PERSPECTIVES ON PHYSICIAN PREGNANCY (REPPP). R. M. Whyntott; 11:40 AM O-18 DO REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY FELLOWSHIP WEBSITES REFLECT A COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION? J. Eliwa; 11:51 AM O-19 MATCHING DURING A CRISIS: RECRUITMENT OF REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY FELLOWS OUTSIDE OF THE FORMAL MATCH PROCESS DURING THE COVID-19 PANDEMIC. E. M. Stylli; 12:02 PM O-20 CAREER OUTCOMES OF OBSTETRICS AND GYNECOLOGY RESIDENTS WHO COMPLETE AN AWAY ELECTIVE IN REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY. R. Yamada





MONDAY, OCTOBER 21, 2024

10:45 AM - 12:15 PM

OSM-03 ORAL ABSTRACT SESSION: GENETICS- PGT (1 OF 2)

- 10:45 AM O-21 OUTCOMES FROM IVF CYCLES USING PREIMPLANTATION TESTING FOR ANEUPLOIDY (PGT-A) IN LEAN VS. OVERWEIGHT PATIENTS WITH POLYCYSTIC OVARY SYNDROME (PCOS) M. Madjunkov
- 10:56 AM O-22 THE ROLE OF PGT-A ON SIBLING EMBRYOS GENERATED FROM OOCYTES OF DIFFERENT AGES. O. M. Kocur
- 11:07 AM O-23 PERFORMANCE OF TWO PGT PLATFORMS UTILIZED WITHIN A SINGLE ASSISTED REPRODUCTIVE CENTER. D. Garro
- 11:18 AM O-24 EVALUATION OF NO-CALL ETIOLOGIES IN PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A): INFLUENCE ON GENETIC AND CLINICAL OUTCOMES FOLLOWING REBIOPSY. F. Barrett
- 11:29 AM O-25 EFFECT OF TROPHECTODERM REBIOPSY ON SERUM -HUMAN CHORIONIC GONADOTROPIN LEVELS IN PREGNANCIES RESULTING IN LIVE BIRTHS. R. Zhuo
- 11:40 AM O-26 MULTI-GENERATIONAL BLINDING OF PRE-IMPLANTATION GENETIC TESTING RESULTS FOR HUNTINGTON'S DISEASE: A CASE REPORT. S. R. Raine
- 11:51 AM O-27 DEFINING SEGMENTAL ANEUPLOIDY LIMITS OF DETECTION WITH PGT. H. Garnsey
- 12:02 PM O-28 A SINGLE BASE RESOLUTION PGT-SR TEST USING WHOLE GENOME APPROACH. N. Arrach

MONDAY, OCTOBER 21, 2024

10:45 AM - 12:15 PM

OSM-04 ORAL ABSTRACT SESSION: FERTILITY PRESERVATION- GENERAL (1 OF 2)

- 10:45 AM O-29 ASSESSING THE REPRODUCTIVE POTENTIAL OF LATE MATURE OOCYTES IN EGG FREEZING CYCLES. K. Bergin
- 10:56 AM O-30 PRIOR TESTOSTERONE USE DOES NOT APPEAR TO IMPACT OOCYTE CRYOPRESERVATION OUTCOMES IN TRANSGENDER PATIENTS: FINDINGS FROM A MULTICENTER HEALTH MAINTENANCE ORGANIZATION. N. Raj-Derouin
- 11:07 AM O-31 EVALUATING THE EFFECTS OF INTRAOVARIAN PLATELET-RICH PLASMA (PRP) ADMINISTRATION ON OVARIAN RESPONSE IN PATIENTS WITH DIMINISHED OVARIAN RESERVE: A SYSTEMATIC REVIEW AND META-ANALYSIS. S. Qaderi
- 11:18 AM O-32 RISK OF SERIOUS ADVERSE EVENT AFTER FERTILITY PRESERVATION PROCEDURES: A COMPARISON OF CANCER AND NON-CANCER PATIENTS. M. Grynberg
- 11:29 AM O-33 A SERIES OF FOUR OVARY ALLOTRANSPLANTS REQUIRING IMMUNOSUPPRESSION. S. Silber
- 11:40 AM O-34 ATTITUDES REGARDING ELECTIVE CRYOPRESERVATION AMONG MEDICAL TRAINEES. R. Nelson
- 11:51 AM O-35 OOCYTE CRYOPRESERVATION OUTCOMES IN PATIENTS WITH SEVERE BENIGN HEMATOLOGIC DISEASES PRIOR TO CURATIVE TREATMENT. A. J. Claffey
- 12:02 PM O-36 DEMOGRAPHIC FACTORS PREDICT OOCYTE UTILIZATION WHILE CLINICAL METRICS DETERMINE OUTCOMES FOR PATIENTS UNDERGOING PLANNED FERTILITY PRESERVATION. R. Dauria





MONDAY, OCTOBER 21, 2024

10:45 AM - 12:15 PM

OSM-05 ORAL ABSTRACT SESSION: ART- LAB

- 10:45 AM O-37 RE-EXPANSION CAPABILITY OF EUPLOID BLASTOCYSTS AFTER WARMING IS PREDICTIVE OF PREGNANCY OUTCOME, BUT NOT THE EXPANSION DEGREE AT THE TIME OF BIOPSY. T. Takeuchi
- 10:56 AM O-38 COMPARISON OF ONE-STEP AND MULTI-STEP WARMING PROTOCOLS: A SERIES OF 1689 BLASTOCYTS. H. K. Yelke
- 11:07 AM O-39 ONE-STEP WARMING: OPTIMIZES WORKFLOW AND EFFICIENCY IN THE IVF LABORATORY WITHOUT COMPROMISING OUTCOMES. R. S. Chrobocinski
- 11:18 AM O-40 IMPROVEMENT OF EPIGENETIC MODIFICATION AND DEVELOPMENTAL RATE BY SCRIPTAID IN ROSI. A. Tanaka
- 11:29 AM O-41 CAN IMMATURE OOCYTES 'CATCH-UP'? EMBRYO DEVELOPMENT AND REPRODUCTIVE POTENTIAL OF LATE-MATURED CRYOPRESERVED OOCYTES K. Bergin
- 11:40 AM O-42 LABORATORY OUTCOMES AFTER ULTRA-RAPID WARMING OF HUMAN CRYOPRESERVED CLEAVAGE-STAGE EMBRYOS. N. Younis
- 11:51 AM O-43 "QUICK AS LIGHTNING": A FRENCH 12-MONTH EXPERIENCE OF ULTRAFast BLASTOCYST WARMING ON MORE THAN 1000 SINGLE FROZEN-THAWED BLASTOCYST CYCLES. H. Joris
- 12:02 PM O-44 PRE-TRANSFER ENDOMETRIAL GROWTH AND BLASTOCYST TROPHECTODERM MEASUREMENT CORRELATE WITH BIRTH WEIGHT AFTER CONTROLLING FOR GESTATIONAL AGE, BODY MASS INDEX, AND INFANT SEX. C. E. Bedient

MONDAY, OCTOBER 21, 2024

10:45 AM - 12:15 PM

OSM-06 ORAL ABSTRACT SESSION: PRE-CLINICAL AND BASIC RESEARCH- ANIMAL MODELS

- 10:45 AM O-45 ALTERED GAP JUNCTION GENE EXPRESSION IN CUMULUS CELLS MAY CONTRIBUTE TO DECREASED OOCYTE QUALITY WITH AGING. S. M. Briley
- 10:56 AM O-46 MITOQUINOL IMPROVES IONOMYCIN-INDUCED PARTHENOGENETIC EMBRYONIC DEVELOPMENT. M. Zhang
- 11:07 AM O-47 PROLONGED INGESTION OF CRUDE OIL SPILL CONTAMINATED WATER AFFECTS MALE REPRODUCTIVE SYSTEM, HORMONES AND ACCESSORY ORGANS IN PIGS. L. C. Ajonuma
- 11:18 AM O-48 EFFECTS OF EXPERIMENTAL TESTICULAR HEAT EXPOSURE ON SPERM DNA INTEGRITY AND MITOCHONDRIAL ACTIVITY. M. A. Miyazaki
- 11:29 AM O-49 A COMPARATIVE ANALYSIS OF THE USE OF CRISPR/dCas9 ENGINEERED MSCs AND EXOSOMES VERSUS NON-ENGINEERED MSCs AND EXOSOMES FOR PREVENTION OF CISPLATIN-INDUCED OVARIAN FAILURE IN MICE. I. Yilmaz
- 11:40 AM O-50 HYALURONIC ACID SYSTEM IN RHESUS MONKEYS AS A MODEL FOR STUDYING THE PATHOGENESIS OF EARLY ENDOMETRIOTIC LESIONS. K. E. Kostroun
- 11:51 AM O-51 SENESCENT CELL CLEARANCE PROTECTS THE OVARIAN RESERVE IN AGING MICE. A. N. Kallen
- 12:02 PM O-52 DIFFERENCES IN SERUM METABOLOME PROFILES IN FSHB NULL FEMALE MICE EXPRESSING WILD-TYPE OR RE-ROUTED FOLLICLE-STIMULATING HORMONE. S. Elder

MONDAY, OCTOBER 21, 2024

11:45 AM - 12:15 PM

OSM-07 ORAL ABSTRACT SESSION: ADVANCE PRACTICE PROVIDERS (1 OF 2)

- 11:45 AM O-53 MIND-BODY INTERVENTIONS PROGRAM IMPROVES DEPRESSION, ANXIETY AND STRESS SYMPTOMS IN PATIENTS UNDERGOING FERTILITY TREATMENT. N. K. Callahan
- 11:56 AM O-54 PERSPECTIVES ON ADVANCED PRACTICE PROVIDERS (APPS) PARTICIPATION IN REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY (REI) DIFFERS BASED ON PRACTICE EXPERIENCE. A. M. Brown



MONDAY, OCTOBER 21, 2024

11:45 AM - 12:15 PM

OSM-08 ORAL ABSTRACT SESSION: GENETIC COUNSELING (1 OF 3)

- | | | | | | |
|----------|------|--|----------|------|--|
| 11:45 AM | O-55 | A RANDOMIZED CONTROLLED TRIAL(RCT) OF COUNSELING AND EDUCATIONAL METHODS ON PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY(PGT-A) FOR IVF PATIENTS. P. Singh | 11:56 AM | O-56 | THE EFFECTIVENESS AND UTILITY OF LIVE PRE-TEST PGT-A GROUP GENETIC COUNSELING WEBINAR. A. Jordan |
|----------|------|--|----------|------|--|

MONDAY, OCTOBER 21, 2024

11:45 AM - 12:15 PM

OSM-09 ORAL ABSTRACT SESSION: LAW, POLICY, AND ADVOCACY (1 OF 3)

- | | | | | | |
|----------|------|---|----------|------|---|
| 11:45 AM | O-57 | IMPACT OF STATE LEGISLATION MANDATING FERTILITY PRESERVATION COVERAGE ON FERTILITY PRESERVATION RATES IN TRANSGENDER AND GENDER NON-BINARY PATIENTS. R. Mickelsen | 11:56 AM | O-58 | LANGUAGE MATTERS: DIFFERENCES IN SERVICES AND POPULATIONS COVERED BY STATE FERTILITY PRESERVATION INSURANCE MANDATES. B. J. Peipert |
|----------|------|---|----------|------|---|

MONDAY, OCTOBER 21, 2024

11:45 AM - 12:15 PM

OSM-10 ORAL ABSTRACT SESSION: MENTAL HEALTH (1 OF 3)

- | | | | | | |
|----------|------|---|----------|------|--|
| 11:45 AM | O-59 | ASSOCIATIONS BETWEEN PRE-PREGNANCY ENDOMETRIOSIS AND POSTPARTUM PSYCHIATRIC DISORDERS. T. Hsieh | 11:56 AM | O-60 | PREVALENCE OF MENTAL HEALTH DIAGNOSES IN A RECURRENT PREGNANCY LOSS (RPL) POPULATION. S. L. Kruger |
|----------|------|---|----------|------|--|

MONDAY, OCTOBER 21, 2024

11:45 AM - 12:15 PM

OSM-11 ORAL ABSTRACT SESSION: NURSING (1 OF 3)

- | | | | | | |
|----------|------|---|----------|------|---|
| 11:45 AM | O-61 | IMPACT OF A NURSE NAVIGATOR PROGRAM ON REFERRAL RATES AND USE OF FERTILITY PRESERVATION: A 14-YEAR RETROSPECTIVE COHORT STUDY. K. Sorouri | 11:56 AM | O-62 | MEDIATING EFFECT OF PSYCHOLOGICAL RESILIENCE BETWEEN INFERTILITY-RELATED STRESS AND PSYCHOLOGICAL DISTRESS AMONG ENDOMETRIOSIS-ASSOCIATED INFERTILITY FEMALES: A STRUCTURAL EQUATION MODELING ANALYSIS. S. Xu |
|----------|------|---|----------|------|---|





MONDAY, OCTOBER 21, 2024

1:30 PM - 2:45 PM

OSM-12 2024 Scientific Congress Prize Paper Session (2 of 2)

1:30 PM	O-7	PREGNANCY-INDUCED HYPERTENSION (PIH) AND THE NUMBER OF CORPUS LUTEA IN EARLY PREGNANCY. D. Huang	2:03 PM	O-10	NOVEL CHARACTERISATION TOOLS FOR HUMAN PLOIDY ABNORMALITIES REVEALS A LINK TO MEIOTIC RECOMBINATION AND THE IDENTIFICATION OF A PREVIOUSLY UNDESCRIBED PHENOMENON. L. Picchetta
1:41 PM	O-8	A NOVEL APPROACH TO ASSESSING EMBRYO QUALITY IN ASSISTED REPRODUCTIVE TECHNOLOGY: DNA METHYLATION. X. Yao	2:14 PM	O-11	EMBRYONIC DE NOVO COPY NUMBER VARIANTS IDENTIFIED IN EUPLOID PREGNANCY LOSSES. C. Wageman
1:52 PM	O-9	TRAJECTORIES IN ANTIMULLERIAN HORMONE (AMH) DECLINE ACROSS THE MENOPAUSE TRANSITION; STUDY OF WOMEN'S HEALTH ACROSS THE NATION (SWAN). L. Bozzuto	2:25 PM	O-12	DO GUIDELINES MATTER? A COMPARISON OF MULTIPLE BIRTH RATES BEFORE AND AFTER THE PUBLICATION OF THE 2017 ASRM/SART EMBRYO TRANSFER GUIDELINE. K. M. Baker

MONDAY, OCTOBER 21, 2024

1:30 PM - 2:45 PM

OSM-13 ORAL ABSTRACT SESSION: SMRU TRAVELING SCHOLARS

1:30 PM	O-63	WHAT DO PATIENTS ACTUALLY WANT WHEN PROVIDING SEMEN SAMPLES? A MIXED METHODS SURVEY ASSESSING PATIENTS' SEMEN COLLECTION ROOM EXPERIENCES AND PREFERENCES. K. M. Black	2:03 PM	O-66	CHARACTERISTICS OF OLDER FATHERS IN THE UNITED STATES: DATA FROM THE NATIONAL SURVEY OF FAMILY GROWTH. J. Stinson
1:41 PM	O-64	SCROTAL ULTRASOUND CAN BE USED AS AN ADJUNCT TEST TO RULE IN VARICOCELES FOR PATIENTS BEING EVALUATED BY MALE REPRODUCTIVE UROLOGISTS WITH TELEMEDICINE. C. S. Nam	2:14 PM	O-67	THE ASSOCIATION BETWEEN SOCIOECONOMIC DEPRIVATION STATUS AND PM2.5 EXPOSURE AND SEMEN PARAMETERS AMONG MEN PRESENTING FOR FERTILITY EVALUATION L. C. Gago
1:52 PM	O-65	CRYOPRESERVED TESTICULAR SPERMATOZOA AMONG PATIENTS WITH AZOOSPERMIA. R. Bitan	2:25 PM	O-68	GEOGRAPHIC TRENDS OF ENVIRONMENTAL EXPOSURES FOR MEN PURSUING SEMEN ANALYSIS. T. Maloney

MONDAY, OCTOBER 21, 2024

1:30 PM - 2:45 PM

OSM-14 REPRODUCTIVE MEDICINE (NON INFERTILITY)- PCOS AND MENOPAUSE

1:30 PM	O-69	COMET-PCOS: RANDOMIZED CONTROLLED TRIAL OF ORAL CONTRACEPTIVE PILLS (OCPS), METFORMIN OR BOTH FOR 24 WEEKS IN WOMEN WITH PCOS AND OBESITY SHOWS NO DIFFERENCE IN PREVALENCE OF METABOLIC SYNDROME. A. Dokras	2:03 PM	O-72	THE ASSOCIATION BETWEEN DEPRESSIVE SYMPTOMS AND CHANGES IN QUALITY-OF-LIFE IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME. C. Murphy
1:41 PM	O-70	2, 4, 6, 8 HOW MANY MEASURES DOES IT TAKE? ACCURACY OF FINAL MENSTRUAL PERIOD (FMP) PREDICTIONS USING REPEATED MEASURES OF ANTIMULLERIAN HORMONE (AMH) FROM THE STUDY OF WOMEN ACROSS THE NATION (SWAN) M. D. Sammel	2:14 PM	O-73	IS UNDETECTABLE ANTIMULLERIAN HORMONE (AMH) REVERSIBLE? AN ANALYSIS OF REBOUND IN AMH AND ESTRADIOL (E2) IN THE STUDY OF WOMEN'S HEALTH ACROSS THE NATION (SWAN). K. S. Acharya
1:52 PM	O-71	ASSOCIATION OF POLYCYSTIC OVARIAN SYNDROME WITH EXCESSIVE GESTATIONAL WEIGHT GAIN. R. Solmonovich	2:25 PM	O-74	THE ASSOCIATION BETWEEN PRIMARY OVARIAN INSUFFICIENCY AND INCREASED MULTIMORBIDITY IN A LARGE PROSPECTIVE COHORT. A. Kirubarajan



MONDAY, OCTOBER 21, 2024

1:30 PM - 2:45 PM

OSM-15 ORAL ABSTRACT SESSION: HEALTH DISPARITIES & HEALTH EQUITY- GENERAL (1 OF 2)

Table with 4 columns: Time, ID, Title, and Author. Abstracts include: SELF-ASSESSMENT OF HEALTHCARE WORKER COMMUNICATION WITH LANGUAGE DIVERSE PATIENTS...; UTILIZATION OF LOW-COST PADS ALPHA FETOPROTEIN DETECTION PADS...; RACIAL AND ETHNIC DIFFERENCES IN GESTATIONAL CARRIERS...; FACTORS ASSOCIATED WITH FERTILITY TREATMENT DISCONTINUATION...; ASSOCIATION BETWEEN SOCIOECONOMIC DEPRIVATION, LIFE EXPECTANCY AND SERUM AMH LEVELS...; UTILIZING MAIL-IN SEMEN ANALYSIS TO IMPROVE TIME TO COMPLETION OF THE INFERTILITY WORKUP...

MONDAY, OCTOBER 21, 2024

1:30 PM - 2:45 PM

OSM-16 ORAL ABSTRACT SESSION: ART-OUTCOMES

Table with 4 columns: Time, ID, Title, and Author. Abstracts include: COST-CONSCIOUS FERTILITY CARE: NATURAL AND STIMULATED INTRAUTERINE INSEMINATION CYCLES...; EVALUATING THE IMPACT OF PHYSICAL ACTIVITY AND STRESS ON FROZEN EMBRYO TRANSFER...; THE IMPACT OF A PRIOR CESAREAN DELIVERY ON IVF OUTCOMES...; EMBRYO MORPHOLOGY ACCORDING TO SOCIETY FOR ASSISTED REPRODUCTIVE TECHNOLOGY (SART) CRITERIA...; ADVANCED SPERM AGE ≥50 YEAR IS ASSOCIATED WITH AN INCREASE IN SEGMENTAL ANEUPLOIDY RATES...; "BLIND" OVULATORY TRIGGER COMPARED TO STANDARD OVULATORY TRIGGER...

MONDAY, OCTOBER 21, 2024

1:30 PM - 2:45 PM

OSM-17 ORAL ABSTRACT SESSION: PRE-CLINICAL AND BASIC RESEARCH- STEM CELLS AND REGENERATIVE MEDICINE

Table with 4 columns: Time, ID, Title, and Author. Abstracts include: HOW ABOUT REPLICATING THE MALE GENOME?; THE USE OF AMD3100 FOR BONE MARROW DERIVED MESENCHYMAL STEM CELLS MOBILIZATION...; AUTOLOGOUS CELL THERAPY WITH CD133+ BONE MARROW-DERIVED STEM CELLS REVERT MODERATE/SEVERE ASHERMAN'S SYNDROME...; EDITING THE HAPLOID GENOME OF ANDROGENETIC EMBRYONIC STEM CELL...; CRISPR/CAS9 BASE EDITING ENABLES PRECISE GENE EDITING IN PREIMPLANTATION HUMAN EMBRYOS...; GENERATION OF BLASTOCYST-LIKE STRUCTURES VIA 3D ACOUSTIC TWEEZERS...





MONDAY, OCTOBER 21, 2024

3:30 PM - 4:45 PM

OSM-18 ORAL ABSTRACT SESSION: SURGERY

3:30 PM	O-93	EIGHT YEARS OF UTERUS TRANSPLANTS IN THE UNITED STATES: UPDATE ON SURGICAL, REPRODUCTIVE, NEONATAL, AND CHILD DEVELOPMENTAL OUTCOMES. L. A. Humphries	4:03 PM	O-96	CONGENITAL COMPLEX UTERINE ANOMALIES (CUA) CARRY COMPLEX COMPLICATIONS: AN EVALUATION OF ART OUTCOMES. K. Mecklai
3:41 PM	O-94	PREOPERATIVE HORMONE USE AND SURGICAL COMPLEXITY IN ENDOMETRIOSIS CASES. M. A. Rush	4:14 PM	O-97	CARBON FOOTPRINT IN GYNECOLOGIC SURGERY: SURVEY OF SURGEON PERSPECTIVES ON ENVIRONMENTAL WASTE IN THE OPERATING ROOM. E. Gargus
3:52 PM	O-95	INCIDENCE AND MANAGEMENT OF PELVIC PAIN IN PATIENTS WITH OBSTRUCTIVE AND NON-OBSTRUCTIVE MULLERIAN ANOMALIES. M. A. Rush	4:25 PM	O-98	ECONOMIC BURDEN OF INFERTILITY IN WOMEN FOLLOWING INTRAUTERINE SURGERY: A RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA. P. Bortoletto

MONDAY, OCTOBER 21, 2024

3:30 PM - 4:45 PM

OSM-19 ORAL ABSTRACT SESSION: TECHNOLOGY & INNOVATION

3:30 PM	O-99	DEVELOPMENT OF A VAGINAL DILATOR DEVICE AND A HOME INSEMINATION DEVICE FOR CIS- AND TRANSGENDER PEOPLE, BASED ON THE ACTUAL ANATOMY OF THE PELVIS. E. Dadashian	4:03 PM	O-102	ONE-STEP WARMING PROTOCOL FOR VITRIFIED BLASTOCYSTS RESULTS IN SIGNIFICANT REDUCTION OF WARMING TIME WITH NO DIFFERENCE IN CRYOSURVIVAL. C. A. Leisinger
3:41 PM	O-100	IMPROVING OVULATION TRIGGER TIMING WITH ARTIFICIAL INTELLIGENCE (AI) TO INCREASE FROZEN EMBRYO YIELD DURING OVARIAN STIMULATION CYCLES. R. Garcia Sanchez	4:14 PM	O-103	OVARIAN SUPPORT CELL-ASSISTED IN VITRO MATURATION OF IMMATURE OOCYTES FROM TRUNCATED HORMONAL STIMULATION USED IN DONOR EGG CYCLES. C. C. Kramme
3:52 PM	O-101	THE EFFECTS OF SURGICAL PROCEDURE VS PLATELET-RICH PLASMA ON OVARIAN FOLLICULAR ACTIVATION AND BIOMECHANICAL CHANGES USING EXPERIMENTAL SHEEP MODEL: A PILOT STUDY. M. Méndez	4:25 PM	O-104	ASSESSMENT OF HUMAN OVARIAN STIFFNESS USING SHEAR WAVE ELASTOGRAPHY (SWE) AS A NON-INVASIVE BIOMARKER OF

MONDAY, OCTOBER 21, 2024

3:30 PM - 4:45 PM

OSM-20 ORAL ABSTRACT SESSION: GENETICS- PGT (2 OF 2)

3:30 PM	O-105	SINGLE EUPLOID EMBRYO TRANSFERS IN PATIENTS UTILIZING PGT-M: IS PARITY ASSOCIATED WITH OUTCOMES? J. A. Suskin	4:14 PM	O-109	LEVERAGING HIGH RESOLUTION SNP DATA IN THE PGT TRIO TO CONFIRM PARENTAGE IN AN EMBRYO TROPHECTODERM BIOPSY WITH ULTRA HIGH CONFIDENCE. A. Griffith
3:41 PM	O-106	EXPANDING USE OF PREIMPLANTATION GENETIC TESTING FOR MONOGENIC DISORDERS (PGT-M) AMONG CARRIER COUPLES FOR CYSTIC FIBROSIS (CF). J. Lindberg	4:25 PM	O-110	A CONTEMPORARY ANALYSIS METHOD TO UNCOVER LOSS OF HETEROZYGOSITY: EMPLOYING PAIRED SINGLE NUCLEOTIDE VARIANT (SNV) AND COPY NUMBER VARIANT (CNV) DATA WITHIN CLINICAL PGT-A CASES. K. McKissock
3:52 PM	O-107	RE-BIOPSY OF BLASTOCYSTS WITH SEGMENTAL ANEUPLOIDY AFTER PGT-A: CLINICAL BENEFITS AND CONSIDERATIONS. R. Abramov			
4:03 PM	O-108	EVALUATING HUMAN BLASTOCYST MORPHOLOGY AND POLYGENIC DISEASE RISK SCORES. J. O'Donnell			



MONDAY, OCTOBER 21, 2024

3:30 PM - 4:45 PM

OSM-21 ORAL ABSTRACT SESSION: HEALTH DISPARITIES & HEALTH EQUITY- GENERAL (2 OF 2)

3:30 PM	O-111	DISPARITIES IN TIME TO ENDOMETRIOSIS DIAGNOSIS: A LARGE RESEARCH NETWORK STUDY. M. R. Imbroane	4:03 PM	O-114	OUTCOMES FROM A FELLOW AND RESIDENT-RUN, MONITORED OVULATION INDUCTION (OI) PROGRAM AT THE LARGEST SAFETY NET HOSPITAL IN NEW YORK CITY. G. Stein
3:41 PM	O-112	EVALUATING THE NEED FOR EMERGENCY CONTRACEPTION RESOURCES AT THE UNIVERSITY OF TEXAS AT AUSTIN. N. Levy-Thiebaut	4:14 PM	O-115	CHARACTERISTICS OF SPERM DONORS IN THE UNITED STATES. R. Passarelli
3:52 PM	O-113	THE IMPACT OF RELIGION ON DECISION MAKING OF INFERTILE COUPLES. A. Garcia Keeme-Sayre	4:25 PM	O-116	THE ASSOCIATION OF IN VITRO FERTILIZATION WITH SEVERE MATERNAL MORBIDITY ACROSS MATERNAL AGE GROUPS. S. E. Phillips

MONDAY, OCTOBER 21, 2024

3:30 PM - 4:45 PM

OSM-22 ORAL ABSTRACT SESSION: INFERTILITY- GENERAL

3:30 PM	O-117	THE USE OF VIRTUAL REALITY TECHNOLOGY PRIOR TO EMBRYO TRANSFER: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL. J. Ozsarfati	4:03 PM	O-120	MARKERS OF FEMALE ADIPOSITY AND LIVE BIRTH IN PATIENTS SEEKING INFERTILITY CARE. I. T. Lee
3:41 PM	O-118	SHORT AND LONG-TERM EFFECTS OF EXPERIMENTAL VARICOCELE. R. P. Bertolla	4:14 PM	O-121	EVALUATING THE IMPACT OF FROZEN PARTNER SPERM IN NON-DONOR INTRAUTERINE INSEMINATION CYCLES. A. HUTTLER
3:52 PM	O-119	DOES TRIGGER TYPE MATTER? EXPLORING OOCYTE YIELD AND BLASTOCYST UTILIZATION BY TRIGGER TYPE J. Ewy	4:25 PM	O-122	IMPACT OF INFERTILITY DIAGNOSIS ON PLOIDY RATE IN ADVANCED MATERNAL AGE. A. L. DOMNEY

MONDAY, OCTOBER 21, 2024

3:30 PM - 4:45 PM

OSM-23 ORAL ABSTRACT SESSION: PRE-CLINICAL AND BASIC RESEARCH- GENERAL (1 OF 2)

3:30 PM	O-123	BLASTOCYST SEGMENTAL ANEUPLOIDY BREAKPOINTS ARE HIGHLY CORRELATED WITH HUMAN GENOME FRAGILE SITES. E. deQuadros	4:03 PM	O-126	DISRUPTION OF METHYLATION REPROGRAMING IN EARLY EMBRYONIC TISSUE LINEAGES WITH PATERNAL AGING. B. R. McCallie
3:41 PM	O-124	IL-22's DUAL NATURE: BALANCING PROTECTION AND RISK IN PREGNANCY AMID INFLAMMATORY CHALLENGES. U. Ganieva	4:14 PM	O-127	GENERATION OF GENOTYPED ARTIFICIAL OOCYTES FROM ENDOMETRIAL STROMAL CELLS AND BONE MARROW MESENCHYMAL STEM CELLS. P. Xie
3:52 PM	O-125	DEFICIENCY OF DNA REPAIR IN HUMAN PREIMPLANTATION EMBRYOS REVEALED BY CRISPR-Cas9: IMPLICATIONS GENOME STABILITY, IN VITRO EMBRYO CULTURE, AND THE EFFICACY OF CLINICAL GENE EDITING. D. Wells	4:25 PM	O-128	REPRODUCTIVE POTENTIAL IS PRIMARILY DRIVEN BY THE MOLECULAR ACTIVITY OF THE FUTURE FETAL TISSUE LINEAGE. M. Katz-Jaffe





TUESDAY, OCTOBER 22, 2024

10:45 AM - 12:15 PM

OST-01 ORAL ABSTRACT SESSION: SART CORS

10:45 AM	O-129	UNITED STATES RACIAL/ETHNIC DISPARITIES IN PGT-A UTILIZATION: AN ANALYSIS OF 2014-2020 SART CORS DATABASE. A. T. Mason-Otey	11:29 AM	O-133	NEIGHBORHOOD DISADVANTAGE AND RACE ARE ASSOCIATED WITH DECISIONS REGARDING PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A). O. O. Akin-Olugbade
10:56 AM	O-130	A POPULATION-BASED STUDY OF THE CO-OCCURRENCE OF HYPOSPADIAS AND CONGENITAL HEART DEFECTS AMONG BOYS CONCEIVED WITH ASSISTED REPRODUCTIVE TECHNOLOGY. M. A. Richard	11:40 AM	O-134	RACIAL DISPARITIES IN ART OUTCOMES IN THE SOCIETY OF ASSISTED REPRODUCTIVE TECHNOLOGY (SART CORS) DATABASE: 2014-2021. M. H. Vu
11:07 AM	O-131	THE RISK OF BIRTH DEFECTS IDENTIFIED DURING THE FIRST YEAR OF LIFE ASSOCIATED WITH PREIMPLANTATION TESTING AMONG CHILDREN CONCEIVED WITH IN VITRO FERTILIZATION (IVF) AND FROZEN EMBRYO TRANSFER. K. E. Cameron	11:51 AM	O-135	MORE ISN'T ALWAYS BETTER: A SART CORS ANALYSIS OF SURPLUS CRYOPRESERVED BLASTOCYSTS IN FRESH DONOR OOCYTE CYCLES. S. Spring
11:18 AM	O-132	NEONATAL OUTCOMES WORSEN WITH INCREASING BODY MASS INDEX: AN ANALYSIS OF 37,081 EUPLOID FROZEN EMBRYO TRANSFERS FROM THE SART CORS DATABASE. S. Bensouda	12:02 PM	O-136	OPTIMIZING THE NUMBER OF FROZEN DONOR OOCYTES TO FERTILIZE WHILE MINIMIZING SUPERNUMERARY EMBRYOS: A SART CORS ANALYSIS. S. Spring

TUESDAY, OCTOBER 22, 2024

10:45 AM - 12:15 PM

OST-02 ORAL ABSTRACT SESSION: FERTILITY PRESERVATION- GENERAL (2 OF 2)

10:45 AM	O-137	UNDERSTANDING PEDIATRIC FERTILITY PRESERVATION IN THE UNITED STATES. I. C. Band	11:40 AM	O-142	RAPAMYCIN IMPROVES OOCYTE QUALITY BY PROMOTING METABOLIC AND MITOPHAGY ACTIVITIES IN MICE AND HUMAN GRANULOSA CELLS. A. Nahar
10:56 AM	O-138	CAUTION IN THE USE OF ANTI-MULLERIAN HORMONE (AMH) IN COUNSELING YOUNGER PATIENTS UNDERGOING OOCYTE CRYOPRESERVATION (OC). E. Minis	11:51 AM	O-143	TOO MUCH OF A GOOD THING? ASSESSING THE OPTIMAL NUMBER OF OOCYTES TO THAW TO PREDICT THE LIKELIHOOD DEVELOPING TWO OR MORE BLASTOCYSTS E. A. Clarke
11:07 AM	O-139	PRELIMINARY RESULTS ON THE EFFECTS OF PRP ON ASTHENOSPERMIC SEMEN SAMPLES. A. Bos-Mikich	12:02 PM	O-144	WHAT TO EXPECT FROM YOUR FROZEN EGGS? CUMULATIVE LIVE BIRTH RATES (CLBRs) BY AGE AT PLANNED OOCYTE CRYOPRESERVATION (OC) AND NUMBER OF METAPHASE II OOCYTES (M2S) THAWED C. M. Parra
11:18 AM	O-140	THE IMPACT OF STATE INSURANCE MANDATES ON FERTILITY PRESERVATION ACCESS. J. M. Morris			
11:29 AM	O-141	EFFECT OF PROLONGED OOCYTE CRYOPRESERVATION ON FERTILIZATION AND PREGNANCY OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS. A. Kauffman			



TUESDAY, OCTOBER 22, 2024

10:45 AM - 12:15 PM

**OST-03 ORAL ABSTRACT SESSION: HEALTH DISPARITIES & HEALTH EQUITY-
UNDERREPRESENTED AND UNDERSERVED POPULATIONS**

10:45 AM	O-145	INVESTIGATING SOCIAL FACTORS CONTRIBUTING TO THE LACK OF DIVERSITY AMONG SPERM DONORS IN THE UNITED STATES. O. G. Anderson	11:29 AM	O-149	DISPARITIES IN FERTILITY PRESERVATION COUNSELING AND REFERRALS FOR PATIENTS SEEKING GENDER-AFFIRMING CARE. G. Ficerai-Garland
10:56 AM	O-146	COMPARING FAMILY PLANNING DESIRES AND BARRIERS BETWEEN GAY AND LESBIAN MILITARY SERVICE MEMBERS. D. Boedeker	11:40 AM	O-150	LOW INCOME AFRICAN AMERICAN WOMEN WITH A HISTORY OF RECURRENT PREGNANCY LOSS ARE AT INCREASED RISK OF HYPERTENSIVE DISORDERS OF PREGNANCY AND POOR BIRTH OUTCOMES THAN RACE AND INCOME MATCHED PEERS. M. S. Wyszewianski
11:07 AM	O-147	COMPARING FAMILY-BUILDING DESIRES AMONG TRANSGENDER AND CISGENDER GAY, BISEXUAL, AND LESBIAN MILITARY SERVICE MEMBERS. D. Boedeker	11:51 AM	O-151	LAG TIME BETWEEN SCHEDULING DATE AND APPOINTMENT DATE FOR INITIAL INFERTILITY EVALUATION: DOES PREFERRED PRIMARY LANGUAGE PLAY A ROLE? B. Schiffman
11:18 AM	O-148	LIVE BIRTH RATES IN SAME-SEX FEMALE COUPLES ARE SIMILAR BETWEEN CO-IN-VITRO FERTILIZATION (CO-IVF) AND AUTOLOGOUS IVF. B. Dubois	12:02 PM	O-152	BARRIERS TO FERTILITY PRESERVATION TREATMENT PRIOR TO GENDER-AFFIRMING BOTTOM SURGERY WITHIN THE

TUESDAY, OCTOBER 22, 2024

10:45 AM - 12:15 PM

OST-04 ORAL ABSTRACT SESSION: ART- GENERAL

10:45 AM	O-153	SURGICAL AND MEDICAL MANAGEMENT OF EARLY PREGNANCY FAILURE (EPF): REPRODUCTIVE POTENTIAL IN SUBSEQUENT SINGLE EUPLOID EMBRYO TRANSFER (SEET) CYCLES. E. A. Clarke	11:29 AM	O-157	OUTCOMES AFTER PROGRAMMED FROZEN EMBRYO TRANSFER FAILURE: DOES CHANGING THE PROTOCOL IMPROVE OUTCOMES? J. Chae-Kim
10:56 AM	O-154	IMPACT OF GONADOTROPIN SELECTION ON RISK OF OVARIAN HYPERSTIMULATION SYNDROME (OHSS) IN PREDICTED HIGH RESPONDERS UNDERGOING OVARIAN STIMULATION: A MEGASET HR TRIAL ANALYSIS. R. A. Foulk	11:40 AM	O-158	WHO BENEFITS MOST FROM A FREEZE-ALL EMBRYO TRANSFER STRATEGY? AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (INFORM) R. Wang
11:07 AM	O-155	BREAKING THE ICE: A DEEP DIVE INTO AGE-DEPENDENT EFFECTS OF ENDOMETRIAL PREPARATION PROTOCOLS IN FROZEN EMBRYO TRANSFER OUTCOMES FROM A LARGE MONOCENTRIC COHORT (4662 CYCLES). N. Massin	11:51 AM	O-159	MODE OF DELIVERY IMPACTS SUBSEQUENT PREGNANCY ATTEMPTS IN PATIENTS RETURNING FOR SINGLE, EUPLOID FET USING THE SAME EMBRYO COHORT. S. Willson
11:18 AM	O-156	THE IMPACT OF ENDOMETRIAL AND EMBRYO RELATED FACTORS ON CLINICAL OUTCOMES AND LIVE BIRTH IN PROGRAMMED AND MODIFIED NATURAL FET CYCLES WITH EUPLOID EMBRYO TRANSFERS. C. Halicigil	12:02 PM	O-160	SUPPLEMENTAL ESTROGEN FOR ENDOMETRIAL THICKENING DOES NOT IMPROVE PREGNANCY RATES IN ORAL OVULATION INDUCTION INTRAUTERINE INSEMINATION CYCLES. F. Osei





TUESDAY, OCTOBER 22, 2024

10:45 AM - 12:15 PM

OST-05 ORAL ABSTRACT SESSION: INFERTILITY- DIAGNOSIS & TREATMENT

10:45 AM	O-161	ROUTINE HYPERPROLACTINEMIA SCREENING IN THE INITIAL FERTILITY EVALUATION: A RETROSPECTIVE ANALYSIS OF INDICATED AND UNINDICATED TESTING. B. Schiffman	11:29 AM	O-165	MULTIPLE GESTATION PREGNANCY RATES AFTER ULTRASOUND MONITORED VS OVULATION PREDICTOR KIT MONITORED OVULATION STIMULATION-INTRAUTERINE INSEMINATION CYCLES. E. L. Wolfe
10:56 AM	O-162	RANDOMIZED CONTROLLED TRIAL OF HOME SEMEN TESTING FOR PROSPECTIVE FATHERS: SEMEN ANALYSIS RESULTS AND 3-MONTH FOLLOW UP. D. R. Greenberg	11:40 AM	O-166	MIG-6 LOSS OF ECTOPIC LESIONS CAUSES IMPLANTATION FAILURE IN ENDOMETRIOSIS. H. Hosseini-rad
11:07 AM	O-163	ANALYZING ENDOMETRIOSIS-RELATED INFERTILITY CONTENT ON TIKTOK: WHO IS SAYING WHAT? H. Naveed	11:51 AM	O-167	ASSOCIATION OF ELEVATED MIDCYCLE LUTEINIZING HORMONE AND PREGNANCY OUTCOMES IN PROGRAMMED FROZEN EMBRYO TRANSFER CYCLES. A. Ulker
11:18 AM	O-164	HOW DOES A SHORT-TERM DROP IN ANTI-MULLERIAN HORMONE (AMH) IMPACT IN VITRO FERTILIZATION (IVF) OUTCOMES AMONG NORMAL RESPONDERS? A. D. Kadash	12:02 PM	O-168	PRESENCE OF CD138 (+) PLASMA CELLS IN THE ENDOMETRIUM DOES NOT CORRELATE WITH HISTORY OF PRIOR IMPLANTATION FAILURE, ENDOMETRIAL BCL6 LEVELS OR ENDOMETRIAL RECEPTIVITY TESTING. B. D. Yilmaz

TUESDAY, OCTOBER 22, 2024

10:45 AM - 12:15 PM

OST-06 ORAL ABSTRACT SESSION: PRE-CLINICAL AND BASIC RESEARCH (2 OF 2)

10:45 AM	O-169	EPITHELIAL-TO-MESENCHYMAL TRANSITION INDUCTION BY HUMAN UMBILICAL CORD PLATELET-RICH PLASMA IN HUMAN ENDOMETRIAL ORGANOID: DIFFERENTIATION STATE MATTERS. M. Agustina-Hernández	11:40 AM	O-174	THE EFFECTS OF THE ENDOCRINE-DISRUPTING CHEMICAL TRICLOSAN ON OVARIAN RESERVE AND FECUNDITY IN A MOUSE MODEL. K. M. Baker
11:07 AM	O-171	MULTI-OMICS ANALYSIS REVEALS TRANSLATIONAL LANDSCAPES AND REGULATIONS IN MOUSE AND HUMAN OOCYTE AGING. J. Huang	11:51 AM	O-175	THE ORIGIN OF MONOSOMY X IN THE HUMAN BLASTOCYST. J. Xu
11:18 AM	O-172	OVARIAN SUPPORT CELL IN VITRO MATURATION RESULTS IN HEALTHY MURINE LIVE BIRTHS WITH NO EVIDENCE OF REPROTOXICOLOGY IN A MULTIGENERATIONAL STUDY. C. C. Kramme	12:02 PM	O-176	EXPLORING THE MECHANISM OF ENDOMETRIAL MICRORNA REGULATION IN SUCCESSFUL IMPLANTATION. C. Lee
11:29 AM	O-173	ROLE AND MECHANISM OF NUCLEAR PORE PROTEIN NUP205 INVOLVED IN FOLLICLE DEVELOPMENT. S. Cai			





TUESDAY, OCTOBER 22, 2024

10:45 AM - 12:15 PM

OST-07 ASRM RESEARCH INSTITUTE: RESEARCHER SPOTLIGHT

- 10:45 AM O-177 SHARED GENOMIC SEGMENT ANALYSIS IN LARGE HIGH-RISK STILLBIRTH PEDIGREES IMPLICATES GENES IN INHERITED STILLBIRTH RISK. T. Workalemahu
- 10:56 AM O-178 FOLLICULAR FLUID LEVELS OF THE CHEMOKINE CCL2 CORRELATE WITH OOCYTE MATURATION RATES. Y. Gamaleri
- 11:07 AM O-179 UNRAVELING THE ROLE OF SIRTUIN 7 IN REPRODUCTIVE AGING. K. A. Schindler
- 11:18 AM O-180 ATTITUDES TOWARDS SPERM DONATION IN BLACK CISGENDER MEN. K. L. King
- 11:29 AM O-181 UNDERSTANDING PREGNANT AND EXPECTING DONOR GAMETE AND EMBRYO RECIPIENTS' AND CLINICIANS' PERCEPTIONS ABOUT COMPONENTS FOR EXPANDING THE TELL TOOL FOR USE DURING PREGNANCY. P. E. Hershberger
- 11:40 AM O-182 RANDOMIZED CONTROLLED TRIAL OF COMBINED LETROZOLE AND CLOMIPHENE (CLC II) VERSUS LETROZOLE MONOTHERAPY FOR WOMEN WITH ANOVULATION. R. B. Mejia
- 11:51 AM O-183 ALTERED ENDOMETRIAL CELL PROGESTERONE RESPONSIVENESS IN THE ETIOLOGY OF ENDOMETRIOSIS. K. D. Coyne

TUESDAY, OCTOBER 22, 2024

11:45 AM - 12:15 PM

OST-08 ORAL ABSTRACT SESSION: ADVANCE PRACTICE PROVIDERS (2 OF 2)

- 11:45 AM O-184 PATTERNS OF UTILIZATION OF ADVANCED PRACTICE PROVIDERS IN REPRODUCTIVE ENDOCRINOLOGY: A 2023 NATIONAL SURVEY. B. Tanaka
- 11:56 AM O-185 IMPROVING FROZEN EMBRYO TRANSFER CONSENT TIMELY RETURN RATE TO REDUCE ADVERSE EVENTS AND IMPROVE PATIENT AND PROVIDER SATISFACTION. J. Feingold

TUESDAY, OCTOBER 22, 2024

11:45 AM - 12:15 PM

OST-09 ORAL ABSTRACT SESSION: GENETIC COUNSELING (2 OF 3)

- 11:45 AM O-186 IDENTIFYING THE GENETIC ETIOLOGY OF INFERTILITY AND RECURRENT PREGNANCY LOSS THROUGH A LARGE-SCALE WHOLE GENOME SEQUENCING DATASET. R. Zemet
- 11:56 AM O-187 DISCREPANCIES IN INFORMATION PROVIDED BY PROSPECTIVE OVUM DONORS IN THEIR APPLICATION COMPARED TO CONSULTATION WITH CERTIFIED GENETIC COUNSELOR AS PART OF ROUTINE SCREENING IN LARGE FERTILITY NETWORK. C. V. Varriale

TUESDAY, OCTOBER 22, 2024

11:45 AM - 12:15 PM

OST-10 ORAL ABSTRACT SESSION: LAW, POLICY, AND ADVOCACY (2 OF 3)

- 11:45 AM O-188 IMPACT OF STATE INSURANCE MANDATES ON IN VITRO FERTILIZATION UTILIZATION AMONG PATIENTS WITH RECURRENT PREGNANCY LOSS. M. Pollie
- 11:56 AM O-189 DO STATE INSURANCE MANDATES PROTECT FERTILITY PATIENTS? A. Adeyeye





TUESDAY, OCTOBER 22, 2024

11:45 AM - 12:15 PM

OST-11 ORAL ABSTRACT SESSION: MENTAL HEALTH (2 OF 3)

- | | | | | | |
|----------|-------|---|----------|-------|--|
| 11:45 AM | O-190 | THE PREVALENCE OF POST-TRAUMATIC STRESS DISORDER SYMPTOMS IN INDIVIDUALS PRESENTING FOR FERTILITY CARE: A CROSS-SECTIONAL STUDY. S. J. Melville | 11:56 AM | O-191 | THE IMPACT OF PCOS ON THE RURAL INDIAN SUBFERTILE POPULATION WITH RESPECT TO EMOTIONAL & MENTAL WELL-BEING; AN OBSERVATIONAL STUDY. S. T. Pandey |
|----------|-------|---|----------|-------|--|

TUESDAY, OCTOBER 22, 2024

11:45 AM - 12:15 PM

OST-12 ORAL ABSTRACT SESSION: NURSING (2 OF 3)

- | | | | | | |
|----------|-------|--|----------|-------|--|
| 11:45 AM | O-192 | RECOGNIZING AND IMPROVING TRAUMA INFORMED CARE IN THE FERTILITY CLINIC SETTING. J. Price | 11:56 AM | O-193 | RELATING TO THE PREVALENCE OF DEPRESSION SYMPTOMS IN INFERTILE WOMEN AND SOCIAL,PSYCHOLOGICAL CHARACTERISTICS. M. Kwon |
|----------|-------|--|----------|-------|--|

TUESDAY, OCTOBER 22, 2024

1:30 PM - 2:45 PM

**OST-13 ORAL ABSTRACT SESSION: BENIGN GYNECOLOGICAL DISEASE-
ENDOMETRIOSIS AND ADENOMYOSIS**

- | | | | | | |
|---------|-------|---|---------|-------|---|
| 1:30 PM | O-194 | PREVENTING TRANSMISSION OF AN ENDOMETRIOSIS-LIKE PHENOTYPE AND RISK OF PRETERM BIRTH IN ADULT DAUGHTERS OF DIOXIN EXPOSED MALE MICE. K. Bruner-Tran | 2:14 PM | O-198 | GENOTYPE-PHENOTYPE ASSOCIATIONS IN ENDOMETRIOSIS AND ADENOMYOSIS: USING WHOLE-EXOME SEQUENCING TO CHARACTERIZE GENETIC BURDEN IN CANDIDATE GENES ASSOCIATED WITH ENDOMETRIOSIS. L. A. Humphries |
| 1:41 PM | O-195 | ELECTROPHYSIOLOGICAL IMAGING IDENTIFIES DISRUPTED UTERINE PERISTALSIS IN WOMEN WITH ENDOMETRIOSIS. C. Murphy | 2:25 PM | O-199 | DISPROPORTIONALITY ANALYSIS WITH COMPARISON OF ELAGOLIX VERSUS LEUPROLIDE SAFETY IN WOMEN WITH ENDOMETRIOSIS USING DATA FROM THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS). M. E. Gornet |
| 1:52 PM | O-196 | PREVALENCE OF SOMATIC CANCER DRIVER MUTATIONS IN EPITHELIAL CELLS IN CASES OF EXTREME ENDOMETRIOSIS COMPARED TO SUPERFICIAL ENDOMETRIOSIS. E. Schlant | | | |
| 2:03 PM | O-197 | ABERRANT MAPK3/1 AND AKT SIGNALING PATHWAYS IN GRANULOSA CELLS MAY CONTRIBUTE TO THE COMPROMISED FOLLICULAR DEVELOPMENT OF THE ENDOMETRIOSIS PATIENTS. G. K. Cork | | | |





TUESDAY, OCTOBER 22, 2024

1:30 PM - 2:45 PM

OST-14 ORAL ABSTRACT SESSION: REPRODUCTIVE UROLOGY (1 OF 2)

1:30 PM	O-200	SURGICAL SPERM RETRIEVAL OUTCOMES IN PATIENTS WITH AZOOSPERMIA AND ITS CORRELATION WITH PREGNANCY AND FEMALE AGE, A COMPARATIVE AUDIT AT A TERTIARY CENTRE. N. Wajidi	2:03 PM	O-203	EVALUATING THE RELATIONSHIP BETWEEN EJACULATORY ABSTINENCE AND THE INCIDENCE OF EMBRYO MOSAICISM. A. Ghofranian
1:41 PM	O-201	DELAYED STENOSIS RATE POST VASECTOMY REVERSAL: A MULTICENTER COHORT. N. Deebel	2:14 PM	O-204	MULTISTEP DENSITY GRADIENT SELECTS A POPULATION OF SPERM WITH IMPROVED DNA INTEGRITY. T. M. Nicholson
1:52 PM	O-202	ISOTRETINOIN IMPROVES DE NOVO SPERM PRODUCTION IN NONOBSTRUCTIVE AZOOSPERMIC AND CRYPTOZOOSPERMIC MEN. M. Jessup	2:25 PM	O-205	CAN WE PREDICT PRESENCE OF RESIDUAL SPERMATOGENESIS IN NONOBSTRUCTIVE AZOOSPERMIC MEN? S. Cheung

TUESDAY, OCTOBER 22, 2024

1:30 PM - 2:45 PM

OST-15 REPRODUCTIVE MEDICINE (NON INFERTILITY)- GENERAL

1:30 PM	O-206	PERFLUOROOCCTANOIC ACID (PFOA) INHIBITS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) EXPRESSION THROUGH NF- B/MIR-10b PATHWAY IN HUMAN GRANULOSA CELLS. Y. Ye	2:03 PM	O-209	POLYCYSTIC OVARIAN SYNDROME, DIETARY SUPPLEMENTS, AND TIKTOK: A BALANCED SUPPLEMENT STEW OR EVERYTHING BUT THE KITCHEN SINK? A. Almgren-Bell
1:41 PM	O-207	VITAMIN D AND CYCLE LENGTH IN A PROSPECTIVE COHORT STUDY. A. Z. Jukic	2:14 PM	O-210	OOPHORECTOMY AT TIME OF GENDER AFFIRMING HYSTERECTOMY IN YOUNG ADULTS. J. Batchelor
1:52 PM	O-208	EXAMINING HYPERTENSION AT OOCYTE RETRIEVAL AS A PREDICTOR OF PREECLAMPSIA RISK IN PREGNANCIES CONCEIVED THROUGH IN-VITRO FERTILIZATION. K. Loo	2:25 PM	O-211	THE ASSOCIATION BETWEEN PREGESTATIONAL DIABETES IN WOMEN WITH POLYCYSTIC OVARY SYNDROME AND ADVERSE OBSTETRIC OUTCOMES. M. A. Hincapie

TUESDAY, OCTOBER 22, 2024

1:30 PM - 2:45 PM

OST-16 ORAL ABSTRACT SESSION: INFERTILITY- OUTCOMES

1:30 PM	O-212	THE INTERTWINED RELATIONSHIP BETWEEN DIMINISHED OVARIAN RESERVE AND MATERNAL AGE IMPACTS REPRODUCTIVE OUTCOMES. M. Katz-Jaffe	2:03 PM	O-215	IMPACT OF EXTENDED DURATION LOW MOLECULAR WEIGHT HEPARIN ON INCREASED RISKS OF PREECLAMPSIA IN INFERTILITY PATIENTS WITH ANTI-PHOSPHOLIPID ANTIBODIES. Z. Husnain
1:41 PM	O-213	MODIFIED NATURAL LETROZOLE FET RESULTS IN HIGHER LIVE BIRTH RATES IN WOMEN ≥40 IN COMPARISON TO PROGRAMMED FET: AN ANALYSIS OF 1,076 CYCLES. I. Okeigwe	2:14 PM	O-216	CAN MICROFLUIDIC SPERM SELECTION OPTIMIZE INTRAUTERINE INSEMINATION OUTCOMES IN COUPLES WITH IDIOPATHIC INFERTILITY? O. M. Kocur
1:52 PM	O-214	MALE NEOGAMETOGENESIS INDUCED IN A THREE-DIMENSIONAL CULTURE SYSTEM CAPABLE OF SUPPORTING SUCCESSFUL FERTILIZATION AND PROPER EMBRYO DEVELOPMENT. P. Massaad	2:25 PM	O-217	LOW BIRTH WEIGHT AND PREMATURITY TRENDS IN IVF-CONCEIVED NEWBORNS: AN ANALYSIS OF 41,579 BIRTHS OVER 25 YEARS (1999-2023). A. Reig



TUESDAY, OCTOBER 22, 2024

1:30 PM - 2:45 PM

OST-17 ORAL ABSTRACT SESSION: ART- ARTIFICIAL INTELLIGENCE

1:30 PM	O-218	NOVEL CELL-BASED STRATEGY UTILIZING OVARIAN SUPPORT CELLS FOR IN VITRO MATURATION: FROM PROOF-OF-CONCEPT TO CLINICAL MANUFACTURING. C. C. Kramme	2:03 PM	O-221	A SINGLE, REFERENCE-FREE PREIMPLANTATION GENETIC TEST FOR ANEUPLOIDY AND MONOGENIC DISORDERS (PGT-A+M): PLOIDY AND DEEP MUTATION ANALYSIS FOR RAPID AND ACCURATE RESULTS IN DIFFICULT CASES. C. Weier
1:41 PM	O-219	A RANDOMIZED TRIAL OF PLATELET-RICH PLASMA BEFORE FROZEN EMBRYO TRANSFER IN THE GENERAL INFERTILITY POPULATION. M. Kappy	2:14 PM	O-222	HIGHER AREA UNDER THE CURVE CORRELATES WITH SHORTER TIME TO PREGNANCY IN MACHINE LEARNING MODELS FOR EMBRYO EVALUATION. A. Boussommier
1:52 PM	O-220	ACCELERATED RESPONSE AWARENESS TO CATASTROPHIC EVENTS USING WEIGHT-BASED REMOTE MONITORING OF CRYOSTORAGE TANKS. M. C. Schiewe	2:25 PM	O-223	AN ARTIFICIAL INTELLIGENCE (AI) MODEL NON-INVASIVELY IDENTIFIES OOCYTES THAT CORRELATE WITH GREATER EMBRYO IMPLANTATION POTENTIAL. J. Fjeldstad

TUESDAY, OCTOBER 22, 2024

3:30 PM - 4:45 PM

OST-18 ORAL ABSTRACT SESSION: ART- CLINICAL (1 OF 2)

3:30 PM	O-224	DISENTANGLING RISK OF ADVERSE PERINATAL EVENTS ASSOCIATED WITH INFERTILITY AND MEDICALLY ASSISTED REPRODUCTION: A POPULATION-BASED COHORT STUDY. W. Li	4:14 PM	O-228	MINIMAL FSH-PRIMING STRATEGY RESULTED IN SIGNIFICANTLY INCREASED OOCYTE RECOVERY FROM PCOS PATIENTS UNDERGOING OOCYTE IN VITRO MATURATION CYCLES WITH HIGH SUCCESS IN EMBRYO DEVELOPMENT AND LIVE BIRTH. E. A. Jannaman
3:41 PM	O-225	EXPLORING THE LINK BETWEEN OVARIAN RESERVE AND EMBRYO QUALITY: INSIGHTS FROM A COMPARATIVE STUDY OF PGT-A CYCLES. O. Barbosa Duarte Filho	4:25 PM	O-229	THE EFFECTS OF PROLONGED DIENOGEST ADMINISTRATION ON LIVE BIRTHS IN WOMEN WITH ENDOMETRIOSIS UNDERGOING IN VITRO FERTILIZATION: A THREE-ARM PROSPECTIVE RANDOMIZED CLINICAL TRIAL. J. T. Awwad
3:52 PM	O-226	DOES THE ABSENCE OF CORPUS LUTEUM INCREASE THE RISK OF EARLY PREGNANCY LOSS?: A RETROSPECTIVE STUDY ON 1086 FROZEN-THAWED SINGLE EUPLOID BLASTOCYST TRANSFER CYCLES S. Han			
4:03 PM	O-227	GESTATIONAL CARRIER SCREENING AND EXCLUSION PATTERNS IN NEW YORK STATE FOLLOWING LEGALIZATION UNDER THE CHILD-PARENT SECURITY ACT. R. A. Frankel			





TUESDAY, OCTOBER 22, 2024

3:30 PM - 4:45 PM

OST-19 ORAL ABSTRACT SESSION: FERTILITY PRESERVATION- INFERTILITY AND CANCER

3:30 PM	O-230	OUTCOMES OF OVARIAN HYPERSTIMULATION IN WOMEN PREVIOUSLY EXPOSED TO GONADOTOXIC TREATMENT. M. E. Gornet	4:14 PM	O-234	LIVE BIRTH RATES FROM OVER 900 AUTOLOGOUS OOCYTE THAW CYCLES STRATIFIED BY AGE AND INDICATION FOR CRYOPRESERVATION. A. Namath
3:41 PM	O-231	EVALUATING THE SAFETY AND OUTCOMES OF OVARIAN TISSUE CRYOPRESERVATION IN LEUKEMIA PATIENTS. S. Patel	4:25 PM	O-235	IMPACT OF THE FERTILITY PRESERVATION INSURANCE MANDATE ON FERTILITY PRESERVATION SERVICES AMONG REPRODUCTIVE-AGED FEMALE BREAST CANCER PATIENTS IN RHODE ISLAND. M. Sauerbrun-Cutler
3:52 PM	O-232	REVIEWING THE UPPER AGE LIMIT FOR OVARIAN TISSUE CRYOPRESERVATION IN ONCOLOGIC AND NON-ONCOLOGIC POPULATIONS. S. Patel			
4:03 PM	O-233	THE USE OF FERTILITY PRESERVATION AMONG REPRODUCTIVE-AGED MALE PATIENTS DIAGNOSED WITH HEMATOLOGIC MALIGNANCY. D. R. Greenberg			

TUESDAY, OCTOBER 22, 2024

3:30 PM - 4:45 PM

OST-20 ORAL ABSTRACT SESSION: GENETICS- MOSAICISM

3:30 PM	O-236	REBIOPSY OF INCONCLUSIVE BLASTOCYST: PGT RESULTS AND REPRODUCTIVE OUTCOMES. E. Caviglia	4:03 PM	O-239	QUESTIONING THE BENEFIT OF REPORTING LOW LEVEL SEGMENTAL MOSAICISM: SIMILAR OBSERVED REPRODUCTIVE POTENTIAL COMPARED TO EUPLOID EMBRYOS. A. G. Besser
3:41 PM	O-237	POST-DELIVERY CHROMOSOMAL ANALYSIS OF PLACENTAS ARISING FROM THE TRANSFER OF EMBRYOS DIAGNOSED AS MOSAIC. J. Buldo-Licciardi	4:14 PM	O-240	CAN CHROMOSOME NUMBER PREDICT MOSAIC EMBRYO TRANSFER OUTCOME? A. G. Besser
3:52 PM	O-238	DO MISCARRIAGES AFTER TRANSFERS OF EMBRYOS DEFINED AS "ABNORMAL" BY PGT-A STILL REQUIRE KARYOTYPING OF PRODUCTS OF CONCEPTION? N. Gleicher	4:25 PM	O-241	SPECTRUM OF VARIOUS TYPES OF MOSAICISM ACROSS THE FEMALE AGE: AN ANALYSIS OF 35,723 BLASTOCYSTS BY PGT-A. M. Jeon

TUESDAY, OCTOBER 22, 2024

3:30 PM - 4:45 PM

OST-21 ORAL ABSTRACT SESSION: RECURRENT PREGNANCY LOSS

3:30 PM	O-242	KARYOTYPE OF PRODUCTS OF CONCEPTION AFTER MISCARRIAGE IN IVF (IN VITRO FERTILIZATION) POPULATION IS NOT PREDICTIVE OF CLINICAL OUTCOME IN SUBSEQUENT TRANSFER. A. Hollingsworth	4:14 PM	O-246	DO GLUCOCORTICOID OR HYDROXYCHLOROQUINE IMPROVE LIVE BIRTH RATES IN PATIENTS WITH REFRACTORY UNEXPLAINED RECURRENT PREGNANCY LOSS? A 2-YEAR SINGLE CENTER RETROSPECTIVE REVIEW OF CLINICAL OUTCOMES M. Boivin
3:41 PM	O-243	RECURRENT PREGNANCY LOSS (RPL): VARIATIONS IN EVALUATION AND RACIAL DISPARITIES. S. Martinez	4:25 PM	O-247	HISTORY OF RECURRENT IMPLANTATION FAILURE IS NOT ASSOCIATED WITH AN INCREASED ODDS OF HAVING A NON-RECEPTIVE ENDOMETRIAL RECEPTIVITY ANALYSIS RESULT. K. M. Schwartz
3:52 PM	O-244	THE FETAL ANXA5 M2 HAPLOTYPE CONTRIBUTES TO SPORADIC MISCARRIAGE OF EUPLOID FETUSES AFTER IVF TREATMENT. M. Madjunkov			
4:03 PM	O-245	CHROMOSOME MOSAICISM IN PRODUCTS OF CONCEPTION SAMPLES. J. Klavarian			



TUESDAY, OCTOBER 22, 2024

3:30 PM - 4:45 PM

OST-22 ORAL ABSTRACT SESSION: PATIENT CENTERED CARE

3:30 PM	O-248	IMPACT OF FAMILY PLANNING DECISIONS AMONG WOMEN IN THE U.S. MILITARY A. J. Dunn	4:03 PM	O-251	ASSISTED REPRODUCTIVE TECHNOLOGY USE AND OTHER BASELINE CHARACTERISTICS IMPACT THE ACCEPTABILITY OF TREATMENT FOR PREGNANCY OF UNKNOWN LOCATION: SECONDARY ANALYSIS OF THE ACTORNOT TRIAL. R. S. Weinerman
3:41 PM	O-249	PROGESTIN OVULATION SUPPRESSION COMPARED TO OTHER STIMULATION PROTOCOLS IN THE SAME PATIENT: THE GRASS IS NOT ALWAYS GREENER. S. C. Pierpoint	4:14 PM	O-252	EMBRYO DONATION (ED) MOTIVATIONS, BARRIERS, AND INTERESTS AMONG INDIVIDUALS STORING SURPLUS EMBRYOS. D. Roberts
3:52 PM	O-250	EVALUATION OF MEAN CHANGES IN WEIGHT DURING AND AFTER OVARIAN STIMULATION. S. Elder	4:25 PM	O-253	PGT POST-DOBBS: REI PHYSICIAN PERCEPTIONS OF IMPACT ON COUNSELING AND PATIENT DECISION MAKING. L. Manguso

WEDNESDAY, OCTOBER 23, 2024

10:45 AM - 12:15 PM

OSW-01 ORAL ABSTRACT SESSION: BENIGN GYNECOLOGICAL DISEASE- PCOS AND FIBROIDS

10:45 AM	O-254	AN UP TO 37-YEAR PROSPECTIVE COHORT STUDY OF WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS) AND OVULATORY CONTROLS COMPARING RATES OF CHRONIC DISEASE IN THE AGED. N. Kugelman	11:29 AM	O-258	INCIDENT UTERINE FIBROID DIAGNOSIS AND VARIATION BY RACE AND ETHNICITY IN A LARGE INTEGRATED HEALTHCARE SYSTEM, 2009-2022. S. D. Mitro
10:56 AM	O-255	ENHANCED FKBP51-GLUCOCORTICOID SIGNALING INDUCES LEIOMYOMA CELLS TOWARD A MYOFIBROBLAST PHENOTYPE. C. Malcom	11:40 AM	O-259	AI VERSUS RADIOLOGISTS IN DETECTING POLYCYSTIC OVARIAN SYNDROME BY ULTRASOUND: A SYSTEMATIC REVIEW AND META ANALYSIS. H. Hashim
11:07 AM	O-256	A 37-YEAR PROSPECTIVE STUDY OF PATIENTS WITH POLYCYSTIC OVARY SYNDROME: COMPARING CHRONIC MORBIDITY AND MORTALITY IN PATIENTS WITH AND WITHOUT SONOGRAPHIC STRING OF PEARLS POLYCYSTIC OVARY APPEARANCE. M. H. Dahan	11:51 AM	O-260	THE EFFECT OF INTRAUTERINE LIDOCAINE INSTILLATION ON PAIN SCORES AMONG WOMEN UNDERGOING HYSTEROSCOPY GUIDED BIOPSY: A DOUBLE BLINDED RANDOMIZED PLACEBO CONTROLLED TRIAL. A. T P
11:18 AM	O-257	CUT-OFF VALUE FOR ANTI-MÜLLERIAN HORMONE IN THE DIAGNOSTIC CRITERIA FOR POLYCYSTIC OVARY SYNDROME. H. Noguchi	12:02 PM	O-261	ASSOCIATION BETWEEN GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS USE AND REDUCED RISK OF NEW-ONSET FIBROIDS AMONG WOMEN WITH TYPE 2 DIABETES. T. Hsieh



WEDNESDAY, OCTOBER 23, 2024

10:45 AM - 12:15 PM

OSW-02 ORAL ABSTRACT SESSION: COMPLEX FAMILY PLANNING

10:45 AM	O-262	PGT-A IS NOT ASSOCIATED WITH A REDUCED LIKELIHOOD OF UNDERGOING AN INDUCED ABORTION. G. Beroukhim	11:29 AM	O-266	ESTRADIOL SUPPLEMENTATION FOR ENDOMETRIAL REGENERATION AFTER MISCARRIAGE DILATION AND CURETTAGE: A RETROSPECTIVE COHORT STUDY. M. Strug
10:56 AM	O-263	COVID-19 INFECTION AS A RISK FACTOR FOR SPONTANEOUS ABORTION: EVIDENCE FROM A RETROSPECTIVE COHORT STUDY. B. Q. Nguyen	11:40 AM	O-267	ASSESSING PATIENT PERCEPTIONS AND UNDERSTANDINGS OF GENETIC TESTING AFTER PREGNANCY LOSS. E. Hrach
11:07 AM	O-264	IMPACT OF PRIOR CONTRACEPTION METHOD ON CONTINUATION OF PARTICIPANTS IN A PHASE 3 STUDY OF A COPPER 175mm2 INTRAUTERINE DEVICE. M. A. Thomas	11:51 AM	O-268	EFFICACY OF PHARMACOLOGIC HEMORRHAGE PROPHYLACTICS IN SECOND TRIMESTER ABORTIONS: A SYSTEMATIC REVIEW. K. Hunkler
11:18 AM	O-265	IS HISTORY OF AN IUD OR DURATION OF EXPOSURE ASSOCIATED WITH OOCYTE RETRIEVAL OUTCOMES? A. Namath	12:02 PM	O-269	US WOMEN'S LIFETIME EXPERIENCE OF FORCED VAGINAL INTERCOURSE (FVI) AND PRESENT USE OF CONTRACEPTIVE METHODS. E. Long-Mills

WEDNESDAY, OCTOBER 23, 2024

10:45 AM - 12:15 PM

OSW-03 ORAL ABSTRACT SESSION: GENETICS-GENERAL

10:45 AM	O-270	WE PROPOSE AN EXPEDIENT WAY TO EDIT THE SPERM GENOME BY CRISPR-Cas9 IN A MOUSE MODEL. A. B. De Jesus	11:29 AM	O-274	PREIMPLANTATION GENETIC TESTING FOR MONOGENIC DISEASE (PGT-M) FOR MITIGATION OF REPRODUCTIVE RISK FOLLOWING OCCURRENCE OF APPARENTLY DE NOVO VARIANTS IN OFFSPRING: TECHNICAL AND CLINICAL EXPERIENCE. A. Iturriaga
10:56 AM	O-271	THE X FILES: PREVALENCE OF X-LINKED GENE VARIANTS IN PATIENTS UNDERGOING PREIMPLANTATION GENETIC TESTING AND THE LIMITATIONS OF CURRENT CARRIER SCREENING PANELS. N. Gupta	11:40 AM	O-275	THE EFFECT OF FRAGILE X PREMUTATION STATUS ON OOCYTE MATURITY. K. McCarter
11:07 AM	O-272	LOSS OF THE MATERNAL EFFECT GENE Nlrp2 IMPAIRS EMBRYONIC AND EXTRA-EMBRYONIC DEVELOPMENT, UNVEILING A NOVEL CAUSE OF CONGENITAL ANOMALIES. M. Sharif	11:51 AM	O-276	COMPREHENSIVE CHROMOSOME INHERITANCE DATA ANALYSIS TO HELP SET EXPECTATIONS FOR PGT-SR PATIENTS. D. Leahy
11:18 AM	O-273	CELL-FREE DNA LEVELS IN SPENT IVF CULTURE MEDIUM: ASSESSING CORRELATIONS WITH EMBRYO MORPHOLOGY AND CHROMOSOMAL INTEGRITY. C. Giménez-Rodríguez	12:02 PM	O-277	NEW DEVELOPMENTS AND CLINICAL UTILIZATION OF COMPREHENSIVE PGT-SR FOR DETECTION OF BALANCED REARRANGEMENTS AND MICRODELETIONS/DUPLICATIONS IN EMBRYOS. S. Madjunkova





WEDNESDAY, OCTOBER 23, 2024

10:45 AM - 12:15 PM

OSW-04 ORAL ABSTRACT SESSION: ART- CLINICAL (2 OF 2)

10:45 AM	O-278	COMPARISON OF EMBRYOLOGIC AND REPRODUCTIVE OUTCOMES OF FOLLICULAR AND LUTEAL PHASE STIMULATION IN THE SAME CYCLE: IS DUOSTIM BETTER? M. Sharon-Weiner	11:29 AM	O-282	INTERVENTIONS TO OPTIMIZE OUTCOMES IN INTRAUTERINE INSEMINATION CYCLES USING DONOR SPERM. S. Nedelcu
10:56 AM	O-279	PROLONGED ORAL GnRH ANTAGONIST ADMINISTRATION PRIOR TO EUPLOID EMBRYO TRANSFER (ET) IN ENDOMETRIOSIS (ENDO) PATIENTS: A PROSPECTIVE RANDOMIZED NON-INFERIORITY TRIAL. E. Surrey	11:51 AM	O-284	COMPARING SUBCUTANEOUS PROGESTERONE VS. VAGINAL PROGESTERONE SUPPLEMENTED WITH INTRAMUSCULAR PROGESTERONE EVERY THIRD-DAY IN HORMONE REPLACEMENT TREATMENT VITRIFIED WARMED BLASTOCYST TRANSFER CYCLES S. Mumusoglu
11:07 AM	O-280	HIGHER DOSE GONADOTROPINS DO NOT IMPROVE CLINICAL OUTCOMES IN POOR PROGNOSIS PATIENTS: RESULTS OF A MULTI-CENTER RANDOMIZED CONTROLLED TRIAL (RCT). P. Kovacs	12:02 PM	O-285	EPIDIDYMAL TAIL SPERM RETRIEVAL - INNOVATIVE METHOD FOR PATIENTS WITH SPINAL CORD INJURY -. A. Tanaka
11:18 AM	O-281	LEVERAGING NATIONAL CLAIMS DATA TO COMPARE BASELINE OBSTETRIC COMORBIDITIES IN IVF VERSUS NON-IVF PREGNANCIES. E. M. Stylli			

WEDNESDAY, OCTOBER 23, 2024

10:45 AM - 12:15 PM

OSW-05 ORAL ABSTRACT SESSION: INFERTILITY- ENVIRONMENTAL FACTORS AND NUTRITION

10:45 AM	O-286	IS POOR SLEEP ASSOCIATED WITH POOR SEX? AN ANALYSIS OF SEXUAL DYSFUNCTION IN MEN WITH SLEEP DISORDERS UNDERGOING FERTILITY TESTING A. K. Seyer	11:40 AM	O-291	MALE PARTNER PESTICIDE RESIDUE EXPOSURE FROM FRUIT AND VEGETABLE INTAKE IN RELATION TO FERTILIZATION RATE. M. Kazemi
10:56 AM	O-287	IS CANNABIS USE ASSOCIATED WITH A PSYCHIATRIC DIAGNOSIS IN COUPLES WITH INFERTILITY? K. Matevossian	11:51 AM	O-292	DOES METABOLICALLY UNHEALTHY/HEALTHY STATUS IMPACT IVF OUTCOMES IN WOMEN WITH SIMILAR BODY MASS INDEX: EVIDENCE FROM A LARGE RETROSPECTIVE COHORT STUDY. L. Mu
11:07 AM	O-288	SEMEN PARAMETERS AND EXPOSURE RISKS IN MILITARY MALES (SPERMM). A. J. Dunn	12:02 PM	O-293	CONSUMPTION OF ULTRA-PROCESSED FOODS IS NOT ASSOCIATED WITH FEMALE INFERTILITY: A CROSS-SECTIONAL STUDY OF THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES), 2013-2018. A. T. Evans
11:18 AM	O-289	PHYSICAL ACTIVITY DURING FERTILITY CARE (PACE): A RANDOMIZED CONTROLLED TRIAL OF EXERCISE DURING OVARIAN STIMULATION. M. Shapiro			
11:29 AM	O-290	DIETARY AND/OR PHYSICAL ACTIVITY INTERVENTIONS PRIOR TO FERTILITY TREATMENT TO IMPROVE LIVE BIRTH RATE – FOR WHOM? AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS (VENUS-IPD) R. Wang			



WEDNESDAY, OCTOBER 23, 2024

10:45 AM - 12:15 PM

OSW-06 ORAL ABSTRACT SESSION: REPRODUCTIVE UROLOGY (2 OF 2)

10:45 AM	O-294	ASSESSING REPRODUCTIVE OUTCOMES BETWEEN FRESH AND CRYOPRESERVED TESTICULAR SPERM IN MALES WITH ELEVATED SPERM DNA FRAGMENTATION. D. R. Siegel	11:29 AM	O-298	GENERATIONAL IMPACT OF CHANGES TO SPERM CHROMATIN ARCHITECTURE WITH PATERNAL AGING. M. M. Denomme Tignanelli
10:56 AM	O-295	DEVELOPMENT AND PRELIMINARY TESTING OF A FULLY AUTOMATED SEMEN PREPARATION ROBOT. C. Millan	11:40 AM	O-299	ACCURACY AND USABILITY OF THE YO (3.0) HOME SPERM TEST N. Bar-Chama
11:07 AM	O-296	THE PREVALENCE OF KARYOTYPE ABNORMALITIES IN OLIGOSPERMIC MENIN NORTH AMERICAN AND EUROPEAN STUDIES: A SYSTEMATIC REVIEW AND META-ANALYSIS. T. Kohn	11:51 AM	O-300	IMPACT OF THE COLLECTION ENVIRONMENT ON SPERM PHYSIOLOGY AND BIOCHEMISTRY AND ITS IMPLICATIONS FOR LONG-TERM OUTCOMES. S. D. Prien
11:18 AM	O-297	PREDICTING SUCCESS OF TESTICULAR SPERM RETRIEVAL THROUGH MULTI-OMICS ANALYSIS OF CELL-FREE SEMINAL PLASMA IN NOA MEN. L. Ng	12:02 PM	O-301	HIGH ANXIETY IS POSITIVELY ASSOCIATED WITH SEXUAL DYSFUNCTION AMONG MEN UNDERGOING FERTILITY TESTING. D. T. Lybbert

WEDNESDAY, OCTOBER 23, 2024

10:45 AM - 12:15 PM

OSW-07 ORAL ABSTRACT SESSION: GENETIC COUNSELING (3 OF 3)

11:45 AM	O-302	NOVEL FOLLICLE-STIMULATING HORMONE RECEPTOR MUTATIONS CAUSING OVARIAN DYSGENESIS AND PRIMARY OVARIAN INSUFFICIENCY. L. Chen	11:56 AM	O-303	COMPREHENSIVE FAMILY MEDICAL HISTORY EVALUATIONS ARE CRITICAL FOR CORRELATING CARRIER SCREENING FINDINGS WITH DOMINANT GENETIC DISEASE RISKS FOR PATIENT HEALTH AND REPRODUCTIVE MANAGEMENT. P. Callum
----------	-------	---	----------	-------	--

WEDNESDAY, OCTOBER 23, 2024

10:45 AM - 12:15 PM

OSW-08 ORAL ABSTRACT SESSION: LAW, POLICY, AND ADVOCACY (3 OF 3)

11:45 AM	O-304	THE IMPACT OF OVERTURNING ROE V. WADE ON THE PRACTICE OF ASSISTED REPRODUCTIVE TECHNOLOGIES (ART): A PILOT STUDY N. M. Fischer	11:56 AM	O-305	EFFECT OF ABORTION LEGISLATION ON ELECTIVE UTILIZATION OF PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) IN LOW-RISK PATIENTS, INCLUDING DONOR OOCYTE RECIPIENTS. A. L. Bernard
----------	-------	--	----------	-------	---





WEDNESDAY, OCTOBER 23, 2024

10:45 AM - 12:15 PM

OSW-09 ORAL ABSTRACT SESSION: MENTAL HEALTH (3 OF 3)

11:45 AM O-307 USE OF A DIGITAL HEALTH PLATFORM TO
MAINTAIN WORKPLACE PRODUCTIVITY WHILE
TRYING TO CONCEIVE. N. Henrich

WEDNESDAY, OCTOBER 23, 2024

10:45 AM - 12:15 PM

OSW-10 ORAL ABSTRACT SESSION: NURSING (3 OF 3)

11:45 AM O-308 SURROGACY: PRACTICES, CHALLENGES,
GLOBAL STANDARDS-INSIGHT FROM NURSING
PROFESSIONALS. S. Allahyar Shafiq





Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-01 PATIENT CENTERED CARE- EDUCATION & INFORMATION (1 OF 2)

- P-12 ADDRESSING THE FERTILITY EDUCATION GAP WITH DIGITAL HEALTH. S. Spiro
- P-13 TIKTOK FOR LOW T: THE CURRENT LANDSCAPE OF TESTOSTERONE REPLACEMENT THERAPY MISINFORMATION AND SUPPLEMENTATION ON A POPULAR VIDEO PLATFORM. L. G. Cheng
- P-14 TURNING TO TIKTOK: PRECONCEIVED NOTIONS AMONG PATIENTS ABOUT VASECTOMIES. L. G. Cheng
- P-15 ARE THE DAYS OF IN-PERSON IVF MEDICATION INJECTION TRAINING OVER? A COMPARISON ANALYSIS BETWEEN ONLINE EDUCATION AND IN-PERSON TRAINING N. Stansbury
- P-16 IMPACT OF AGE ON THE EFFECTIVENESS OF FERTILITY AWARENESS EDUCATION (FERTILITYED) FOLLOWING EXPOSURE TO TikTok™-STYLE VIDEOS VERSUS BROCHURE. J. Desposorio
- P-17 ARTIFICIAL INTELLIGENCE AS A FERTILITY PATIENT EDUCATOR: DOES CHATGPT DO THE JOB? J. Reich

PSM-02 PATIENT CENTERED CARE- EDUCATION & INFORMATION (2 OF 2)

- P-18 THE END OF AN INJECTION FOR OVULATION SUPPRESSION ERA: ORAL PROGESTIN-SUPPRESSED IN VITRO FERTILIZATION CYCLES PRODUCE SIMILAR OUTCOMES TO TRADITIONAL PROTOCOLS. L. R. Goodman
- P-19 TIKTOK FERTILITY TRENDS: A QUALITATIVE ANALYSIS OF POSTS ON SOCIAL MEDIA. M. Chapalamadugu
- P-20 GLP-1 RECEPTOR AGONIST FOR WEIGHT LOSS AND INFERTILITY: COMPARISON BETWEEN SOCIAL MEDIA PERCEPTION AND ONLINE SEARCH VERSUS EVIDENCE-BASED MEDICINE. Z. Merhi
- P-21 ASSISTED REPRODUCTIVE TECHNOLOGY (ART) OUTCOMES IN PATIENTS WITH CARDIOVASCULAR AND METABOLIC CONDITIONS. W. Urian
- P-22 TIKTOK, CYCLE TRACKING, AND #TRYINGTOCONCIEVE: A VIDEO CONTENT ANALYSIS OF AT-HOME URINARY HORMONE MONITORS ON SOCIAL MEDIA. P. A. Kamat
- P-23 SOCIAL MEDIA AND MEN’S SEXUAL HEALTH: A SYSTEMATIC REVIEW. L. G. Cheng

PSM-03 PATIENT CENTERED CARE- RESPECT FOR PATIENT PREFERENCE

- P-24 ADVANCING FERTILITY EQUITY: UPLIFTING BLACK WOMEN’S VOICES TO DESIGN CULTURALLY RESPONSIVE SUPPORT SOLUTIONS. L. Clarke
- P-25 OPPORTUNITIES TO OPTIMIZE PATIENT EXPERIENCE IN THE IN VITRO FERTILIZATION (IVF) CLINIC AND THE ROLE OF GENETIC COUNSELORS. R. Thoeny
- P-26 EXAMINING THE FATE OF FROZEN EMBRYOS: TO DISCARD OR DONATE? P. E. Voigt
- P-27 INSIGHTS INTO FERTILITY CARE: A PILOT STUDY MAPPING FERTILITY CARE EXPERIENCES USING ARTIFICIAL INTELLIGENCE. J. Araj
- P-28 WEIGHING IN ON PATIENT-CENTERED CARE: PATIENT EXPERIENCES WITH INFERTILITY AND OBESITY. V. E. Elliott
- P-29 OOCYTE DONOR CHARACTERISTICS AND PREFERENCES TOWARDS AN OPEN-IDENTITY DONATION PROGRAM. I. A. Alland





Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-04 PATIENT CENTERED CARE- ACCESS TO CARE

- P-30 OOCYTE RETRIEVAL PERI-OPERATIVE OUTCOMES AND COMPLICATIONS IN PATIENTS WITH CLASS III/IV OBESITY VERSUS NORMAL BMI. A. Johnson
- P-32 FERTILITY ED: EVALUATING THE EFFECTIVENESS OF SOCIAL MEDIA AS A TOOL TO INCREASE FERTILITY AWARENESS AMONG GRADUATE STUDENTS. J. Shaffer
- P-33 HOW PATIENTS ARE UTILIZING MAIL-IN SEMEN ANALYSIS TESTING FOR FERTILITY EVALUATION; AN ASSESSMENT OF 3,159 PATIENTS SEEKING CARE ONLINE AND THROUGH UROLOGY, REI, OBGYN, AND WELLNESS PRACTICES. J. R. Morris
- P-34 TELEHEALTH NEW PATIENT CONSULTATIONS INCREASE CONVERSION TO FERTILITY TREATMENT. M. S. Stevenson
- P-35 "EVERYBODY WOULD LISTEN- THEY'D HAVE SUPER BIONIC EARS": BLACK WOMEN'S PERSPECTIVES ON UTOPIC ART CARE. B. Slocum
- P-693 MAIL-IN SEMEN ANALYSIS PERFORMED FOLLOWING VASECTOMY REVERSAL IS ASSOCIATED WITH EXCELLENT KIT COMPLETION RATES AND TURNAROUND TIMES INDEPENDENT OF SOCIOECONOMIC BARRIERS. K. Asanad

PSM-05 PATIENT CENTERED CARE- GENERAL

- P-36 ENHANCING INFERTILITY CARE WITH A CHATGPT-BASED CHATBOT: INTEGRATING CLINICAL AND COMMUNITY INSIGHTS FOR IMPROVED PATIENT SUPPORT. H. Lee
- P-37 FERTILITY TREATMENT AFTER SEXUAL TRAUMA. I. Feferkorn
- P-38 AUTOMATED TOTAL CRYOMANAGEMENT PLATFORM ENABLES NEW INSIGHTS TO PATIENT ENGAGEMENT AND MAY HELP IN DEVELOPMENT OF IMPROVED CLINICAL POLICIES AND PROCEDURES. J. E. Swain
- P-39 EMOTIONAL DYNAMICS AND INFORMATIONAL NEEDS IN ONLINE FERTILITY FORUMS: INSIGHTS FROM USER INTERACTIONS. S. Di-Castro Shashua
- P-40 THE USE OF ELECTRONIC CONSENTS TO EVALUATE TRENDS IN FINAL DISPOSITION DECISIONS FOR CRYOPRESERVED REPRODUCTIVE TISSUE. E. M. Weidenbaum
- P-41 ENHANCING PATIENT COMMUNICATION AND REDUCING NURSE WORKLOAD IN IVF USING AN ADVANCED PATIENT APP: A STATISTICAL ANALYSIS OF REAL-WORLD DATA. R. Hourvitz

PSM-06 ART- ARTIFICIAL INTELLIGENCE (1 OF 5)

- P-42 DEEP LEARNING OUTPERFORMS TRADITIONAL IMAGE SEGMENTATION AND FEATURE EXTRACTION METHODS IN AUTOMATIC FOLLICLE COUNTING. P. Wygocki
- P-43 A LARGE AI FOUNDATION MODEL FOR EMBRYOLOGY ENABLES MULTIPLE PREDICTION TASKS. I. Hajirasouliha
- P-44 COMPARISON OF ARTIFICIAL INTELLIGENCE-GENERATED PATIENT EDUCATION FERTILITY CONTENT WITH RESPECT TO GENDER. D. Boedeker
- P-45 ARTIFICIAL INTELLIGENCE (AI) IN THE IVF LABORATORY: COMPARISON AMONG ALGORITHMS RESULTS, EMBRYO MORPHOLOGY, EUPLOIDY AND CLINICAL PREGNANCY OUTCOMES. C. Z. Berto
- P-46 THE IMPACT OF THE MALE FACTOR ON EGG DONATION CYCLES: A MORPHOKINETICS EMBRYO STUDY. M. Cozzolino
- P-47 PREGNANCY PREDICTABILITY OF TWO DEEP-LEARNING AI MODELS IN TIME LAPSE BASED ON FRESH SET. J. Jaldo Garcia





Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-07 ART- ARTIFICIAL INTELLIGENCE (2 OF 5)

- | | | | |
|------|--|------|--|
| P-48 | MACHINE LEARNING PREDICTIVE MODELING FOR MATURE OOCYTE RETRIEVAL: A TRANSCONTINENTAL STUDY WITH VARIOUS TREATMENT PROTOCOLS. R. Hourvitz | P-51 | RELATIONSHIP OF EMBRYO EUPLOIDY WITH PGT(A) AND EMBRYO SELECTION METHODS SUPPORTED BY ARTIFICIAL INTELLIGENCE. A. Carvajal |
| P-49 | GENERATIVE ARTIFICIAL INTELLIGENCE SUBSTANTIALLY ENHANCES THE ACCURACY OF EMBRYO SELECTION MODELS. P. Cao | P-52 | COMPARISON OF AN AI CLINICAL DECISION SUPPORT SYSTEM VERSUS EMBRYOLOGISTS; A PROSPECTIVE CLINICAL TRIAL. M. Salih |
| P-50 | ADVANCED ARTIFICIAL INTELLIGENCE FOR ACCURATE EMBRYO IDENTIFICATION IN IVF. V. S. Jiang | P-53 | NEW APPROACH OF ARTIFICIAL INTELLIGENCE FOR FERTILITY TREATMENT KNOWLEDGE ACCESS AND DECISION-MAKING. K. Zhioua |

PSM-08 ART- ARTIFICIAL INTELLIGENCE (3 OF 5)

- | | | | |
|------|--|------|--|
| P-54 | DEVELOPING AN ARTIFICIAL INTELLIGENCE (AI) MODEL TO EFFICIENTLY MEASURE ENDOMETRIAL THICKNESS WITHIN ULTRASOUND (US) IMAGES. N. Mercuri | P-57 | EMBRYO SURFACE AREA BEFORE AND AFTER COLLAPSE AND PERCENTAGE OF EMBRYO DETACHMENT FROM THE ZONA PELLUCIDA ARE PREDICTIVE BIOMARKERS OF CLINICAL MISCARRIAGE. K. Wiemer Phd |
| P-55 | THE ROLE OF PATIENT FACTORS ON EMBRYO QUALITY, PLOIDY AND CLINICAL OUTCOMES FOLLOWING ASSESSMENT BY AN ARTIFICIAL INTELLIGENCE (AI) ALGORITHM. J. Farfan | P-58 | APPLICATION OF MACHINE LEARNING ALGORITHMS TO PREDICT THE ONGOING PREGNANCY RATE (OPR) IN SINGLE EUPLOID FROZEN EMBRYO TRANSFER (SEFET) CYCLES. E. Kalafat |
| P-56 | DEEP LEARNING IMPROVES CONSISTENCY OF EMBRYO RANKING AND POTENTIAL REDUCTION IN TIME TO PREGNANCY. H. V. Aycok | P-59 | GENERATIVE AI SOLUTIONS FOR OVERCOMING INFORMATION RETRIEVAL CHALLENGES IN FERTILITY CARE. S. Di-Castro Shashua |

PSM-09 ART- ARTIFICIAL INTELLIGENCE (4 OF 5)

- | | | | |
|------|--|------|---|
| P-60 | ENHANCING IVF SUCCESS PREDICTION WITH AI: INTEGRATING PATIENT DATA, CYCLE METRICS, AND EMBRYO IMAGING. V. S. Jiang | P-63 | IMPROVED PREDICTION OF TROPHECTODERM GRADING THROUGH INTEGRATION OF BLASTOCOEL AREAS IN AI MODELS. H. Lee |
| P-61 | IS iDAScore™ v2.0 USEFUL FOR PREDICTING PREGNANCY IN FROZEN BLASTOCYST TRANSFER? R. Momma | P-64 | AI MANAGED SELECTIVE MODIFIED NATURAL CYCLE FROZEN EMBRYO TRANSFER (SMNC-FET). M. Youngster |
| P-62 | A PRELIMINARY EVALUATION OF AN ARTIFICIAL INTELLIGENCE (AI)-DRIVEN ROBOTIC SYSTEM FOR OOCYTE RETRIEVAL AND DENUDATION. A. Flores Saiffe Farias | P-65 | DEVELOPMENT OF AN ARTIFICIAL INTELLIGENCE MODEL SPECIFICALLY DESIGNED AND TRAINED WITH VITRIFIED-WARMED BLASTOCYST IMAGES: IMPLANTATION PREDICTION IN FROZEN CYCLES. L. Conversa Martínez |



Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-10 ART- ARTIFICIAL INTELLIGENCE (5 OF 5)

- P-66 CLINICAL OUTCOMES OF IN VITRO FERTILIZATION MONITORING BY AI ULTRASOUND ALONE VERSUS AI ULTRASOUND AND HORMONAL LEVELS. J. A. Schnorr
- P-67 ARTIFICIAL INTELLIGENCE NEURAL NETWORK TRAINED WITH POST-THAW TIME-LAPSE MORPHOKINETICS AND PROTEOMIC PROFILE FROM SPENT CULTURE MEDIA PREDICTS PREGNANCY IN WARMED BLASTOCYSTS. L. Conversa Martínez
- P-68 ASSESSING PRE- AND POST-INTRACYTOPLASMIC SPERM INJECTION (ICSI) OOCYTE IMAGES WITH ARTIFICIAL INTELLIGENCE (AI): PREDICTING FERTILIZATION AND BLASTOCYST DEVELOPMENT. L. Murria
- P-69 AI-POWERED OOCYTE PREDICTION FOR TRIGGER TIMING: CROSS-CONTINENTAL VALIDATION OF DATA FROM PREVIOUSLY UNSEEN CLINICS. R. Hourvitz
- P-70 PREDICTING IVF LIVE BIRTH PROBABILITIES USING MACHINE LEARNING, CENTER-SPECIFIC AND NATIONAL REGISTRY-BASED MODELS. E. T. Nguyen
- P-71 HOW MORPHOKINETICS CAN BE ANALYZED BY AI TO SELECT EUPLOID EMBRYOS FOR TRANSFER: THE IMPACT OF EMBRYO DEVELOPMENT ON LIVE BIRTH RATE. K. A. Miller

PSM-11 BENIGN GYNECOLOGICAL DISEASE- ENDOMETRIOSIS & ADENOMYOSIS (1 OF 3)

- P-72 THERAPEUTIC EFFECT OF ENDOMETRIOSIS ASSOCIATED MICRO-RNAS ON HUMAN ENDOMETRIOSIS XENOTRANSPLANTS. N. Gawde
- P-73 LONG-TERM ELAGOLIX + ADD-BACK THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN FOR 48 MONTHS + 12 MONTH POST-TREATMENT FOLLOW-UP: A SAFETY UPDATE ON BONE MINERAL DENSITY DATA OF A PHASE 3 STUDY. J. Kim
- P-74 IL-6 PREVENTS EXCESSIVE INVASION IN ENDOMETRIOSIS. R. Mamillapalli
- P-75 THE ASSOCIATION BETWEEN BACTERIAL VAGINOSIS AND ADENOMYOSIS. A. N. Valdez-Sinon
- P-76 ENDOMETRIOSIS IN IVF: THE TREATMENT WITH DEGARELIX BEFORE IVF ATTEMPT IMPROVES PATIENT' S REPRODUCTIVE OUTCOME. M. Sbracia
- P-77 INCIDENCE OF FALLOPIAN TUBE ENDOMETRIOSIS AND ITS ASSOCIATION WITH ENDOMETRIOMAS, HYDROSALPINX, AND PERITUBAL ADHESIONS: A PROSPECTIVE COHORT STUDY. E. Demirel

PSM-12 BENIGN GYNECOLOGICAL DISEASE- ENDOMETRIOSIS & ADENOMYOSIS (2 OF 3)

- P-78 THE ASSOCIATION OF REVISED MORPHOLOGICAL UTERUS SONOGRAPHIC ASSESSMENT (MUSA) FEATURES OF ADENOMYOSIS AND IVF OUTCOMES: A PROSPECTIVE COHORT STUDY. H. Choi
- P-79 Anoctamin 1 IS A POSSIBLE REGULATOR OF CYP19A1 IN THE DEVELOPMENT OF ENDOMETRIOSIS. A. Luo
- P-80 ASSESSING DEMOGRAPHIC PROFILES AND REFERRAL ORIGINS OF PATIENTS WITH UNEXPLAINED INFERTILITY SEEKING ENDOMETRIOSIS CARE: A COMPREHENSIVE EXAMINATION OF HEALTH DISPARITIES IN DIAGNOSIS AND TREATMENT. F. Khoyloo
- P-81 IMPACT OF IL-8/TNF- ON LHCGR EXPRESSION AND OVULATORY DYSFUNCTION IN ENDOMETRIOSIS. Y. Yin
- P-82 CONTROLLED TRIAL TO INVESTIGATE THE EFFECT OF ENDOMETRIOSIS ON THE HUMAN FOLLICULAR FLUID (HFF) MICROENVIRONMENT USING SHOTGUN PROTEOMICS FOR PATIENTS UNDERWENT FERTILITY TECHNIQUES. S. Alshehre
- P-83 SYMPTOMS AND CLINICAL CHARACTERISTICS IN ENDOMETRIOSIS PATIENTS AND ITS RELATIONSHIP WITH POTENTIALLY TOXIC ELEMENTS (PTE) CONTENT IN PERITONEAL FLUID: A PRELIMINARY STUDY. M. Acien



Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-13 BENIGN GYNECOLOGICAL DISEASE- ENDOMETRIOSIS & ADENOMYOSIS (3 OF 3)

- | | | | |
|------|--|------|---|
| P-84 | LAPAROSCOPY IN STAGE III/ IV ENDOMETRIOSIS AND SUBSEQUENT PREGNANCIES. S. Gainder | P-87 | DIAGNOSIS OF CONCURRENT ENDOMETRIOSIS ALONG WITH OTHER INFERTILITY DIAGNOSES, AND ITS EFFECT ON OUTCOMES OF SINGLE EUPLOID BLASTOCYST TRANSFER (SEBT): A RETROSPECTIVE STUDY OF SARTCORS DATA. J. Jayakumaran |
| P-85 | THE DIAGNOSTIC VALUE OF SERUM AND PERITONEAL MARKERS IN ENDOMETRIOSIS: A SYSTEMATIC REVIEW. A. Zhang | P-88 | EXAMINING miRNA PROFILES IN PERIPHERAL BLOOD EXTRACELLULAR VESICLES: A COMPARISON BETWEEN PATIENTS WITH AND WITHOUT ENDOMETRIOSIS. L. Benaglia |
| P-86 | HUMAN MICROBIOME AND ENODMETRIOSIS. E. Neisani Samani | P-89 | MULTIFACETED IMPACT OF PELVIC PAIN ON YOUNG WOMEN'S QUALITY OF LIFE AND WELL-BEING: A CROSS SECTIONAL STUDY. L. E. Chapman |

PSM-14 BENIGN GYNECOLOGICAL DISEASE- FIBROIDS

- | | | | |
|------|---|------|--|
| P-90 | SYSTEMIC IMMUNOLOGICAL CHANGES IN THE PRESENCE OF NON-CAVITY DISTORTING FIBROIDS. N. Kaur | P-93 | INTRAMYOMETRIAL INJECTION OF TERLIPRESSIN, CARBETOCIN, AND PLACEBO: IMPACT ON HEMOGLOBIN AND BLOOD LOSS IN OPEN MYOMECTOMY WITH HEMOSTATIC TOURNIQUETS - A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL. W. S. Elbanna |
| P-91 | EXPLORING THE DUAL HORMONAL AND ANTI-FIBROTIC ROLE OF RELAXIN-2 IN UTERINE FIBROIDS. Z. Garman | P-95 | THE UNIQUE CELLULAR RESPONSE TO COMPRESSION OBSERVED IN UTERINE LEIOMYOMA CELLS. A. J. Gordon |
| P-92 | GLOBAL INSIGHTS: PATIENT EXPERIENCES WITH UTERINE FIBROIDS - FINDINGS FROM AN INTERNATIONAL SURVEY BY A PATIENT ADVOCACY ORGANIZATION. A. Kendall | | |

PSM-15 BENIGN GYNECOLOGICAL DISEASE- GENERAL (1 OF 2)

- | | | | |
|-------|--|-------|---|
| P-98 | TIKTOK'S ROLE IN INFORMING: NAVIGATING POLYCYSTIC OVARIAN SYNDROME EDUCATION IN THE DIGITAL ERA. S. J. Hiitt | P-101 | CHANGES IN OVULATION INDUCTION PRESCRIPTION PRACTICES AFTER THE PPCOS II (PREGNANCY IN POLYCYSTIC OVARY SYNDROME II) TRIAL IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME. J. Applebaum |
| P-100 | COMPARING SURGICAL CARE OF ENDOMETRIOSIS IN ADOLESCENCE VERSUS ADULTHOOD. A. Scatoni | | |



Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-16 PRE-CLINICAL & BASIC RESEARCH- REPRODUCTIVE BIOLOGY (1 OF 2)

- P-102 RGMC BASED PEPTIDE MEDICINE RESTORE FUNCTIONAL ACTIVITY OF AGED HUMAN CUMULUS CELLS. J. Lee
- P-103 ANTI-INFLAMMATION AGENTS AS MIT-001 RESTORE FUNCTIONAL ACTIVITY IN HUMAN AGED CUMULUS CELLS. Y. Shim
- P-104 INVESTIGATING THE CAUSAL INTERPLAY BETWEEN IMMUNE CELL TRAITS AND THE RISK OF PREMATURE OVARIAN INSUFFICIENCY. Y. Du
- P-105 AGE-RELATED TRANSCRIPTOMIC PROFILING IN HUMAN GRANULOSA CELLS REVEALS MITOCHONDRIAL INSUFFICIENCY AND MICRORNA REGULATION OF KEY OVARIAN MICROENVIRONMENT DYNAMICS. H. Rogers
- P-106 TRANSCRIPTOMIC PROFILING OF DAY 3 HUMAN EMBRYOS WITH POOR QUALITY REVEALS MOLECULAR LINKS TO DIVERGENT DEVELOPMENTAL TRAJECTORIES. Y. Li
- P-107 UNVEILING ENDOMETRIOSIS: TRANSCRIPTOMIC PROFILING REVEALS MOLECULAR DYSREGULATION IN GESTATIONAL ENDOMETRIAL ORGANOID. A. Bas-Rivas

PSM-17 PRE-CLINICAL & BASIC RESEARCH- REPRODUCTIVE BIOLOGY (2 OF 2)

- P-108 ENDOMETRIAL STROMAL CELLS ENHANCE PLURIPOTENT STEM CELL CULTURE FOR MODELING EARLY HUMAN DEVELOPMENT IN VITRO. T. Ezashi
- P-109 AGE-RELATED VARIATIONS IN EMBRYO SECRETOME PROFILES DURING IVF CYCLES: A COMPREHENSIVE METABOLOMIC STUDY. E. G. Lo Turco
- P-110 CYTOKINE SECRETION PROFILE OF ISOLATED T-HELPERS COMPARED TO THAT OF PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC). M. Ruseva
- P-111 SENESCENT p21+ SPERMATOZOA IN HUMAN EJACULATE. M. Handzhiyska
- P-112 AT-56 RESCUES OOCYTE DYSFUNCTION IN OOCYTE-SPECIFIC KNOCKOUT CLPX MICE BY INHIBITING PGD2 SYNTHESIS. R. Hua
- P-113 THE MECHANOSENSOR PIEZO1 IS ESSENTIAL FOR ENDOMETRIAL RECEPTIVITY AND EMBRYO IMPLANTATION. J. Zheng

PSM-18 ART- THIRD PARTY REPRODUCTION

- P-114 HOW DONOR OOCYTE SOURCE RELATES TO RECIPIENT OUTCOME. E. A. Clarke
- P-115 AN ANALYSIS OF POOR PROGNOSIS PATIENTS AND LIVE BIRTH POTENTIAL AFTER FIRST EMBRYO TRANSFER WITH DONOR OOCYTE. E. A. Clarke
- P-116 IN-VITRO FERTILIZATION WITH PREIMPLANTATION GENETIC TESTING COMPARED WITH DONOR SPERM AND NATURAL CONCEPTION AMONG MALE ROBERTSONIAN TRANSLOCATION CARRIERS: A COST-EFFECTIVENESS ANALYSIS. S. J. Melville
- P-117 CRYOPRESERVED DONOR OOCYTES EXHIBIT DELAYED BLASTULATION IN COMPARISON TO A FRESH DONOR OOCYTE SOURCE. L. C. George
- P-118 TOP CONSIDERATIONS OF POTENTIAL SPERM DONORS BY ETHNIC BACKGROUND: HOW CAN WE IMPROVE DONOR RECRUITMENT, SCREENING, AND EDUCATION? T. Di Bernardino
- P-119 EGG DONOR GAINED EXPERIENCES (EDGE) STUDY: SELF-REPORTED SHORT AND LONG-TERM SYMPTOMS AND COMPLICATIONS AFTER OOCYTE DONATION. J. R. Morris





Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-19 ART- GENERAL (1 OF 3)

- P-120 COMPARISON OF EMBRYO MORPHOKINETIC PARAMETERS FOLLOWING ASSISTED SPERM FUSION INSEMINATION AND INTRACYTOPLASMIC SPERM INJECTION ON SIBLING OOCYTES. S. Hatakeyama
- P-121 THE TRANSITION FROM CONJUGALITY TO PARENTHOOD IN MALE SAME-SEX COUPLES UNDERGOING IN VITRO FERTILIZATION TREATMENTS. D. Pagliarin
- P-122 GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR DURING IN VITRO OOCYTE MATURATION IMPROVES IMPLANTATION AND FETAL NUMBERS. A. Saini
- P-123 IMPACT OF IMPORTING CRYOPRESERVED EMBRYOS ON FET OUTCOMES. E. Minis
- P-124 RECURRENT EUPLOID IMPLANTATION FAILURE PREVALENCE AND CLINICAL RISK FACTORS: A SART CORS ANALYSIS. A. H. Liu
- P-125 DOES OOCYTE DONATION HAVE AN EFFECT ON IMPLANTATION AND OTHER PREGNANCY OUTCOMES IN WOMEN OF ADVANCED REPRODUCTIVE AGE UNDERGOING SINGLE, EUPLOID EMBRYO TRANSFER? A FOLLOW UP STUDY OF 5,381 CYCLES S. Willson

PSM-20 ART- GENERAL (2 OF 3)

- P-126 "HOW DID IT GO?" - INVESTIGATION OF A PHYSICIAN'S SUBJECTIVE EXPERIENCE DURING EMBRYO TRANSFER AND SUBSEQUENT PREGNANCY OUTCOMES S. C. Pierpoint
- P-127 MINIMUM STIMULATION PROTOCOL AS THE UMBRELLA PROTOCOL FOR ALL AGE GROUPS: A SOUTH EAST ASIAN POPULATION PERSPECTIVE. D. Mishra
- P-128 A COMPARATIVE STUDY: MISCARRIAGE RATES IN "TRANSFER THE BEST, BIOPSY THE REST" TREATMENT STRATEGY VERSUS PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY. D. C. Gonullu-Rotman
- P-129 MORPHOKINETIC DIFFERENCES IN INDIVIDUAL AND GROUP EMBRYO CULTURE: EFFECTS ON EARLY DEVELOPMENT AND CLINICAL OUTCOMES IN ASSISTED REPRODUCTIVE TECHNOLOGY. H. Oh
- P-130 IMPACT OF TESTICULAR SPERM EXTRACTION PROCEDURES ON TROPHECTODERM QUALITY OF EMBRYOS IN MALE FACTOR INFERTILITY PATIENTS UNDERGOING IVF. I. Peregrin Alvarez
- P-131 TIME INTERVAL BETWEEN SPERM PROCESSING AND INTRACYTOPLASMIC SPERM INJECTION (ICSI) OUTCOMES IN PREIMPLANTATION GENETIC TESTING CYCLES (PGT-A): IMPLICATIONS FOR LABORATORY MANAGEMENT. C. Hernandez-Nieto

PSM-21 LAW, POLICY, AND ADVOCACY (1 OF 2)

- P-132 EMBRYO DISPOSITION PREFERENCES OF SUPERNUMERARY EMBRYOS DO NOT CHANGE BEFORE AND AFTER THE COVID-19 PANDEMIC AT A LARGE ACADEMIC FERTILITY CENTER. C. Cherston
- P-133 OPEN-IDENTITY AT AGE 18 SPERM DONATION: DONOR AVAILABILITY. A. A. Valido
- P-134 INVESTIGATING THE ETHICAL PERMISSIBILITY OF OFFERING THE OPPORTUNITY TO SELECT THE SEX OF EMBRYOS FOR TRANSFER: AN ANALYSIS OF A CLINIC'S SEX SELECTION PRACTICES AND OUTCOMES. A. Huttler
- P-135 ABORTION SERVICES FOR OUT-OF-STATE PATIENTS: A WEBSITE CONTENT ANALYSIS OF ABORTION PROVIDERS. M. Miyasaka
- P-136 INSIGHTS INTO THE NEW INDIAN ART REGULATIONS: VOICES OF THE INDIAN FERTILITY COMMUNITY. K. Mantravadi





Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-22 LAW, POLICY, AND ADVOCACY (2 OF 2)

- P-137 A SURVEY-BASED EVALUATION OF PUBLIC AWARENESS AND OPINIONS CONCERNING THE ALABAMA SUPREME COURT RULING REGARDING FROZEN EMBRYOS. A. Combs
- P-138 THE #TIKTOK RESPONSE AGAINST IN VITRO FERTILIZATION: A CROSS-SECTIONAL CONTENT ANALYSIS. A. H. Liu
- P-139 UNDERSTANDING POSTPARTUM PSYCHOSIS AS IT RELATES TO SENTENCING DECISIONS IN THE COURTROOM. K. Shah
- P-140 ABANDONED AND SURPLUS EMBRYOS: WHAT TO DO WITH THEM? A BRIEF STUDY OF BRAZILIAN LEGISLATION É. M. Padre e Fechine

PSM-23 RECURRENT PREGNANCY LOSS (1 OF 2)

- P-141 AN EXPLORATORY STUDY OF ENDOMETRIAL DYSBIOSIS IN RECURRENT EARLY PREGNANCY LOSS AND ASSOCIATED REPRODUCTIVE OUTCOMES. P. Patel
- P-142 STRUCTURAL VARIANTS IN GENOMES OF PATIENTS WITH RECURRENT PREGNANCY LOSS (RPL): THE UTILITY OF OPTICAL GENOME MAPPING (OGM). R. G. Handelsman
- P-143 LIVE BIRTH OUTCOMES IN PATIENTS WITH INHERITED THROMBOPHILIA AND RECURRENT PREGNANCY LOSS. K. Ziafat
- P-144 T REGULATORY CELL (TREG) TESTING IN THE DIAGNOSTIC EVALUATION OF PATIENTS WITH RECURRENT PREGNANCY LOSS (RPL): MAY IT SHOW CLINICAL VALUE? F. Scarpellini
- P-145 IS THE PLOIDY STATUS AFFECTED BY OVARIAN RESERVE IN UNEXPLAINED RECURRENT PREGNANCY LOSS FOLLOWING IVF/ICSI? D. G. Rao

PSM-24 RECURRENT PREGNANCY LOSS (2 OF 2)

- P-146 METFORMIN ENHANCES ENDOMETRIAL RECEPTIVITY IN POLYCYSTIC OVARY SYNDROME: UNRAVELING THE ROLE OF THE -ENOLASE. Y. Xie
- P-147 DONOR OOCYTE AND IN VITRO FERTILIZATION WITH PREIMPLANTATION GENETIC TESTING FOR STRUCTURAL REARRANGEMENTS ARE COST-EFFECTIVE STRATEGIES FOR FEMALE ROBERTSONIAN 13;14 TRANSLOCATION CARRIERS. J. Shi
- P-148 NON-SELECTION, RETROSPECTIVE ANALYSIS IDENTIFIES OPTIMAL HISTOCOMPATIBILITY BETWEEN MATERNAL KIR HAPLOTYPE AND EMBRYONIC HLA-C GENOTYPE FOR IMPLANTATION SUCCESS. M. M. Denomme Tignanelli
- P-149 COVID-19 AND RECURRENT PREGNANCY LOSS: TRENDS IN ACCESS TO CLINICAL CARE IN A SOCIOECONOMICALLY DIVERSE POPULATION. S. Balachandran
- P-150 DNA FRAGMENTATION ASSAYS FOR RECURRENT PREGNANCY LOSS: PRACTICE PATTERNS AMONG UROLOGISTS AND REPRODUCTIVE ENDOCRINOLOGISTS. K. M. Black

PSM-25 ART- LAB (1 OF 10)

- P-151 NON-INVASIVE BIOMARKERS FOR EMBRYO SELECTION IN IVF: UNVEILING SECRETED SIGNATURES FOR IMPLANTATION PREDICTION. R. Yagüe Serrano
- P-152 CLINICAL OUTCOMES OF SINGLE MOSAIC EMBRYO TRANSFER IN TERMS OF TYPES AND LEVELS OF MOSAICISM. S. Hwang
- P-153 SEMEN TREATMENT FOR THE ICSI PROCEDURE: IS IT REALLY NECESSARY? M. Casalechi
- P-154 VITRIFICATION OF HUMAN TESTICULAR AND EPIDIDYMAL SPERMATOZOA WITHOUT PERMEABLE CRYOPROTECTANTS: CLINICAL OUTCOMES. V. Kuznyetsov
- P-155 CLINICAL EFFICACY OF PGT-A ON DAY 7 BLASTOCYSTS. K. Murakami



Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-26 ART- LAB (2 OF 10)

- | | | | |
|-------|--|-------|--|
| P-156 | WHEN CONFIRMATION OF OVULATION DATE IS UNCLEAR DURING NATURAL CYCLE FROZEN EMBRYO TRANSFER, SHOULD IT BE THAWED THE DAY BEFORE OR THE NEXT DAY? G. KIM | P-159 | EMPIRICAL ASSESSMENT OF LABORATORY WORKLOAD VARIABILITY AND ITS IMPACT ON ICSI FERTILIZATION, BLAST, AND USABLE BLAST RATES. A. Freedman |
| P-157 | TO SPLIT OR NOT TO SPLIT? RE-EVALUATING MONOZYGOTIC TWIN (MZT) RISK FACTORS AT A LARGE ACADEMIC FERTILITY CENTER A. G. Kelly | P-160 | A COMPREHENSIVE MULTI-BIOASSAY APPROACH TO UNRAVEL MALE GAMETE FERTILIZATION DYSFUNCTION. O. M. Kocur |
| P-158 | CLINICAL AND METABOLIC EFFECTS OF ULTRA RAPID VITRIFICATION AND THAWING ON OOCYTE AND EMBRYO VIABILITY. D. Gudkova | | |

PSM-27 ART- LAB (3 OF 10)

- | | | | |
|-------|---|-------|--|
| P-161 | OPTIMIZING REPRODUCTIVE OUTCOMES IN MEN WITH SEVERE OLIGO-ASTHENO-TERATOZOOSPERMIA- IS THERE AN IDEAL SPERM PREPARATION TECHNIQUE? K. Mantravadi | P-163 | IMPACT OF EMBRYO GLUE USE ON IN VITRO FERTILIZATION/ FROZEN EMBRYO TRANSFER OUTCOMES: AN 8-YEAR RETROSPECTIVE ANALYSIS. H. Kim |
| P-162 | AROMATASE INHIBITION DURING CONTROLLED OVARIAN HYPERSTIMULATION (COH) SHOWS THE CHOLESTEROL/ STEROID PATHWAY COMPENSATES: FINDINGS FROM A PILOT STUDY. N. S. Jain | P-164 | A PHYSIOLOGICAL APPROACH FOR OOCYTE ACTIVATION TO OVERCOME FERTILIZATION FAILURE WITH ICSI. P. Xie |
| | | P-165 | RAPID WARMING PROTOCOL OF HUMAN OOCYTES: A RANDOMIZED CONTROLLED TRIAL. L. Murria |

PSM-28 ART- LAB (4 OF 10)

- | | | | |
|-------|--|-------|--|
| P-166 | PROSPECTIVE OBSERVATIONAL STUDY OF SERUM PROGESTERONE LEVEL ON THE DAY OF EMBRYO TRANSFER(ET) AND DAY 7 POST ET AMONG WOMEN UNDERGOING FROZEN EMBRYO TRANSFER(FET) AND CORRELATION WITH OUTCOME. D. P. Shivalingegowda | P-169 | EXPLORING THE LINK BETWEEN ESTROGEN AND PROGESTERONE RECEPTOR POLYMORPHISMS AND IDIOPATHIC THIN ENDOMETRIUM. J. Farfan |
| P-167 | IMPACT OF ZONA PELLUCIDA PRESENCE ON LIVE BIRTH RATES: A RETROSPECTIVE STUDY. D. Alvarado | P-170 | EXAMINING RELEVANCE OF AGE AND BODY MASS INDEX FOR EMBRYO MORPHOKINETICS. A. C. Dzienny |
| P-168 | SINGLE EMBRYO TRANSFER PREGNANCY OUTCOMES COMPARED BETWEEN BLASTOCYSTS DIAGNOSED AS EUPLOID VERSUS THOSE NOT UNDERGOING BIOPSY OR PREIMPLANTATION GENETIC TESTING (PGT) PRIOR TO TRANSFER. S. T. Daneshmand | | |



Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-29 ART- LAB (5 OF 10)

- | | |
|--|--|
| <p>P-171 THE EFFECTS OF NATURAL VERSUS PROGRAMMED FROZEN EMBRYO TRANSFER CYCLES ON PLACENTAL HISTOPATHOLOGY. A. Machado-Gédéon</p> <p>P-172 IMPACT OF THE COMBINATION OF POLSCOPE-BASED ICSI AND PHYSIOLOGICAL ICSI ON POOR RESPONDER PATIENTS. H. Jang</p> <p>P-173 EVALUATING OUTCOMES OF INTRACYTOPLASMIC SPERM INJECTION USING CRYOPRESERVED SURGICALLY RETRIEVED SPERM VIA TESTICULAR SPERM ASPIRATION TREATED WITH PENTOXIFYLLINE. N. George</p> | <p>P-174 EFFECT OF DELAYED DEVELOPMENT OF EMBRYOS 7 DAYS ON EMBRYO QUALITY, PLOIDY AND REPRODUCTIVE CYCLE OUTCOMES. K. Chernoshitan</p> <p>P-175 INTRACYTOPLASMIC SPERM INJECTION VERSUS CONVENTIONAL IN VITRO FERTILIZATION IN COUPLES WITH INFERTILITY AND NORMAL TOTAL SPERM COUNT AND MOTILITY: DOES SPERM MORPHOLOGY MATTER? D. D. Pham</p> |
|--|--|

PSM-30 ART- LAB (6 OF 10)

- | | |
|---|---|
| <p>P-176 IMPACT OF CLEAVAGE STAGE VS. BLASTOCYST STAGE ASSISTED HATCHING FOR SINGLE EUPLOID FROZEN EMBRYO TRANSFERS ON PREGNANCY OUTCOMES C. K. Arkfeld</p> <p>P-177 A COMPARISON OF THE DYNAMIC PARAMETERS OF EMBRYOS DEVELOPED FROM VITRIFIED VERSUS FRESH OOCYTES. J. LIU</p> <p>P-178 ROLE OF MICROFLUIDICS SPERM SORTING IN OPTIMIZING OUTCOMES OF AN IUI CYCLE. K. Mantravadi</p> | <p>P-179 PARENTAL INHERITANCE OF MONOPRONUCLEAR BLASTOCYSTS FROM ICSI CYCLES AND ITS CORRELATION WITH PARTICULAR MORPHOKINETIC CHARACTERISTICS. T. Wen</p> <p>P-180 SERUM ANTI-MULLERIAN HORMONE IS ASSOCIATED WITH PREOVULATORY FOLLICLE CUMULUS CELL MITOCHONDRIAL DNA COPY NUMBER. M. Volovsky</p> |
|---|---|

PSM-31 ART- LAB (7 OF 10)

- | | |
|--|--|
| <p>P-181 TIME LAPSE (TL) CULTURE CAN IMPROVE BLASTOCYST DEVELOPMENT WHEN COMPARED TO NON-TL INCUBATORS. S. Phillips</p> <p>P-182 MATERNAL SPINDLE TRANSFER (MST) CAN HELP RESTORE DEVELOPMENTAL POTENTIAL, MAINTAIN DNA INTEGRITY AND REDUCE THE INCIDENCE OF ANEUPLOIDIES OCCURRING DURING MEIOSIS II IN IN VITRO AGED OOCYTES. N. Costa Borges</p> <p>P-183 A BETTER, IMPROVED RAPID OOCYTE WARMING TECHNOLOGY YIELDS HIGHER GOOD BLASTOCYST RATES THAN STANDARD WARMING PROTOCOL. H. Chen</p> | <p>P-184 LOW-LEVEL VOLATILE ORGANIC COMPOUNDS DISRUPT EMBRYO MORPHOKINETICS AND DEVELOPMENT IN MURINE PREIMPLANTATION EMBRYOS. M. Orsolini</p> <p>P-185 THE USE OF THE BOVINE OVARIAN MODEL TO ESTABLISH A HUMAN OVARIAN TISSUE CRYOPRESERVATION QUALITY CONTROL PROGRAM. O. Perez</p> |
|--|--|



Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-32 ART- LAB (8 OF 10)

- P-186 INSIGHTS FROM VOLATILE ORGANIC COMPOUNDS MONITORING IN IVF LABS: LESSONS LEARNED. Y. Ying
- P-187 COMPARATIVE DEVELOPMENTAL POTENTIAL OF MATURE AND IMMATURE OOCYTES IN IN VITRO FERTILIZATION TREATMENTS: INSIGHTS FROM A SELF-CONTROLLED CASE SERIES. G. N. Cecchino
- P-188 REPEATED ADDITION OF ANTIOXIDANTS TO THE CULTURE MEDIA SLIGHTLY DECREASES EARLY AND LATE PREGNANCY LOSS IN ART CYCLES. J. González Martínez
- P-189 IMPACT OF ONE-DAY DELAYED CALCIUM IONOPHORE OOCYTE ACTIVATION ON EMBRYONIC DEVELOPMENT FOLLOWING ICSI. H. Park
- P-190 UTILIZATION OF A RAPID BLASTOCYST WARMING PROTOCOL & IMPACT ON FROZEN EMBRYO TRANSFER (FET) OUTCOMES: A QUALITY IMPROVEMENT (QI) INITIATIVE. E. M. Weidenbaum

PSM-33 ART- LAB (9 OF 10)

- P-191 PIEZO-ASSISTED INTRACYTOPLASMIC SPERM INJECTION (PIEZO-ICSI) IMPROVED BLASTOCYST FORMATION AND DECREASED DEGENERATION COMPARED WITH CONVENTIONAL ICSI (C-ICSI) AMONG 15,198 ICSI CYCLES. T. Horikawa
- P-192 EMBRYO BIOPSY: IS IT WORTH THE WAIT? A NEW PERSPECTIVE E. L. Iniguez-Arteaga
- P-193 ASSISTED HATCHING AND CLINICAL PREGNANCY RATE FOLLOWING FRESH EMBRYO TRANSFER. N. Guardino
- P-194 THE USE OF AUTOLOGOUS PLATELET-RICH PLASMA (PRP) IN EMBRYO CULTURE TO OBTAIN HIGH-QUALITY EMBRYOS. Y. Rhee
- P-195 PREDICTION OF CONVENTIONAL-IVF FERTILIZATION RATE USING PERCENTAGE OF SPERM WITH HIGH MOTILITY OR IMMOTILE SPERM. S. Ikuta

PSM-34 ART- LAB (10 OF 10)

- P-197 ULTRAFAST WARMING OF CONVENTIONALLY VITRIFIED HUMAN METAPHASE II OOCYTES: A PILOT STUDY. I. Kuznyetsova
- P-198 PATIENTS WITH POOR BLASTOCYST FORMATION RATES IN AN INITIAL CYCLE HAVE IMPROVED OUTCOMES IN SUBSEQUENT CYCLES WITH OR WITHOUT USE OF CALCIUM IONOPHORE ACTIVATION POST-ICSI. J. G. Kim
- P-199 COMPARISON OF OOCYTE VITRIFICATION/WARMING METHODS WITH ANONYMOUS DONOR OOCYTES. Y. Ren

PSM-35 INFERTILITY- DIAGNOSIS & TREATMENT (1 OF 3)

- P-202 EFFECT OF RE-DOSING LETROZOLE IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME UNDERGOING OVULATION INDUCTION WITH INSEMINATION. K. Bethel Fields
- P-203 UNDER PRESSURE: STRESS IS NEGATIVELY ASSOCIATED WITH LIBIDO AND INTERCOURSE FREQUENCY. A. K. Seyer
- P-204 AZF MICRODELETION INCIDENCE AMONG INFERTILE MALES AND ITS CORRELATION WITH IVF/ICSI OUTCOMES. H. Bach
- P-205 COVID-19 INFECTION AND SUBSEQUENT INFERTILITY RISKS IN WOMEN: A RETROSPECTIVE COHORT STUDY. B. Q. Nguyen



Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-36 INFERTILITY- DIAGNOSIS & TREATMENT (2 OF 3)

- P-206 ABILITY OF HYSTEOSALPINGOGRAPHY TO DIAGNOSE PATHOLOGY CONFIRMED TUBAL DISEASE IN INFERTILE PATIENTS. C. Moutos
- P-207 EMBRYONIC APOPTOTIC DYSREGULATION CONTRIBUTES TO IMPLANTATION FAILURE AND INFERTILITY. K. J. McCarty
- P-209 IMPACT OF ANTIBIOTIC TREATMENT FOR CHRONIC ENDOMETRITIS ON PREGNANCY OUTCOMES IN SUBSEQUENT SINGLE EUPLOID FROZEN-THAWED EMBRYO TRANSFER CYCLES OF INFERTILE WOMEN: A PROPENSITY SCORE MATCHING STUDY. M. Kim
- P-210 OPTIMAL RESTORATION OF SPERMATOGENESIS FOLLOWING TESTOSTERONE THERAPY USING HCG AND FSH. B. T. Stocks

PSM-37 INFERTILITY- ENVIRONMENTAL FACTORS (1 OF 2)

- P-211 THE IMPACT OF ENVIRONMENTAL FACTORS AND CHRONIC MEDICAL CONDITIONS ON SEMEN QUALITIES: A TEN-YEAR LONGITUDINAL ANALYSIS. M. J. Scott
- P-212 EXPOSURE TO WILDFIRE SMOKE IS ASSOCIATED WITH DECREASED SEMEN QUALITY. J. M. Ramsay
- P-213 MARIJUANA SMOKING AND OVARIAN RESERVE AMONG FEMALES PRESENTING TO AN ACADEMIC FERTILITY CENTER. S. Kitazawa
- P-214 HIGH THROUGHPUT SCREEN DOSE-DEPENDENT EFFECTS AND TRANSCRIPTOMIC EFFECTS ASSAYS SHOW LARGER ADVERSE EFFECTS IN TSC THAN ESC, THUS PREDICTING MISCARRIAGE. D. Rappolee

PSM-38 INFERTILITY- ENVIRONMENTAL FACTORS (2 OF 2)

- P-216 IMPACT OF HIGH-ALTITUDE OVER THE LEVEL OF REACTIVE OXYGEN SPECIES (ROS) IN HUMAN SEMEN AND SPERM DNA FRAGMENTATION. J. Vasquez
- P-217 MILITARY EXPOSURES AND REPRODUCTIVE HEALTH OUTCOMES: FINDINGS FROM THE GULF WAR COHORT STUDY. A. Altman
- P-218 ASSOCIATIONS OF SLEEP CHARACTERISTICS WITH REPRODUCTIVE HORMONES AND THYROID FUNCTIONS AMONG WOMEN WITH INFERTILITY: A CROSS-SECTIONAL STUDY. J. Li
- P-219 RESIDENTIAL AIR POLLUTION LEVELS DO NOT APPEAR TO AFFECT EMBRYOLOGY OUTCOMES IN PATIENTS UNDERGOING IN VITRO FERTILIZATION (IVF): INSIGHTS FROM 5,687 CYCLES CONDUCTED IN NEW JERSEY FROM 2020 TO 2023. B. Vessa
- P-220 UNDIAGNOSED CARDIAC RISK FACTORS ARE HIGHLY PREVALENT IN YOUNG MEN PRESENTING WITH INFERTILITY. J. O. Rust

PSM-39 INFERTILITY- OUTCOMES (1 OF 3)

- P-221 SEEING THE UNSEEN: IDENTIFYING UNCOVERED IN VITRO FERTILIZATION CYCLES IN MEDICAL CLAIMS DATA. R. L. Dunn
- P-222 RELATIONSHIP BETWEEN ANTI-MULLERIAN HORMONE AND MII OOCYTE YIELD CONSISTENT ACROSS RACE AND ETHNICITY GROUPS, WITH VARIATION IN MAGNITUDE OF ASSOCIATION. J. Chae-Kim
- P-223 COMPARING PREGNANCY OUTCOMES BETWEEN SPORADIC AND SEQUENTIAL INTRAUTERINE INSEMINATION (IUI) CYCLES. S. Jilani
- P-224 WHEN TRANSFERING FROZEN EMBRYOS, IS MODIFIED NATURAL CYCLE ACTUALLY BETTER? H. Hamze
- P-225 PREVALENCE OF PERINATAL AND OBSTETRIC OUTCOMES IN ASSISTED REPRODUCTIVE TECHNOLOGIES WITH MODERATE AND SEVERE MALE FACTOR: 14 YEARS EXPERIENCE REPORT. S. A. Davila Garza





Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-40 INFERTILITY- GENERAL (1 OF 4)

- P-226 IMPACT OF LOW MOLECULAR WEIGHT HEPARIN ON PREGNANCY OUTCOMES IN INFERTILITY PATIENTS WITH EXTENDED PANEL ANTI-PHOSPHOLIPID ANTIBODIES. Z. Husnain
- P-227 FERTILIZATION BY INTRACYTOPLASMIC SPERM INJECTION (ICSI) FOR NON-MALE FACTOR INFERTILITY DID NOT LEAD TO INCREASED EUPLOIDY OR LIVE BIRTH RATES COMPARED TO ICSI FOR MALE FACTOR INFERTILITY. N. K. Strauch
- P-228 PROGESTERONE AND ESTROGEN LEVELS AT TIME OF POSITIVE HCG PREDICTIVE OF LIVE BIRTH RATE IN NATURAL FROZEN EMBRYO TRANSFER CYCLES. D. Miranian
- P-229 THE GUT AND VAGINAL MICROBIOME ARE ASSOCIATED WITH, AND CAN PREDICT, IVF CYCLE OUTCOMES – A METAGENOMIC SEQUENCING STUDY USING LINEAR AND MACHINE LEARNING (ML) MODELS. M. Youngster
- P-230 EXPOSURE TO SMOKE AND HEAVY METALS IS ASSOCIATED WITH POORER SEMEN QUALITY IN FERTILE MEN. C. Rubio Lluesa

PSM-41 ART- CLINICAL (1 OF 10)

- P-231 AT-HOME SELF ADMINISTERED TRANSVAGINAL ULTRASOUND FOR TRACKING FOLLICLE MEASUREMENTS DURING FERTILITY PRESERVATION CYCLES: REMOVING BARRIERS TO ACCESS CARE. M. Olcha
- P-232 THE RELATIVE EFFECT OF VERY LOW, NORMAL, AND INCREASED SERUM ANTI-MULLERIAN HORMONE (AMH) LEVELS ON OUTCOME FOLLOWING FRESH EMBRYO TRANSFER (ET) IN WOMEN OF ADVANCED REPRODUCTIVE AGE. J. H. Check
- P-233 BETTER LATE THAN NEVER – IS THE REPRODUCTIVE POTENTIAL OF DAY 7 EUPLOID EMBRYOS PREDICTIBLE BY THE COHORT OF EMBRYOS FROM WHICH IT WAS DERIVED? M. Sharon-Weiner
- P-234 AN INTERVENTION ACCORDING TO THE RESULTS OF A NEW ENDOMETRIAL MICROBIOME TESTING IMPROVES ART OUTCOMES IN RECURRENT IMPLANTATION FAILURE PATIENTS. T. Takeuchi
- P-235 COMPARISON OF THE LIVE BIRTH RATE IN ENDOMETRIOMA PATIENTS USING GnRH AGONIST AND ANTAGONIST PROTOCOLS A PROPENSITY SCORE-MATCHED STUDY. Y. Chen

PSM-42 ART- CLINICAL (2 OF 10)

- P-236 IMPACT OF ADENOMYOSIS ON IVF CUMULATIVE LIVE BIRTH RATE: A RETROSPECTIVE COHORT STUDY. M. Cozzolino
- P-237 ENDOMETRIAL MICROBIOME TESTING: A SINGLE CENTRE EXPERIENCE. R. Habte
- P-238 PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY IN UNEXPLAINED RECURRENT PREGNANCY LOSS: A SYSTEMATIC REVIEW AND META-ANALYSIS. S. Mumusoglu
- P-239 THE EFFECT OF ENDOMETRIOSIS ON EMBRYO IMPLANTATION COMPETENCE AND IN BLASTOCYST MORPHOLOGY/MORPHOKINETICS GRADING IN YOUNG WOMEN. A. R. Lorenzon
- P-240 SUB-ENDOMETRIAL INSTILLATION OF PLATELET RICH PLASMA (SE-PRP) FOR THIN REFRACTORY ENDOMETRIUM IN WOMEN UNDERGOING FROZEN EMBRYO TRANSFER (FET) – A PILOT STUDY. N. Malhotra



Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-43 ART- CLINICAL (3 OF 10)

- P-241 THE RISK OF BIRTH DEFECTS IDENTIFIED DURING THE FIRST YEAR OF LIFE IS NOT ASSOCIATED WITH GRADE OF BLASTOCYST MORPHOLOGY AMONG CHILDREN CONCEIVED WITH IN VITRO FERTILIZATION (IVF). K. E. Cameron
- P-242 IS A DECLINE IN ESTRADIOL (E2) ON THE DAY OF TRIGGER ASSOCIATED WITH LOWER OOCYTE MATURATION? A RETROSPECTIVE ANALYSIS OF PLANNED OOCYTE CRYOPRESERVATION CYCLES AT A SINGLE INSTITUTION L. Hughes
- P-243 THE AGE-DEPENDENT EFFECTIVENESS OF GROWTH HORMONE IN POOR RESPONDERS: A RETROSPECTIVE COHORT STUDY. N. Ho
- P-244 COMPARISON OF PREGNANCY OUTCOMES BETWEEN EUPLOID SINGLE EMBRYO TRANSFER (SET) AND MOSAIC DOUBLE EMBRYO TRANSFER (DET) IN PATIENTS AGED ≥ 40 YEARS. H. Ryu
- P-245 ANALYSIS OF SPINDLE CHARACTERISTICS AND EMBRYO QUALITY IN ADVANCED-AGE WOMEN TRIGGER WITH GnRH AGONIST AND HCG (DUAL TRIGGER) VERSUS DOUBLE-DOSE (500) HCG USING POLSCOPE IMAGING. J. Baek

PSM-44 ART- CLINICAL (4 OF 10)

- P-246 IMPACT OF PROGESTIN-PRIMED OVARIAN STIMULATION ON OOCYTE COMPETENCE AND EMBRYONIC PLOIDY IN CYCLES STARTED IN THE FOLLICULAR AND LUTEAL PHASES ACCORDING TO OVARIAN RESPONSES. R. B. Tomioka
- P-247 COMPARATIVE CLINICAL OUTCOME FOLLOWING INDIVIDUALIZED FOLLITROPIN DELTA DOSING IN JAPANESE WOMEN UNDERGOING PROGESTIN-PRIMED OVARIAN STIMULATION FOR IVF/ICSI. K. Miyazaki
- P-248 BIOSIMILARS VERSUS THE ORIGINATOR OF FOLLITROPIN ALFA FOR OVARIAN STIMULATION IN ASSISTED REPRODUCTIVE TECHNOLOGY (ART): A SYSTEMATIC REVIEW AND META-ANALYSIS. C. Venetis
- P-249 TWO-STEP DOUBLE TRANSFER OF GENETICALLY TESTED EMBRYOS IN PATIENTS WITH IMPLANTATION FAILURE. I. Sudoma
- P-250 COMPARISON OF FEATURES BETWEEN FRESH AND AUTOLOGOUS VITRIFIED OOCYTES AFTER SIMULTANEOUS FERTILIZATION: CULTURE PARAMETERS AND EMBRYO DEVELOPMENT MORPHOKINETICS RELATED TO AGE. C. Gonzalez-Trigo

PSM-45 ART- CLINICAL (5 OF 10)

- P-251 ATTEMPT TO SHORTEN THE WARMING PROCESS IN HUMAN VITRIFIED BLASTOCYSTS. H. Tomari
- P-252 FROM EMBRYO WARMING TO EMBRYO TRANSFER IN 3,325 EMBRYO TRANSFERS: CULTURE DURATION CAN BE EXTENDED UP TO NINE HOURS WITHOUT AN EFFECT ON CLINICAL PREGNANCY RATES. E. E. Dipietro
- P-253 RECONSTRUCTING THE FERTILITY OF INDIVIDUALS WITH MALE REPRODUCTIVE MATURATION DISORDERS. M. Xia
- P-254 DENSITY GRADIENT COMBINED WITH SWIM-UP OUTPERFORMS SWIM-UP ALONE IN FERTILIZATION RATE FOR CONVENTIONAL IN-VITRO FERTILIZATION: A WITHIN-SUBJECT COMPARATIVE STUDY. C. LU
- P-255 EFFECT OF A NEW FERTILIZATION MEDIUM CONTAINING OPTIMIZED AMINO ACID COMPONENTS DERIVED FROM HUMAN OVIDUCT FLUID ON THE FERTILIZATION RATE AND EMBRYO QUALITY AFTER CONVENTIONAL IVF. Y. Harada





Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-46 ART- CLINICAL (6 OF 10)

- P-256 THE INSULIN RESISTANCE INDEX, TYG-BMI, IS A POTENTIAL EARLY INDICATOR OF METABOLIC AND OBESOGENIC DISTURBANCES THAT AFFECT IVF. Y. Reyes-Albarracin
- P-257 HIGHER LUTEINIZING HORMONE (LH) LEVELS ON THE DAY OF TRIGGER ARE ASSOCIATED WITH LOWER OOCYTE MATURATION IN WOMEN UNDERGOING PLANNED OOCYTE CRYOPRESERVATION. V. Kalinowska
- P-258 MIFEPRISTONE-MISOPROSTOL VERSUS MISOPROSTOL ALONE FOR EARLY MISSED ABORTION AFTER ART AND SPONTANEOUSLY CONCEIVED PREGNANCIES. H. Hassan
- P-259 DONOR SIDE EFFECTS EXPERIENCED UNDER MINIMAL CONTROLLED OVARIAN STIMULATION (COS) WITH IN VITRO MATURATION (IVM) VERSUS CONVENTIONAL COS FOR IN VITRO FERTILIZATION (IVF) TREATMENT. S. Piechota
- P-260 MINIMAL IMPACT OF GONADOTROPIN DOSING ON OVARIAN RESPONSE: AN ANALYSIS OF 44,667 IVF CYCLES. A. Reig

PSM-47 ART- CLINICAL (7 OF 10)

- P-261 SPERM PARAMETERS ACCORDING TO PATERNAL AGE POST-PROCESSING WITH DENSITY GRADIENT CENTRIFUGATION (DGC) VS. MICROFLUIDICS (MF): A SECONDARY ANALYSIS OF A DOUBLE-BLINDED PROSPECTIVE RANDOMIZED TRIAL E. Almanza
- P-262 INNOVATIVE CONTROLLED OVARIAN STIMULATION FOR PCOS COMBINED WITH LETROZOLE, CABERGOLINE AND GnRH ANTAGONIST TO PREVENT OVARIAN HYPERSTIMULATION SYNDROME AND PRODUCE HIGH QUALITY EMBRYOS. A. Tanaka
- P-263 ANTI-CENTROMERE ANTIBODIES AFFECT EMBRYONIC DEVELOPMENT. Y. Kumagawa
- P-264 TRENDS IN UTILIZATION OF PRE-IMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) PRE AND POST DOBBS DECISION IN RESTRICTIVE AND PROTECTIVE STATES. K. Hunkler
- P-265 EFFECTIVENESS OF ENDOMETRIAL RECEPTIVITY ANALYSIS TEST IN RECURRENT IMPLANTATION FAILURE PATIENTS UNDERGOING FROZEN EMBRYO TRANSFER. X. Zhou

PSM-48 ART- CLINICAL (8 OF 10)

- P-266 IMPROVING ACCESS TO ASSISTED REPRODUCTIVE TECHNOLOGY SERVICES IN LOW-RESOURCE SETTINGS: DEVELOPMENT AND EVALUATION OF A LOW-COST OOCYTE RETRIEVAL SIMULATOR. P. E. Sefogah
- P-267 PREDICTORS OF LIVE BIRTH AFTER USE OF A NATURAL (NC), MODIFIED (MNC) OR ARTIFICIAL (AC) CYCLE FOR ENDOMETRIAL PREPARATION BEFORE FROZEN EMBRYO TRANSFER (FET). L. N. Vuong
- P-268 THE EFFECT OF TWO DIFFERENT INTRAUTERINE INFUSION TREATMENTS IN PATIENTS WITH THIN ENDOMETRIUM DURING FROZEN-THAWED EMBRYO TRANSFER CYCLES. X. Chen
- P-269 COMPARISON OF CLOMIPHENE CITRATE + LETROZOLE ADD-ON VS CLASSICAL OVARIAN STIMULATION PROTOCOLS IN POOR OVARIAN RESERVE. M. Tunç
- P-270 WHICH DOSE AND ROUTE OF PROGESTERONE, IS BETTER FOR LUTEAL PHASE SUPPORT? SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROL TRIALS. D. G. Rao



Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-49 ART- CLINICAL (9 OF 10)

- P-271 OPTIMAL CONTROLLED OVARIAN STIMULATION PROTOCOL FOR POLYCYSTIC OVARY SYNDROME PATIENTS UNDERGOING IN VITRO FERTILIZATION/INTRACYTOPLASMIC SPERM INJECTION: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. J. Tan
- P-272 CLINICAL EVALUATION OF FROZEN MOSAIC EMBRYO TRANSFER: DOES MOSAIC EMBRYO TRANSFER CONTRIBUTE TO SUCCESSFUL CLINICAL OUTCOMES? M. Kang
- P-274 CONTRACTIONS AFTER BLASTOCYST VITRIFICATION-WARMING: SHRINKAGE RATE AND TIMING CORRELATE WITH ONGOING PREGNANCY. L. Conversa Martínez
- P-275 PREGNANCY OUTCOMES ACCORDING TO TIMING OF EXPANSION, BIOPSY, AND CRYOPRESERVATION AMONG A CONSECUTIVE SERIES OF 3271 TRANSFERS OF SINGLE EUPLOID BLASTOCYST STAGE IN VITRO FERTILIZED EMBRYOS. S. T. Daneshmand

PSM-50 ART- CLINICAL (10 OF 10)

- P-276 THE EFFECT OF OVARIAN STIMULATION PROTOCOL ON FOLLICULAR ASYNCHRONY DURING IN-VITRO FERTILIZATION. A. Hochberg
- P-277 THE EFFECT OF BREASTFEEDING ON TREATMENT OUTCOMES IN FRESH IN-VITRO FERTILIZATION STIMULATION CYCLES AND FROZEN EMBRYO TRANSFER CYCLES. A. Hochberg
- P-278 CLINICAL OUTCOMES OF ROUND SPERMATID INJECTION VERSUS INTRA-CYTOPLASMIC SPERM INJECTION: THE POTENTIAL ROLE OF HORMONAL MANIPULATION OF MALE PATIENT. N. Cheng
- P-279 OPTIMIZING CLINICAL OUTCOMES IN SINGLE VITRIFIED-THAWED BLASTOCYST TRANSFER CYCLES: IMPACT OF BLASTOCYST RE-EXPANSION STATUS. S. Kheddache
- P-280 RELATIONSHIP BETWEEN EMBRYO MORPHOLOGY AND HYPERTENSIVE DISORDERS OF PREGNANCY IN SINGLETON IN VITRO FERTILIZATION PREGNANCIES. C. Moutos

PSM-51 FERTILITY PRESERVATION- GENERAL (1 OF 7)

- P-281 MICROFLUIDIC SELECTION IMPROVES SPERMATOZOA PROGRESSIVE MOTILITY, GENOMIC INTEGRITY, AND ENHANCES CRYOSTRESS TOLERANCE. O. M. Kocur
- P-282 OVARIAN TISSUE CRYOPRESERVATION IN GIRLS AND ADOLESCENTS WITH TURNER SYNDROME: TO OFFER OR NOT TO OFFER? J. C. Yano
- P-283 A SIXTEEN-YEAR EXPERIENCE OF OVARIAN TISSUE CRYOPRESERVATION FROM A SINGLE CENTER ENROLLING 364 PATIENTS. A FURTHER SURVEY ON PATIENTS' THOUGHTS REGARDING THE CRYOPRESERVED OVARIAN TISSUES M. Sonmezer
- P-284 ASSOCIATION OF AGE, AMH, AND GONADOTROPIN DOSING ON IVF OUTCOMES IN FERTILITY PRESERVATION CYCLES FOR PATIENTS LESS THAN 35 UNDERGOING CHEMOTHERAPEUTIC TREATMENT: A RETROSPECTIVE COHORT STUDY. R. Ryan
- P-285 THE EFFECTS OF COBALAMIN ON CELL VIABILITY DURING COOLED TRANSPORTATION OF OVARIAN TISSUE. Y. Guo



Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-52 FERTILITY PRESERVATION- GENERAL (2 OF 7)

- P-286 IRON OVERLOAD COMPROMISES OVARIAN RESERVE AND OOCYTE MATURATION IN VITRO IN PEDIATRIC PATIENTS WITH SEVERE THALASSEMIA. J. Li
- P-287 IMPROVING PATIENT COUNSELING IN PLANNED OOCYTE CRYOPRESERVATION (OC) OUTCOMES. O. Chafitz
- P-288 RETURN RATES AND PREGNANCY OUTCOMES AFTER SOCIAL OOCYTE PRESERVATION: A SYSTEMATIC REVIEW AND META-ANALYSIS. A. Kirubarajan
- P-289 PLOIDY IN EMBRYOS DERIVED FROM CRYOPRESERVED OOCYTES COMPARED TO FRESH OOCYTES FROM INFERTILE PATIENTS UNDERGOING FERTILITY TREATMENT. E. A. Clarke
- P-290 AN INTERVENTION TO INCREASE FERTILITY PRESERVATION COUNSELING PRIOR TO STARTING GENDER AFFIRMING HORMONE THERAPY. E. P. New

PSM-53 FERTILITY PRESERVATION- GENERAL (3 OF 7)

- P-291 GONADOTROPIN USAGE AMONG OOCYTE CRYOPRESERVATION CYCLES: DOES THE LIMIT EXIST? Q. Heyward
- P-292 HOW YOUNG IS TOO YOUNG FOR FERTILITY: TRANSCRIPTOMIC ANALYSIS OF ADOLESCENT CUMULUS CELLS REVEALS DYSREGULATED GENE EXPRESSION COMPARED TO OOCYTE DONORS. D. Gokyer
- P-293 FERTILITY OUTCOMES SEVERAL YEARS AFTER FERTILITY PRESERVATION FOR ENDOMETRIOSIS. M. Grynberg
- P-294 ACCESS TO, AND USE OF, FERTILITY PRESERVATION SERVICES AMONG TRANSGENDER INDIVIDUALS. E. L. Kelley
- P-295 WHAT HAPPENS AFTER THE FREEZE: POST TREATMENT TRENDS AFTER TWO DECADES OF PLANNED OOCYTE CRYOPRESERVATION (OC) FOR DELAYED REPRODUCTION (DR). A. Dennis

PSM-54 FERTILITY PRESERVATION- GENERAL (4 OF 7)

- P-296 AN INTRAUTERINE DEVICE (IUD) DOES NOT IMPACT OOCYTE YIELD DURING FERTILITY PRESERVATION: AN ANALYSIS OF 560 CYCLES INCLUDING PATIENTS (PTS) WITH DIMINISHED OVARIAN RESERVE (DOR). P. E. Voigt
- P-297 ASSOCIATION OF LEVELS OF ADIPOKINES AND CYTOKINES IN INDIVIDUAL FOLLICLES WITH IN VITRO FERTILIZATION OUTCOMES IN WOMEN WITH DIFFERENT OVARIAN RESERVE. C. Li
- P-298 EGG FREEZERS ARE FINALLY COMING BACK: AUTOLOGOUS OOCYTE (AO) THAW OUTCOMES FROM A LARGE U.S. SINGLE-CENTER COHORT OF PLANNED OOCYTE CRYOPRESERVATION (OC) PATIENTS (PTS) C. M. Parra
- P-299 THAW AND UTILIZATION AFTER PLANNED OOCYTE CRYOPRESERVATION OVER A 5-7 YEAR FOLLOW-UP PERIOD. M. B. Lee
- P-300 APPLICATION OF TWO DIFFERENT VITRIFICATION SYSTEMS TO THE PRESERVATION OF OVARIAN PREANTRAL FOLLICLES. M. Attard



Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-55 FERTILITY PRESERVATION- GENERAL (5 OF 7)

- P-301 TRENDS IN PLANNED OOCYTE CRYOPRESERVATION FROM 2014-2021. M. B. Lee
- P-302 UTILIZATION AND TIMING OF CRYOPRESERVATION RELATIVE TO HORMONAL THERAPY INITIATION IN ATRANSGENER POPULATION. S. Allu
- P-303 EXPERT AND STAKEHOLDER VIEWS ON POSTHUMOUS ASSISTED REPRODUCTION POLICY: A QUALITATIVE STUDY. M. J. Bayefsky
- P-304 PATIENTS WITH POOR OVARIAN RESPONSE (POR) ARE LESS LIKELY TO SUCCEED IN ELECTIVE FERTILITY PRESERVATION AND REQUIRE TWICE AS MANY CYCLES TO DO SO, INDEPENDENT OF THE DEGREE OF POR. B. Vessa
- P-305 INSIGHTS OF SOCIAL EGG FREEZING AMONG CHILDLESS WOMEN IN TAIWAN: AN EXAMPLE OF EXTREMELY LOW BIRTH RATE COUNTRY. W. Tseng

PSM-56 INFERTILITY- NUTRITION & OBESITY (1 OF 2)

- P-306 MULTIDISCIPLINARY APPROACH TO WEIGHT NAVIGATION AND OPTIMIZING FERTILITY GOALS FOR PATIENTS WITH CLASS III VS. CLASS I/II OBESITY D. Stelmak
- P-307 COMPARISON OF IVF OUTCOMES IN PATIENTS WITH CLASS I-II VS CLASS III OBESITY. A. Namath
- P-308 AN ASSESSMENT OF THE QUALITY OF YOUTUBE VIDEOS AS A SOURCE FOR INFORMATION ON SUPPLEMENTS FOR IVF AND INFERTILITY. A. K. Kosturakis
- P-309 GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AGONISTS DURING OOCYTE AND EMBRYO CRYOPRESERVATION. K. Roberts
- P-310 BODY MASS INDEX (BMI) THRESHOLDS FOR FERTILITY TREATMENT MARKEDLY DELAY AND OFTEN DENY ACCESS TO CARE. K. Smigoc

PSM-57 INFERTILITY- NUTRITION & OBESITY (2 OF 2)

- P-311 OBESITY DOES NOT IMPACT PREGNANCY OUTCOMES IN NATURAL FROZEN EMBRYO TRANSFER (FET) CYCLES. A. D. Kadesh
- P-312 GONADOTROPINS ARE LOWER IN WOMEN AFTER INITIATING A LIFESTYLE WEIGHT LOSS INTERVENTION. A. E. Caldwell
- P-313 THE IMPACT OF NON-MALE FACTOR INTRACYTOPLASMIC SPERM INJECTION (ICSI) ON FERTILITY OUTCOMES IN OVERWEIGHT AND OBESE WOMEN. T. Khader
- P-314 INTRAMUSCULAR (IM) AND SUBCUTANEOUS (SC) ADMINISTRATION OF GONADOTROPINS YIELD SIMILAR IN-VITRO FERTILIZATION (IVF) OUTCOMES IN A PROPENSITY MATCHED COHORT OF PATIENTS WITH CLASS II AND III OBESITY. L. Fischer
- P-315 VISCERAL FAT IS ASSOCIATED WITH INFERTILITY AMONG NORMAL-WEIGHT PARTICIPANTS: ANALYSIS OF THE 2013-2018 NHANES CROSS-SECTIONAL STUDY. E. Lopez-Bayghen



Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-58 INFERTILITY- GENERAL (2 OF 4)

- P-316 MODIFIED NATURAL FET CYCLES HAVE EQUIVALENT LIVE BIRTH RATES TO PROGRAMMED IN PATIENTS WITH PCOS. A. S. Farrell
- P-317 FOODBORNE CARBON DOT-INDUCED GUT MICROBIOTA DYSBIOSIS LEAD TO REPRODUCTIVE TOXICITY IN MALE MICE. P. Chen
- P-318 EVALUATING THE RELATIONSHIP BETWEEN BODY MASS INDEX, SERUM PROGESTERONE, AND PREGNANCY OUTCOMES IN PROGRAMMED SINGLE EUPLOID EMBRYO TRANSFER CYCLES. A. Ghofranian
- P-319 AMBIENT AIR POLLUTION AND FECUNDABILITY IN A PRECONCEPTION TIME-TO-PREGNANCY COHORT. M. R. Klawans
- P-320 MELATONIN-PRIMED OVARIAN STIMULATION IN GOOD RESPONDERS: A NEW STRATEGY TO ENHANCE THE EFFICIENCY? N. Pylypenko

PSM-59 INFERTILITY- COMPLEMENTARY & ALTERNATIVE THERAPIES (1 OF 3)

- P-321 FRACTION B FROM CATFISH SKIN SECRETIONS CAUSES RECOVERY OF DIABETIC REPRODUCTIVE COMPLICATIONS BY MODULATING THE APOPTOSIS AND DNA OXIDATIVE DAMAGE PATHWAYS IN RATS. W. W. Renno
- P-322 EFFECTIVENESS OF AUTOLOGOUS PLATELET-RICH PLASMA (PRP) THERAPY FOR IMPROVING ENDOMETRIAL THICKNESS AND PREGNANCY OUTCOMES IN WOMEN WITH THIN ENDOMETRIUM : A RANDOMISED CONTROLLED TRIAL. K. Nayar
- P-323 DESTINATION OF SURPLUS EMBRYOS CRYOPRESERVED FOR MORE THAN 3 YEARS IN A UNIVERSITY HOSPITAL IN BRAZIL. A. Bonganha Zanon
- P-324 ADJUVANT HUMAN GROWTH HORMONE IS EFFECTIVE IN IMPROVING BLASTOCYST DEVELOPMENT: A PAIRED ANALYSIS. C. N. Seeco
- P-325 PLATELET-RICH PLASMA (PRP) ADMINISTRATION IN WOMEN WITH DIMINISHED OVARIAN RESERVE DOES NOT IMPROVE OVARIAN RESERVE MARKERS. F. I. Sharara

PSM-60 INFERTILITY- COMPLEMENTARY & ALTERNATIVE THERAPIES (2 OF 3)

- P-326 PERCEPTIONS AND UTILIZATION OF SUPPLEMENTS BY IN-VITRO FERTILIZATION (IVF) PATIENTS: A QUALITATIVE ANALYSIS OF IVF SUBREDDIT POSTS. A. Tomlinson
- P-327 DYDROGESTERONE-PRIMED OVARIAN STIMULATION (DPOS) FOR OOCYTE ACCUMULATION IN DIMINISHED OVARIAN RESERVE: COMPARABLE PREGNANCY RATES BUT IMPROVED OOCYTE OUTCOMES. N. Vy D. T.
- P-328 PROSPECTIVE STUDY ON THE CLINICAL BENEFITS OF AUTOLOGOUS OVARIAN PLATELET-RICH PLASMA LYSATE INJECTIONS. C. Lee
- P-329 ENHANCING MICROTSE SUCCESS: PROLISTEM SUPPLEMENT FOR NON-OBSTRUCTIVE AZOOSPERMIA. A. Abu Zahra
- P-330 TAMOXIFEN COMBINED WITH HORMONE REPLACEMENT IN WOMEN WITH THIN ENDOMETRIUM RECEIVING FROZEN-THAWED EMBRYO TRANSFER FOR PROMOTING ENDOMETRIAL GROWTH: A DOUBLE-BLINDED, RANDOMIZED CONTROLLED TRIAL. Q. Shi



Monday, October 21, 2024

For updated presentation times, please refer to the Congress mobile app.

PSM-61 ASRM 2024 TOP POSTER SESSION (1 OF 2)

- | | |
|--|--|
| <p>P-1 MEDICAL VERSUS SURGICAL MANAGEMENT OF EARLY PREGNANCY LOSS OFFER SIMILAR TIMELINE TO COMPLETE RESOLUTION IN AN INFERTILE POPULATION. T. Bawa</p> <p>P-2 A NOVEL APPLICATION OF THE SPERM VITRIFICATION DEVICE FOR CRYOPRESERVATION OF MULTIPLE OVARIAN FOLLICLES. M. Attard</p> <p>P-3 THIRD PARTY REVIEW OF REQUESTS FOR MULTIPLE EMBRYO TRANSFER SIGNIFICANTLY LOWERS THE RATE OF MULTIPLE GESTATION WITHOUT COMPROMISING PREGNANCY RATE. K. Bergin</p> | <p>P-5 POLYCYSTIC OVARY SYNDROME PREVALENCE AND MANAGEMENT IN PATIENTS WITH RECURRENT EARLY PREGNANCY LOSS: INSIGHTS FROM A CANADIAN POPULATION STUDY. A. Kulshreshtha</p> |
|--|--|

Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-01 ASRM 2024 TOP POSTER SESSION (2 OF 2)

- | | |
|---|--|
| <p>P-6 IMPACT OF EMBRYO PERSONHOOD STATUS ON IN VITRO FERTILIZATION (IVF) IN ALABAMA: A COST-EFFECTIVENESS ANALYSIS. D. M. Monroe</p> <p>P-7 LACK OF REACH BY STATE FERTILITY PRESERVATION BENEFIT MANDATES. K. Nguyen</p> <p>P-8 USE OF ARTIFICIAL INTELLIGENCE FOR PREDICTING LIVE BIRTH IN VITRIFIED BLASTOCYST CYCLES. L. Conversa Martínez</p> <p>P-9 INSIGHTS INTO CHROMOSOMAL ABERRATIONS IN IMPLANTED MOSAIC EMBRYOS: ANALYSIS OF 184 CHORIONIC VILLUS SAMPLING CASES. P. Lin</p> | <p>P-10 GLUCAGON-LIKE PEPTIDE-1 AGONIST USE AND OOCYTE RETRIEVAL IN CONTROLLED OVARIAN HYPERSTIMULATION. V. K. Lazarov</p> <p>P-11 FROZEN VERSUS FRESH EMBRYO TRANSFER IN WOMEN WITH LOW PROGNOSIS. D. WEI</p> |
|---|--|





Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-02 REPRODUCTIVE UROLOGY- DIAGNOSIS & MANAGEMENT (1 OF 2)

- P-331 LEVEL OF SPERM REACTIVE OXYGEN AND SPERM DNA FRAGMENTATION INDEX INCREASED AMONG INFERTILE MEN WITH VARICOCELE. L. Ye
- P-332 THE ROLE OF VARICOCELECTOMY IN INFERTILE MEN WITH CLINICAL VARICOCELE, NORMAL SEMEN PARAMETERS AND ISOLATED HIGH SPERM DNA FRAGMENTATION. S. Al-Said
- P-333 TESTICULAR CORE EXTRACTION REDUCES NEED FOR MICROSCOPIC TESTICULAR SPERM EXTRACTION BY 75% IN MEN WITH NON-OBSTRUCTIVE AZOOSPERMIA. A. G. Oppenheimer
- P-334 EXCISION VS EXTENSION: EVALUATING ART OUTCOMES FOR OF EXTENDED SPERM SEARCH AND MICROFREEZE (ESSM) VERSUS SURGICALLY RETRIEVED SPERM (SRS). E. M. Weidenbaum
- P-335 SPERM MORPHOLOGY AT INSEMINATION: CLINICAL PREGNANCY AND LIVE BIRTH RATES. J. N. Tozour
- P-336 RELATIONSHIP BETWEEN EJACULATORY ABSTINENCE LENGTH AND IVF OUTCOMES. E. A. Capper

PST-03 REPRODUCTIVE UROLOGY- DIAGNOSIS & MANAGEMENT (2 OF 2)

- P-337 THE ASSOCIATION BETWEEN VARICOCELE AND SEMINAL STATIC OXIDATION-REDUCTION POTENTIAL MEASUREMENTS IN MALE PATIENTS SEEKING CONCEPTION. A. Komiya
- P-338 THE DISTRIBUTION OF FELLOWSHIP TRAINED ANDROLOGISTS IN THE UNITED STATES. L. Lai
- P-339 EFFECT OF EARLY VARICOCELECTOMY INTERVENTION ON MALE HORMONE LEVELS IN ADOLESCENT MALES. J. O. Rust
- P-340 MAIL-IN SEMEN ANALYSIS: A CONVENIENT AND POTENTIALLY TIME SAVING METHOD OF FERTILITY EVALUATION. R. P. Smith
- P-341 INVESTIGATING RELATIONSHIPS BETWEEN MASTURBATION FREQUENCY AND SEXUAL DYSFUNCTION IN MEN UNDERGOING FERTILITY TESTING. A. K. Seyer
- P-342 DELAY OF CARE NEGATIVELY IMPACTS FEMALE PARTNERS OF PATIENTS WITH MALE FACTOR INFERTILITY. A. G. Oppenheimer

PST-04 REPRODUCTIVE UROLOGY- GENERAL (1 OF 2)

- P-343 HSF1/HSP25 PROTECTS MITOCHONDRIA FUNCTION FROM HEAT STRESS AND KEEPS STAR SYNTHESIS IN MOUSE LEYDIG CELLS. S. Oka
- P-344 CONVENTIONAL CIGARETTE VERSUS ELECTRONIC CIGARETTE USE: IMPACT ON SPERM AND IVF/ICSI OUTCOMES. T. Kim
- P-345 ANALYSIS OF MULTI-OMICS BIOMARKERS IN EJACULATES OF YOUNG ADULTS. O. Sergeyev
- P-346 THE MOBYUS CONSORTIUM: DEMOCRATIC, DECENTRALIZED, DYNAMIC MALE INFERTILITY RESEARCH. B. D. Naelitz
- P-347 EMBEDDING GENOME SEQUENCING AND GENETIC COUNSELLING INTO THE MALE INFERTILITY PRACTICE. C. J. Warren
- P-348 DEVELOPMENT OF MACHINE LEARNING MODEL TO PREDICT SPERM RETRIEVAL IN MICRODISSECTION TESTICULAR SPERM EXTRACTION. T. Takeshima





Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-05 REPRODUCTIVE UROLOGY- GENERAL (2 OF 2)

- | | | | |
|-------|---|-------|--|
| P-349 | "FIBROUS CORD-LIKE STRUCTURES AND ERRONEOUS SEMEN ANALYSIS (SA) MASK A CASE OF CBAVD (CONGENITAL BILATERAL ABSENCE OF THE VAS DEFERENS)". J. Castillo | P-352 | A PROSPECTIVE OBSERVATIONAL TRIAL OF AN EPIGENETIC SPERM QUALITY TEST ("SPERMQT") TO PREDICT SUCCESS RATES OF INTRAUTERINE INSEMINATION TREATMENT: PRELIMINARY RESULTS. D. R. Siegel |
| P-350 | CLINICAL IMPACT OF WEIGHT ON THE CHANGE IN TOTAL SPERM MOTILITY COUNT STATUS POST VARICOCELECTOMY. S. Vallabhaneni | P-353 | OVER 90% OF FERTILITY PATIENTS COMPLETE MAIL-IN SEMEN ANALYSIS WITHIN 2 MONTHS. J. R. Morris |
| P-351 | SEXUAL FUNCTION AFTER VASECTOMY IS BETTER COMPARED TO THOSE SEEKING FERTILITY EVALUATION: A REVIEW OF 7,332 MEN UNDER 50. C. M. Deibert | P-354 | PRECISION AND ACCURACY OF THE SQA-IOW SPERM QUALITY ANALYZER IN THE HANDS OF CLIA WAIVED RN OPERATORS. N. Bar-Chama |

PST-06 REPRODUCTIVE UROLOGY- SURGERY

- | | | | |
|-------|--|-------|---|
| P-355 | OFFICE-BASED MICRODISSECTION TESTICULAR SPERM EXTRACTION FOR NONOBSTRUCTIVE AZOOSPERMIA RESULTS IN HIGH SPERM RETRIEVAL RATES. A. K. Seyer | P-358 | THE POWER OF THE MAP: TESTICULAR MAPPING TO GUIDE SURGICAL SPERM RETRIEVAL IN PATIENTS WITH NONOBSTRUCTIVE AZOOSPERMIA. A. Amighi |
| P-356 | INDICATION AND TIMING OF VARICOCELE REPAIR DURING ADOLESCENCE. K. Shiraishi | P-359 | CONTEMPORARY CHARACTERISTICS OF MEN UNDERGOING VASECTOMY REVERSAL. K. Asanad |
| P-357 | IDENTIFYING SEMINIFEROUS TUBULES FOR SPERM RETRIEVAL DURING MICRODISSECTION TESTICULAR SPERM EXTRACTION (M-TESE) USING DEEP LEARNING. A. Elenkov | P-360 | ADOLESCENT MICROSURGICAL VARICOCELECTOMY AND CHANGES IN SPERM PARAMETERS: A PROSPECTIVE MATCHED COHORT ANALYSIS. N. Deebel |

PST-07 GLOBAL HEALTH (1 OF 2)

- | | | | |
|-------|---|-------|--|
| P-361 | EXPLORING PUBLIC VIEWS ON ARTIFICIAL INTELLIGENCE IN HEALTHCARE ACROSS SOUTH EAST ASIA. C. Selvakumaran | P-364 | FERTILITY CARE DISTRIBUTION IN BRAZIL - A CONTINENTAL-SIZED DEVELOPING COUNTRY ON A STILL A LONG ROAD TO EQUAL ACCESS. M. R. Hentschke |
| P-362 | THE TEMPORAL DECLINE IN SPERM COUNT IS GEOGRAPHICALLY DEPENDENT. I. Becker | P-365 | ENGLISH AS A SECOND LANGUAGE WITHIN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT. J. Park |



Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-08 GLOBAL HEALTH (2 OF 2)

- P-366 PERCEPTIONS AND ATTITUDES TOWARD ARTIFICIAL INTELLIGENCE IN HEALTHCARE AMONG HEALTHCARE PROFESSIONALS IN SOUTH EAST ASIA. Y. Woo
- P-367 INCIDENCE OF IN VITRO FERTILIZATION OUTSIDE THE UNITED STATES AND ASSOCIATED PREGNANCY OUTCOMES. S. Rodriguez
- P-368 CANADIAN WILDFIRE-INDUCED AIR POLLUTION MEASURED BY AIR QUALITY INDEX (AQI) HAD A LIMITED IMPACT ON IN VITRO FERTILIZATION (IVF) CYCLES IN THE SPRING OF 2023 IN NEW JERSEY. B. Vessa
- P-369 ANALYSIS OF SEVERE MATERNAL MORBIDITY AT DELIVERY IN SINGLETON AND MULTIFETAL PREGNANCIES. K. Erickson
- P-370 ASSESSING KNOWLEDGE AND PERCEPTIONS OF FERTILITY PRESERVATION AMONG MEDICAL PRACTITIONERS AND STUDENTS IN MEXICO: A CROSS-SECTIONAL STUDY. S. Yu

PST-09 GENETICS- GENERAL (1 OF 3)

- P-371 UNRAVELLING THE GENETIC DETERMINANTS OF IDIOPATHIC SEVERE SPERMATOGENIC FAILURE: INSIGHTS FROM A COMPREHENSIVE ANALYSIS OF SPERMATOGENESIS-RELATED GENES. E. Criado
- P-372 SINGLE-CELL TRANSCRIPTOMIC ANALYSIS OF SEMINAL CELL POPULATIONS IN INFERTILE MEN DISPLAYING DIFFERENT PATTERNS OF SEVERE SPERMATOGENIC FAILURE. E. Criado
- P-373 UNVEILING SUBSTANTIAL DISCREPANCIES AMONG EXPANDED CARRIER SCREENING PANELS IN REPRODUCTIVE MEDICINE: A COMPREHENSIVE COMPARATIVE ANALYSIS INVOLVING OVER 24,000 PATIENTS. E. Caviglia
- P-374 HARNESSING LONG-READ SEQUENCING FOR COMPREHENSIVE GENOMIC PROFILING OF MEN WITH INFERTILITY. T. X. Garcia
- P-375 ASSESSING THE CLINICAL IMPACT OF GENETIC CARRIER SCREENING PRIOR TO ASSISTED REPRODUCTIVE TECHNOLOGY: SEX-BASED DISPARITIES IN ACCEPTANCE. A. Sandefer
- P-376 TRANSCRIPTOMIC INVESTIGATION OF THE ENDOMETRIOSIS GENE SIGNATURE. C. L. Furtado

PST-10 GENETICS- GENERAL (2 OF 3)

- P-377 UTILIZATION OF CUSTOM DESIGNED PGT-M FOR TECHNICALLY CHALLENGING GENETIC INDICATIONS TO IMPROVE ACCESS TO CARE. R. I. Awwad
- P-378 CAN PREIMPLANTATION GENETIC TESTING FOR RECURRENT SEGMENTAL ANEUPLOIDY PREDICT PARENTAL CARRIERS OF RECIPROCAL TRANSLOCATIONS? T. Gordon
- P-379 PRENATAL GENETIC DIAGNOSIS FOR MITOCHONDRIAL DNA DISEASE: A CASE STUDY FOR A FAMILY WITH LEIGH SYNDROME. M. Shishimorova
- P-381 DOES THE INCIDENCE OF EMBRYONIC MOSAICISM VARY WITH GENETIC INDICATION FOR IN VITRO FERTILIZATION. T. Alkon-Meadows
- P-382 UTILIZATION OF PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) IN CYCLES WITH ONLY ONE BLASTOCYST DECREASES RISK OF MISCARRIAGE. M. Cetinkaya



Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-11 GENETICS- GENERAL (3 OF 3)

- P-383 FIRST CANADIAN CLINICAL CASES OF NON-INVASIVE MISCARRIAGE TESTING USING CELL-FREE DNA. A. Magwood
- P-384 IMPLICATIONS OF BIALLELIC AND PERSONAL RISK FOR ASSISTED REPRODUCTIVE TECHNOLOGY (ART) PATIENTS WITH A HEREDITARY CANCER SYNDROME. S. Horan
- P-385 GENES AND GUIDANCE: ANALYZING REI CLINIC WEBSITES FOR THE PROMOTION AND AVAILABILITY OF GENETIC COUNSELING ACROSS THE U.S. A. M. Herweck
- P-386 REPRODUCTIVE OUTCOMES OF MOSAIC EMBRYO TRANSFER: A MULTICENTER STUDY IN ARGENTINA. E. Caviglia
- P-387 RISK OF MISINTERPRETATION OF HAPLOBLOCK OF KARYOMAPPING FOR PGT-M WHEN ANEUPLOIDY OR MOSAICISM OCCURS IN THE CHROMOSOME CONTAINING TARGET GENE. G. Han
- P-388 UNDERSTANDING THE UNTAPPED POTENTIAL OF CHAOTIC EMBRYOS: A SINGLE SITE'S EXPERIENCE. M. Palmor

PST-12 ART- OUTCOMES (1 OF 10)

- P-389 RATES OF PRETERM BIRTH AND LOW BIRTH WEIGHT IN IVF COMPARED TO UNASSISTED CONCEPTION: A COMPARISON OF 36,930 IVF-CONCEIVED WITH 79,391,393 UNASSISTED PREGNANCIES OVER 20 YEARS (2003-2022). A. Reig
- P-390 GEOSPATIAL AND DEMOGRAPHIC ANALYSIS OF INFERTILITY TREATMENT AND NEONATAL INTENSIVE CARE UNIT ADMISSIONS. G. Brolly
- P-391 FOLLITROPIN DELTA AS A PREFERABLE GONADOTROPIN FOR COMBINED PROGESTINE-PRIMED OVARIAN STIMULATION (PPOS). N. Iwami
- P-392 COMPARING THE LIVE BIRTH RATE (LBR) AFTER CRYOPRESERVED EMBRYO TRANSFER (CET) CYCLES USING FROZEN EMBRYOS DERIVED FROM FRESH VERSUS FROZEN DONOR OOCYTES. M. Oliva
- P-393 ARTIFICIAL REMOVAL OF THE ZONA PELLUCIDA (ZP-FREE) IN PATIENT OF REPEATED FAILURE WITH SEVERE FRAGMENTATION IMPROVED EMBRYONIC DEVELOPMENT AND PREGNANCY OUTCOMES. R. Mae
- P-394 EFFECT OF INTRALIPID IMMUNOTHERAPY ON PREGNANCY RATES IN PATIENTS WHO HAVE EXPERIENCED IVF FAILURE. K. Min Ji

PST-13 ART- OUTCOMES (2 OF 10)

- P-395 STAIR-STEPPING IN LETROZOLE-STIMULATED NATURAL FET (LET-FET) CYCLES PRODUCED SIMILAR PREGNANCY OUTCOMES AS NON-STAIR-STEPPED LET-FET AND PROGRAMMED FET CYCLES. J. K. Cheung
- P-396 INVESTIGATIONS OF GENETIC VARIANTS IN DONOR-CONCEIVED PERSONS: A COLLABORATION BETWEEN THREE LARGE U.S. GAMETE BANKS K. Lockwood
- P-397 IMPACT OF CHRONIC ENDOMETRITIS ON EMBRYONIC DEVELOPMENTAL POTENTIAL: EVIDENCE FROM AN IN VITRO FERTILIZATION CASE-CONTROL STUDY. G. N. Cecchino
- P-398 CUMULATIVE LIVE BIRTH RATES IN EGG DONATION CYCLES ACCORDING TO THE OOCYTE STATE; FRESH OR CRYOPRESERVED OOCYTES? E. Papanikolaou
- P-399 WHAT DO YOUR PATIENTS WANT? EXPECTATIONS AND DISCREPANCIES IN PATIENT-CENTERED CARE (PCC) BETWEEN INFERTILITY PATIENTS AND PHYSICIANS A. D. Domar
- P-400 BODY MASS INDEX CLASSIFICATION AND IVF OUTCOMES AMONG ASIAN AMERICAN PATIENTS. R. Bruno





Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-14 ART- OUTCOMES (3 OF 10)

- P-401 CULTURING BLASTOCYSTS TO DAY 7 OF DEVELOPMENT YIELDS DECREASED ODDS OF LIVE BIRTH FOLLOWING EUPLOID FROZEN EMBRYO TRANSFER. B. Opene
- P-402 CUMULATIVE LIVE BIRTH RATE (CLBR) WHEN TWO EMBRYOS ARE AVAILABLE FOR TRANSFER: A MULTICENTER, MARKOV DECISION-ANALYTIC MODEL ACCORDING TO TRANSFER STRATEGY INCLUDING 33,896 EMBRYO TRANSFER (ET) CYCLES. J. Rodriguez Purata
- P-403 IMPACT OF BLASTOCYST QUALITY ON REPRODUCTIVE OUTCOMES OF RE-BIOPSIED EUPLOID EMBRYOS. K. Trowbridge
- P-404 HIGHER LIVE BIRTH RATE IN ENDOMETRIOSIS OR ADENOMYOSIS PATIENTS ASSOCIATED WITH A GnRH AGONIST/AROMATASE INHIBITOR PROTOCOL BEFORE FROZEN EMBRYO TRANSFER. N. O. Francone
- P-405 SUBCHORIONIC HEMATOMA RATES ARE SIMILAR BETWEEN TYPES OF FROZEN EMBRYO TRANSFER. J. Almgren-Bell
- P-406 EVALUATING THE EFFECTIVENESS OF CONVENTIONAL IVF IN CASES WITH LOW OOCYTE YIELD AND ADVANCED MATERNAL AGE (AMA). S. M. Nichols-Burns

PST-15 ART- OUTCOMES (4 OF 10)

- P-407 ASSISTED REPRODUCTIVE TECHNOLOGY (ART) OUTCOMES IN TRANSGENDER AND GENDER DIVERSE (TRANS) INDIVIDUALS COMPARED TO MATCHED CISGENDER (CIS) CONTROLS. B. Lesser-Lee
- P-408 RACIAL/ETHNIC VARIATION IN OVARIAN RESPONSIVENESS TO GONADOTROPIN STIMULATION AND OUTCOMES FOLLOWING IN VITRO FERTILIZATION. I. T. Lee
- P-409 IMPACT OF A 10-MINUTE POST-IUI IMMOBILE PERIOD ON PREGNANCY OUTCOMES ACROSS DIFFERENT TOTAL MOTILE SPERM COUNTS. C. K. Arkfeld
- P-410 ONE AND DONE REVISITED: ACHIEVING TWO LIVE BIRTHS FROM ONE OVARIAN STIMULATION CYCLE. A. Huttler
- P-411 ONGOING PREGNANCY RATE IS ASSOCIATED WITH PRE-TRIGGER PROGESTERONE LEVEL IN LETROZOLE/CLOMIPHENE INTRAUTERINE INSEMINATION CYCLES. C. Malcom
- P-412 PREIMPLANTATION GENETIC TESTING FOR STRUCTURAL REARRANGEMENTS - WHAT SHOULD WE EXPECT? J. M. Morris

PST-16 ART- OUTCOMES (5 OF 10)

- P-413 OPTIMIZING IN VITRO FERTILIZATION SUCCESS: ENHANCED CLINICAL OUTCOMES THROUGH LETROZOLE-INDUCED OVULATION AND HCG TRIGGER IN FROZEN-THAWED EUPLOID BLASTOCYST TRANSFERS AMONG WOMEN WITH REGULAR CYCLES. M. Roque
- P-414 GESTATIONAL CARRIER CYCLES AMONG MALE SAME-SEX COUPLES IN THE UNITED STATES, 2017-2020. B. Monseur
- P-415 THE THE EFFECT OF A GnRH AGONIST TRIGGER ON THE LENGTH OF THE SUBSEQUENT NATURAL FOLLICULAR PHASE. R. b. Berkovitz Shperling
- P-416 IS TROPHECTODERM GRADE ASSOCIATED WITH BIRTH WEIGHT IN PATIENTS UNDERGOING SINGLE EUPLOID EMBRYO TRANSFERS? S. C. Roger
- P-417 THE DEVELOPMENT OF A NEW MODEL OF HCG DYNAMICS TO PREDICT PREGNANCY OUTCOME. A. Ghofranian
- P-418 INDIVIDUALIZED LUTEAL PHASE PROGESTERONE SUPPORT IN LETROZOLE STIMULATED EMBRYO TRANSFER CYCLES. A. Krall



Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-17 ART- OUTCOMES (6 OF 10)

- P-419 THE USE OF EJACULATED VS TESTICULAR SPERM IN MEN WITH EITHER CRYPTOZOOSPERMIA OR NON-OBSTRUCTIVE AZOOSPERMIA. A. G. Oppenheimer
- P-420 REPRODUCTIVE POTENTIAL OF LATE MATURING OOCYTES WITH SAME DAY AND NEXT DAY ICSI. E. A. Ortega
- P-421 PREGNANCY OUTCOMES BY MATERNAL AGE IN NATURAL VERSUS PROGRAMMED FROZEN EMBRYO TRANSFER CYCLES. S. McLean
- P-422 ASSOCIATION OF PREGNANCY OUTCOMES WITH OVULATION TRIGGER ADMINISTRATION IN FRESH AND FROZEN EMBRYO TRANSFER CYCLES IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME. E. Manvelyan
- P-423 ENHANCED PREGNANCY OUTCOMES VIA LYMPHOCYTE IMMUNOTHERAPY IN RECURRENT IMPLANTATION FAILURE: A RETROSPECTIVE COHORT STUDY IN A CHINESE POPULATION. Q. Li
- P-424 CONTRIBUTION OF ASSISTED REPRODUCTIVE TECHNOLOGY TO OVERALL LIVE-BORN INFANTS BY MATERNAL RACE AND ETHNICITY AND AGE, UNITED STATES, 2017-2021. A. Jewett

PST-18 ART- OUTCOMES (7 OF 10)

- P-425 FROM A SINGLE CYCLE TO A MULTICYCLE COUNSELING APPROACH IN IVF: EFFECTS OF STRATEGIC AND TECHNOLOGICAL CHANGES ON SUCCESS AND TREATMENT DISCONTINUATION RATES ACROSS 11 YEARS AT A PRIVATE CLINIC. A. Vaiarelli
- P-426 RISK FACTORS FOR MONOZYGOTIC TWINNING AFTER SINGLE FROZEN BLASTOCYST TRANSFER. V. T. Lai
- P-427 DUOSTIM + PGT-A: A COMPARISON BETWEEN FOLLICULAR AND LUTEAL PHASE STIMULATION PROTOCOLS. M. M. Horton
- P-429 CANNABIS CONSUMPTION REDUCES THE NUMBER OF EUPLOID EMBRYOS AVAILABLE FOR TRANSFER: A RETROSPECTIVE STUDY. C. Duval
- P-430 COMPARISON OF PERINATAL OUTCOMES BETWEEN PROGESTIN PRIME OVARIAN STIMULATION (PPOS) PROTOCOL AND GNRH ANTAGONIST PROTOCOL: THE IMPACT OF PPOS ON BIRTH GENDER. N. Iwami
- P-763 DELAYED IMPLANTATION IS EXTREMELY UNCOMMON IN FET CYCLES. F. I. Sharara

PPST-19 ART- OUTCOMES (8 OF 10)

- P-431 ASSOCIATION BETWEEN MATERNAL AGE AND EUPLOID TRANSFER SUCCESS IN AUTOLOGOUS AND DONOR EGG-DERIVED EUPLOID EMBRYO TRANSFER CYCLES AMONG PATIENTS WITH ADVANCED AGE. P. G. Lindner
- P-432 SARTCORS REGISTRY AND FERTILITY PRESERVATION: A. UNDERESTIMATING THE LIVE BIRTH RATE FOR OOCYTE RETRIEVALS WHEN CYCLES WITH NO DEMONSTRATED ATTEMPT AT EMBRYO TRANSFER ARE INCLUDED IN THE DENOMINATOR D. H. McCulloh
- P-433 THE IMPACT OF PATIENT AGE ON PATIENT-CENTERED CARE (PCC) PRIORITIES: A SURVEY OF 1500 ART PATIENTS ACROSS THE US. A. D. Domar
- P-434 NEONATAL OUTCOMES OF PATIENTS UNDERGOING INTRAVAGINAL CULTURE COMPARED TO TRADITIONAL IN VITRO FERTILIZATION: A SART CORS STUDY. A. J. Roshong
- P-435 IS MOSAIC EMBRYO FORMATION ASSOCIATED WITH IN VITRO FERTILIZATION (IVF) CYCLE CHARACTERISTICS? H. Kim
- P-436 MIXTURES OF URINARY PHTHALATE METABOLITES AND SERUM OMEGA-3 FATTY ACIDS IN RELATION TO LIVE BIRTH AMONG WOMEN UNDERGOING IN VITRO FERTILIZATION. L. Minguez-Alarcon





Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-20 ART- OUTCOMES (9 OF 10)

- P-437 MONITORING WOMEN UNDERGOING OVARIAN STIMULATION FOR IVF ONLY ON 5-WEEKDAYS DOES NOT COMPROMISE ART OUTCOME: A MULTI-CENTER STUDY. I. Tur-Kaspa
- P-438 INSIGHTS INTO PATIENT DECISIONS REGARDING PGT-M FOR HEREDITARY CANCERS. D. Klepacka
- P-439 THE METHODS USED TO AVOID OVARIAN HYPERSTIMULATION SYNDROME DO NOT HAVE ANY NEGATIVE IMPACT ON SUCCESS WITH IN VITRO FERTILIZATION (IVF) IN YOUNGER WOMEN WITH HIGH ANTI MULLERIAN HORMONE (AMH) LEVELS. B. Neumann
- P-440 RISK OF PLACENTA ACCRETA SPECTRUM AND RETAINED PLACENTA IN PREGNANCIES CONCEIVED VIA ASSISTED REPRODUCTIVE TECHNOLOGY: A LARGE NETWORK STUDY. M. R. Imbroane
- P-441 ASSISTED HATCHING ON DAY 3 VS. ZONA BREACHING ON DAYS 5-7: THE IMPACT ON CLINICAL OUTCOMES OF FET CYCLES WITH PGT-A TESTED EMBRYOS E. A. Ortega
- P-442 DOES SERUM ESTRADIOL LEVELS PRIOR TO PROGESTERONE ADMINISTRATION IN PROGRAMMED FROZEN EMBRYO TRANSFER CYCLE IMPACTS LIVE BIRTH RATE ? : A PROSPECTIVE COHORT STUDY N. Singh

PST-21 ART- OUTCOMES (10 OF 10)

- P-443 ANTI-MÜLLERIAN HORMONE (AMH) IN PATIENTS WITH ONE OVARY UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION (COH). E. A. Clarke
- P-444 MILD ADENOMYOSIS DOES NOT IMPACT PREGNANCY RATE OR PREGNANCY OUTCOMES IN SINGLE EUPLOID FROZEN EMBRYO TRANSFERS. A. Messelt
- P-445 SUCCESS OF SINGLE EUPLOID EMBRYO TRANSFER IN PATIENTS EXPERIENCING PRIMARY VERSUS SECONDARY INFERTILITY. K. Bergin
- P-446 THE EFFECT OF IMPLEMENTATION OF MATRICE LAB RECOMMENDATIONS ON EMBRYO TRANSFER TREATMENT OUTCOMES IN UNEXPLAINED REPEATED IMPLANTATION FAILURE PATIENTS – A SINGLE-CENTER RETROSPECTIVE COHORT STUDY. A. Hochberg
- P-447 FOLLITROPIN DELTA (REKOVELLE®) IN GROUP 3 AND 4 POSEIDON PATIENTS UNDERGOING IVF/ICSI FOR IN VITRO FERTILIZATION : IS ANTAGONIST PROTOCOL THE BEST? E. Glowaczower
- P-448 EFFECTIVENESS AND SAFETY OF RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE (RHFSH) IN INFERTILE WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGY (ART): A KOREAN NATIONWIDE RETROSPECTIVE COHORT STUDY. J. Lee

PST-22 FERTILITY PRESERVATION- INFERTILITY & CANCER (1 OF 5)

- P-449 SINGLE-CELL RNA SEQUENCING REVEALS THE INTERCELLULAR CROSSTALK AND REGULATORY LANDSCAPE DURING MOUSE OVARIAN TRANSPLANTATION. Q. Mei
- P-450 USE OF FERTILITY PRESERVATION AND ARTIFICIAL REPRODUCTIVE TECHNOLOGY AMONG YOUNG WOMEN WITH BREAST CANCER: A MULTI-CENTRE, PROSPECTIVE COHORT STUDY. K. Sorouri
- P-451 ADMINISTRATION OF CYCLOPHOSPHAMIDE INDUCES UP-REGULATION OF INFLAMMATORY MARKERS AS EARLY AS 12 HOURS POST-INJECTION. L. Man
- P-452 REPRODUCTIVE IMPACT OF IMMUNE CHECKPOINT INHIBITOR THERAPY IN WOMEN WITH MELANOMA. Q. Rhodes
- P-453 DISPARITIES IN REFERRALS TO FERTILITY PRESERVATION SERVICES. E. Isaacson





Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-23 FERTILITY PRESERVATION- INFERTILITY & CANCER (2 OF 5)

- P-454 SINGLE EUPLOID EMBRYO TRANSFER OUTCOMES IN PATIENTS WITH A HISTORY OF CANCER TREATMENT: IS THERE A LONG-TERM EFFECT OF CHEMOTHERAPY BEYOND GONADOTOXICITY? K. Bergin
- P-455 IMPLEMENTATION OF AN ELECTRONIC BEST PRACTICE ADVISORY TO IMPROVE FERTILITY PRESERVATION SERVICES. C. J. Warren
- P-456 CRYOPRESERVED SPERM AMONG PATIENTS WITH OLIGOASTHENOTERATOZOOSPERMIA. R. Bitan
- P-457 FEMALE PATIENTS WITH BRCA MUTATIONS DEMONSTRATE WORSE OUTCOMES FROM IVF WITH PRE-IMPLANTATION GENETIC TESTING FOR MONOGENIC DISORDERS (PGT-M) COMPARED TO MALE PARTNERS WITH BRCA MUTATIONS. S. C. Cromack
- P-458 KNOWLEDGE AND ATTITUDES REGARDING FERTILITY PRESERVATION STRATEGIES AMONG WOMEN WITH A HEREDITARY PREDISPOSITION TO OVARIAN CANCER. R. A. Martel

PST-24 FERTILITY PRESERVATION- INFERTILITY & CANCER (3 OF 5)

- P-459 HOW THE FEMALE AGE AT OOCYTE VITRIFICATION AFFECTS OUTCOMES IN NON-MEDICAL AUTOLOGOUS USE. J. Cura Ruiz
- P-460 OOCYTE RETRIEVAL FOR PATIENTS WITH MALIGNANCY: ASSESSMENT OF CLINICAL CHARACTERISTICS. A. Masjedi
- P-461 EXPLORING INFERTILITY AND SEMEN PARAMETERS IN YOUNG ADULT CANCER SURVIVORS. D. M. Langston
- P-462 IT SHOULD BE POPULAR, IT'S NOT POPULAR: PERSPECTIVES ON FERTILITY PRESERVATION AMONG GHANAIAI WOMEN LIVING WITH BREAST CANCER. P. E. Sefogah
- P-463 LONG TERM SAFETY OF CONTROLLED OVARIAN STIMULATION FOR FERTILITY PRESERVATION PRIOR TO CHEMOTHERAPY TREATMENT IN BREAST CANCER PATIENTS. M. Shapira

PST-25 FERTILITY PRESERVATION- INFERTILITY & CANCER (4 OF 5)

- P-464 FERTILITY PRESERVATION OUTCOMES AMONG PATIENTS WITH LEUKEMIA. R. Sharma
- P-465 ESTROGEN SPECIFICALLY DECREASED THE EXPRESSION OF ROUND SPERMATID, BUT NOT OTHER MARKERS OF SPERMATOGENESIS UNDER IN VITRO MATURATION CONDITIONS; POSSIBLE REGULATION BY SERTOLI AND LEYDIG CELLS. M. Huleihel
- P-466 EXPLORING FACTORS ASSOCIATED WITH FERTILITY PRESERVATION UTILIZATION IN PEDIATRIC AND ADOLESCENT PATIENTS UNDERGOING OVARIAN-TOXIC TREATMENTS. C. A. Henshaw
- P-467 FERTILITY PRESERVATION PREFERENCES FOR TELEHEALTH CONSULTATION: A PROSPECTIVE COHORT STUDY. J. A. Suskin
- P-468 A PILOT STUDY ON AMHR2BP FOR THE PREVENTION OF CYCLOPHOSPHAMIDE (CX)-INDUCED OVARIAN FOLLICLE DEPLETION IN MICE. L. Detti



Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-26 FERTILITY PRESERVATION- INFERTILITY & CANCER (5 OF 5)

- P-469 ONCOFERTILITY REFERRAL PRACTICE PATTERNS- OPPORTUNITIES FOR IMPROVEMENT. E. Zitekovsky
- P-470 CLINICAL AND FERTILITY OUTCOMES IN LYNCH SYNDROME PATIENTS WITH CONSERVATIVELY MANAGED GRADE 1 ENDOMETRIAL CANCER. S. Yin
- P-471 OVARIAN TISSUE CRYOPRESERVATION: CHARACTERIZING PATIENT FACTORS AND OUTCOMES AT A LARGE ACADEMIC CENTER IN THE UNITED STATES. M. Pollie
- P-472 FERTILITY DYNAMICS AND REPRODUCTIVE HEALTH STATUS AMONG FEMALE PATIENTS WITH CANCER: INSIGHTS FROM THE ENGENDERING REPRODUCTIVE HEALTH WITHIN ONCOLOGIC SURVIVORSHIP - EROS (ECOG-ACRIN E1Q11). N. O. Francone

PST-27 FERTILITY PRESERVATION- GENERAL (6 OF 7)

- P-473 CORRELATION OF MATERNAL FACTORS IN EGG FREEZING CYCLES WITH IVF OUTCOMES OF BOTH IN VIVO AND RESCUE IN VITRO MATURED OOCYTES. E. A. Jannaman
- P-474 DOES A HIGH NUMBER OF MATURE OOCYTES ON THE SAME VITRIFICATION STRAW REDUCE THE POST WARMUP BIOLOGICAL OUTCOMES? C. Sifer
- P-475 1 OUT OF 5 PATIENTS (PTS) WHO FREEZE EGGS AT 40+ YEARS WILL HAVE A BABY: AUTOLOGOUS OOCYTE THAW (OT) OUTCOMES FROM A LARGE PLANNED OOCYTE CRYOPRESERVATION (OC) 40+ COHORT. A. G. Kelly
- P-476 SOCIAL DETERMINANTS OF HEALTH ASSOCIATED WITH PROXIMITY TO FERTILITY PRESERVATION SERVICES IN YOUNG CANCER SURVIVORS. A. Zhang
- P-477 FREEZING FIRST: INSIGHTS FROM 8 YEARS OF PLANNED OOCYTE CRYOPRESERVATION (OC) AT AN "EGG FREEZING CLINIC". J. U. Klein
- P-376 TRANSCRIPTOMIC INVESTIGATION OF THE ENDOMETRIOSIS GENE SIGNATURE. C. L. Furtado

PST-28 FERTILITY PRESERVATION- GENERAL (7 OF 7)

- P-478 AGE AND ETHNICITY AFFECT TIME TO UTILIZATION OF CRYOPRESERVED OOCYTES. C. Rosenbaum
- P-479 PATIENTS THOUGHTS ON HETEROTOPIC OVARIAN TRANSPLANTATION AS A MEANS OF NATURAL HORMONE REPLACEMENT OR TO DELAY MENOPAUSE. M. Sonmezer
- P-480 POSTHUMOUS SPERM RETRIEVAL: SURVEY OF KNOWLEDGE OF INTENSIVE CARE UNIT PROVIDERS. C. Hayden
- P-481 FERTILITY PRESERVATION AMONG TRANSGENDER YOUTH WITH TESTES IN A MULTIDISCIPLINARY GENDER PROGRAM. H. Wurst
- P-482 SPERM QUALITY AND FERTILITY OUTCOMES IN MEN WHO PRESERVED THEIR SEMEN FOR FERTILITY PRESERVATION DUE TO A DIAGNOSIS OF ONCOHEMATOLOGICAL CANCER. M. Reschini





Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-29 GENETICS- PGT (1 OF 5)

- | | | | |
|-------|---|-------|---|
| P-483 | NON-INVASIVE PGT-A AS A CLINICAL ALTERNATIVE TO RE-BIOPSY FOR PRIOR INCONCLUSIVE BLASTOCYSTS. A. Wynn | P-486 | FACTORS AFFECTING THE LIVE BIRTH RATE AFTER MOSAIC EMBRYO TRANSFER. A. Akça |
| P-484 | EVALUATION OF A PREDICTIVE MODEL FOR PLOIDY BASED ON OOCYTE MEIOTIC SPINDLE POSITION AND EMBRYO MORPHOKINETIC CHARACTERISTICS IN PGT-A CYCLES. S. Yoon | P-487 | TIME TO PREGNANCY AFTER "TRANSFER THE BEST AND BIOPSY THE REST," REALLY A CONCERN? D. C. Gonullu-Rotman |
| P-485 | IDENTIFICATION OF ANEUPLOID EMBRYOS USING CELL-FREE DNA IN EMBRYO CULTURE MEDIUM COMPARISON WITH TE BIOPSY FROM THE PERSPECTIVE OF TEST ACCURACY. H. Watanabe | | |

PST-30 GENETICS- PGT (2 OF 5)

- | | | | |
|-------|---|-------|---|
| P-488 | COMPARISON OF IVF TREATMENT STRATEGIES: AN EVALUATION OF "TRANSFER THE BEST AND BIOPSY THE REST" VERSUS PGT-A UP-FRONT. D. C. Gonullu-Rotman | P-491 | DEVELOPMENT OF CONCURRENT PREIMPLANTATION GENETIC TESTING FOR 22q11.2 DELETION SYNDROME AND ANEUPLOIDY SCREENING FROM A SINGLE TROPHECTODERM BIOPSY USING TARGETED NEXT-GENERATION SEQUENCING (TNGS) V. Guo |
| P-489 | UTILIZATION OF PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) IN YOUNG FEMALES (<35) RESULTS IN HIGHER LIVE BIRTH WHILE DECREASING MISCARRIAGES. M. Cetinkaya | P-492 | RAPID, EFFICIENT, DECENTRALIZED PGT-A WITH NANOPORE SEQUENCING. S. Lu |
| P-490 | EFFECT OF TROPHECTODERM (TE) BIOPSY SPECIMEN SIZE ON MOSAIC BLASTOCYSTS IN PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A). J. Han | | |

PST-31 GENETICS- PGT (3 OF 5)

- | | | | |
|-------|---|-------|--|
| P-493 | IMPACT OF INCREASING TIME FROM EMBRYO BIOPSY TO PCR TUBE LOADING ON PGT DATA QUALITY. C. Gibbs | P-496 | EMBRYO GRADING: IS IT A GOOD PREDICTOR FOR EUPLOIDY? J. Mouhanna |
| P-494 | USING THE BINOMIAL THEOREM TO PREDICT THE DISTRIBUTION OF NORMAL EUPLOID BLASTOCYSTS WITHIN A COHORT SIMPLY BASED UPON THE COHORT'S DISCRETE SIZE. T. T. Huang | P-497 | ORIGIN OF ANEUPLOIDY PREDICTION WITH TIME-LAPSE MORPHOKINETIC ANALYSES. E. Kalafat |
| P-495 | THREE YEARS OF EXPERIENCE WITH SINGLE CRYOPRESERVED BLASTOCYST TRANSFERS OF IN VITRO FERTILIZED (IVF) EMBRYOS DIAGNOSED AS LOW OR HIGH MOSAIC THROUGH PREIMPLANTATION GENETIC TESTING (PGT). C. Cinnioglu | | |





Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-32 GENETICS- PGT (4 OF 5)

- | | | | |
|-------|--|-------|--|
| P-498 | DIAGNOSING MONOGENIC CONDITIONS THROUGH WHOLE-GENOME EMBRYO SCREENING WITHOUT PARENTAL DNA. M. H. Katz | P-501 | LIKELIHOOD OF OBTAINING A USABLE EMBRYO FOR TRANSFER AFTER IVF WITH PGT-A AND PGT-M FOR TWO VARIANTS. M. A. Rasouli |
| P-499 | CHALLENGING PGT-M CASES RESOLVED WITH WHOLE GENOME SEQUENCING (WGS) OF EMBRYOS. M. H. Katz | P-502 | FINAL RESULTS OF A MULTICENTER STUDY COMPARING CELL-FREE DNA AND TROPHECTODERM BIOPSIES IN 2539 HUMAN BLASTOCYSTS. C. Rubio Lluesa |
| P-500 | INCIDENTAL FINDINGS OF Y CHROMOSOME DELETIONS AND DUPLICATIONS ON PGT-A: A CASE SERIES. L. Rabkina | | |

PST-33 GENETICS- PGT (5 OF 5)

- | | | | |
|-------|--|-------|--|
| P-503 | INTEGRATING COPY NUMBER ANALYSIS AND TARGETED ASSESSMENT OF GENETIC VARIANTS: ADVANCING PRECISION IN EMBRYO SCREENING. Y. Chen | P-506 | MOSAICISM AND ANEUPLOIDY IN EACH CHROMOSOME AND THEIR RELATIONSHIP WITH CHROMOSOME LENGTH : ANALYSIS OF 8,653 BLASTOCYSTS BY NEXT- GENERATION SEQUENCING (NGS). L. Noriega Hoces |
| P-504 | ARTIFICIAL INTELLIGENCE CLARIFIES LOW-LEVEL MOSAIC FINDINGS IN PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY. C. Giménez | P-507 | RECURRENT BENIGN Y CHROMOSOME DELETIONS AND DUPLICATIONS ON PGT-A: A CASE SERIES. L. Rabkina |
| P-505 | IMPROVED CLINICAL OUTCOMES WITH NON-INVASIVE PREIMPLANTATION GENETIC TESTING IN FROZEN-THAWED EMBRYO TRANSFER CYCLES. Y. Tang | | |

PST-34 GENETICS- GENETIC COUNSELING (1 OF 2)

- | | | | |
|-------|--|-------|--|
| P-508 | MINING AND COMPARING THE EXPERIENCES OF PRECONCEPTION AND PRENATAL GENETIC COUNSELORS ON MOSAIC EMBRYO TRANSFER. J. Miller | P-511 | PATIENT DECISION MAKING WHEN FACED WITH THE CHOICE OF MOSAIC EMBRYO TRANSFER. E. A. Clarke |
| P-509 | PGT FOR RECURRENT RISK OF A DE NOVO MUTATION: ALLELE DROP OUT RATE WITH DIRECT MUTATION ANALYSIS. D. Marin | P-512 | PREIMPLANTATION GENETIC TESTING FOR POLYGENIC DISEASE RISK: WILL WE KNOW WHEN TO STOP? A. S. Setti |
| P-510 | ASSESSING NEONATAL OUTCOMES AND THE FACTORS CONTRIBUTING TO NON-COMPLIANCE WITH RECOMMENDED PRENATAL TESTING WITH AMNIOCENTESIS AFTER MOSAIC EMBRYO TRANSFER. K. White | | |



Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-35 GENETICS- GENETIC COUNSELING (2 OF 2)

- P-513 ASSESSMENT FOR PREDICTORS OF EMBRYO PLOIDY FOLLOWING INCONCLUSIVE NEXT-GENERATION SEQUENCING (NGS)-BASED PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A). C. G. Durbin
- P-514 A PROCEDURAL ERROR AND POTENTIAL MISDIAGNOSIS DETECTED AND AVOIDED BY ADVANCED PGT-A TECHNOLOGY. A. Snider
- P-515 BALANCING IT OUT: IN VITRO FERTILIZATION OUTCOMES AFTER PRE-IMPLANTATION GENETIC TESTING FOR CHROMOSOMAL STRUCTURAL REARRANGEMENTS AMONG CARRIERS OF ROBERTSONIAN AND RECIPROCAL TRANSLOCATIONS. J. Pecoriello
- P-517 EXPANDING GENETIC COUNSELING IN PGT-SR: ASSESSING THE INFLUENCE OF CHROMOSOMAL REARRANGEMENT TYPE AND CARRIER GENDER ON THE ACQUISITION OF TRANSFERABLE EMBRYOS. E. Caviglia
- P-387 RISK OF MISINTERPRETATION OF HAPLOBLOCK OF KARYOMAPPING FOR PGT-M WHEN ANEUPLOIDY OR MOSAICISM OCCURS IN THE CHROMOSOME CONTAINING TARGET GENE. G. Han
- P-388 UNDERSTANDING THE UNTAPPED POTENTIAL OF CHAOTIC EMBRYOS: A SINGLE SITE'S EXPERIENCE. M. Palmor

PST-36 BUSINESS OF MEDICINE & PROFESSIONAL DEVELOPMENT

- P-518 COST-EFFECTIVENESS OF SINGLE VS DOUBLE EMBRYO TRANSFER TO GESTATIONAL CARRIERS FOR MALE SAME-SEX COUPLES. A. Khorshid
- P-519 WORKFORCE TRENDS AFTER GRADUATION FROM REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY (REI) FELLOWSHIP: AN ONLINE SEARCH TO ANALYZE A DECADE OF EVOLUTION IN THE PROFESSIONAL MARKETPLACE. A. M. Lew
- P-520 DIFFERENCES IN RESOURCE UTILIZATION BETWEEN NATURAL AND PROGRAMMED FROZEN EMBRYO TRANSFER CYCLES AT A SINGLE ACADEMIC FERTILITY PRACTICE. B. J. Peipert
- P-521 ARE COUNCIL ON RESIDENT EDUCATION IN OBSTETRICS AND GYNECOLOGY (CREOG) SCORES USEFUL IN EVALUATING A CURRICULUM TO ENHANCE RESIDENCY EDUCATION IN REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY (REI)? E. Heisler
- P-522 ANALYSIS OF CHARACTERISTICS OF PRINCIPAL INVESTIGATORS RECEIVING NATIONAL INSTITUTES OF HEALTH (NIH) FUNDING FOR INFERTILITY PROJECTS. V. C. Nemov

PST-37 INFERTILITY- GENERAL (3 OF 4)

- P-523 RISK FACTORS FOR PREGNANCY COMPLICATIONS IN COUPLES UNDERGOING INFERTILITY TREATMENT. A. Ulker
- P-524 DO LOW ANTIMULLERIAN HORMONE (AMH) LEVELS NECESSARILY MEANS THE NEED OF ART? A SERIES CASE REPORT. S. A. Davila Garza
- P-525 UTILITY OF POST-TRIGGER LABORATORY VALUES FOR ASSESSING ADEQUATE RESPONSE BY OVULATION TRIGGER TYPE. J. Evvy
- P-526 THE ASSOCIATION OF MITOCHONDRIAL DNA (mtDNA) PROPORTION IN TROPHOBLAST CELLS WITH THE IMPLANTATION OUTCOME OF EMBRYO TRANSFER. Y. Wang
- P-527 TRENDS AND OUTCOMES OF IVF/ICSI WITH PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY IN YOUNG WOMEN WITH RECURRENT PREGNANCY LOSS CONSIDERING THE IMPACT OF OVARIAN RESERVE. A. N. Gathoo
- P-400 BODY MASS INDEX CLASSIFICATION AND IVF OUTCOMES AMONG ASIAN AMERICAN PATIENTS. R. Bruno



Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-38 PRE-CLINICAL & BASIC RESEARCH- ANIMAL MODELS (1 OF 4)

- | | | | |
|-------|---|-------|---|
| P-528 | A NOVEL CHIMERIC IMMUNOCONJUGATE MOLECULE (ICON3) SUPPRESSES ENDOMETRIOSIS IN A MURINE MODEL. A. Garg | P-530 | CURRENT GUIDELINES ON THE MOUSE EMBRYO ASSAY (MEA) CAN ALLOW SUBOPTIMAL PRODUCTS TO BE USED WITHIN IVF LABS. E. Strait |
| P-529 | MOUSE EMBRYO ASSAY (MEA): SHOWING THAT THE 1-CELL EMBRYO IS A MORE SENSITIVE STARTING POINT THAN THE 2-CELL. P. Cowan | P-531 | EXOGENOUS PUTRESCINE SUPPLEMENTATION IMPROVES CYCLOPHOSPHAMIDE-INDUCED PREMATURE OVARIAN INSUFFICIENCY IN MICE. C. Zhao |

PST-39 PRE-CLINICAL & BASIC RESEARCH- ANIMAL MODELS (2 OF 4)

- | | | | |
|-------|---|-------|--|
| P-533 | DIRECT EFFECT OF CCR2 RECEPTOR ON FOLLICLE ACTIVATION. Y. Gamaleri | P-536 | TRANSTHYRETIN (TTR) AS NON-INVASIVE DIAGNOSTIC MARKER TO DIFFERENTIATE UTERINE LEIOMYOSARCOMA FROM UTERINE FIBROIDS. M. M. Omran |
| P-535 | RAPID AND REVERSIBLE CEP192 DEPLETION DURING MURINE GAMETOGENESIS USING THE AUXIN-INDUCIBLE DEGRON (AID) PROTEIN DEGRADATION SYSTEM. M. Skinner | | |

PST-40 PRE-CLINICAL & BASIC RESEARCH- ANIMAL MODELS (3 OF 4)

- | | | | |
|-------|--|-------|---|
| P-537 | DECREASED ENDOMETRIOTIC LESION FORMATION IN CD44-/-/RHAMM-/- DOUBLE KNOCK-OUT MICE. C. M. Schenken | P-540 | CHRONIC ORAL INGESTION OF CRUDE OIL SPILL CONTAMINATED WATER AFFECTS SPERM PARAMETERS, SPERM MOVEMENT KINETICS AND INDUCE OXIDATIVE STRESS IN PIGS. L. C. Ajonuma |
| P-538 | EFFECTS OF HYPERHOMOCYSTEINEMIA ON FOLLICULAR DEVELOPMENT AND OOCYTES QUALITY. R. Hu | P-541 | LASER IMMOBILIZATION OF SPERMATOZOA FOR INTRACYTOPLASMIC SPERM INJECTION (ICSI): AN EXPLORATORY AND SAFETY STUDY IN THE MOUSE MODEL. N. Costa Borges |
| P-539 | ANTI-MÜLLERIAN HORMONE TREATMENT REGULATES EARLY CELL-CYCLE GENES IN THE PREIMPLANTATION MOUSE EMBRYO. V. S. Jiang | | |

PST-41 PRE-CLINICAL & BASIC RESEARCH- ANIMAL MODELS (4 OF 4)

- | | | | |
|-------|--|-------|--|
| P-542 | MELATONIN-ENRICHED CULTURE MEDIA PARTIALLY RESCUES EPIGENETIC AND PLACENTAL CHANGES INDUCED BY BLASTOCYST CULTURE. M. S. Kornfield | P-545 | DOES RAPAMYCIN DELAY OVARIAN AGING AND DECREASE SENESCENCE? A FIRST-EVER ANALYSIS IN A NON-HUMAN PRIMATE MODEL M. L. Bonus |
| P-544 | NON-INVASIVE METABOLIC IMAGING OF EARLY EMBRYOS IS ASSOCIATED WITH ALTERED METABOLIC SIGNATURES AND REPRODUCTIVE OUTCOMES IN AGING. F. Horta | | |



Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-42 MENTAL HEALTH

- P-546 PSYCHOLOGICAL DISTRESS AND QUALITY OF LIFE IN INFERTILE COUPLES ATTENDING INFERTILITY CLINIC IN SOUTH INDIA: A PILOT STUDY. A. T P
- P-547 HOW HAVING POLYCYSTIC OVARIAN SYNDROME (PCOS) INFERTILITY IMPACTS IDENTITY OF BEING A MOTHER AND A WOMAN. S. L. Weatherhead
- P-548 MIND MATTERS IN FERTILITY CARE: A NATIONWIDE ANALYSIS OF MENTAL HEALTH AND RELAXATION PROMOTIONS ON CLINIC WEBSITES. A. M. Herweck
- P-549 THE EFFECT OF A MINDSET MANAGEMENT INTERVENTION ON STRESS LEVELS IN WOMEN WITH INFERTILITY: INTERIM RESULTS OF A RANDOMIZED CONTROLLED TRIAL. M. Edelson
- P-550 HEIGHTENED PARAMETERS OF NEGATIVE PHYSIOLOGICAL STRESS PARAMETERS DURING ART: A COMPARISON OF IVF PATIENTS AT BASELINE TO THE STIMULATION PHASE. A. D. Domar

PST-43 TECHNOLOGY & INNOVATION- ART (1 OF 5)

- P-551 EVALUATION OF THE EFFECT ON ONGOING PREGNANCY RATE OF USING ARTIFICIAL INTELLIGENCE FOR EMBRYO PRIORITIZATION: AN INTERIM ANALYSIS OF A PROSPECTIVE RANDOMIZED CONTROL TRIAL. M. VerMilyea
- P-552 DEVELOPMENT OF A DEEP LEARNING MODEL BASED ON CASCADE MASK REGIONAL CONVOLUTIONAL NEURAL NETWORK TO NONINVASIVELY AND ACCURATELY IDENTIFY HUMAN ROUND SPERMATIDS. L. Zhang
- P-553 BRIDGING SUBJECTIVITY WITH OBJECTIVITY: ASSESSING EMBRYOLOGIST COMPETENCE IN EMBRYO GRADING THROUGH AI ANNOTATION CONCORDANCE. C. L. Curchoe
- P-554 SUCCESSFUL MULTICENTRE PROSPECTIVE VALIDATION OF AN IN-HOUSE MACHINE LEARNING SOLUTION FOR LIVE BIRTH PREDICTION, FOR THE ASSESSMENT AND SELECTION OF 2389 BLASTOCYSTS. R. Smith
- P-555 UTERINE CONTRACTILITY CHANGES AFTER SUCCESSFUL EMBRYO IMPLANTATION. B. C. Schoot

PST-44 TECHNOLOGY & INNOVATION- ART (2 OF 5)

- P-556 EMBRYONIC QUALITY AS ASSESSED BY KIDSCORE D5 IS POSITIVELY ASSOCIATED WITH PERINATAL OUTCOMES IN INTRACYTOPLASMIC SPERM INJECTION CYCLES. A. S. Setti
- P-557 NON-INVASIVE SINGLE BLASTOCYST METABOLIC ASSESSMENT REVEALED QUIESCENT METABOLIC ACTIVITY ASSOCIATED WITH IMPROVED DEVELOPMENTAL POTENTIAL. M. Cheng
- P-558 OOCYTE ASSESSMENT BASED ON ARTIFICIAL INTELLIGENCE (AI) FOR THE PREDICTION OF BLASTOCYST DEVELOPMENT: A COMPARATIVE ANALYSIS OF FRESH AND VITRIFIED DONOR OOCYTES. L. Murria
- P-559 AUTOMATED REAL-TIME SPERM SELECTION FOR INTRACYTOPLASMIC SPERM INJECTION (ICSI): SIBLING OOCYTE EVALUATION. L. Bori Arnal
- P-560 INVESTIGATING THE EFFECT OF INTERMEDIATE AND HEAVY OILS ON PREIMPLANTATION EMBRYONIC DEVELOPMENT: INSIGHTS FROM TIME-LAPSE AND PGT-A ANALYSIS IN SIBLING OOCYTES SPLIT STUDY. M. Hozyen





Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-45 TECHNOLOGY & INNOVATION- ART (3 OF 5)

- P-561 UNDERSTANDING UTERINE PERISTALSIS PATTERNS IN PATIENTS UNDERGOING FROZEN EMBRYO TRANSFER USING ELECTROPHYSIOLOGICAL IMAGING. C. Murphy
- P-562 IMPROVING PREGNANCY SUCCESS RATES: A LARGE MULTI-CENTER RANDOMIZED CLINICAL TRIAL UTILIZING A NOVEL DECISION SUPPORT TOOL. U. Diwekar
- P-563 FABRICATION OF LOW-ABERRATION 3D WELL-OF-THE-WELL (WOW) MICROWELL DISHES FOR IN SITU EMBRYO IMAGING. Y. Zhao
- P-564 NORMAL BLASTOCYST DEVELOPMENT VERIFIED IN ULTRA-FAST VITRIFIED/RAPID ELUTED MATURE HUMAN OOCYTES. M. C. Schiewe
- P-565 OOCYTE ASSESSMENT BASED ON ARTIFICIAL INTELLIGENCE (AI). ARE OOCYTE SCORES RELATED TO SUBSEQUENT EMBRYO QUALITY? L. Murria

PST-46 TECHNOLOGY & INNOVATION- ART (4 OF 5)

- P-566 NICOTINAMIDE MONONUCLEOTIDE SUPPLEMENTATION ENHANCES THE DEVELOPMENTAL POTENTIAL OF IN VITRO MATURATION OOCYTES IN ADVANCED MATERNAL AGE WOMEN BY SAFEGUARDING MITOCHONDRIAL FUNCTION. Y. Liu
- P-567 IMPROVING BLASTULATION WITH AI-POWERED REAL-TIME MOTILITY ANALYSIS OF SINGLE SPERM DURING ICSI. O. Paredes
- P-568 A NOVEL INTELLIGENT ROBOTIC MICROMANIPULATION SYSTEM ENABLES REMOTE ICSI PROCEDURES. G. Mendizabal
- P-569 CLINICAL APPLICATION OF AN ARTIFICIAL INTELLIGENCE (AI) BASED PREIMPLANTATION GENETIC SCREENING TOOL. D. Gilboa
- P-570 THE ROLE OF PYRUVATE IN IMPROVING MATURATION RATES AFTER RESCUE IN VITRO MATURATION OF GERMINAL VESICLE STAGE OOCYTES. G. Ardestani

PST-47 TECHNOLOGY & INNOVATION- ART (5 OF 5)

- P-571 FIRST CASE OF REPORTED POSITIVE PREGNANCY FROM NOVEL OVARIAN SUPPORT CELL-ASSISTED IN VITRO MATURATION OF IMMATURE OOCYTES DERIVED FROM TRUNCATED HORMONAL STIMULATION. L. Guzman
- P-572 DONOR OOCYTE SELECTION THROUGH ARTIFICIAL INTELLIGENCE: A NOVEL PREDICTIVE MODEL TO SUPPORT CLINICAL DECISION-MAKING AND IMPROVE IVF OUTCOMES. D. Gudkova
- P-573 PATIENTS WITH RECURRENT ART FAILURE DUE TO SEVERE FRAGMENTATION AT THE EARLY CLEAVAGE; CAN THE ARTIFICIAL REMOVAL OF ZONA PELLUCIDA (ZP) AT THE 2 PRONUCLEI (2PN) STAGE BE BENEFICIAL? K. Yumoto
- P-574 ACCURATE PREDICTION OF IVF-DERIVED BLASTOCYST FAMILIAL RELATIONSHIPS AS AN IVF AND PGT LAB QUALITY CONTROL TOOL. J. Xu
- P-575 VALIDATION OF A NOVEL NON-DMSO SOLUTION FOR ULTRA-FAST VITRIFICATION (UFV) AND RAPID (ONE-STEP) ELUTION (RE) OF HUMAN BLASTOCYSTS. M. C. Schiewe



Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-48 TECHNOLOGY & INNOVATION- GENERAL (1 OF 3)

- P-576 HYPERSPECTRAL IMAGING AS A POTENTIALLY NON-INVASIVE METHOD ALLOWING DISCRIMINATION OF ENDOMETRIAL MENSTRUAL CYCLE PHASES AND IDENTIFICATION OF THE WINDOW OF IMPLANTATION IN NORMO-OVULATORY WOMEN. D. Marti-Garcia
- P-577 WEARABLE DEVICES AND FERTILITY: INVESTIGATING SLEEP PARAMETERS AS OVULATORY PREDICTORS. B. Q. Mauerhan
- P-578 PREDICTION OF POLYCYSTIC OVARY SYNDROME (PCOS) USING SELF-REPORTED CHARACTERISTICS FROM A DIGITAL COHORT IN THE UNITES STATES. Z. Wang
- P-579 EVALUATION OF DECREASE IN PAIN AFTER EGG RETRIEVAL WITH RECTAL TYLENOL: DEPART TRIAL. P. Sarkar
- P-580 ASSESSING THE RELIABILITY OF CHATGPT AS A RESOURCE FOR INFERTILITY INFORMATION. K. N. Le

PST-49 TECHNOLOGY & INNOVATION- GENERAL (2 OF 3)

- P-581 FREE ANDROGEN INDEX (FAI) AS A TREATMENT RESPONSE PREDICTOR AMONG PATIENTS WITH POLYCYSTIC OVARY SYNDROME (PCOS) UNDERGOING OVULATION INDUCTION/INTRAUTERINE INSEMINATION (OI/IUI). M. Kavelidou
- P-582 NEXT-GENERATION PGT: COMBINED GENOME AND TRANSCRIPTOME ANALYSIS. S. Lu
- P-583 CERVICAL MUCUS ELECTRICAL IMPEDANCE TRENDS CORRELATE WITH CERVICAL MUCUS OBSERVATIONS. S. Tabbaa
- P-584 ANTRAL FOLLICLE COUNT (AFC): AN EXPLORATORY STUDY USING THREE-DIMENSIONAL ULTRASOUND (3DUS). A. Palumbo
- P-585 ASSESSING THE IMPACT OF BMI ON UTERINE PERISTALSIS PATTERNS ACROSS THE MENSTRUAL CYCLE USING ELECTROPHYSIOLOGICAL IMAGING. C. Murphy

PST-50 TECHNOLOGY & INNOVATION- GENERAL (3 OF 3)

- P-586 VALIDATION OF THE "SPERM CLASS ANALYZER® COMPUTER AIDED SPERM ANALYSIS" SYSTEM IN THE AUTOMATION OF IN VITRO FERTILIZATION LABORATORIES. M. Toschi
- P-587 IMPACT OF SPONTANEOUS COLLAPSE AND CYTOPLASMIC STRINGS ON EUPLOIDY AND PREGNANCY OUTCOMES IN TIME-LAPSE CULTURED EMBRYOS. T. Shin
- P-589 THE APPLICATION OF THE FIRST FULLY AUTOMATIC LIQUID PHASE EMBRYO STORAGE REPOSITORY HATCHFERTI: SAFETY COMPARISON OF DIFFERENT STORAGE TIMES AND METHODS. Y. Meng
- P-590 USE OF BRILLOUIN SPECTROSCOPY AS A NON-CONTACT, NON-DESTRUCTIVE METHOD TO DETECT BIOMECHANICAL CHANGES IN MOUSE OOCYTES DURING FERTILIZATION. R. Taft





Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-51 PRE-CLINICAL & BASIC RESEARCH- STEM CELLS & REGENERATIVE MEDICINE

- P-591 ENHANCEMENT OF THE BLASTOCYST-DERIVED TROPHOBLAST DIFFERENTIATION BY LOW MOLECULAR WEIGHT HEPARIN. J. Lee
- P-592 ACTIVATION OF INNATE IMMUNE PATHWAYS VIA INTERFERON REGULATORY FACTOR 3 IN DIFFERENTIATED HUMAN TROPHOBLASTS. J. S. Hynes
- P-593 A NEW APPROACH TO PROMOTE CELL FUSION IN NUCLEAR TRANSPLANTATION AIMING AT NEOGAMETOGENESIS. P. Xie
- P-594 OVARIAN SUPPORT CELLS ENHANCE OOCYTE MATURATION AND DEVELOPMENTAL COMPETENCE BY RECREATING A COMPLEX FOLLICLE-LIKE ENVIRONMENT IN VITRO . C. C. Kramme
- P-595 ENDOMETRIAL AND IMPLANTATION MODELING UTILIZING A HIGH-THROUGHPUT 3D SPHEROID GENERATION SYSTEM. A. N. Vélez-Avilés

PST-52 PRE-CLINICAL & BASIC RESEARCH- EXPERIMENTAL

- P-597 ACTIVATED MYOFIBROBLASTS MAY SUPPORT NEUROGENESIS IN FIBROIDS UNDER HYPOXIC CONDITIONS. W. H. Catherino
- P-598 OOCYTE VITRIFICATION ALTERS DEVELOPMENTAL SNCRNA EXPRESSION IN A HUMAN MODEL OF EMBRYO DEVELOPMENT. S. Russell
- P-599 THE USE OF THE FLUORESCENT NUCLEAR STAIN DAPI TO IDENTIFY SEMINAL LEUKOCYTES. B. T. Stocks
- P-600 T LYMPHOCYTES IN HUMAN SEMEN: INSIGHTS INTO IMMUNE TOLERANCE OF SPERMATOGENESIS. B. T. Stocks

PST-53 PRE-CLINICAL & BASIC RESEARCH- GENERAL (1 OF 3)

- P-601 SPERMATOZOA CONTAIN MULTIPLE IGF2 TRANSCRIPT VARIANTS AMENABLE TO RAPID IDENTIFICATION VIA qPCR. R. Cannarella
- P-602 TINAGL-1 (TUBULOINTERSTITIAL NEPHRITIS ANTIGEN LIKE-1) IS HIGHLY EXPRESSED IN PCOS PATIENTS UNDERGOING OVARIAN STIMULATION: A NOVEL FINDING. H. Ramadan
- P-603 EARLY SEXUAL DIMORPHISM IN THE PRE-IMPLANTATION MOUSE EMBRYO. E. Minis
- P-604 DYNAMICS OF YAP LOCALIZATION IN HUMAN OOCYTES AND GRANULOSA CELLS ACROSS FOLLICULOGENESIS IN AN IN VITRO OVARIAN TISSUE CULTURE SYSTEM. J. H. Machlin
- P-605 COMPARISON BETWEEN FRESH AND CRYOPRESERVED OOCYTES ISOLATED FROM HUMAN OVARIAN CORTEX USING SINGLE-OOCYTE RNA-SEQUENCING. J. H. Machlin

PST-54 PRE-CLINICAL & BASIC RESEARCH- GENERAL (2 OF 3)

- P-606 THE ROLE OF ORAL ESTROGEN AND 2-METHOXYESTRADIOL LEVELS ON TROPHOBLAST INVASION AND ADVERSE PREGNANCY OUTCOMES IN PROGRAMMED FROZEN EMBRYO TRANSFER CYCLES. J. N. Tozour
- P-607 THE EFFECTS OF LOW DOSE ASPIRIN (LDA) ON HUMAN ENDOMETRIAL STROMAL CELLS (HESCS) AND TROPHOBLAST CELLS (TCS) - UNDERSTANDING THE MECHANISMS OF IMPROVING PREGNANCY OUTCOMES. J. Garcia De Paredes
- P-608 SINGLE-CELL RNA SEQUENCING OF GRANULOSA CELLS ACROSS OOCYTE DEVELOPMENT IN NORMAL OVARIAN RESERVE PATIENTS UNDERGOING DIFFERENT STIMULATION PROTOCOLS. M. Handa
- P-609 DETECTION OF THE INTERCHROMOSOMAL EFFECT WITH PARENT OF ORIGIN ANALYSIS OF HUMAN EMBRYONIC ANEUPLOIDY IN PGT-SR CASES. H. Garnsey
- P-610 IMAGING MASS CYTOMETRY FOR ASSESSMENT OF THE ENDOMETRIAL IMMUNE MICROENVIRONMENT IN ASHERMAN SYNDROME: A FEASIBILITY STUDY. Y. Alebrahim



Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-55 PRE-CLINICAL & BASIC RESEARCH- GENERAL (3 OF 3)

- P-612 MULTI-OMIC ANALYSIS OF ENDOMETRIAL DECIDUALIZATION RESISTANCE UNVEILS A MOSAIC EPITHELIALSTROMAL SHIFT. I. Muñoz Blat
- P-613 EPIGENETIC ENDOMETRIAL AGE ACCELERATION INCREASES IN IVF WOMEN SPECIALLY IN THOSE YOUNGER THAN 35 YEARS OLD. N. Del Aguila de Cárdenas
- P-614 EFFECT OF CATHEPSIN B INHIBITION ON MOUSE OOCYTE MATURATION AND EMBRYONIC DEVELOPMENT IN VITRO. S. Yoon

PST-56 COMPLEX FAMILY PLANNING- CONTRACEPTION

- P-615 CONSENSUS RECOMMENDATIONS FOR MEASURING THE IMPACT OF CONTRACEPTION ON THE MENSTRUAL CYCLE IN CONTRACEPTIVE CLINICAL TRIALS. A. Cordova-Gomez
- P-616 THE IMPACT OF INTRAUTERINE DEVICE USE ON ENDOMETRIAL LINING THICKNESS IN THE FERTILITY CLINIC SETTING: A RETROSPECTIVE COHORT STUDY. E. H. Chung
- P-617 FACTORS THAT INFLUENCE VASECTOMY UTILIZATION: MALE SEX RATIO, AGE SPREAD, AND PREGNANCY ATTITUDE OF OFFSPRING. A. A. Badewa
- P-618 "WHAT PUSHED IT FOR ME WAS THE OVERTURNING OF ROE V. WADE": EVALUATING THE IMPACT OF SOCIOPOLITICAL ISSUES AND REPRODUCTIVE HEALTH LEGISLATION ON PATIENTS' VASECTOMY DECISIONS L. G. Cheng
- P-619 #HORMONEFREEBIRTHCONTROL: A CROSS-SECTIONAL STUDY ON THE QUALITY OF HORMONE-FREE BIRTH CONTROL EDUCATION ON TIKTOK. A. Dennis

PST-57 COMPLEX FAMILY PLANNING- GENERAL

- P-620 ASSOCIATION BETWEEN ANATOMICAL LOCATION OF ECTOPIC PREGNANCY AND HETEROTOPIC PREGNANCY: NATIONAL INPATIENT SAMPLE ANALYSIS. Z. S. Anderson
- P-621 ULTRASOUND-GUIDED INJECTIONS OF AUTOLOGOUS PLATELET-RICH PLASMA (PRP) IN THE ENDOMYOMETRIAL JUNCTION LAYER FOR WOMEN WITH PERSISTENTLY THIN ENDOMETRIAL LINING. M. Mouanness
- P-622 TRENDS IN POST VASECTOMY SEMEN ANALYSIS (PVSA) UTILIZATION PRE- AND POST-DOBBS V JACKSON: DATA FROM A LIBERAL-LEANING STATE. A. Ayaz
- P-623 UTERINE SYNECHIAE IN INFERTILE WOMEN WITH A HISTORY OF INTRAUTERINE DEVICE AND NO ADDITIONAL RISK FACTORS. L. X. Zalles

PST-58 HEALTH DISPARITIES & HEALTH EQUITY- ACCESS TO CARE (1 OF 2)

- P-624 ARE FEMALES WITH OBESITY AND INFERTILITY LESS LIKELY TO ATTAIN THEIR IDEAL FAMILY SIZE? A CROSS-SECTIONAL ANALYSIS OF THE NATIONAL SURVEY OF FAMILY GROWTH, 2011-2019 A. T. Evans
- P-625 ARE MEDICAL PROVIDERS TALKING ABOUT VASECTOMY ENOUGH? DISPARITIES IN CONTRACEPTIVE COUNSELING: INSIGHTS FROM THE 2017-2019 NATIONAL SURVEY FOR FAMILY GROWTH. C. J. Warren
- P-626 CONTROLLED OVARIAN HYPERSTIMULATION AND IVF OUTCOMES IN PATIENTS WITH CLASS III/IV OBESITY VERSUS NORMAL BMI. A. Johnson
- P-627 MEDICAL AND SOCIAL REASONS TO DENY FERTILITY TREATMENT: A MULTIDISCIPLINARY SURVEY OF CLINICIANS, FERTILITY PATIENTS, AND THE PUBLIC. J. Jones
- P-628 SOCIAL CLASS, RACE AND EXPERIENCE SEEKING ASSISTED REPRODUCTIVE TECHNOLOGIES. B. Slocum



Tuesday, October 22, 2024

For updated presentation times, please refer to the Congress mobile app.

PST-59 HEALTH DISPARITIES & HEALTH EQUITY- UNDERREPRESENTED & UNDERSERVED POPULATIONS (1 OF 2)

- P-629 IS RESIDENCY A BARRIER TO FAMILY BUILDING WITH LGBTQ+ RESIDENTS?: A CROSS-SECTIONAL SURVEY OF ALL US RESIDENTS A. M. Ryan
- P-630 EVALUATING CHATGPT'S COMPETENCY AS A HEALTH EDUCATION RESOURCE FOR TRANSGENDER PEOPLE SEEKING FERTILITY INFORMATION. M. Palmor
- P-631 THE STATE OF RESEARCH ON FERTILITY FOR LGBTQ+ PEOPLE: A SCOPING REVIEW. D. Glujovsky
- P-632 MISSING THE STARTING BLOCKS: THE SLIPPING OF ELITE FEMALE ATHLETES' REPRODUCTIVE HEALTH NEEDS. C. Traub
- P-633 CERVICAL EPITHELIAL THICKNESS ON TOTAL HYSTERECTOMY SPECIMENS OF TRANSGENDER MALES TAKING TESTOSTERONE. M. A. Mathes

PST-60 HEALTH DISPARITIES & HEALTH EQUITY- GENERAL (1 OF 2)

- P-634 AREAS WITH HIGH NEIGHBORHOOD DEPRIVATION INDEX HAVE HIGHER RATES OF PCOS, ENDOMETRIOSIS AND UNEXPLAINED INFERTILITY. J. C. Armstrong
- P-635 UNITED STATES RACIAL/ETHNIC DISPARITIES IN OUTCOMES USING PGT-A: AN ANALYSIS OF 2014-2020 SART CORS DATABASE. A. T. Mason-Otey
- P-636 DISCREPANCIES IN THE EVALUATION OF RECURRENT PREGNANCY LOSS AMONG ACADEMIC-AFFILIATED CLINICS. J. M. Konel
- P-637 UPDATE: SECOND TRIMESTER PREGNANCY LOSS FOLLOWING IN-VITRO FERTILIZATION (IVF). O. N. Nussbaum
- P-638 NEIGHBORHOOD DISADVANTAGE IS ASSOCIATED WITH LOWER COUNT AND PROPORTION OF EUPLOID EMBRYOS FOLLOWING PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY. A. S. Komorowski

PST-61 REPRODUCTIVE MEDICINE (NON-INFERTILITY)- GENERAL (1 OF 2)

- P-639 HORMONAL MANAGEMENT OF MENSTRUAL-RELATED PAIN IN ADOLESCENTS WITH SICKLE CELL DISEASE. C. A. Henshaw
- P-640 PHENOTYPE-A REDUCES VITALITY SCORE IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME. C. Gennari Verruma
- P-641 PEROXIREDOXIN 4 PROTECTS AGAINST LATE ONSET HYPOGONADISM BY AMELIORATING OXIDATIVE STRESS AND ENDOPLASMIC RETICULUM STRESS IN TESTICULAR LEYDIG CELLS. S. Yuan
- P-642 POLYCYSTIC OVARY SYNDROME RISK ALGORITHM (PRISKA): A PILOT STUDY. J. S. Laven



Wednesday, October 23, 2024

For updated presentation times, please refer to the Congress mobile app.

PSW-01 PROFESSIONAL DEVELOPMENT & EDUCATION (1 OF 2)

- P-643 PREDICTORS OF SUCCESSFUL MATCH AMONG APPLICANTS TO REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY FELLOWSHIPS. L. A. Humphries
- P-644 PROGRAM AND ASSOCIATE PROGRAM DIRECTORS PERCEIVE HIGH RESIDENT CONFIDENCE IN BASIC INFERTILITY DIAGNOSIS AND MANAGEMENT. M. S. Stevenson
- P-645 INTERSECTIONALITY WITHIN TRAINEES RESULTS IN A REDUCED TRAINEE EXPERIENCE WHEN COMPARED TO TRAINEES WITHOUT DIVERSITY. Z. W. Walker
- P-646 A QUALITY IMPROVEMENT INITIATIVE TO IMPROVE COMPLETION OF THE INITIAL INFERTILITY EVALUATION AT AN ACADEMIC RESIDENT-RUN OB/GYN CLINIC WITH A 90% MINORITY PATIENT POPULATION. E. Brenner
- P-647 DOES MACHINE LEARNING PERFORM SIMILARLY TO TRADITIONAL FELLOWSHIP APPLICATION REVIEW? A RETROSPECTIVE ANALYSIS OF CANDIDATE INTERVIEW SELECTION AT A REPRODUCTIVE ENDOCRINOLOGY & INFERTILITY PROGRAM L. Hughes
- P-648 NATIONAL SURVEY: A DECADE OF REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY (REI) JOB SELECTION TRENDS. A. M. Lew

PSW-02 PROFESSIONAL DEVELOPMENT & EDUCATION (2 OF 2)

- P-649 DEVELOPMENT AND PILOT OF TRAINERS IN ONCOFERTILITY REPRODUCTIVE COMMUNICATION AND HEALTH (TORCH) PROGRAM. D. Jalili
- P-650 UTILIZING HIGH FIDELITY SIMULATION FOR EMERGENCY PREPAREDNESS IN AN OUTPATIENT IN VITRO FERTILIZATION (IVF) PROCEDURE SETTING. H. Kim
- P-651 IMPLEMENTATION OF A REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY CASE-BASED LEARNING CURRICULUM FOR RESIDENT PHYSICIANS AND MEDICAL STUDENTS IMPROVES KNOWLEDGE AND CONFIDENCE. K. Hunkler
- P-652 ASSESSING THE IMPACT OF AN ELEARNING PLATFORM FOR EDUCATING FERTILITY PROFESSIONALS. T. J. Jellereite-Nolan
- P-653 FELLOWSHIP PROGRAM FACTORS IMPACTING SATISFACTION AMONGST REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY FELLOWS. A. Masjedi
- P-654 INCLUSIVE PRACTICES IN REI FELLOWSHIP TRAINING: A WEB-BASED EXAMINATION OF LGBTQ+ REPRESENTATION. K. L. Budge

PSW-03 BUSINESS OF MEDICINE

- P-656 COST-EFFECTIVENESS ANALYSIS OF IVF PGT-SR AND FROZEN OOCYTE DONATION FOR CONCEPTION AMONG FEMALE 14;21 TRANSLOCATION CARRIERS. A. D. Mandelbaum
- P-657 COST ANALYSIS OF OPERATING AN OOCYTE DONOR PRODUCTION CENTER. Z. Patel
- P-658 AN OVERVIEW OF PATIENT EXPERIENCE INTERVENTIONS, IMPLEMENTED OVER THE COURSE OF ONE YEAR AND THE MEASURABLE IMPACTS OF THE INTERVENTIONS AS REFLECTED IN PATIENT NPS SCORES. J. Straub
- P-659 A TIME-DRIVEN ACTIVITY BASED COSTING ANALYSIS OF STAFF RESPONSIBILITIES IN A FERTILITY NETWORK. Q. Heyward
- P-660 AUTOMATED TOTAL CRYOMANAGEMENT PLATFORM ENABLES NEW INSIGHTS INTO CRYOBILLING AND POSITIVELY CORRELATES WITH ONGOING COLLECTIONS. C. A. Lynch





Wednesday, October 23, 2024

For updated presentation times, please refer to the Congress mobile app.

PSW-04 BENIGN GYNECOLOGICAL DISEASE- GENERAL (2 OF 2)

- P-661 SLC1A5-DEPENDENT METABOLIC REPROGRAMMING IN GRANULOSA CELLS IMPAIRS FOLLICULAR DEVELOPMENT IN POLYCYSTIC OVARY SYNDROME. Y. Wang
- P-662 MULTIDISCIPLINARY CARE FOR PCOS: INSIGHTS FROM A PATIENT SATISFACTION SURVEY. E. Bergl
- P-663 ASSOCIATIONS BETWEEN ENDOMETRIOSIS AND RISK OF COGNITIVE DISORDERS. T. Hsieh
- P-664 ESTABLISHMENT OF NON-INVASIVE PREDICTION MODELS FOR DIAGNOSIS OF SUBTYPES AND COLLAGEN CONTENT OF UTERINE LEIOMYOMAS BY MACHINE LEARNING USING MRI DATA. T. Tamehisa
- P-666 ESTABLISHMENT OF EXPERIMENTAL PROTOCOLS FOR MICROPLASTIC EXPOSURES IN HUMAN ENDOMETRIAL CELLS AND POSSIBLE ASSOCIATION OF MICROPLASTICS IN THE PATHOGENESIS OF ENDOMETRIOSIS. H. Park

PSW-05 ART- GENERAL (3 OF 3)

- P-667 HYPERTENSIVE DISORDERS OF PREGNANCY (HDP) IN PATIENTS WITH UNDERLYING INFERTILITY. D. Song
- P-668 USE OF ORAL CONTRACEPTIVE PILLS PRIOR TO NATURAL FROZEN EMBRYO TRANSFER CYCLES: IMPACT ON PREGNANCY AND LIVE BIRTH. M. Pollie
- P-669 ADVANCED MATERNAL AGE AND FREQUENCY OF DIFFERENT CHROMOSOMAL ABNORMALITIES IN MISCARRIAGES. M. Ruseva
- P-670 THE USE OF COMBINED ORAL CONTRACEPTIVE PILL VS. PROGESTIN ONLY PILL PRIOR TO A SINGLE EUPLOID FROZEN EMBRYO TRANSFER CYCLE DOES NOT IMPACT CLINICAL OUTCOMES D. Sachdev
- P-671 TOP CLINICAL INDICATIONS IN EXCLUDED SPERM AND OOCYTE DONOR APPLICANTS' PERSONAL AND FAMILY MEDICAL HISTORIES: HOW CAN WE IMPROVE OUR DONOR SCREENING AND BETTER UNDERSTAND RISK ASSESSMENT BARRIERS? J. Park
- P-672 PROGESTIN-SUPPRESSED IN VITRO FERTILIZATION CYCLES PRODUCES SIMILAR OUTCOMES TO TRADITIONAL PROTOCOLS IN PATIENTS WITH DIMINISHED OVARIAN RESERVE. L. R. Goodman

PSW-06 REPRODUCTIVE SURGERY- OUTCOMES (1 OF 2)

- P-673 RISK FACTORS FOR SURGICAL COMPLICATIONS IN PATIENTS WITH ENDOMETRIOSIS: INSIGHTS FROM A TERTIARY CARE CENTER. Y. D. Liu
- P-674 OUTCOMES OF PAIN AND DISCHARGE COURSE FOLLOWING ULTRASOUND (US)- GUIDED TRANSVERSUS ABDOMINIS PLANE BLOCK FOR PATIENTS UNDERGOING ABDOMINAL MYOMECTOMY. P. Singh
- P-675 REPRODUCTIVE SURGERY IN PRACTICE: DOES FELLOWSHIP TRAINING AT A PROGRAM WITH A SURGICAL SCHOLARS TRACK MAKE A DIFFERENCE? M. R. Imbroane
- P-676 COMPLIANCE OF SEMEN TESTING IN MEN AFTER POTENTIAL VASECTOMY FAILURE. M. D. Sandler
- P-677 RECURRENCE OF HYDROSALPINGES AFTER NEOSALPINGOSTOMY USING MICROSURGICAL TECHNIQUE. A. J. Matthaeus
- P-678 OPPORTUNISTIC SALPINGECTOMY VS TUBAL LIGATION AT CESAREAN SECTION: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS. R. G. GERMANO TOLEDO



Wednesday, October 23, 2024

For updated presentation times, please refer to the Congress mobile app.

PSW-07 REPRODUCTIVE SURGERY- OUTCOMES (2 OF 2)

- P-679 ENDOMETRIAL POLYP ON EMB AND FOLLOW-UP SALINE INFUSED SONOHYSTEROGRAM: WHAT DO WE SEE? M. C. Gigg
- P-680 SIMPLE VERSUS COMPLEX CONGENITAL UTERINE ANOMALY (CUA) REPAIR: ARE THE OUTCOMES SIMILAR? E. Heisler
- P-681 AN UP-TO-DATE PROFILE OF THE VASECTOMY REVERSAL PATIENT. A. G. Oppenheimer
- P-682 DOES HYSTEROSCOPIC INSTRUMENT USED DURING A POLYPECTOMY IMPACT TIME TO PREGNANCY POSTOPERATIVELY? E. Minis
- P-683 COMPARISON OF SURGICAL OUTCOMES AND RATE OF CESAREAN SECTION FOLLOWING FERTILITY SPARING MYOMECTOMY: A 10-YEAR EXPERIENCE FROM A SPECIALIZED FIBROID CENTER. S. Arora
- P-684 EFFECT OF ISTHMOCELE REPAIR ON PREGNANCY OUTCOME IN SECONDARY INFERTILITY PATIENTS WITH ENDOMETRIAL FLUID COLLECTION(EFC) WHO ARE UNDERGOING FROZEN EMBRYO TRANSFER CYCLE: A RETROSPECTIVE STUDY. L. Chirumamilla

PSW-08 REPRODUCTIVE SURGERY- GENERAL

- P-685 DOES HYSTEROSCOPIC INSTRUMENT TYPE IMPACT DEPTH OF POLYP RESECTION? K. C. Hammer
- P-686 TYPE OF MYOMECTOMY DOES NOT INFLUENCE FETAL OUTCOMES DURING SUBSEQUENT CESAREAN DELIVERY IN REPRODUCTIVE AGE WOMEN. C. Rosenbaum
- P-687 AN OROGASTRIC TUBE IS NOT NECESSARY FOR LOW-RISK LAPAROSCOPY: A RANDOMIZED CONTROL TRIAL. A. Gauf
- P-688 REPRODUCTIVE OUTCOME AFTER METROPLASTY OF T-SHAPED UTERUS IN INFERTILE PATIENTS. M. I. Abuzeid
- P-689 TRANSVAGINAL MYOLYSIS: PRELIMINARY DATA FROM A LARGE TERTIARY CENTER REGISTRY. B. S. Hurst
- P-690 ETIOLOGY OF THIN ENDOMETRIUM AND PREGNANCY OUTCOMES IN SINGLE EUPLOID EMBRYO TRANSFER (SEET) CYCLES. E. A. Clarke

PSW-09 HEALTH DISPARITIES & HEALTH EQUITY- ACCESS TO CARE (2 OF 2)

- P-691 EXPANDED CARRIER SCREENING: FAIR FOR ALL FERTILITY PATIENTS? J. Saben
- P-692 ASSESSING GEOGRAPHIC DISTRIBUTION AND CONCENTRATION OF ASSISTED REPRODUCTIVE SERVICES IN THE UNITED STATES. L. B. Ramirez
- P-694 A SURVEY-BASED EVALUATION OF PUBLIC PERCEPTION OF THE REVISED ASRM DEFINITION OF INFERTILITY AND ITS IMPACT ON PUBLIC SUPPORT FOR INSURANCE COVERAGE OF FERTILITY TREATMENT. A. Combs
- P-695 IMPACT OF AN EDUCATIONAL INTERVENTION ON HEALTH INSURANCE LITERACY AND INSURANCE BENEFIT UTILIZATION: A RANDOMIZED CONTROLLED TRIAL. O. M. Dayo
- P-696 PREDICTORS OF DEFAULT FROM CARE AND DELAYED TREATMENT INITIATION AMONG NEW PATIENTS SEEKING FERTILITY CARE. N. Gupta



Wednesday, October 23, 2024

For updated presentation times, please refer to the Congress mobile app.

PSW-10 HEALTH DISPARITIES & HEALTH EQUITY- UNDERREPRESENTED AND UNDERSERVED POPULATIONS (2 OF 2)

- P-697 A QUALITATIVE ANALYSIS OF FAMILY BUILDING DESIRES AND BARRIERS AMONG LGBTQ+ MILITARY SERVICE MEMBERS. D. Boedeker
- P-698 INTRAUTERINE INSEMINATION USING DONOR SPERM: EXPLORING CLINICAL PREGNANCY RATES IN SAME SEX FEMALE COUPLES, SINGLE FEMALES, AND HETEROSEXUAL COUPLES. B. Dubois
- P-699 MIND MATTERS: A PROSPECTIVE ASSESSMENT OF THE PSYCHOLOGICAL EXPERIENCE OF TRANSGENDER WOMEN AND NONBINARY PEOPLE PROVIDING A SEMEN SAMPLE WHILE USING GENDER-AFFIRMING HORMONES. R. I. Tristano
- P-700 FERTILITY TREATMENT IS NOT ASSOCIATED WITH SEVERE MATERNAL MORBIDITY IN RURAL PATIENTS. C. Braun
- P-701 MAPPING FERTILITY TRAJECTORIES: EXAMINING BLACK WOMEN'S FERTILITY EXPERIENCES AND PATHWAYS THROUGH INFERTILITY TREATMENT. I. Morgan
- P-702 THE PROMISE AND CHALLENGES OF FERTILITY PRESERVATION COUNSELING OF BREAST CANCER PATIENTS IN AN UNDER-RESOURCED POPULATION. J. CHERVENAK

PSW-11 HEALTH DISPARITIES & HEALTH EQUITY- GENERAL (2 OF 2)

- P-703 SHARING IS CARING: IMPACT OF SINGLE VS. SHARED FRESH DONOR OOCYTE CYCLES S. Spring
- P-704 COMPARING FERTILITY PRESERVATION OUTCOMES AMONG ADOLESCENTS AND YOUNG ADULTS WITH AND WITHOUT SICKLE CELL DISEASE. A. J. Claffey
- P-705 HISPANIC ETHNICITY AND NEIGHBORHOOD POVERTY ARE ASSOCIATED WITH DECREASED ELIGIBILITY FOR MANDATED INSURANCE COVERAGE FOR MEDICALLY-INDICATED FERTILITY PRESERVATION. K. M. Chacon
- P-706 GENETIC TESTING OF MISCARRIAGES: THE HISPANIC EXPERIENCE FROM THE HARNESS MULTIPLE OPPORTUNITIES FOR PREGNANCY LOSS EXPLORATION (HOPE) NATIONAL REGISTRY. G. Rivera-Cruz
- P-707 DECREASED PROBABILITY OF LIVE BIRTH IN PATIENTS RESIDING IN ECONOMICALLY DISADVANTAGED NEIGHBORHOODS AFTER EUPLOID FROZEN EMBRYO TRANSFER. S. Willson
- P-708 A PROSPECTIVE COHORT STUDY: LUTEINIZING HORMONE AND ESTRADIOL LEVELS MAY PREDICT SPERM IN THE EJACULATE OF TRANSGENDER WOMEN USING GENDER AFFIRMING HORMONES. A. B. Hood

PSW-12 REPRODUCTIVE MEDICINE (NON-INFERTILITY)- PCOS

- P-709 ANTI-MÜLLERIAN HORMONE TO DETERMINE POLYCYSTIC OVARIAN MORPHOLOGY: A SUB-ANALYSIS OF THE APHRODITE STUDY IN AN ASIAN POPULATION. J. S. Laven
- P-710 ADULT C-KIT+ STEM/PROGENITOR CELLS ORIGINATED FROM BROWN ADIPOSE TISSUE AND ITS ROLE IN POLYCYSTIC OVARY SYNDROME PATHOLOGICAL MECHANISM. Y. Yu
- P-711 SPONTANEOUS BRAIN ACTIVITY ALTERATIONS REFLECTING MOOD DISORDERS IS ASSOCIATED WITH INSULIN RESISTANCE IN OBESE/OVERWEIGHT WOMEN WITH PCOS. J. Wang
- P-712 IMPROVING POLYCYSTIC OVARIAN SYNDROME RELATED QUALITY-OF-LIFE WITH THE USE OF A PATIENT-CENTERED TREATMENT PLAN. C. Murphy
- P-713 A MULTIDISCIPLINARY APPROACH TO WEIGHT MANAGEMENT IS EFFECTIVE AMONG INDIVIDUALS WITH PCOS. D. Stelmak
- P-714 POLYCYSTIC OVARY SYNDROME VIDEOS ON TIKTOK: ASSESSING QUALITY, UNDERSTANDABILITY, AND ACTIONABILITY. L. M. BUI



Wednesday, October 23, 2024

For updated presentation times, please refer to the Congress mobile app.

PSW-13 REPRODUCTIVE MEDICINE (NON-INFERTILITY)- NUTRITION & ENVIRONMENTAL FACTORS

- P-715 IDENTIFYING NUTRITIONAL AND PHARMACOLOGICAL TARGETS FOR ALLEVIATING POLYCYSTIC OVARY SYNDROME USING GENOMIC-DRIVEN MACHINE LEARNING. S. Hanassab
- P-717 WEIGHT LOSS FOR PCOS: HOW MUCH WEIGHT SHOULD WE GIVE THE INFORMATION WE SEE ON TIKTOK? R. Darcy
- P-718 UNDERSTANDING THE INFLUENCE OF BMI AND POLYCYSTIC OVARY SYNDROME (PCOS) ON MENSTRUAL CYCLE AND OVULATION TRENDS. A. A. Divaraniya
- P-719 PHTHALATES ARE DETECTED IN THE FOLLICULAR FLUID OF ADOLESCENTS AND OOCYTE DONORS WITH ASSOCIATED CHANGES IN THE CUMULUS CELL TRANSCRIPTOME. D. Gokyer
- P-720 EFFECTS OF GREEN SPACE ON DONOR OOCYTE OUTCOMES. K. E. Andre

PSW-14 REPRODUCTIVE MEDICINE(NON-INFERTILITY)- REPRODUCTIVE ENDOCRINOLOGY

- P-721 INTRAFOLLICULAR TRANSFORMING GROWTH FACTOR 3 INDUCES THROMBOXANE PRODUCTION RELATED TO OOCYTE MATURATION DURING CONTROLLED OVARIAN STIMULATION. T. Lai
- P-722 HIGH TESTOSTERONE LEVEL COULD BE AN INDEPENDENT RISK FACTOR AFFECTING OOCYTE MATURATION RATE: A RETROSPECTIVE STUDY. S. Tian
- P-723 THE ROLE OF BROMODOMAIN AND EXTRA-TERMINAL PROTEINS IN INFLAMMATION AND UTERINE FIBROIDS. Q. Yang
- P-724 ESTRADIOL REPLACEMENT AND PSYCHOLOGICAL HEALTH IN WOMEN WITH FUNCTIONAL HYPOTHALAMIC AMENORRHEA: A PILOT RANDOMIZED CONTROLLED TRIAL. N. Safwan
- P-725 DETERMINING THE EFFECTS OF PRIMARY OVARIAN INSUFFICIENCY ON SEXUAL HEALTH AND QUALITY OF LIFE IN ADOLESCENTS. K. M. Mehta
- P-726 THE WINDOW OF IMPLANTATION DETECTED BY ENDOMETRIAL RECEPTIVITY ARRAY MAY NOT BE CONSTANT AND VARY DEPENDING ON STEROID HORMONE MILIEU. N. Ho

PSW-15 REPRODUCTIVE MEDICINE(NON-INFERTILITY)- GENERAL (2 OF 2)

- P-727 39-WEEK INTRA-VAGINAL TAMOXIFEN (DARE-VVA 1) DOSE TOXICITY AND TOXICOKINETICS STUDY IN THE RABBIT. D. R. Friend
- P-728 CERAMIDE TEST IN PATIENTS WITH ERECTILE DYSFUNCTION TO ASSESS CARDIOVASCULAR RISK. A. Guillen Lozoya
- P-729 IS HISTORY OF POLYCYSTIC OVARY SYNDROME (PCOS) RELATED TO SLEEP QUALITY IN POSTMENOPAUSAL WOMEN IN THE STUDY OF WOMEN'S HEALTH ACROSS THE NATION. S. Alur-Gupta
- P-730 IS LOW SERUM PROGESTERONE THE DAY BEFORE SINGLE EUPLOID EMBRYO TRANSFER CYCLE ASSOCIATED WITH POOR PREGNANCY OUTCOMES DESPITE PROGESTERONE SUPPLEMENTATION? A. Ghofranian
- P-731 PSYCHIATRIC MANIFESTATIONS AFTER TESTOSTERONE PELLET USE IN A POST-MENOPAUSAL WOMAN. N. Daram
- P-732 EFFECT OF NEONICOTINOID INSECTICIDES IN FOLLICULAR FLUID AND SERUM ON REPRODUCTIVE OUTCOMES AMONG WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGIES. Z. Liu



**AUTHOR AND SPOUSE/PARTNER DISCLOSURES INDEX:
ORAL AND POSTER SESSIONS**

All oral and poster presenters at the ASRM 2024 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships their partners/spouses disclosed.

¹Company Officer ²Direct Stockholder ³Full-Time Company Employee ⁴Grant Recipient ⁵Honoraria
⁶Paid Consultant ⁷Speaker's Bureau ⁸Other ^aSelf ^bImmediate Family Member ^cInstitution

Adeleye, A.	Carrot2 ^a ; Frame ^a ; Kompass Diagnostics ^a
Albertini, D. F.	Gameto, Inc ^{6a}
Aleriano, K.	Conceivable Life Sciences ^a
Alikani, M.	Conceivable Life Sciences ^b ; Conceivable Life Sciences ^a ; Kindbody ^{8b} (SAB); TMRW ^{8b} (SAB); TMRW ^{8a} (Scientific Advisory Board)
Alouf, C. A.	Genomic Prediction ^{3a} ; Invitae ^{23a}
Armer-Cabral, M.	Natera ^a
Arrach, N.	Progenesis ^a
Augustine, L.	Ferring Pharmaceuticals ^a
Babu, V.	University of Pittsburgh ^a ; UPMC ^a
Baillargeon, J.	Ferring Canada Inc ^c ; McKesson Canada ^a
Baker, V. L.	Ferring ^a ; IBSA ^a
Bar-Chama, N.	Genentech/ Roche Pharmaceuticals ^a ; WINFertility ^a
Barad, D. H.	Fertility Neutraceuticals ^{8a} (Patent Royalties)
Barrachina, F.	Gameto Inc. ^{3a}
Barragan, C. P.	Conceivable Life Sciences ^a
Belamino, A.	Fellow Health ^{6a}
Benn, P.	Natera, Inc ^a
Berger, D. S.	Eastern Virginia Medical School ^{5a} ; Fertility Tomorrow ^{6a} ; Illume Fertility ^{6a} ; Triangle Genomics ^{2a}
Bhagavath, B.	Portal Instruments ^{6a}
Bharadwaz, M. P.	Rejoni ^c
Bhattacharya, S.	Ferring ^a ; Merck ^a ; Organon ^a
Bissonette, E. A.	Sebela ^a
Black, L. D.	Inception Fertility ^a
Blue, N. R.	Samsung Medison ^{4a}
Boussommier, A.	ImViro ^{12a}
Brannigan, R. E.	American Board of Urology ^{8a} (Examination Committee Senior Consultant); American Urological Association ^{8a} (AUA Update Series Editorial Committee Member)
Brennan, D. C.	Care Dx ^{6a} ; Sanofi ^{6a} ; Vera Therapeutics ^{6a}
Brinson, A.	Maven Clinic ^a
Brogaard, K.	Inherent Biosciences ^{12a}



**AUTHOR AND SPOUSE/PARTNER DISCLOSURES INDEX:
ORAL AND POSTER SESSIONS**

All oral and poster presenters at the ASRM 2024 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships their partners/spouses disclosed.

¹Company Officer ²Direct Stockholder ³Full-Time Company Employee ⁴Grant Recipient ⁵Honoraria
⁶Paid Consultant ⁷Speaker's Bureau ⁸Other ^aSelf ^bImmediate Family Member ^cInstitution

Brown, K.	CooperSurgical ^a
Caesar, K.	GeneScreen ^a
Callum, P.	Calitar Consulting, LLC ^{1a} ; Cooper Surgical ^{6a} ; NorthStar Fertility/Everie ^{6a} ; Tandem Genetics ^{8b} (Part Time Employee); Tandem Genetics ^{1a}
Cameron, K. E.	Becton Dickinson ^{3b} ; Siemens Healthineers ^b
Capalbo, A.	Juno Genetics ^{1a}
Caviglia, E.	Novagen ^{3a}
Cedars, M. I.	AGOS ^{8a} (Executive Board member)
Choi, S.	Sanofi ^a
Cinnioglu, C.	NextGen Genetics MSO, LLC ^{123a}
Civello, D.	Fellow Health, Inc. ^a ; GRAIL, Inc. ^a
Cohen, J.	Althea Science ^a ; Conceivable Life Sciences ^a ; IVF 2.0 ^a ; KindBody ^a ; TMRW ^a
Copeland, M.	Sumitomo Pharma America, Inc. ^a
Copperman, A. B.	Progyny ^{12a}
Costa Borges, N.	Conceivable Life Sciences ^c ; Embryotools SL ^a
Craig, L. B.	American Board of Obstetrics & Gynecology, Division of REI ^{5a} ; Ferring Pharmaceutical ^{8a} (site investigator for a study); Ferring Pharmaceuticals ^{6a} ; MayHealth ^{8a} (site investigator)
Culwell, K.	Evoform Biosciences ^a ; Sebela Women's Health Inc ^a
Daftary, G. S.	Ferring Pharmaceuticals ^{3a}
Dahan, M. H.	Elsevier ^{8a} (Editor of a Text Book on Infertility); EMD Serono ^{467a} ; Ferring ^{67a} ; Journal of Clinical and Experimental Obstetrics and Gynecology ^{38a} (Editor and Chief of the Journal); Organon (As Merck) ^{6a} ; OriginElle Fertility Center ^{1a} ; OvaSciences ^{6a} ; Web of Science Inc ^{8a} (Editor of a text book on IVM)
Dalton, V.	Medical Letter ^{8a} (Contributing Editor); Merck ^{8a} (Expert witness); Society of Family Planning ^{8a} (Course Instructor); Up to Date ^{8a} (Author)
Daugherty, E.	GeneScreen Counseling, LLC ^a
Díaz, Y.	Novagen ^{3a}
Ding, X.	Portal ^{8a} (Scientific Advisory Board Member)
Dissler, N.	ImViro ^{3a}
Dokras, A.	Ablacare/Mayhealth ^{6a} ; AEPPOS Society ^{8a} (Executive Director); Ferring ^{6a} ; Organon ^a ; Veera Health ^{6a}
Domar, A. D.	Curio ^{6a} ; EMD Serono ^{4a} ; Ferring ^{7a} ; Inception Fertility ^{3a} ; Oto ^{4a} ; UptoDate ^{6a}
Duncan, F. E.	Merck KGaA ^a



**AUTHOR AND SPOUSE/PARTNER DISCLOSURES INDEX:
ORAL AND POSTER SESSIONS**

All oral and poster presenters at the ASRM 2024 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships their partners/spouses disclosed.

¹Company Officer ²Direct Stockholder ³Full-Time Company Employee ⁴Grant Recipient ⁵Honoraria
⁶Paid Consultant ⁷Speaker's Bureau ⁸Other ^aSelf ^bImmediate Family Member ^cInstitution

Dupree, J. M.	ASRM ^{8a} (Program Committee Member); Blue Cross Blue Shield of Michigan ^{4a} ; Ferring ^a ; Lipocine ^{2a} ; NIH ^{4a} ; Posterity Health ^{28a} (Scientific Advisory Board); SSMR ^{1a}
Duval, A.	ImViro ^a
Eccles, J.	Genomic Prediction ^{3a}
Eisenberg, M.	Doveras ^{8a} (advisor); Illumicell ^a (advisor); Next ^{8a} (advisor); Ro ^{8a} (advisor); VSeat ^{8a} (advisor)
Fabbro, M.	NOVAGEN ^{3a}
Feldberg, I. B.	Rejoni, Inc ^a
Fernandez, C.	Novagen, Cegy ^{3a}
Fjeldstad, J.	Future Fertility ^{3a}
Flores, V. A.	Abbvie ^{7a} ; Myovanta; Myovant ^{78a} (Advisory Board)
Flores Saiiffe Farías, A.	Conceivable Life Sciences ^a
Foong, S.	EMD Serono ^a ; Organon Canada ^a
Foster, E. D.	Ferring Pharmaceuticals ^a
Fritz, R.	Cradle Genomics ^{8a} (Medical Advisory Board)
Galain, M.	Novagen ^{3a}
Gale, J.	Ferring Pharmaceuticals ^a
Garnsey, H.	Genomic Prediction ^a
Garro, D.	Genomic Prediction ^a
Genest, G.	Ferring ^a ; Organon ^a
Gleicher, N.	Fertility Nutraceuticals ^{2a} ; Patents ^{8a} (Co-owner of several awarded and pending US patents)
Goldman, R. H.	UpToDate ^{8a} (Peer-Reviewer)
Goldman, K. N.	WndrHLTH ^a
Gomez, C.	Igenomix R&D SL ^{3a}
Goodman, L. R.	LiNA Medical ^{6a}
Gordon, T.	CooperSurgical ^{23a}
Gray, B. A.	Sebela ^a
Griffith, A.	CooperSurgical ^{3a} ; CooperSurgical ^a
Guzman, L.	Cooper Surgical ^a ; Gameto Inc ^c
Haj Ali, A.	Juno Genetics ^a
Hajirasouliha, I.	Fairtility ^a ; Noor Sciences Inc. ^a



**AUTHOR AND SPOUSE/PARTNER DISCLOSURES INDEX:
ORAL AND POSTER SESSIONS**

All oral and poster presenters at the ASRM 2024 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships their partners/spouses disclosed.

¹Company Officer ²Direct Stockholder ³Full-Time Company Employee ⁴Grant Recipient ⁵Honoraria
⁶Paid Consultant ⁷Speaker's Bureau ⁸Other ^aSelf ^bImmediate Family Member ^cInstitution

Halicigil, C.	Progenisis ^a
Halpern, J. A.	Posterity Health ^{3a}
Heiser, P. W.	Ferring Pharmaceuticals, Inc. ^{3a}
Hennebold, J. D.	iGenomix ^{8a} (Sponsored Research Agreement); Notify Therapeutics ^a (Sponsored Research Agreement); Regeneron ^{8a} (Sponsored Research Agreement)
Henrich, N.	Maven Clinic ^a
Hoek, A.	Ferring Pharmaceutical Company the Netherlands ^c
Homer, M. V.	Alife ^a ; U. S. Fertility ^{2a} ; USF Pharmaceutical Contracting Alliance ^{2a}
Hong, C. X.	Cosm Medical ^a
Hornberger, K. L.	Igenomix ^{6a} ; Seattle Sperm Bank ^{8a} (Part Time Company Employee)
Hotaling, J. M.	Abbvie, Pfizer, Novartis, Elli Lilly (wife as rheumatologist) ^{6b} ; Advanced Conceptions ^{2a} ; Andro360 ^{2a} ; Carrot Fertility ^{6a} ; FirmTech ^{12a} ; Inherent Bio ^{2a} ; Maximus ^{2a} ; Paterna Bio ^{12a} ; Repronovo ^a ; StreamDx ^{2a} ; Turtle Health ^{26a}
Hourvitz, A.	Fertilai ^{26a}
Howard, K. L.	Natera, Inc. ^{23a}
Huddleston, H. G.	Allara ^{6a} ; Amazon ^{6a} ; May Health ^{6a}
Isley, L.	CooperSurgical ^{23a}
Iturriaga, A.	Juno Genetics ^a
Jahnke, H. R.	Maven Clinic ^{3a}
Jalas, C.	Juno Genetics ^{3a}
Jaswa, E.	Oura ^a
Johnson, M.	Gameto ^a
Johnstone, E.	American Board of Obstetrics and Gynecology ^{8a} (REI Division Member); Ferring Pharmaceuticals ^{8a} (speaker - one conference)
Jones, C.	EMD Serono Canada ^{8a} (The GREI Fellowship Fund at the University of Toronto receives grants from these institutions for which I am the Fellowship Program Director); Ferring Canada ^a (The GREI Fellowship Fund at the University of Toronto receives grants from these institutions for which I am the Fellowship Program Director)
Joris, H.	Vitrolife BV ^a
Kallen, A. N.	ACOG ^{8a} (Past Connecticut Section Chair); Flo ^{8a} (Medical Reviewer); Healthline ^{8a} (Medical Reviewer)
Kang, H.	CHA Biotech ^{3a}
Karlamangla, A.	OptumRx ^a
Kavoussi, P. K.	Halozyme Therapeutics ^a ; PS Fertility ^a



**AUTHOR AND SPOUSE/PARTNER DISCLOSURES INDEX:
ORAL AND POSTER SESSIONS**

All oral and poster presenters at the ASRM 2024 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships their partners/spouses disclosed.

¹Company Officer ²Direct Stockholder ³Full-Time Company Employee ⁴Grant Recipient ⁵Honoraria
⁶Paid Consultant ⁷Speaker's Bureau ⁸Other ^aSelf ^bImmediate Family Member ^cInstitution

Kelly, L.	Ferring Pharmaceuticals ^{3a}
Kenfield, S. A.	Fellow Health, Inc. ^a
Kerestes, C.	Organon ^a
Kimble, T. D.	AbbVie ^a ; Exeltis ^a ; Mayne Pharma ^a ; Mercka; Mylan ^a ; Organon ^a ; Sebela ^a
Klatsky, P.	Gameto ^a
Klavanian, J.	Natera ^{23a}
Kramme, C. C.	Gameto ^{123a}
Krivoi, A.	Future Fertility ^{12a}
Kubikova, N.	Juno Genetics ^{3b}
Kumar, J.	Rejoni (institution) ^c
Kunselman, A. R.	Merck ^{2a}
Lai, S.	IDT Australia ^a
Lalwani, S. I.	Ferring Pharmaceuticals ^{3a}
Lanes, A.	BORN Ontario ^{6a}
Laven, J. S.	AnshLabs ^{45a} ; ART Pred ^{4a} ; Ferring ^{456a} ; Gedeon Richter ^{6a} ; Merck ^{4a} ; Roche Diagnostics ^{4a}
Le, C.	Sebela Women's Health Inc ^c
Leahy, D.	Genomic Prediction ^{3a}
Legro, R. S.	Celmatix ^a ; Covis ^{6a} ; Exeltis ^a ; Guerbet ^{4a} ; Insudd ^{6a} ; Monsanto ^a ; Novo Nordisk ^{6a} ; Organon ^a
Lim, R. M.	Sema4/GeneDx ^a
Lipshultz, L. I.	Lipocine ^a
Loia, N. D.	Juno Genetics ^a
Madden, T.	Bayer Healthcare Pharmaceuticals ^{58a} (serve on data safety monitoring committee for Phase 4 studied); CooperSurgical ^a (serve on data safety monitoring committee for Phase 4 studied)
Maheshwari, A.	Ferring Pharmaceutical ^a ; Geodon Ritcher ^a ; Merck Serono ^a
Marchante, M.	Gameto ^{3a}
Marin, D.	Genomic Prediction Inc. ^a
Marsh, E. E.	ACOG ^{8a} (Board Member); Alnylam ^{6a} ; Myovant Sciences ^{6a} ; SREI ^{8a} (President)
Martin, C.	Rejoni Inc. ^c
Martinez Carreon, D. S.	Conceivable Life Sciences ^a ; Conceivable Life Sciences ^a
Massin, N.	CooperSurgical ^a ; Ferring ^a ; GE ^a ; IBSA ^a ; Merck ^a ; Organon ^a ; Theramex ^a



**AUTHOR AND SPOUSE/PARTNER DISCLOSURES INDEX:
ORAL AND POSTER SESSIONS**

All oral and poster presenters at the ASRM 2024 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships their partners/spouses disclosed.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

McCulloh, D. H.	Biogenetics Corporation ^{3a} ; Biogenetics Laboratory ^{3a} ; Buffalo IVF ^{6a} ; Gameto, Inc ^{136a} ; New York University Langone Fertility Center ^{36a} ; ReproART:Georgian American Center for Reproductive Medicine ^{1a} ; Sanford Reproductive Endocrinology ^{6a} ; Sperm and Embryo Bank of New York ^{3a}
McKenzie, L.	Springworks Pharmaceuticals ^{6a}
McKissock, K.	Cooper Surgical ^{3a}
Mclernon, D. J.	Merck ^a
Mecklai, K.	Modern Fertility (A Ro Company) ^{6a}
Medina, V.	Conceivable Life Sciences ^a
Meltzer, J. T.	Natera ^{23a}
Mendizabal, G.	Conceivable Life Sciences ^a
Mercuri, N.	Future Fertility ^{3a}
Meseguer, M.	AIVF ^{8a} (Speaker Fee); Angelini ^{8a} (Speaker Fee); Cooper Surgical ^{8a} (Speaker); Fertility ^{8a} (Speaker Fee); Ferring ^{8a} (Speaker Fee); Fujifilma(Speaker Fee); Genea Biomedx ^{8a} (Speaker Fee); Gideon Richter ^{8a} (Speaker Fee); Merck ^{8a} (Speaker Fee); Theramex ^{8a} (Speaker Fee); Vitrolife ^{8a} (Speaker Fee)
Mestres, E.	Embryotools ^a
Millan, C.	Conceivable Life Sciences ^a
Miller, K. A.	aLIFE Health, Inc ^{8a} (Scientific Advisory Board); Fairfertility ^{8a} (Scientific Advisory Board); Future Fertility ^a (Scientific Advisory Board); Genomic Prediction Inc. ^{78a} (Scientific Advisory Board); Igenomix ^{68a} (Scientific Advisory Board)
Miller, J.	Rejoni ^c
Mol, B. W.	Ferring ^a ; Merck ^{6a} ; Norgine ^a ; ObsEva2 ^{6a} ; Organon ^{4a}
Morrison, A.	Ansh Labs ^a
Moss, C.	Maven ^a
Mounds, E.	Juno Genetics ^{3a}
Mumford, S. L.	Society for Epidemiologic Research ^{8a} (Member at Large on Executive Committee)
Munne, S.	Genembryomics ^a ; GenEmbryomics ^a ; Homu Health Ventures ^{1a} ; Overture Life ^{1a} ; Progenesis ^{3a}
Munro, M. G.	Daiichi-Sankyo ^a ; Hologic Inc ^a ; Okon Medical ^a ; Pharmacosmos ^a ; Rejoni Inc ^a ; Shield Therapeutics ^a ; Womed ^a
Nangia, A.	Ferring ^{4a} ; NICHD ^{4a} ; South Central section of the American Urological Association ^{8a} (Treasurer)
Nassab, P.	Igenomix ^{3a}
Nayot, D.	Bird&Be Company ^a ; Future Fertility ^{26a} ; MonCap ^a ; The Fertility Partners ^a



**AUTHOR AND SPOUSE/PARTNER DISCLOSURES INDEX:
ORAL AND POSTER SESSIONS**

All oral and poster presenters at the ASRM 2024 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships their partners/spouses disclosed.

¹Company Officer ²Direct Stockholder ³Full-Time Company Employee ⁴Grant Recipient ⁵Honoraria
⁶Paid Consultant ⁷Speaker's Bureau ⁸Other ^aSelf ^bImmediate Family Member ^cInstitution

Nedelcu, S.	Hertility ^a
Nicholson, T. M.	Tasso, Inc ^{12b}
Nodar, F.	Cegyr ^{2a}
Nolte, D.	Exact Sciences ^{8a} (Summer Intern); Fellow Health, Inc. ^{3a}
Olson, A.	Inherent Biosciences ^{123a}
Papier, S. D.	ALMER ^{5a}
Park, A.	UptoDate ^a
Paulsen, B.	Gameto, Inc. ^{3a}
Penrose, L. L.	Reproductive Solutions ^{24a}
Penzias, A. S.	AutoIVF ^a ; Fairtality ^a
Picchetta, L.	Ferring Pharmaceuticals ^a
Piechota, S.	Gameto Inc ^a
Pierre-Louis, J.	GeneScreen Counseling, LLC ^a
Pinborg, A. B.	Ferring ^a ; Gedeon Richter ^a ; Merck A/S ^a
Popper, B.	ImVitro ^a
Porrett, P. M.	United Therapeutics ^a
Prien, S. D.	Reproductive Solutions Inc ^{246a}
Purcell, S. H.	PS Fertility ^{6a}
Quaas, A. M.	Ferring Pharmaceuticals ^{57a}
Rabkina, L.	Igenomix ^{3a}
Raffo, D.	locatorapps.com ^a
Ratts, V.	Aesculap Implant Systems ^{6b} ; Bill and Melinda Gates Foundation ^{4a} ; Kaliber ^{2b} ; Medtronic ^{48b} (Royalties); Midwest Imaging ^{2b} ; MRI Partners of Chesterfield ^{2b} ; Nocimed ^{2b} ; Optum Fertility Solutions Expert Panel ^{8a} (Expert panel member); OuroBoros ^{2b} ; Pain and Rehabilitation Specialists, LLC ^{2b} ; Paradigm Spine ^{2b} ; St. Louis Spine and Orthopedic Surgery Center ^{2b}
Roeca, C.	Ferring Pharmaceuticals ^{6a}
Sakkas, D.	ALIFE ^{8a} (Options); AUTOIVF ^a (Options); EMD Serono ^{7a} ; Intelon ^a ; Legacy ^{8a} (Options); TMRW ^a (Options)
Santamaria, X.	Asherman Therapya; Asherman Therapy3a
Santoro, N.	Amazon (Project Ember/Emblem) ^{6a} ; Ansh Labs ^{6a} ; Astellas Pharma ^{6a} ; FertilityIQ ^{6a} ; Menogenix Inc ^{8a} (Advisory Committee)
Santos-Ribeiro, S.	Ferring Pharmaceuticals ^a ; Gedeon-Richter ^a ; Merck Serono ^a ; Organon ^a ; Theramex ^c



**AUTHOR AND SPOUSE/PARTNER DISCLOSURES INDEX:
ORAL AND POSTER SESSIONS**

All oral and poster presenters at the ASRM 2024 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships their partners/spouses disclosed.

¹Company Officer ²Direct Stockholder ³Full-Time Company Employee ⁴Grant Recipient ⁵Honoraria
⁶Paid Consultant ⁷Speaker's Bureau ⁸Other ^aSelf ^bImmediate Family Member ^cInstitution

Segars, J. H.	Aspira ^a ; Myovant ^a ; Organon LLC ^a
Shapiro, M.	Apple ^a ; Optum ^a
Sharma, P. A.	Bird and Bee ^a ; Carrot Fertility ^a ; Future Fertility ^a
Shea, A.	Bayer ^a ; Eisai ^a ; Lupin ^a ; Organon ^a ; Pfizer ^a
Silvestri, G.	Conceivable Life Sciences ^a ; IVF 2.0 ^a
Smith, K. N.	EMD Serono ^a ; Ferring ^{7a}
Smith, J. F.	Fellow Health ^{1a} ; Inherent Biosciences ^{28a} (Scientific advisor); Posterity Health ^{28a} (Scientific Advisor)
Sobti, D.	Rejoni ^c
Spiro, S.	Maven Clinic ^a
Srouji, S. S.	Ferring ^{8a} (Served on Ferring advisory board once)
Surrey, E.	AbbVie ^{4a} ; Organon ^a
Tanaka, B.	Ferring Pharmaceuticals, Inc. ^a
Tao, X.	Juno Genetics US Inc ^{3a}
Taylor, H. S.	Abbvie ^c ; Dot Lab ^a ; Organon ^c
Terlecki, R.	Boston Scientific ^a
Thomas, M. A.	Levocept ^{48a} (Monies to University. Clinical trial); Organon ^{48a} (Monies to University. Clinical Trial)
Tobias, T.	Ferring Pharmaceuticals ^{6a}
Treff, N. R.	EMD Serono ^{7a} ; Genomic Prediction Inc ^{12a}
Trost, L.	Endo Pharmaceuticals ^a ; Laboratory and Procedural Services ^a ; Male Fertility and Peyronie's Clinic ^a ; PathRight Medical ^a ; THPS ^a ; THS ^a
Tsai, S.	ME ^{2a}
Turek, P. J.	AlphaSperm, Inc ^{12a} ; Arex Bioscience ^{6a} ; Arex Bioscience, Inc ^a ; BioQ, Inc ^{2a} ; CellArts, Inc ^{12a} ; Contraline, Inc ^{6a} ; Doximity, Inc ^a ; Future Family ^{2a} ; Give Legacy Inc ^{2a} ; Inherent Biosciences ^{6a} ; Inherent Biosciences, Inc ^a ; MandalMed, Inc ^{12a}
Turok, D. K.	Bayer Women's Healthcare ^{4a} ; Cooper Surgical ^{4a} ; Medicines360 ^{4a} ; Organon ^{4a} ; Sebela Women's Health Inc. ^{46a}
Valbuena Perilla, D.	Igenomix R&D ^{3a}
Van Den Veyver, I. B.	Baylor Genetics Laboratories ^a ; Illumina ^a
Varriale, C. V.	Inception Fertility ^a
Vaughan, D. A.	Ferring ^{6a} ; Testasy ^{2a}
Vega, C.	Juno Genetics ^a



**AUTHOR AND SPOUSE/PARTNER DISCLOSURES INDEX:
ORAL AND POSTER SESSIONS**

All oral and poster presenters at the ASRM 2024 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships their partners/spouses disclosed.

- ¹Company Officer
- ²Direct Stockholder
- ³Full-Time Company Employee
- ⁴Grant Recipient
- ⁵Honoraria
- ⁶Paid Consultant
- ⁷Speaker's Bureau
- ⁸Other
- ^aSelf
- ^bImmediate Family Member
- ^cInstitution

Venetis, C.	Ferring ^{45a} ; IBSA ^a ; Merck ^{45a} ; Merck, Sharp & Dohme ^{5a} ; Organon ^a ; Virtus Health ^{2b}
Villanueva, P.	Gameto Inc ^c
Vitek, W. S.	Turtle Health ^{6a}
Wang, R.	Rejoni ^c
Wantman, E.	Redshift Technologies ^{1a} ; SART ^{6a}
Weier, C.	CooperSurgical ^{3a}
Wells, D.	Juno Genetics ^{23a}
Widen, E.	Genomic Prediction, Inc ^{236a}
Winer, S. A.	Astellis Pharmaceutical ^a ; Mayne Pharmaceutical ^a
Wright, J. D.	Merck ^a ; UpToDate ^a
Xu, J.	Genomic Prediction, Inc. ^{1a}
Yang, E.	Inti Labs ^{1a}
Zaninovic, N.	AIVF ^{6a} ; ALIFE ^{6a} ; Apricity ^{6a} ; Fairtility ^{6a}
Zhan, Y.	Juno Genetics ^{3a}



**AUTHOR AND SPOUSE/PARTNER DISCLOSURES INDEX:
VIDEO SESSIONS**

All oral and poster presenters at the ASRM 2024 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships their partners/spouses disclosed.

- ¹Company Officer ²Direct Stockholder ³Full-Time Company Employee ⁴Grant Recipient ⁵Honoraria
- ⁶Paid Consultant ⁷Speaker’s Bureau ⁸Other ^aSelf ^bImmediate Family Member ^cInstitution

Brennan, D. C.	Care Dx ^{6a} ; Sanofi ^{6a} ; Vera Therapeutics ^{6a}
De Vos, M.	Gameto ^a
Gilchrist, R. B.	City Fertility ^{6a}
Goodman, L. R.	LiNA Medical ^{6a}
Kramme, C. C.	Gameto ^{123a}
Miller, C. E.	Blue Seas Med Spa ^{8a} (Investor); Gynesonics ^{26a} ; Hologic ^a ; LiNA Medical ^a ; Medtronic ^{6a} ; Olympus ^{6a} ; RF Medical, Co. Ltd. ^a ; Seikagaku Corporation ^a ; Storz ^a
Petrozza, J. C.	IMMA ^{8a} (Unpaid consultant); NESA ^{6a}
Sasaki, K.	Johnson and Johnson ^{6a}




Featured Exhibitor

NHP = New Horizons Pavilion

Exhibiting As	Booth
Ablavision Inc.	4824
Advocate Genetics	4859
AIVF	4269
Alife	4551
Allwin Medical Devices Inc.	238
Alto Pharmacy	224
America Medic & Science	4058
American Association of Bioanalysts	4437
Angels Creation Reproductive Center (ACRC Global)	4719
ARC Fertility	4427
ARKCryo	4853
ARSCI	4837
Artisan Medical Solutions	162
Asherman Therapy	4842
Asian Egg Bank	4529
ASKION GmbH	4514
ASRM Central	4037
ASTEC Co. Ltd	323
BabySentry	4447
Baylor University Medical Center	4520
Berry Fertility	4717
Boreas Monitoring Solutions	4611
Brown & Brown Lone Star Insurance Service Inc.	4544
BTI Biotechnology Institute	4608
Calibre Scientific	149
Cariad Medical Technology Co., Ltd.	411
Carrot Fertility	4554
CaseBioscience	143
Catalyst Healthcare Marketing	259
Centers for Disease Control and Prevention - Division of Reproductive Health	4861
Cicero Diagnostics, Inc.	4258

Exhibiting As	Booth
CNY Fertility	4606
Conceive Inc	4820
Cook Medical Incorporated	4408
CooperSurgical	343 & 348
Cryo Bio System	215
CryoFuture	4449
Cryohexagon Ltd.	4834
CryoMate Inc	4716
Cryoport	4062
Cryos International - USA	4051
cryo-transport.com	4829
Cycle Clarity	4317
Defense Health Agency Civilian Medical Corps	4643
DeTech	4644
Donor Conceived Community	4831
DrCatalyst	4817
Eastern Virginia Medical School	4847
Egg Donor IDEAS Agency	4405
eIVF	168
Embie	NHP-6
Embryo Connections	4605
Embryo Solution LLC	4841
Embryotech Laboratories, Inc.	260
EMD Serono	4022
EMPOWER with Moxi	4860
Encompass Fertility	4634
EngagedMD	4466
Esco Technologies Inc.	4261
ESHRE	4443
Eurofins CellTx	4271
EVERSANA	4738
Evident Scientific	4830
Evvy	223
ExEm Foam	4627

Exhibiting As	Booth
Fairfax Cryobank, Fairfax EggBank, and Fairfax Surrogacy	4016
Fairhaven Health	4429
Fairtility	4366
Fellow	4170
Femasys Inc.	243
Ferring Pharmaceuticals Inc.	4027
FertilAI	4619
Fertility Billing Solution	125
Fertility Pharmacy of America	4653
Fertility Pro	164
Fertility Specialists Network	4720
Fertility Technology Resources, Inc.	4654
Fertsy Technology Company Limited	213
FertyLink	4470
First Fertility	4171
Frame	4832
Freedom Fertility by Evernorth	357
FUJIFILM Irvine Scientific	326
Fulgent Genetics	4851
Future Fertility	4519
Gaia	316
Gameto	4439
Gattaca Genomics	127
GE HealthCare	268
Genea Biomedx	4034
GeneScreen Counseling, LLC	4667
Genomic Prediction, Inc.	160
GENTIS - Genetic Testing Services Joint Stock Company	4618
Give Legacy, Inc.	4827
Global Medical Virtual Assistants	4742



Featured Exhibitor

NHP = New Horizons Pavilion

Exhibiting As	Booth
Global Premier Fertility	4622
Hann's Fertility Pharmacy	4739
Heranova Lifesciences	229
IFFS	4442
Inception Fertility	335
Indian Egg Donors	4413
Innovative Health Diagnostics	4823
International Fertility Group	4066
Invitrocare, Inc.	4537
INVO Bioscience	4651
IVF Academy	4533
IVF Couriers	4743
IVF On Demand (IVFOD)	135
IVF STORE	341
IVF USA. Ltd	4666
IVFCloud	4517
Jabrehoo Med Tech Co.	126
Journey Genomics Sl.	4852
Juniper Genomics	NHP-2
Juno Genetics	132
Kai Health	4828
Kaleidoscope Anesthesia Associates	4441
Kaneka	4854
Karl Storz Endoscopy-America	250
Kitazato - Dibimed	4012
Lab Protector	218
Labcorp	4451
Labryo Fertility	247
LeadSquared	4612
Levy Health USA, Inc.	145
LG Pharmaceutical Corp.	4844
LifeAire Systems LLC	4316
LiNA Medical	4524
Luminary Life Sciences	363
Mandell's Clinical Pharmacy	4754

Exhibiting As	Booth
Maven Clinic	4816
Mavida Health	NHP-4
MDR Fertility Pharmacy	157
Medical Electronic Systems, LLC	266
MediFirst	4266
Meditab Software (FertilityEHR)	361
Meitheal Pharmaceuticals, Inc.	4521
Mellowood Medical-Ideas	4416
Men Having Babies, Inc.	4621
MicroData Instrument Inc.	141
Microsurgery Instruments Inc	148
MIM Fertility	4438
Mindray North America	4543
Minerva Surgical	4814
Monarch Medical Products, Inc.	4857
Myart Medical Ltd.	4866
Nableivf	4538
Narishige International USA, Inc.	257
Natera, Inc.	415
NextGen Lifelabs	367
Nikon Instruments Inc.	4453
Northstar Fertility Group	331
Nvva Life Technology	4631
Okolab SRL	4856
Oova Inc.	4766
Orchid	4420
Organon LLC	4047
OriGyn Medical	4351
Overture, Inc.	222
Ovobank US	4647
PatientFi	4822
PCRS - Pacific Coast Reproductive Society	4534
Perel Health	313
PharmaWatch	4639
phasetwo	4862

Exhibiting As	Booth
PherDal Fertility Science, Inc.	NHP-3
Philips Healthcare	166
Pinnacle Egg Bank	315
Posterity Health	142
Postpartum Support International (PSI)	4613
Pregmune	4849
Premom	4167
PRIME INSTRUMENTS CORP. (PRIME LIFE SCIENCE)	4313
Progyny	4527
Prolistem	4369
Proov	4848
QuickSTAT, A Kuehne + Nagel Company	4553
Quten Research	4740
Raeyco Lab Equipment Systems Management Ltd.	4751
Recurrent Pregnancy Loss Association (RPLA)	4850
Rejoni	4843
Reproduction Resources	4714
Reproductive Genetic Innovations	167
Reproductive Sciences Management Company	4067
Reproductive Solutions	129
REPROLIFE	4019
ReproSource Fertility Diagnostics	4431
ReproTech, LLC	4234
RESOLVE: The National Infertility Association	4548
Reunite RX	4070
Richard Wolf Medical Instruments	4513
Rocket Medical PLC	4352
SafePoint Scientific	138



Featured Exhibitor

NHP = New Horizons Pavilion

Exhibiting As	Booth
SAIPAN IVF CENTER, LLC	4518
Salve Technologies Limited	4468
Samsung	4731
Sanford Health	4505
Sapyen	4506
SCSA Diagnostics	4547
Seattle Sperm Bank	4205
Shandong Weigao Ruisheng Medical Device Co., LTD	226
SMP Pharmacy Solutions	4423
Society for the Study of Reproduction	4540
Sourcepass	4819
Spectrum Technologies-Your Pure Sperm Source	4637
Sumitomo Pharma America and Pfizer	4433
Sunfish Technologies	4418

Exhibiting As	Booth
Sunlight Medical Inc.	159
Tandem Genetics	4652
The Bob Woodruff Foundation	4821
The Hamilton Thorne Group	4008
The Maya's Wings Foundation	4638
The Permanente Medical Group	4737
The Seed Scout, LLC	NHP-5
The World Egg & Sperm Bank	245
Theralogix	262
Thermo Fisher Scientific	4434
Thomas Medical (A MedGyn Company)	4614
TMRW	4005
TOKAI HIT	4616
Tosoh Bioscience	265
U.S. Donor Conceived Council	4718

Exhibiting As	Booth
Univfy Inc.	4314
US Fertility	4054
Vaisala Inc.	4617
Vanguard Communications	150
VirtaMed Inc.	216
VitroDx, Inc	4166
Vitrolife Group	153
wawa fertility	4833
WellPact	220
WINFertility	4516
Worldwide Surrogacy Specialists	4567
Wuhan Huchuang Union Technology Co., Ltd	4839
XiltriX North America	4566
Xytex Corporation	4421
Yikon Genomics	4838
You Healing You	NHP-7

ASRM 2024
**Spotlight &
 Engagement Pavilion**

Discover the ASRM Spotlight & Engagement Pavilion!

The CCC Mile High Ballroom will host non-CME activities, including E-Posters, Spotlight Theater, Abstract Sessions, Industry Lunch Sessions, and Live Events.

E-Poster Hall Hours

Monday, October 21


8:00 AM - 6:00 PM

Tuesday, October 22

8:00 AM - 5:00 PM

Wednesday, October 23

8:00 AM - 2:00 PM







Industry Lunch Symposia
 2c & 3c

ASRM 2024
**Spotlight &
 Engagement Pavilion**
 Located in the Mile High Ballroom
 1st Floor



Spotlight
 Theater
 2a & 3a



Oral Abstract Sessions
 4a-4f

Abstract Sessions

Check the program for topics and times.

**Monday, October 21
 & Tuesday, October 22**


10:45 AM - 12:15 PM

1:30 PM - 2:45 PM

3:30 PM - 4:45 PM

Wednesday, October 23

10:45 AM - 12:15 PM



E-Poster Hall
 1a-1e



ASRM 2024
**Spotlight &
Engagement Pavilion**

Industry Lunch Symposia Schedule

Monday, October 21

12:20 PM - 1:20 PM

INDUSTRY-SPONSORED LUNCH SYMPOSIA (NON-CME)

Clinical Results of Cryotec Ready to Use-Next Generation Oocyte and Embryo Vitrification Method from Japan

Sponsored by REPROLIFE, Inc

Description:

- Introduction of Cryotec Ready to Use and its advantages.
- Reasons to use Cryotec Ready to Use in Sugiyama Clinic.
- Clinical Results of Ready to Use compared to conventional methods

Moderator: Barry Behr, Ph.D., Professor Emeritus, Stanford University of Medicine; **Speakers:** Keiji Man, Managing Director, REPROLIFE, Inc.; Dr. Koji Nakagawa, President, SUGIYAMA Clinic Shinjuku

Breaking the Ice: Exploring the Chill and Thrill of Planned Oocyte Cryopreservation

Sponsored by EMD Serono

Description: Join EMD Serono and experts in exploring the evolving demographics of fertility clinic patients. The increasing prevalence of planned oocyte cryopreservation for non-medical reasons underscores a shift in patient profiles. Unlike those seeking infertility treatment, these patients are not yet ready to start a family. How can we address their unique needs and expectations? Gain insights into caring for this group and explore their distinct journey. The symposium will delve into the unmet needs of this growing patient demographic, highlighting challenges and opportunities in patient care, offering valuable perspectives from the clinician, the embryologist, and the nurse point of view.

Expected Outcomes:

- Understand the unique needs and expectations of planned oocyte cryopreservation patients
- Identify challenges and opportunities associated with caring for these patients
- Understand the changing demographics of fertility clinic patients

Moderator: Kelly Wirka, Director, Fertility and Endocrinology, EMD Serono

Speakers: Kate Devine, MD, Medical Director and Chief Research Officer, Shady Grove Fertility; Marcos Meseguer PhD, Global Director of Embryology Research, IVIRMA Research Alliance; Senior Embryologist at the IVI Valencia IVF Unit, IVIRMA Research Alliance, IVI Valencia IVF Unit; Irina Snellbacher, RN, BSN, Nurse Manager, UCSF Center for Reproductive Health

ASRM CORPORATE MEMBER COUNCIL INDUSTRY SESSION (NON-CME)

Partnering with Industry to Advance Patient Care

Sponsored by ASRM Corporate Member Council

Description: Partnerships between industry and healthcare continue to advance and impact medicine. Through development of new technologies to advance healthcare provider education, industry strives to support healthcare leaders. Come learn during this informative session on how industry helps to advance patient care and medicine through charitable donations and grants that are available to you and/or your institution. Learn different ways through industry leaders on how to request these support mechanisms and come closer to embracing these opportunities.

Speakers: Chair: Keith Gordon Executive Director Medical Affairs, Organon; Gretchen Terry-Leonard, Director of Strategic Alliances EMD Serono; Vrunda Desai, VP, Medical Affairs and Clinical Strategy, CooperSurgical; Denny Sakkas, Boston IVF, Health Care provider; Chevis N. Shannon, DrPH, MBA, MPH, MERC, Chief Education and Science Officer, ASRM

ASRM ACCESS TO CARE SERIES (NON-CME)

Gender Affirming Care

Speakers: Daphna Stroumsa, MD, Reproductive Endocrinology and Infertility, University of Michigan; Elizabeth S. Rubin, MD, Oregon Health and Science University Hospital; Ariella Shikanov, PhD, University of Michigan



ASRM 2024
**Spotlight &
Engagement Pavilion**

Industry Lunch Symposia Schedule

Tuesday, October 22

12:20 PM - 1:20 PM

INDUSTRY-SPONSORED LUNCH SYMPOSIA (NON-CME)

ASRM ACCESS TO CARE SERIES (NON-CME)

Industry-sponsored Lunch Symposium (non-CME)

Shaping Tomorrow's PGT: How Pioneering Innovations of Today May Shape Clinical Practices of Tomorrow
Sponsored by Cooper Surgical, Inc.

Description/Expected Outcome: After attending this session, participants will be able to:

- Better understand advanced and exclusive PGT technologies offered by CooperSurgical
- Create demand and interest for upcoming genomics features
- Generate qualified leads that can be leveraged for downstream marketing

Moderator: Mike Whalley, VP, Global Genomics, CooperSurgical

Speakers: Dr. Tony Gordan, CooperSurgical; Christopher Weier Senior Research Scientist, CooperSurgical; Kenneth K. Moghadam, MD, Medical Director / Founder, Austin Fertility Institute; Mili Thakur, MD, Founder & CEO, GenomeAlly

ASRM Access to Care Series (non-CME)

Invisible Disparities: Seizing the Opportunity to Drive Change

Sponsored by Ferring Pharmaceuticals, Inc.

Speakers: Gloria Richard-Davis, MD; Samantha B. Schon, MD; Stacey A Missmer, MSC

Industry Lunch Symposia Schedule

Wednesday, October 23

12:20 PM - 1:20 PM

ASRM ACCESS TO CARE SERIES (NON-CME)

ASRM Access to Care Series (non-CME)

Reproductive Considerations in People With Sickle Cell Disease

Sponsored by Ferring Pharmaceuticals, Inc.

Speakers: Mindy S. Christianson, MD, Cleveland Clinic Foundation; Lydia H Pecker, MD, Johns Hopkins University School of Medicine; Ojon Bate, PharmD, MBA



ASRM 2024
**Spotlight &
Engagement Pavilion**

Spotlight Theater Schedule

Monday, October 21

10:00 AM - 10:45 AM

Addressing Gaps and Reaching More Patients: Impacting Family Building Through Advocacy and Legislation - Panel Discussion (non-CME)

Sponsored by Ferring Pharmaceuticals, Inc.

Description: A moderated discussion hosted by Ferring that will highlight the state and federal legislative, policy, and health equity advances to expand access to family building care and infertility treatment.

Speakers: Timothy Clark (Moderator), Sean Tipton (Panelist), Serena Chen, MD, (Panelist) and Michael Thomas, MD, (Panelist).

1:30 PM - 2:15 PM

Are You Ready for It? Reproductive Medicine in and Beyond the 2024 Election: An Update from the ASRM Public Affairs Team

Speakers: ASRM Office of Public Affairs

2:30 PM - 3:00 PM

ASRMed Talks: Through the Legal Looking Glass

Title 1: Vulnerable Families and the Current Legal Climate

Speaker 1: Heather Ross, JD

Title 2: The New ART Legal Landscape

Speaker 2: Katherine Kraschel, JD

Tuesday, October 22

10:00 AM - 12:20 PM

Center for Policy & Leadership PRIMED Scholars Showcase

Speakers: Morgan Baker, RN, Valerie Baker, MD; Inger Britt Carlsson, PhD; Tyler Cozzubbo; Elizabeth Lee, BS, RN Gilbert, AZ; Olumayowa Dayo, MD, MPH; Ann Luft, BA, BSN, RN; Aileen Portugal, MD ; Nicole Ulrich; Rachel Whynot, MD; Julie Bindeman, PsyD

1:45 PM - 2:30 PM

Building the Future: Establishing a Next-Generation Sequencing Lab for Cutting-Edge Reproductive Health Testing

Sponsored by Thermo Fisher Scientific

Description: In this comprehensive presentation, we will delve into the essential steps and considerations for establishing a next-generation sequencing (NGS) laboratory dedicated to reproductive health testing. Attendees will gain valuable insights into the latest technological advancements, infrastructure requirements, and practical industry guidance crucial for setting up a state-of-the-art NGS lab. We will explore the critical aspects of selecting appropriate sequencing platforms, optimizing lab workflows, and ensuring data accuracy.

Speaker: Adam Goodman, Chief Technical Advisor, Gattaca Genomics

3:00 PM - 3:30 PM

ASRMed Talks: From Buds to Babies: Navigating Cannabis & Infertility

Title 1: The Reproductive Health Consequences of Cannabis Use

Speaker 1: Jamie Lo, MD

Title 2: Impact of THC on Male Reproductive Health

Speaker 2: Jason Hedges, MD, PhD

Did you know we have new tools to help you optimize your patients' journey?

At EMD Serono, we understand the obstacles your patients might face on their journey to parenthood.

Come and take a peek at our new IVF Patient Journey Tool, helping highlight insights about the IVF patient journey that only EMD Serono can provide.

Join us on **Booth 4022** to learn more and explore how with **passionate dedication**, we can help patients achieve their dream of parenthood.

Discover how we can
**enable wonders,
together**



**EMD
SERONO**

© 2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. Gonal-F and Redi-Ject are registered trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. US-RDJ-00084 09/24

Thank You
Premier Sponsors
2024 ASRM Congress & Expo
Denver, Colorado

Diamond

Cooper Surgical, Inc.
EMD Serono
Ferring Pharmaceuticals, Inc.
Organon, LLC

Gold

Hamilton Thorne, Inc.
Inception Fertility, LLC
US Fertility

Platinum

REPROLIFE
Vitrolife, Inc.

Silver

FUJIFILM Irvine Scientific
IVF Store
Kitazato-Dibimed
NextGen LifeLabs

THANK YOU!

In-kind Educational Support for
ASRM 2024 Hands-on Courses Provided By:

Accurate Surgical & Scientific Instruments

ARTLAB

Hamilton Thorne

IVF Store

Nikon

Olympus America

2024 ASRM Corporate Member Council

Making a Difference One Initiative at a Time

Patient Education

Fact Sheets

Patient Education Videos

ReproductiveFacts.org

In-Training Awards

Question-based Learning Program

Webinar Training

Industry-Specific Sessions

AbbVie

LabCorp

Cook Medical

Natera

Cooper Surgical, Inc.

North Star Fertility
Partners

EMD Serono

Organon, LLC

Ferring
Pharmaceuticals, Inc.

Samsung

Femasys, Inc.

Univfy

International Fertility
Law Group

VirtaMed

Become a member of the ASRM Corporate Member Council!

The Mission of the ASRM Corporate Member Council reflects a partnership between the ASRM Officers and Directors and the Corporate Members and is designed to facilitate open and ongoing dialogue between the two; to identify and maximize common interests related to reproductive medicine; and to develop collaborative educational initiatives which serve to enhance the practice of reproductive medicine.

Why become a Corporate Member?

- Participation in Collaborative Initiatives
- Visibility
- Networking
- Website Link on ASRM Website
- Interaction/Collaboration with ASRM Board of Directors
- Special Recognition
- Preferred Support Opportunities
- Two (full) ASRM Memberships (CMC Representatives)

Join us for the ASRM Corporate
Member Council Industry Lunch
Session: *Partnering with Industry to
Advance Patient Care (non-CME)*
on Monday, October 21 from 12:20
PM to 1:20 PM in the Spotlight &
Engagement Pavilion, Room 2b.




FOR MORE INFORMATION
PLEASE CONTACT KEITH RAY AT
KRAY@ASRM.ORG OR
CALL 205-978-5001



BROWSE OPEN REPRODUCTIVE MEDICINE JOBS!

- Explore new career opportunities for FREE!
- Click on any websites, emails and videos to learn more.
- Download the guide to look back on organizations and opportunities that appeal to you.





THANK YOU


to **CooperSurgical, Inc.** and **EMD Serono**
for their continued support of the
ASRM Career Pathway Program

The purpose of the Career Pathway Program is to facilitate awareness around reproductive health, medicine, and science professions while also creating a network of mentors to support individuals interested in a career within the reproductive health field.

ASRM partners with HBCU's and other institutions supporting underrepresented minorities to identify students interested in medicine, nursing, STEM, business, health policy/law, wet lab, laboratory sciences, public health, clinical psychology and social work.

This year students from the University of Colorado and Colorado State will attend ASRM2024 on Monday, October 21st where they will be paired with a mentor, attend sessions, plenary talks, special programming and social events that will provide them the opportunity to engage with professionals in our field and ASRM leadership.





THANK YOU TO THE SPONSORS OF THE 2024 PRESIDENT'S GALA!

*We extend our heartfelt gratitude to our generous gala sponsors
that made this event a remarkable success.*

Premier Sponsor



Champion Sponsor



Impact Level



Partner Level

ASRM Corporate Member Council

HRC Fertility | USC Fertility

Organon LLC

Reproductive Medicine Associates (RMA) /
Boston IVF

UCSF Center for Reproductive Health

US Fertility

Weill Cornell Medicine Ronald O. Perelman and
Claudia Cohen Center for
Reproductive Medicine

Advocate Level

Future Family

Kindbody

Samantha M. Pfeifer, MD and

Peter N. Schlegel, MD

University of Michigan



EQUITY, ACCESS,
AND INNOVATION